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Abstract 
ABSTRACT 
This thesis investigates the application of cross metathesis and ring-closing metathesis to 
amino acid and peptide-based substrates that are suitably modified to contain an olefm 
tether. 
Chapter One introduces olefin metathesis, describes the mechanism of cross metathesis 
(CM) and ring-closing metathesis (RCM), and outlines the catalysts that can be used for 
these transformations. The application of CM and RCM to amino acid and peptide-based 
systems is reviewed. 
Chapter Two describes the CM coupling between modified lysine- (2.34 - 2.37, 2.43), 
serine- (2.45, 2.46), and cysteine-based (2.48, 2.49a, 2.51) amino acids and dipeptides 
(2.54, 2.57) to a terminal alkene (2.61, 2.65), carbohydrate (1.51b), or fatty acid (2.76) 
target compound using catalyst 1.17. The amino acid and dipeptide-based CM substrates 
were prepared by side-chain acylation of the parent amino acid with carboxylic acids 
containing variable but controllable olefin tether lengths. A CM model study in which 
these amino acid-based substrates were coupled to terminal alkene 2.61 and 2.65 gave CM 
products 2.66 2.74. CM was then carried out between amino acid-based substrates and a 
carbohydrate (1.51b) or fatty acid derivative (2.76), that afforded a novel series of . 
glycoamino acids (2.80 2.85) and lipoamino acids (2.94 2.101). 
Chapter Three describes the synthesis of amino acid dimers by CM. Two serine-based 
(3.22 - 3.23) and two cysteine-based (3.24 3.25) symmetrical dimers along with two 
unsymmetrical serine-cysteine dirners (3.26 - 3.27) were prepared from the same side-
chain acylated amino acid substrates described in chapter 2. These compounds are 
examples of novel cross-linked amino acid-based dirners, and further illustrate the 
versatility of the CM methodology devcloped in this thesis. 
Chapter Four describes the synthesis of cyclic amino acids and dipeptides via RCM of 
acyclic precursors that are suitably modified with acyl olefin tethers of variable length. 
Cyclic compounds based on lysine (4.6, 4.13), serine (4.31, 4.33), and cysteine (4.40, 4.42) 
Abstract II 
single amino acid residues, and compounds based on lysine (4.16, 4.21, 4.27), serine 
(4.3 7), and cysteine (4.45, 4.46) dipeptides were prepared. All these compounds were 
constructed using the same, versatile general method, which involves acylation of the 
natural amino acid substrate with a carboxylic acid of controllable olefin tether length 
followed by ReM with catalyst 1.17 to give cyclic products containing variable ring sizes. 
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INTRODUCTION 
Chapter One - Introduction 
1.1 METATHESIS 
Over the past decade, olefin metathesis has been firmly established as an important and 
general technique in synthetic organic chemistry. It is a carbon-carbon bond forming 
reaction in which a transition metal catalyses the exchange of alkylidene groups of two 
independent olefins to give a newly substituted olefinic product. The word "metathesis" 
comes from the Greek fisTaBsmr; (metathesis), meaning transposition. The first reports of 
olefin metathesis reactions were in the 1950's when researchers at Du Pont, Standard Oil 
and Philips Petroleum reported that propene reacted to give ethylene and 2-butenes when 
heated with [Mo(CO)6J on alumina. Since that time the mechanistic studies of Chauvin 
and metathesis catalyst development by the Schrock and Grubbs research groups have 
propelled the reaction of olefin metathesis into the limelight and into the fume hoods of 
organic chemist's the world over. 
Olefin metathesis provides an alternative to more traditional methods for carbon-carbon 
bond formation such as the Heck and other palladium-mediated reactions. There are a 
number of different types of metathesis reactions, as summarised in Figure 1.1. Cross· 
metathesis (CM) reactions can be carried out on either alkenes l (equation la) or alkynes2 
(equation Ib), likewise for ring-closing metathesis reactions (RCM) (equation 2a)3 and 
(equation 2b).2 This thesis describes alkene CM and RCM reactions carried out with 
modified amino acid and peptide-based substrates. 
Other types of metathesis reactions include acyclic diene metathesis polymerization 
(ADMEP)4 (equation 3) and ring-opening metathesis polymerization (ROMP)5 (equation 
4), which are increasingly finding application in polymer chemistry. Enyne metathesis 
(EYN)6 (equation 5) products are intrinsically set up for cycloaddition reactions on the 
resulting diene, for example Diels Alder reactions, which can be used to further derivatise 
molecules. Ring-opening cross metathesis (ROCM) 7 (equation 6) has also been used in 
synthetic chemistry. In addition to discrete, one step metathesis reactions (equations 1-6), 
there are several variations of one pot reactions that encompass more than one metathesis 
transformation. Some. examples of these are the tandem RCM/CM8 (equation 7) and 
domino metathesis reactions9 (equation 8). As only alkene CM and RCM reactions are 
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carried out in this thesis, the other types of metathesis reactions will not be further 
discussed. 
R1~ + ~R2 ... R1~R2 (1a) 
R1~ 2 R1 == R2 (1b) + ~R .. 
A .. (2a) 
0 ... (2b) 
A ... n (3) 
.. n (4) 
+ ~R2 .. ~R2 (5) 
R1 H 
+ F\ R1 R2 .. (6) 
R1 
R~ +~ .. R~ (7) 
{''''Q b O f ,,\\R R~ + N .. -l'-N (8) 
~)n n 0 
Figure 1.1. Olefin metathesis reactions 
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1.2 MECHANISM 
The generation of a metallacyclobutane intermediate by alternating [2+2] cycloadditions 
and cycloreversions is the generally accepted mechanism for alkene metathesis. This 
mechanism, originally proposed by Chauvin in 1971,10 has been confirmed over the years 
with various mechanistic and labeling studiesll -14 and complex mechanistic elucidation. 15,16 
A simplistic version of the "Chauvin carbene mechanism" is shown in Figure 1.2. The 
catalytic cycle begins with the dissociation of a ligand (Y) from the ruthenium (step A) to 
form the active, 14-electron catalytic species. In the case of Grubbs phosphine catalyst 
1.17 (see section 1.3) Y is the tricyclohexylphosphine (PCY3) ligand, while for the 
phosphine free catalyst 1.20 the dissociating ligand Y is iPrO. Co-ordination of an alkene 
substrate to the 14-electron species (step B) can then occur, which is in competition with 
the re-association of Y (reverse of step A). Depending on electronic and steric effects, the 
co-ordination of substrate H2C=R 1 (Step B) is favoured over both re-coordination of ligand 
Y and co-ordination ofthe other alkene substrate H2C=R2?,13,14 
The [2+2] cycloaddition of alkene H2C=CHR1 to the 14-electron Ru species (step B) 
results in the formation of a four-membered metalla-cycle. This "ruthenacycle" then 
fragments rapidly (step C) to give a newly substituted alkylidene with the release of 
XHC=CH2. X is the functional group on the catalyst carbene in the first catalytic cycle, for 
example the phenyl group in catalyst 1.17. In subsequent catalytic cycles X is the 
functional group of the olefin XHC=CHR2, for example X = H in terminal alkenes which 
gives ethylene as the alkene byproduct (Step C). When this occurs the reaction is 
thermodynamically driven by the removal of the volatile ethylene gas from the reaction 
mixture. 
A second alkene then reacts regio- and stereoselectively with alkylidene [Ru]=CHRl to 
give a second metallacyclobutane (steps Dl or D2). The formation of the metalla-cycle 
shown in step Dl is highly favoured over that in D2 (lmown as degenerate metathesis).17 
The favoured metallo-cycle resulting from step Dl then fragments to regenerate the active 
14-electron catalytic species and the desired CM product R1HC=CHR2 (step E). 
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x 
[Rul~ 
A jf X 
[Rul~ 
i 
Figure 1.2. Catalytic cycle of olefin metathesis 
L 
[Rul = I /CI 
RU'CI 
4 
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1.3 METATHESIS CATALYSTS 
Numerous catalysts have been reported that facilitate olefin metathesis (see Figures 1.3 and 
1.4). Over the past few decades the development of catalysts with improved reactivity, 
selectivity, and stability has enabled the application of olefin metathesis to a wide range of 
synthetic and organic chemistry problems. Reviews have been written summarising the 
history of olefin metathesis catalyst development over the years.3,18,19 The following 
section summarises key aspects of the structure, functional group tolerance, and 
development of metathesis catalysts. 
Schrock's molybdenum alkylidene catalyst 1.1 (Figure 1.3) was one of the first metathesis 
catalysts to be developed.20,21 This catalyst is known to tolerate substrates with ~-lactam 
backbone22 and acrylonitrile functionalities, but substrates with functional groups such as 
unprotected amines, free alcohols, acetate groups, enones, and enoic esters are not 
compatible. Despite these drawbacks, commercially available 1.1 is highly reactive' 
towards a range of substrates that contain a variety of functional groups. In general, 
Schrock's catalyst 1.1 gives shorter reaction times and higher yields than the more widely 
used ruthenium catalysts such as 1.10. However, its general use remains somewhat 
problematic due to sensitivity towards atmospheric oxygen. 
There are a number of other molybdenum catalysts available (see Figure 1.3), for example 
chiral carbenes such as 1.2,23 1.3,24 and 1.4,25 the latter of which is activated in DCM by 
the formation of an alkylidyne species in situ. Catalyst 1.4 has found use in alkyne cross-
metathesis reactions that contain both electron donating and electron withdrawing 
substituents, and where tolerance to polar groups such as ethers, esters, nitriles, acetals, 
sulfones, and silyl ethers is required. Hoveyda and Schrock have more recently developed 
a series of chiral solid-supported molybdenum complexes, for example catalyst 1.5, that 
are efficient in enantioselective olefin metathesis reactions.26 
Titanium and tungsten metals have also been used as the basis for metathesis catalysts 
(Figure 1.3). For example the titanium carbene 1.627 and the tungsten catalysts 1.7 and 1.8 
have found use in CM reactions. 10,28 
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m m 
CF3 MII~ RO"" II MO~Ph F3C+0"" 1 ~ Ph 
RO ...... 
0", ° CF3 
. R = C(CH3)(CF3)2 ~CF3 
1.1 1.2 
'Ph 
1.5 
yQy 
X- ~ ~ {/ ~ Q\\\\\Mo::::-.... IIIII 
- I Ph 
° 
1.3 
Q 
QrTi=CH2 
1.6 1.7 
)---
XN_MO"IN 
--q ~k'y-~~ ~ ~I 
1.4 
CI 
ArO",J.""CI 
CI ..... I .... CI 
OAr 
1.8 
Figure 1.3. Molybdenum, Titanium, and Tungsten olefin metathesis catalysts 
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Catalyst 1.9 (Figure 1.4), one of the first ruthenium carbene catalysts reported,19 has found 
wide use in RCM reactions involving conformationally constrained amino acids and 
peptides.3o However its use has been superceded by what remains the most commonly 
used olefin metathesis catalyst - Grubbs "first generation"* 1.10, a versatile and reliable 
tool for organic syntheses.3! Commercially available 1.10 initiates metathesis reactions 
more rapidly than catalyst 1.9, and can tolerate functionalities such as carbamate 
hydrogens,31 unprotected carboxylic acids,33 and a wide range of peptide protecting 
groups,31 while remaining relatively air and moisture stable. Despite its widespread 
applications in metathesis reactions, catalyst 1.10 does exhibit some drawbacks such as " ' 
sluggish reactivity, especially towards unprotected homoallylic alcohols, 
allyltrimethylsilane,34 and substituted double bondsY The bi-metallic catalyst 1.11 was 
reported to have similar catalytic activity to 1.10 but with the advantage of increased 
stability, ease of storage and an ability to be recovered and recycled. 36 
"First generation" water-soluble ruthenium catalysts such as 1.12 and 1.13 have been 
developed37 to allow metathesis reactions to be carried out in polar solvents, a feature that 
is particularly important if biological applications involving water soluble substrates are to 
be fully realised. These catalysts, synthesized by a ligand exchange of catalyst 1.10, show 
good RCM activity in solvents such as water, methanol, water/THF mixtures, and also 
benzene? 7 Catalysts 1.12 and 1.13 have, however, found limited use to date due to their 
high air sensitivity in solution, decomposing rapidly to form a bright green solution in the 
presence of trace levels of oxygen. It is interesting to note that while catalyst 1.13 is also 
soluble in DCM it does not show activity in this solvent due to instability.38 A number of 
other "first generation" ruthenium based catalysts have also been developed including the 
infrequently used photo inducible dimer 1.1439 and the chiral benzimidazolyidene catalyst 
1.15 that has comparable activity to 1.10.40 
Hoveyda reported a "first generation recoverable" ruthenium-based complex 1.16 in 
1997.41 Compared to 1.10, this catalyst has the advantage that it can be purified for re-use 
from reaction mixtures in high yield by silica gel-based chromatography.!l However, in 
general while 1.16 shows similar catalytic activity to 1.10, it is only reactive towards 
terminal alkenes. 
• In this context, a "first generation catalyst" refers to a ruthenium catalyst that contains at least one 
phosphine ligand, for example PCY3, and no N-heterocyclic ligand. 
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The emergence in 1999 of the now commercially available Grubbs "second generation"* 
catalyst 1.17 proved to be a particularly significance advance in metathesis chemistry.42 
The steric bulk and increased a-donor ability of the five-membered N-heterocyclic carbene 
ligand imparts improved stability and activity compared to the first generation catalyst 
1.10.43 Catalyst 1.17, which has a similar if not improved functional group tolerance 
compared to 1.10, has been used to prepare tri- and tetra- substituted double bonds by both 
RCM and CM.44 It has also found use in CM reactions involving a,~-unsaturated esters, 
ketones, and aldehydes. However, 1.17 remains unreactive towards acrylonitriles and 
other electron deficient substrates such as vinyl sulfones.45 Catalysts such as 1.18 have 
been developed to directly compare the effect the N-heterocyclic ligand has on catalytic 
activity. In this case the bulky 6-membered ligand catalyst 1.18 was shown to have lower 
reactivity compared to parent 1.17.46 Another variant on catalyst 1.17 has been made 
which bears a four-membered N-heterocyclic carbine ligandY This catalyst has been 
shown to have slower olefin metathesis rates as compared to 1.17. However further studies .. 
are required into the coordination properties of this four-membered ring to better 
understand this difference in activity. 
Water-soluble catalysts based on the "second generation" Grubbs scaffold have also been 
developed. The poly( ethylene glycol) conjugated catalyst 1.19 shows activity in ring-
opening metathesis polymerization in water and methanol, while is completely insoluble in 
diethyl ether.48 This latter property allows ease of product purification by precipitating the . 
catalyst from the reaction mixture following metathesis. This has some advantages since 
homogenous metathesis catalysts are often difficult to separate from organic products. 
Commercially available "second generation recoverable" phosphine-free catalyst 1.20 has 
been developed by Hoveyda and co-workers.49 This catalyst is highly reactive in 
metathesis reactions, recyclable via silica gel-based chromatography, and extremely stable 
when exposed to water andlor air. This catalyst is also very effective for CM reactions· 
where one olefin is electron deficient. For example, highly selective CM of a,~­
unsaturated nitriles and acrylonitriles has been achieved using 1.20, but not 1.17. Catalyst· 
1.20 is also compatible with unprotected alcohol5o and acid43 functional groups in the 
metathesis substrates, and it has been used to synthesize unsymmetrical functionalised 
• In this context a "second generation catalyst" refers to a catalyst containing I or less phosphine ligands and 
a N-heterocyc1ic ligand. 
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disubstituted olefins with good stereoselectivity under mild conditions.5o A variety of 
functionalities are tolerated including base-sensitive groups, and as such CM can be used 
to replace Wittig or Horner-Wittig reactions where substrates are base-sensitive. Catalyst 
1.20 is reasonably soluble in methanol at room temperature and readily soluble at SO°C, 
however it remains completely inactive in water-based solvent systems.51 ,52 The 
dendrimeric 1.21 has been reported as an alternative to 1.20, with an improved ability to be 
recycled by silica gel filtration. 49 
Blechert and co-workers reported binol-based ruthenium alkylidene catalysts 1.22 and 1.23 
as an addition to the growing list of second generation catalysts.53 ,54 These catalysts are 
significant in that they display increased activity, relative to 1.17 and 1.20, while retaining 
stability even after exposure to air for one week. The improved reactivity and stability of 
these catalysts has been attributed to the increased steric bulk of the binolligands. 
Various ligand substitutions have been made based around catalyst 1.20, for example 
Buchmeiser and co-workers55 have synthesised ruthenium-based catalysts 1.24 and 1.25, 
which have both been shown to be of equal or better activity than other ruthenium-based 
metathesis catalysts such as 1.17. The two chloro ligands of 1.20 have been substituted 
with the even more electron withdrawing trifluoroacetate ligands in 1.25, leading to even 
higher catalyst activity in some types of olefin metathesis reactions. Catalysts such as 1.24 
and 1.25 posses a nitro functionality that enhances catalytic reactivity presumably due to 
the electron-withdrawing effect of the nitro group. This decreases the electron density at 
the oxygen atom of the ligating iPrO group, such that the dissociation of the oxygen atom 
to form the 14-electron catalytic species is more favoured (step A, Figure 1.2).56 
A variety of solid-phase catalysts derived from 1.20 have also been reported, including 
1.26, 1.27 and 1.28. The deep green resin 1.27, synthesized from 1.17 and immobilized 
onto a Wang resin, is a particularly stable and recyclable catalyst that shows good CM 
activity even with highly electron deficient 0lefins.57 Solid-supported 1.26 shows high 
RCM activity, but much lower CM activity compared to 1.27. Catalyst 1.28 has been used 
for CM reactions in methanol/water mixtures in an air atmosphere. Buchmeiser et al have 
reported catalysts immobilized onto polymeric monolithic discs that are based on the 
scaffold of 1.20, that can be used in combinatorial chemistry, parallel synthesis, and high 
throughout screening.58 The products of metathesis reactions carried out on solid-supports 
Chapter One - Introduction 10 
have been shown to contain very low, residual ruthenium levels,55 which is especially 
advantageous for the synthesis of useful pharmaceutical compounds. The application of 
CM and RCM as applied to combinatorial and parallel synthesis has been reviewed. 59 The 
increasing demand for solid-supported olefin metathesis catalysts is due to issues such as 
contamination, cost, and application to high-throughput screening programs. 
More recently light fluorous versions of catalyst 1.20 have been developed by Curran and 
co-workers. For example catalyst 1.29, which bears a fluorous tag, shows comparable 
reactivity in similar conditions to that of 1.20.60 This catalyst can be separated from the 
metathesis reaction mixture by fluorous solid-phase extraction or by filtration when added 
in supported form on fluorous silica gel. Catalyst 1.29 has also been shown to be 
recyclable and able to be reused five or more times. 
Piers and colleges reported in 2004 the ruthenium-based metathesis catalyst 1.30 that has 
comparable catalytic activity to the Schrock family of catalysts but retains the favourable 
functional-group tolerance of a ruthenium-based system. 61 Catalyst 1.30 is a four-
coordinate, 14-electron phosphonium alkylidene that is synthesised by the transfer of the 
trialkylphosphine ligand onto the carbide atom using [H(OEt2)2t[B(C6F5)4r. The 
increased activity of 1.30 relative to 1.17 is due to the lower energy barrier required for 
olefin binding since ligand dissociation is not required to form the catalytically active 14-
electron species (step A, Figure 1.2). Catalyst 1.30 has been shown to be stable to ambient 
moisture and oxygen, and olefin-metathesis reactions with it have been shown to be high 
yielding at both refluxing and ODC temperatures. 
Ruthenium is the preferred metal centre for olefin metathesis catalysts. This is 
predominantly due to the exceptional functional group tolerance, rather than catalytic 
reactivity of ruthenium-based catalysts. A study of the reactivity of various mono-metallic 
catalytic complexes towards different functional groups has been carried out. 62 This study 
revealed that titanium and tungsten complexes react with groups such as acids, alcohols, 
water, aldehydes, ketones, and amides all in preference to olefins. However, molybdenum 
complexes are more reactive towards olefins but still react with polar or protic groups in 
preference. Ruthenium complexes react preferentially with carbon-carbon double bonds 
over most other species, so have excellent functional group tolerance in metathesis 
reactions. 
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The continued development of olefin metathesis catalysts has made it evident that some 
have a higher catalytic activity in certain types of metathesis reactions, for example CM, 
RCM, ROMP, or EYN. A number of catalysts are now available that have different 
. catalytic activities specifically designed towards different types of alkenes, for example 
tetra-substituted double bonds vs. unsubstituted, or electron withdrawing vs. donating 
alkene substrates. Eventually catalysts could be matched to specific metathesis reactions, 
to allow for good functional group tolerance, desired reaction temperature and solvent, and 
to give quantitative yields of easily purified products every time. 
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"First Generation" Catalysts 
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CI .... I =="'Ph 1.13 
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CI/ I Ph 
PCY3 
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~ /; 
Figure 1.4. Ruthenium-based olefin metathesis catalysts 
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1.4 REACTION SCOPE AND CONDITIONS 
While a variety of conditions have be.en employed in metathesis chemistry there are some 
standard techniques that tend to optimize reaction yields. These are based on factors that 
are known to influence the outcome of metathesis reactions as discussed in this section. 
The efficient formation of coupled products in metathesis reactions can be facilitated by 
the removal. of the olefinic byproduct when this is a volatile compound. For example, the 
conversion of vinylsilanes into CM products is quantitative when ethylene gas is removed 
(using a gentle stream of an inert gas). Yields can decrease considerably to around 20% in 
the absence of purging.13 A static vacuum can also be used to remove the ethylene gas 
when metathesis is carried out with low viscosity oils in solvent free conditions. 63 
The most commonly utilized catalysts 1.10 or 1.17 have predominantly been used in either 
DCM, carbon tetrachloride, benzene, or 1,2-dichloroethane, at both reflux and at room 
temperature. It is important to note that catalyst 1.17 is more thermally stable than catalyst 
1.10, and as such reactions at reflux are best carried out using this catalyst. The use of 
reflux over room temperature conditions has the added advantage of making byproducts 
such as ethylene more volatile, thus thermodynamically driving the catalytic cycle. The 
yield of a particular cross-coupled metathesis product can often be influenced by the 
number of equivalents of alkene substrates used. For example yields of products in CM· 
can be improved by increasing the number of equivalents of one terminal alkene coupling . 
partner (see Figure 1.5). 
The most effective molarity range of Grubbs second generation catalyst 1.17 is in the 
region of 5 mol% to 20 mol% relative to the alkene substrate. 17 Lower equivalents of 
catalyst 1.17 generally result in sluggish reactions with very low yields of product, 
however higher equivalents can give rise to side products in which the benzylidene group 
from the catalyst is transferred to the alkene substrate. 
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Isolation and purification of the olefm product from reactions involving catalysts 1.10 and 
1.17 is often difficult due to the presence of residual ruthenium. As such a number of 
experimental techniques have been developed to aid catalyst by-product removal. Georg 
and co-workers developed an effective method for removing catalyst 1.10 from crude 
RCM reaction mixtures. Here, the crude product is stirred in trimethylphosphine or 
dimethyl sulphoxide (DMSO) and the resulting complex is removed by filtration through 
silica ge1.64 Maynard and Grubbs reported a method in which residual ruthenium 
bypro ducts from 1.10 are removed as water soluble ruthenium tris(hydroxymethyl) 
phosphine cbmplexes.65 However, this method has the draw back that many equivalents of 
the expensive phosphine ligand are required. Residual ruthenium, and other highly 
coloured impurities, can also been effectively removed from crude reaction mixtures by 
oxidation with a small amount of Pb(OAc)4 followed by filtration through a silica plug.66 
Such experimental techniques for the removal of residual ruthenium from crude reaction 
mixtures are somewhat redundant with the advent of catalysts such as 1.20, as this catalyst 
can be separated from reaction mixtures by silica gel based chromatography for recycling. 
The growing number of solid-phase metathesis catalysts such as 1.26, 1,27, and 1.28 also 
reduces the need for extra purification measures, as alkene products can be washed from 
the solid-supported catalyst. 
Various additives have been used to enhance metathesis reactions, for example CuCI, 
Ti(OiPr)4, and F3CC02Li have been used in RCM reactions of modified peptides.67 The 
role of CuCI in enhancing RCM is not completely understood, but it is believed that 
complex formation with the ruthenium species results in a more stable active catalyst. The 
use of Ti(OiPr)4 or F3CC02Li as an additive has been shown to increase RCM product 
yields of peptide-based substrates.67 This is proposed to be due to the co-ordination of 
titanium or lithium to the carbonyl functions of the peptide, thereby preventing undesirable 
carbonyl interaction with the catalyst. 
Microwave-promoted metathesis reactions have also been utilized as an alternative to room 
temperature or thermally heated reaction conditions.3 Microwave energy allows for shorter 
reaction times and lower catalyst loadings. RCM of tri- and tetra-substituted alleene 
substrates containing electron-withdrawing groups has been shown to be far superior using 
microwave reaction conditions.68 The effect of thermal versus non-thermal microwave 
effects on enhanced reaction times and yields has been studied.69 Recently, solvent-free 
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microwave-assisted RCM reactions have also been reported,70 further adding to the "green 
chemistry appeal" of olefin metathesis. In this thesis, a cyclic lysine-based compound 
(4.6) was synthesised using microwave conditions. 
A number of these optimized conditions were used in metathesis reactions carried out in 
this thesis. These included the use of 20 mol% of catalyst 1.17 in refluxing DCM, along 
with a gentle flow of argon to remove the ethylene byproduct from the reaction mixture. 
Following metathesis the crude reaction mixtures were treated with 50 equivalents of 
DMSO relative to catalyst 1.17 to aid in the removal of catalyst by-products. 
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1.5 CROSS METATHESIS 
Early reports of CM involved coupling of allyl methyl sulfide with unfunctionalised 
alkenes using a tungsten-carbene complex,28 or the CM of styrene using Schrock's catalyst 
1.1. 71 Since this time CM has evolved into a highly practicable synthetic tool due to the 
availability of catalysts that provide excellent functional group tolerance, good product 
yields, and an ability to operate under mild reaction conditions (see section 1.3 for catalyst 
discussion). 
A limiting factor in the application of CM to many synthetic processes is the lack of 
predictability of product selectivity and stereochemistry. A general model for selectivity in 
CM was reported by Grubbs and Chatterjee et al in 2003.72 This model, summarised in 
Table 1.1, groups alkenes into four Types based on their relative ability to homodimerise 
and the susceptibility of their homodimers towards secondary CM reactions. This model .. 
also related the olefin Type to reactivity with either catalyst 1.17 or 1.10, which can allow 
for selectivity in a CM reaction based on advantageous catalyst choice. 
Olefins of Type I (e.g. sterically unhindered, electron-rich) undergo rapid metathesis to 
form homodimers, which can then participate in secondary CM with another olefin. Type 
II olefins have slower homodimerisation rates than Type I olefins, and homodimers of this 
type rarely participate in secondary metathesis reactions. Type III olefins are unable to 
form homodimers in the presence of 1.17, 1.10, or 1.1 but can undergo CM with ole fins of 
Type I or Type II. Type IV ole fins (e.g. sterically hindered, electron-deficient) can not 
participate in CM reactions with these catalysts, but do not have a detrimental effect on 
catalyst activity. 
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Olefin 
Grubbs 2nd generation 1.17 Grubbs 1 st generation 1.10 Schrocks 1.1 
Type 
Terminal olefins, 1 ° allylic Terminal olefins, allyl silanes, 1° Terminal 
alcohols, allyl boronate esters, allylic alcohols, ethers, esters, olefins, allyl 
styrenes (no large ortho. substit.) allyl boronate esters, allyl halides silanes 
Type I esters, ally halides, allyl silanes, 
allyl phosponates, allyl silanes, 
allyl phosphine oxides, allyl 
sulfides, protected allyl amines 
Styrenes (large ortho. substit.), Styrene, 2° allylic alcohols, vinyl Styrene, allyl 
acrylates, acrylamides, acrylic dioxolanes, vinyl boronates stannanes 
acids, acrolein, vinyl ketones, 
Type II unprotected 3° allylic alcohols, 
vinyl expoxides, 2° allylic 
alcohols, perfluorinated alkane 
olefms 
1, l-disubstituted olefins, non- Vinyl siloxanes 3° allyl amines, 
bulky trisub. olefins, vinyl acrylonitrile 
Type III phosphonates, phenyl vinyl 
sulfone, 4° allylic carbons, 3° 
allylic alcohols (protected) 
Vinyl nitro olefins, trisubstituted 1, l-disubstituted olefins, disub. l,l-disubstituted 
allyl alcohols (protected) a, ~-unsaturated carbonyls, 4° olefins 
Type IV allylic carbo-containing olefins, 
perfluorinated alkane olefins, 3° 
allyl amines 
* 
IL Table adapted from Grubbs and Chaterjee et al. See references therem for examples of . 
CM reactions with above functional groups. 
Table 1.1. Model for olefin selectivity in CM 
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Reaction between equal amounts Type I olefins results in a statistical distribution of 
metathesis products. The yield of the cross-coupled R1CH=CHR2 product can be 
improved by using more equivalents of one of the Type I olefin substrates, for example 
R1CH=CH2, as shown in Figure 1.5. 
=RI:=RZ eM product yield 
I 1 R~Rl 1:1 50% • 
Rl~ rR2 eM [Rl~R21 2:1 66% + 10 
4:1 80% 
Type I Type I 
R2~R2 10:1 91% 
20:1 95% 
Figure 1.5. Statistical distribution of CM products of olefin Type I 
Olefins of different Types can react in an equi-molar fashion to selectively produce a 
higher cross-coupled product yield, compared to equi-molar reaction of olefins of the same 
Type. For example in a reaction between a Type I and Type II olefin, although the Type I 
olefm may initially homodimerise, the type I homodimer then undergoes secondary 
metathesis with the Type II olefin to form the cross-coupled product. 
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1.5.1 Application of cross metathesis to modified amino acids 
Work in this thesis describes the use of eM to amino acids suitably substituted with an 
olefin functionality. What follows is a summary of previous work involving the use of eM 
coupling reactions with various derivatised amino acids. 
eM has attracted considerable attention as a means to prepare modified amino acids and 
peptidomimetics that possess useful chemical and biological properties. eM reactions with 
amino acid substrates can be categorized based on the position of the olefin substitution. 
For example, a substituent bearing a terminal double bond can be attached at either the (i) 
a-carbon, (ii) amino acid side chain, (iii) amino-terminus, or (iv) carboxyl terminus of an 
amino acid. Reactions can be further classified on the basis of the type of amino acid used. 
a-Carbon Substituted Amino Acids 
Modified glycine has proven to be a popular scaffold for eM chemistry. The first 
examples of eM using amino acid-based substrates were published by Gibson and co-
workers in 1997, where cross-coupling to styrene was described.33 This was followed soon 
after by further systematic studies involving eM of glycine-based 1.31a-c to propene 1.32 
(Scheme 1.1).32 A four-chain alkene tether as in 1.31c gives the highest cross-coupled 
yield. 
(~ 
BOC'-.NXC0
2
Me ~ _1_.1_0_' C_I_CH_2_C_H_2C_I,_ ...... 
H rt, N2 stream 
1.31a-c 
Scheme 1.1. 
1.31a 
1.31b 
1.31c 
n 
o 
1 
2 
1.33a-c 1.34b-c 
eM product 8M dimer 
1.33a,7% 
1.33b,45% 
1.33c, 66% 
1.34b,17% 
1.34c, 28% 
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Heterocycles have also been successfully coupled to allyl glycine. For example, racemic 
methyl N-acetylallylglycinate 1.35 was coupled to 2,8-diallyldibenzothiophene 1.36 as a 
key step in the preparation of antibiotic agents 1.37 and 1.38 (Scheme 1.2).73 
Ac'N~O'M' 
H 
1.35 
Scheme 1.2. 
~-~ 
II ~s.J0 II 
1.36 1.37,13% 
1.10, OCM, reflux 
1.38,41% 
eM reactions have been used as a preliminary step in developing methodology for the 
catalytic cyclisationlcleavage of tetrapeptide-derived macrocycles from solid supportS.74 
Here, the side-chain of Fmoc-allylglycine methyl ester 1.39 was selectively coupled to 0-
trityl-protected alkenols 1.40a-b of differing chain lengths (Scheme 1.3). This gave rise to 
eM products 1.41a-b that were subsequently deprotected, resin-linked, and incorporated 
into tetrapeptides. 
Fm"'N~Me 
H 
1.39 
Scheme 1.3. 
OTr 
r)n n = 1, 8 
1.40a-b 
1.10. OCM, reflux 
I~ FmOCY(~'Me 
H 
1.41a-b, both 75%, EIZ 2:1 
eM of allylsilane substrates gives rise to eM products that can be further elaborated via 
the silyl group. In one example, protected vinyl glycine 1.42 was functionalised using allyl 
trimethyl silane 1.43 in excellent yield and with good stereo selectivity (Scheme 1.4).75 
More recently, Blechert and co-workers employed the second generation catalyst 1.20 for a 
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highly selective CM of protected amino acid 1.31b and acrylonitrile 1.45 - reactions that 
could previously only be achieved using sensitive molybdenum catalysts (Scheme 1.4).42 
Cbz .... N,(02Me 
~SiMe3 LSiMe3 
1.43 
Cbz .... N C02Me II 
H 1.10, DCM, reflux H 
1.42 1.44,95% 
(CN CN 
"OO'N{eO'M' "oe'N(o,M' 1.45 ,. 
H 1.20, DCM, reflux H 
1.31b 1.46,83%, EIZ3:1 
Scheme 1.4. 
Roy and co-workers carried out CM of protected allylglycine 1.47 with suitably substituted 
monosaccharide 1.48 to give C-linked carbohydrate 1.49 that possesses stability towards 
enzymatic and metabolic cleavage (Scheme 1.5).76 Reactions of this type provide 
convenient access to important glycopeptidomimetics, where the parent glycopeptides are 
known to play an important role in a number of important biological processes including 
tumor metastasis and chemotaxis. A series of glycoamino acids (2.80 2.85) were 
prepared in this thesis using CM coupling, as is described in Chapter 2. 
Scheme 1.5. 
eb"N~O'"O 
H 
1.47 
OBn OBn 
A p~OBn 
(~OBn 
1.48 
1.10, DCM, reflux 
~~~O 
eM 'Ni~o,"o 
H 
1.49,60%, BZ 4:1 
Nolen and colleagues have reported the synthesis of C-glycosyl amino acids in good yields 
using Grubbs second generation catalyst 1.17 (Scheme 1.6).77 Here, CM of tetra-O-
protected-glucose substrates 1.51a-d with vinylglycine derivatives 1.42 and 1.50a-b 
Chapter One - Introduction 22 
proceeded efficiently, and the products obtained (1.52a-d) were hydrogenated to give C-
glycosyl asparagines as models for use in enzyme assays. 
R\'N,(02R2 
H 
1.42, 1.50a-b 
1 
-------.. '" R 'N 
1.17, oeM, reflux H 
1.52a-d 
Vinyl glycine Rl R2 Carbohydrate R3 CM product 
1.42 Cbz Me 1.51a Ac 1.52a,82% 
1.42 Cbz Me 1.51b Bn 1.52b,64% 
1.50a Boc Bn 1.51c Ac 1.52c, 94% 
1.50b Fmoc Bn 1.51c Ac 1.52d,77% 
Scheme 1.6. 
C-Glycosyl amino acids can also be prepared by reaction of N-Boc-vinyloxazolidine 1.53, 
a vinylgylcine equivalent, and sugar 1.51 b using Grubbs second generation catalyst 1.17, 
where 1.10 does not catalyse these reactions (Scheme 1.7).78 The resulting metathesis 
product (1.54) was hydrogenated, acylated, and the oxazolidine ring oxidatively cleaved to 
afford a versatile building block (1.55) for the synthesis of modified glycopeptides. eM of 
vinyl glycine derivatives with allylated sugars has also been carried out by Ben and Liu, in 
a study directed towards the development of recrystallisation inhibitors. 79 
8OCN~ 
-To 
1.53 
Scheme 1.7. 
~OBn o OBn OBn OBn  1.51b 
1.54,50%, EIZ 5:1 
--
---ilo'" Boc'N 
H 
1.55 
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Danishefsky and co-workers have synthesised glycosyl ammo acids 1.58a-d via eM, 
which are suitable for incorporation into polymeric antitumour vaccines (Scheme 1.8).80 
Here, Fmoc-L-allylglycine benzyl ester 1.56 was coupled to O-allyl glycosides 1.51c and 
1.57a-c to give the desired eM products in good yields. 
OR OR 
FmOO'N1CQ'B' ( FmO"NIa,B, 1.51 c, 1.57a-c 
.. H H 
1.10, oeM, reflux 
1.58a-d, yields 66 " 70% 1.56 
Q~ ~ \ 0 0 OAeOAe AeO 0 AoO~ AeO 1.57a AeO 0 OAe 
AeO ~ ~ OAe 
1.51c AeO 0 O~ 
R= AeO AeO 
OAe 
1.57b 
OAe OAe AcO OAe ~~e ACO~o~O~ 
-r-o-t, NHA, A:oO\G:o~ (Q~' , 
~ 1.57c AeO AeO~ 
OAe OAe 
Scheme 1.8. 
Other reports on the synthesis of stable glycopeptide analogues using eM methodology 
have appeared with a view to identify potential therapeutic agentsY For example, 
protected C-allyl glycoside 1.60 has been coupled to protected allylglycines 1.59 and 1.39 
using Grubbs second generation catalyst 1.17 - introduced in two equal portions at 24 hour 
intervals - to give moderate-to-good overall yields of coupled products 1.61a-b (Scheme 
1.9). This initial work was extended to allow the conjugation of C-allyllactose as a first 
step in the development of a post-translational glycopeptide synthetic strategy. 
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AcO 
~-"£..-OAeO~OAe 
~I AeO OAe 
AcO 
..-r'-"£..-OAeO~OAC 
AcO OAe 
~_ 1.60 
R'N COzMe ---1.-17-,-D-CM-, r-ef-Iu-x,----.... R'N C0
2
Me 
H H 
1.59, R = Boc 
1.39, R = Fmoc 
Scheme 1.9. 
Side Chain Substituted Amino Acids 
1.61a, R = Boc, 73%, 
1.62b, R = Fmoc, 57% 
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The amino acid serine has been used as a basis for side-chain installation of an olefin 
tether, to give a substrate suitable for CM. Grubbs and colleagues have explored a number 
of examples of CM reactions of serine derivatives with both terminal and substituted 
alkene coupling partners.63 Allyl ethers of protected serine 1.62a and homo serine 1.62b· 
were dimerized by CM under reduced pressure to give dimeric 1.63a-b, while treatment of 
Boc-L-serine( O-allyl) methyl ester 1.62a with bis(9-nonenyl acetate) 1.64, itself made by 
CM, generated lipophilic amino acid 1.65 in high yield and with good stereoselectivity 
(Scheme 1.10). Larger and more complex architectures were also shown to be compatible 
with CM chemistry, for example hydrophobic pentapeptide framework 1.66 (Scheme 
1.10).63 The dimerized pentapeptide 1.67 represents an example of side chain to side chain 
cross linking via a non-native carbon-carbon linkage. The application of CM to the 
formation of amino acid dimers was also investigated in this thesis, and this work is 
discussed in Chapter 3. 
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(tlnO 
BOC'NA C02Me 
H 
1.62a, n:=1 
1.62b, n:=2 
( 
o 
BOC"-Nf C02Me 
H 
1.62a 
Scheme 1.10. 
r=l 
1.10, neat, rt ~O O'y 
--------"'''"" ( n )n 
60-100 mTorr BOC'N C02Me Me02C N;BOC 
ACO~OAC 
1.64 
1.10, OCM, reflux 
H H 
1.63a, 73%, EIZ 2.6:1 
1.63b, 75%, EIZ2.7:1 
~OAC 
o 
BOC'NicozMe 
H 
1.65, 86% yield, EIZ 6:1 
1.67,85%, EIZ3:1 
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Aryl substituted C-fucopeptides 1. 70a-g have been synthesised using eM methodology 
(Scheme 1.11).82 These products are important in that they mimic tetrasaccharide sialyl 
Lewis X, a carbohydrate-based terminal unit found in cell-surface glycoproteins and 
glycolipids, which interacts with E- and P-selectin to mediate the early stages of an 
inflammatory response. It was found that eM at room temperature failed to give the . 
desired coupled products. However, reaction between 1.68 and 1.69a-g at reflux afforded 
an array of eM products in reasonable yields, with the electron poor pentaflurostyrene 
giving the lowest yield. The authors noted that activated aromatic and non-aromatic 
olefins gave a mixture of and Z olefins, with non-activated aromatic olefins strongly . 
favouring the E olefin. 
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1.68 
R 
Bn 
4-MeOC6~ 
C6FS 
2-Naphthyl 
2-Fluorenyl 
4-BinaphthyJ 
Scheme 1.11. 
~R 
1.69a-g 
1.10, OCM, reflux 
eM yield (%) 
65 
79 
17 
71 
70 
73 
26 
""O~R 
1.70a-g 
EIZratio 
72:25 
87:13 
70:30 
>95:05 
>95:05 
>95:05 
Tyrosine-based systems have also been used in CM dimerisation reactions, where the 0-
allyl tether of 1.71 is of sufficient length to allow CM reactions to proceed to afford 
dimeric 1.72 (Scheme 1.12).63 By contrast, the analogous dimerisation of Boc-L-
allylglycine methyl ester 1.59 does not proceed well, where the close proximity of the 
double bond to the amino acid backbone appears to hinder catalyst binding. 
( 
a o 
BOC'-N--Cc:e 
H 
1.71 
Scheme 1.12. 
1.10, OCM, reflux 
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N-Terminus Substituted Amino Acids 
There are comparatively far fewer examples of eM reactions of an olefin attached to the (l-
nitrogen of an amino acid or peptide. Nevertheless, the eM of N-alkenylpeptoids 1.73 and 
O-allyl glycoside 1.51c has been reported by Hu and Roy to give glycopeptide 1.74 
(Scheme 1.13).83 The reaction is tolerant of free carboxylic acids, but not of secondary 
amine functionalities. It was found that a shorter tether between the nitrogen and the 
double bond results in a lower yield of the desired eM product. 
3 H ~~l(N'./C02Me 
Fmoc 0 1.10, OCM, rt 
1.73 
Scheme 1.13. 
C-Terminus Substituted Amino Acids 
eM at the C-terminus of suitably substituted amino acids and peptides has also been 
reported. For example, 9-decen-I-yl Boc-glycinate 1.75 reacts with 9-decen-l-ylacetate 
homodimer 1.64 in the presence of catalyst 1.10, to give a differentially functionalized 9-
octadecene-l,18-diol1.76 (Scheme 1.14).63 Glycine derivative 1.75 also undergoes self-
metathesis to give amino acid homodimer 1.77 in excellent yield. 
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BOC'N~O~ 
H g 8 
1.75 
BOC'N1r°~ 
H 0 8 
1.75 
Scheme 1.14. 
AcO~OAC 
1.64 
1.10, DCM, reflux 
1.10,60-100 mtorr, rt 
Boc'Nl(O~~Ac 
H 0 
1.76,72%, EIZ3.5:1 
1.77,93%, EIZ 5;1 
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c-Tenninally substituted eM reactions have also been extended to the solid phase using a 
polystyrene (1% DVB) resin.84 These resin-bound amino acids and peptides can be 
chemically manipulated and subsequently cleaved from the resin. Schreiber and 
colleagues also report solid phase "intra-site" eM reactions, in near quantitative yields, 
using individual polystyrene polymer beads with a silyl linker (Scheme 1.15).85 It was 
found that the alkyl chain length of 1.78 had little effect on the reaction efficiency. Here, 
the metathesis step to give 1.79 is effectively a ReM reaction, and once the product is 
cleaved from the resin gives the analogous solution phase eM product (1.80). 
~ 
~o~o 
o JNH 
( Fmoc 
Fmoc'N)YO~ 
H 0 ( n 
1.78 I 
o 
Cleavage 
1. HF-Py, THF, rt, 2h 
2. TMSOMe, rt 1h 
Scheme 1.15. 
1.10, OCM, reflux 
= PS (1% OVB) 
1.80 n = 1-3, 7 
near quantitative yields 
EIZ 3:1 
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1.6 RING-CLOSING METATHESIS 
Currently RCM is the most commonly used type of olefin metathesis transformation. A 
number of reviews have been written outlining the reaction scope and wide range of 
substrates that have been constructed using RCM - these include a review on the 
application to heterocycles, alkaloids, and peptidomimetics,86 rigidified amino acids and 
peptides,87 advances in organic synthesis,88 relay RCM for sterically hindered substrates,89 
and cyclic peptidesYo Reviews have also been written that discuss the synthesis of 
oxygen- and nitrogen-containing,91 or phosphorus and sulfur containing92 heterocycles via 
RCM. 
1.6.1 Application of ReM to modified amino acids and peptides 
The use of peptides in drug discovery and therapeutics is often limited by their poor 
bioavailability and proteolytic degradation. RCM is used in the construction of· 
peptidomimetics * for two reasons93,94 - 1) the incorporation of a double bond to help· 
prevent proteolytic cleavage and assist in vivo stability; 2) to restrain the structure into a 
biologically advantageous conformation, for example a fi-turn conformation. Cyclic 
peptidomimetics can be synthesised in many ways other than using RCM, for example by . 
peptide bond formation.95-97 In this thesis the application of RCM to side-chain modified 
amino acids and peptides is examined. What follows are selected literature examples 
demonstrating the use of RCM on various modified amino acids and peptides, illustrating 
the potential scope of this reaction. 
The development of small molecule peptidomimetics based around the fi-turn Pro-Phe 
dipeptide are useful as therapeutics, as this is the peptide bond that is cleaved by HIV-I 
protease. Inhibition of this protease has been shown to be a promising treatment against 
the HIV virus.98 Iqbal and co-workers synthesised the fi-tum mimic 1.82 from pent-4-
enoyl-L-Phe-L-Pro-N-allyl amide 1.81 (Scheme 1.16).99 The importance of chirality of the 
phenylalanine residue was demonstrated by the fact that ReM did not take place using 4-
enoyl-D-Phe-L-Pro-N-allyl dipeptide. This suggests that acyclic diene 1.81 contains some 
• A peptidomimetic is defined as a non-peptide substance that has an analogous structural and/or secondary 
structure to a parent peptide, that allows it to behave in biological systems in a likewise fashion. 
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structural pre-organisation that favours RCM. Fused bicyclic lactam 1.84 has been 
enantiomerically prepared by RCM of 1.83, which was also designed as a f3-turn Pro-Phe 
dipeptide mimic. lOa Conformational analysis of 1.84 by NMR and MD calculations 
confirmed a well-defined f3-turn mimic conformation. Proline-based lactam-bridged type 
VI f3-turn model systems such as 1.86 have also been synthesised by Gmeiner and 
colleges. 101 Here three cyclic structure 1.86 was prepared in good yield by RCM of 1.85. 
Scheme 1.16. 
HN~CY t:: H< 
1.81 
~C02Me 
~O 
C (\HCbz 
Ph 
1.83 
1.10, OCM, reflux 
1.17, toluene, reflux 
J PONH2 d ,,- 1.10, OCM, reflux 
- p --_II 
~,\\\' 
C02Me 
1.85 
HN~~O 
~ 
1.82,68%, E:Z=4:1 
1.84, • R, 85%, 'S, 81% 
(pONH' 
C02Me 
1.86,75% 
Moeller et at have devised a general strategy for the synthesis of bicyc1ic lactam peptide 
building blocks by RCM in an effort to build constrained peptidomimetics of the endocrine 
hormone thyroliberin. ]02 Diene 1.87 was submitted to RCM to give the cyclic product in 
good yield, and this was hydrogenated to afford lactam 1.88 (Scheme 1.17). Lactam 1.88 
was coupled to pyroglutamic acid in several steps to give 1.89, This was used in biological 
studies to investigate the preferred binding conformation at the endocrine receptor TRH-R. 
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H ° BOC-~ PONHz 1) 1.10, OCM, reflux, (62%) 
Ph'''' 0 2) 5% Pd/C, MeOH (93%) ,. # ", \\ 
1.87 1.88 1.89 
Scheme 1.17. 
Yamanaka and colleges synthesised cyclic mimics of a ,a-turn sub-structure of Arg-Gly-
Asp on route to non-peptide platelet aggregation inhibitors (Scheme 1.18).lO3 7- And 8-
membered containing 1.91a-b were prepared in good yields from ~-amino acid-type 
precursors 1.90a-b, both in enantiomerically pure form. The oxazolidinone chiral auxiliary 
is subsequently cleaved from 1.91a-b to give the target compounds. 
Scheme 1.18. 
(~ ) oro 
BOc/NJyN; 
° CH2Ph 
1.90a-b 
1.17, OCM, reflux (£l;°rJO /N N 
Boc 
° CH2Ph 
1.91a, n = 1, 97% 
1.91b, n = 2,96% 
A range of cyclic ~-amino acids have been synthesised using RCM. Pyrrolidine 1.93 and 
piperidine 1.95 ~-amino esters have been synthesised by RCM of acyclic precursors 1.92 
and 1.94 (Scheme 1.19).104 Compounds such as 1.93 and 1.95 are useful building blocks in. 
the synthesis of complex natural products containing ~-amino acid functionalities. Abell 
and colleges have reported a versatile method for the preparation of functionalised cyclic 
~-amino acid esters from methionine, allylglycine, and serine starting materials. !Os ~­
Amino acid ester diene 1.96, synthesised itself from allyl glycine, underwent RCM to 
afford 6-membered derivative 1.97 in high yield (Scheme 1.19). Diene 1.98, synthesised 
itself from methionine in several steps, afforded the RCM product 1.99 that contained a 5- . 
membered ring also in very high yield. 
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Scheme 1.19. 
~~~Ph 
~C02tBu 
1.92 
~~~Ph 
~C02tBu 
1.94 
) fr CbZHN~Me 
C02Me 
1.96 
CbzHN 
1 
",f ~Me 
Me02C 
1.98 
1.10. DCM, reflux 
1.10, DCM, reflux 
1.17, benzene, reflux 
'" 
1.17, benzene, rt 
CN~Ph 
"'" ..--C02fBu 
1.93,76%, >95% d,e, 
Cb'HNYM' 
C02Me 
1.97,96% 
CbzHN 1) /7<Me 
Me02C 
1.99,93% 
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Fustero and co-workers have applied ReM chemistry to the diastereoselective synthesis of . 
seven-membered difluorinated ~-amino acid derivatives. 106 Fluorinated ~-imino esters 
1.100 were cyclised to give 1.101, the imine reduced to give exclusively the cis-amino 
isomer, and then amino deprotected to give fluorinated ~-amino acid mimics 1.102 
(Scheme 1.20). 
N,Ar Ar 
R' 1.17, DCM,reflux ~F C02R ------_)00 F U C02R I I 1.101 
NH2 
_1_)_R_ed_u_cl_io_n_ ..... '" FVYC02R 
2) Deprotection U 
1.102 
1.100 Ar = p-MeOCsH4' p-FCsH4 
R = Et, Bn 
Yields 65-90% 
Scheme 1.20. 
Reichwein and Liskamp synthesised various cyclic dipeptides using an amide-to-amide .. 
ReM cyclisation strategy: N-diallylated diene 1.103 was cyclised using ReM to afford 
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constrained peptides 1.104 that contained an 8-membered ring. The yields of cyclic 
products were dependent on the different substituents used (Scheme 1.21).67 
1.10, TCE, reflux 
Scheme 1.21. 
R1, R2= H, Bn, i-Bu 
R3 = Me, Et 
Yields 27-73% 
Spiroannulated cyclic dipeptides 1.106 have been synthesised by Efskind et al as 
precursors of conformationally restricted cyclic a-amino acids (Scheme 1.22). t07 The 
same authors also report a RCM cascade reaction in the formation of two-ring bisamino 
acid derivatives 1.108a-b that are interconnected by a C4-C6 bridge. t07 Spirocyclopentane 
1.110, designed as a rigid dipeptide mimic, has been synthesised by Scolastico and co-
workers using RCM from diene 1.109 in good yield (Scheme 1.22).100 
~ ~Ny= O_.M ..e_ /. L N" OMe ~ _~ 1.10, DCM, reflux ~ h 
MeO N ~ -.~-------l"'" MeO~N y 
OR OR 
1.105 1.106 
1.10, toluene, reflux 
R = OH or CH20H 
yields 71-75% 
1.108a, n:: 1, 86% 
1.108b, n:: 2,85% 
Scheme 1.22. 
~ 1.10,DCM,rt 
o N C02Me ~~---~ .. 
I Boc 
1.109 
~CO'''' 
I Boc 
1.110,83% 
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a,a-Disubstituted glycines that bear a large hydrophobic ring have been synthesised using 
ReM. 108 The ReM reactions were calTied out on malonate derivatives 1.111 to give cyclic 
products 1.112, with the amide functionality subsequently introduced in several steps to 
give 1.113a-c (Scheme 1.23). The stability of an a-helical 17-amino acid peptide was 
enhanced by the replacement of two alanine residues with two Fmoc a,a-disubstituted 
cyclic residues 1.113b bearing a cyclic I8-membered ring. 
'\ (' . 1.10,DCM, Q 
m(Q {J) n -------ill>.... m( () n 
_X_ reflux 
R 1 02e C02R2 R 1 02C C02R2 
1.111 
1.112 
m =6, 9 
n = 6, 9 
Rl, R2 = Me, Et, Sn 
Yields 43-93%, E/Z 1:1 to 17:3 
(-~~ several step! ~ 15 . 1 ( 
-~ FmocHN" /CI0 2H FmocHN C02H FmocHN C02H ./<...., 
1.113a 1.113b 1.113c 
Scheme 1.23. 
The tripeptide allylic ester 1.114 undergoes ReM to give novel 16-membered cyclic-based 
structure 1.115 (Scheme 1.24).109 The tripeptide ReM substrate 1.114 was itself 
synthesised in single step in an U gi reaction. 
1.114 
Scheme 1.24. 
X·OMe I ~i 1.10, tolUene, rt ... N~~' 
~oOoA9 \--~'VO~ 
o 
1.115,37%, only E isomer 
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A bicyclic side chain knotted pentapeptide has been constructed by Liskamp and colleges, 
to mimic the structure of the glycopeptide antibiotic vancomycin (refer to 2.1, Figure 2.1). 
Bis-RCM precursor 1.116, containing a central di-alkylated aromatic core and two 
allylated serine residues, was cyclised in one step to give knotted peptide 1.117, which 
contains the same side-chain connectivity as vancomycin (Scheme 1.25).110 The RCM was 
carried out in the presence of a small amount on DMF because of the poor solubility of 
1.116. Consequently, a stoichiometric amount of catalyst 1.17 was required for RCM to 
occur since DMF also deactivates the ruthenium catalyst. 
OH ~ ~ 
.4- 0, 1.17, CI2CHCH2CI, DMF 
o H : ........ .. 
~N = 
N :; nNHBOC 
H :; 0 
o H 0,:: 
~N = 
N : nNHBoc 
H : 0 
1.116 1.117,67% 
Scheme 1.25. 
Liskamp and co-workers have synthesised a cross alkene-bridged hexapeptide in a single 
step with two RCM reactions. lll The tethered amino acid side chains that cross over each 
other provide a mimic of the lantiobiotic nisin Z, which contains a thioether "knot" of the 
same geometry. Protected peptide 1.118 was submitted to RCM with 1.17 and the desired 
bicyclic product 1.119 was obtained in 72% (Scheme 1.26). The predominance of product. 
1.119 over other cyclic isomers was consistent with molecular mechanics calculations 
which demonstrated that the corresponding monocyclic precursors to 1.119 had lower 
energy intelmediates than other possible RCM monocycles. 
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1.17, DeM 
1.119,72% 
Scheme 1.26. 
There are many instances in which a disulfide bond between thiol residues in cysteine-
containing peptides has been mimicked using a C-C bond generated by RCM. The 
disulfide bridge of many peptides serves a skeletal role only, such that it can be replaced 
with a non-reducible structural mimic without significantly altering biological activity. For 
example, a synthetic analogue of the tetradecapeptide somatostatin 1.122 has been 
synthesised where the S-S bond was replaced by a C-C double bond (Scheme 1.27).112 
Resin-bound diene 1.120 underwent RCM, and was then hydrogenated, deprotected, and 
cleaved from the resin to give cyclic 1.121 in moderate overall yield. 
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q. c9NH20 N "HFmoo I 0 \r~, . n ~J ~~ "" n Ij _ ~ HNYf!(~ 0 NX'lCJ: O~ ~ ~ · X lC?::: 1) 1.10 f" 0 NH 
- 0 0 0 NH NBoc _2) Hydrogenation, deprotetct~n 0 ~ ] ~. I 
~ )0 H I cleavage from resin j 1~ Y ~NH2 
°1N N~NHBOC HO "",/NH ~ 0 
O)'j" NH H 0 . OH HO/ ~ OtBu 
OJ"'>:, 0 q 1.121,23% overall yield 
1.120 NH2 I ((.iJ~ ~X'~ o HN ""s 0 0 NH NH 
Scheme 1.27. 
S/ • 
~ 0 H I °0NYyN~NH2 
HOJ)"H H ~OHO 
HO 
1.122 
Bicyc1ic hexapeptides containing a carbon-carbon double bond bridge have been prepared. 
Diene 1.123, assembled on solid-phase, underwent RCM to give cyclic 1.124 (Scheme 
1.28).113 Monocyclic 1.124 was then cleaved from the resin and N- to C-terminal 
cyclisation was carried out in solution phase to give bicyclic hexapeptide 1.125. 
Compounds of this type are rigid fi-tum mimics, that contain two fi-tum units and intrinsic 
C2-symmetry. 
I\N ~~Ph Qy~-<Ph "N~ solution phase ~ 0 FO 
~ 0 0 )10 0 HN 
HN ~~ 0 HN~ peptide coupling "'~_'~"" 
0"'9" ~~"'" 0 0 NH 0 
",J" II O~ 0 N 
Ph" NHBoc GY"o-o Ph"'~~~ 
1.123 1.124 1.125 
Scheme 1.28. 
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Burke and co-workers synthesised constrained (Grb) SH2 domain-binding peptides by 
RCM, where the introduced C-C bond mimics the bend conformation of the natural 
peptide. Dienes 1.126a-b were cyclised using catalyst 1.17 in a high molar amount to give 
cyclic 1.127a-b good yields (Scheme 1.29).1l4 Both 1.127a and 1.127b demonstrated 
significant potency in binding experiments to chip-bound Grb2 SH2 domain proteins 
compared to the analogous unconstrained peptides. 
Scheme 1.29. 
1) 1.17, DCM, 
reflux 
1.127a, *L, 73% 
1.127b, *D, 52% 
Amino acid side-chain to side-chain tethered peptides have been synthesised by Grubbs 
and colleges, based around the hydrophobic hexapeptide Boc-Val-Ala-Leu-Aib-Val-Ala-
Leu-OMe that adopts a 31O-helical conformation in CDCh.115 In the modified peptide, the 
Ala residues were both replaced with either L-serine O-allyl ether in 1.128a or L-
homoserine O-allyl ether in 1.128b (Scheme 1.30). Dienes 1.128a-b were then cyclised by 
RCM and the olefin hydrogenated to give stable helices containing 22-membered (1.129a) 
and 23-membered (1.129b) cyclic structures in excellent yields. 
Scheme 1.30. 
~ ~HBOC CO~~HBOC o n 1) 1.10, CHCb, reflux 
~O ------------_____ • 0 
n CO
2 
Me 2) Hydrogenation n CO
2 
Me 
1.128a 
1.128b 
1.129a, n = 1, 83% 
1.129b, n = 2,88% 
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The many examples presented in this chapter illustrate the applicability of RCM to a wide 
variety of synthetic amino acid and peptide transfonnations. Further discussion on the 
benefits and advantages that RCM provides in the construction of peptidomimetics and 
therapeutics are discussed in Section 4.1, Chapter 4. 
In summary, this chapter discusses the various types of metathesis reactions, in particular 
CM and RCM, and outlines the proposed mechanism of olefin metathesis. An overview of 
the development and properties of metathesis catalysts is also presented. Section 1.5 
discusses the CM of amino acid-based substrates with olefin tethers substituted at different 
positions, for example the a-carbon, C-tenninus, N-terminus, or side-chain. Part of this 
thesis focuses on the CM of amino acid and peptide-based compounds with side-chain 
substituted olefin tethers to important biological molecules such as carbohydrates and fatty 
acids (Chapter 2). Currently there are no general and versatile methods for linking a 
functionalised amino acid side-chain to a target molecule using CM. The synthesis of 
amino acid dimers via the same general CM strategy is also addressed in this thesis 
(Chapter 3). Section 1.6 reviews the application of RCM to amino acid and peptide-based 
substrates. Part of this thesis describes a general and versatile method for the synthesis of 
cyclic compounds containing different ring sizes via RCM from acyclic precursors with 
controllable olefin tether lengths (Chapter 4). This method differs from examples given in 
section 1.6 in that it involves amino acid side-chain derivatisation via acylation with 
variable olefin tethers that can be applied to different types of natural amino acids. 
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2.1 INTRODUCTION 
Modifications to peptides and proteins are important biological events that are involved in 
a wide variety of functions such as structural, signalling and catalysis. The ability to 
synthetically modify an amino acid or peptide by covalent attachment of a target molecule 
is crucial in the development of peptidomimetics and therapeutic agents. Examples that 
have generated widespread interest include the conjugation of amino acids or peptides to 
carbohydrates (glycopeptides) or to fatty acids (lipopeptides). The following section 
details some examples that highlight the importance and synthetic preparation of glyco-
and lipopeptides. 
2.1.1 Applications and Synthesis of Glycopeptides 
Carbohydrates are commonly found conjugated to proteins on cell surfaces, and can playa 
crucial role in processes such as immune recognition.1 Glycoproteins and glycopeptides 
also play key roles in cell-adhesion, protease protection, signalling, protein structure, and 
inflammation processes.2 The degree of glycosylation of a peptide can influence its 
biological function. For example the glycosylation state in disorders such as rheumatoid 
arthritis can greatly affect collagen recognition by the immune system.3 Alterations in the 
glycosylation patterns of surface proteins is evident in cancer as a result of oncogenic 
transformation. I The difference in glycosylation state is also important in the blood group 
types A and B, that differ only by a slight structural variation at the terminal galactose. 
The antibiotics vancomycin 2.1 and teicoplanin 2.2 (Figure 2.1) are important examples of 
glycopeptides that are used extensively for the treatment of Gram-positive bacterial 
infections such as Staphylococcus aureus.4 Vancomycin 2.1 consists of a disaccharide 
covalently linked to residue 4 in the peptide backbone, while teicoplanin 2.2 consists of 
three covalently linked monosaccharides and a CIO fatty acyl chain covalently linked 
through an amide bond to the glucosamine carbohydrate moiety. Both antibiotics consist 
of a heptapeptide scaffold that has undergone extensive oxidative cross-linking, setting the 
rigid architecture of the drug scaffold. The increasing number of cases of antibiotic 
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resistance has lead to the construction of semi synthetic derivatives of vancomycin 2.1 (e.g. 
1.117, Scheme 1.25) and teicoplanin 2.2.5 
2.1 Vancomycin 2.2 Teicoplanin 
Figure 2.1. Structures of glycopeptide antibiotics vancomycin and teicoplanin. 
There is also ongoing interest in the synthesis of smaller glycopeptides, both as direct 
therapeutics and as mechanistic probes for various medicinal applications.6 The chemical 
synthesis of glycopeptides has advantages over isolation from natural sources, as it allows 
for the preparation of well-characterised compounds of high purity and reproducibility. An 
example of glycopeptide synthesis is the construction of a-O-glycosyl-linked serine and 
threonine compounds for the preparation of cancer vaccines.7 Synthetic glycopeptides 
such as these mimic the a-O-glycosyl serine moiety that occurs naturally on the surface of 
tumour cells, and have been conjugated to bovine serum albumin and injected in organisms 
for the induction of antibodies. 8 The following section outlines some common synthetic 
methods used in the key conjugation step of linking an amino acid or peptide to a 
carbohydrate moiety. Glycopeptides are categorized according to the type of atom of the 
amino acid that is conjugated to the carbohydrate. 
O-Linked glycopeptides 
a-O-Glycosylated senne and threonine are frequently used in the construction of 
glycopeptides. They are most commonly synthesised by linking the amino acid side chain 
alcohol group to the carbohydrate anomeric carbon. For example glycosyl bromide 2.4 has 
been coupled to threonine 2.3 to afford protected glycoamino acid 2.5 (Scheme 2.1).7 
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Glycoamino acid building block 2.5 was then incorporated into a peptide sequence to give 
glycopeptide 2.6, which is an example of a tumour-associated mucin-type antigen. There 
are many more examples of other similarly linked threonine or serine glycoamino acids 
synthesised using slightly modified coupling methods.9-11 
HOy 
Fmoc'-NA C02Buf 
H 
2.3 
Scheme 2.1. 
AcO OAc AcO~q ~
Br 
2.4 
AcO OAc AoO~ 3
0 
Fmoc'-NX:0 2Bul 
H 
""I OAe 0 j r AoO~ 
Ac-Ala-Pro-Asp,,- Y Arg-Pro-Ala-Pro-Gly Ny 
H 0 
2.6 
Glycoamino acids have also been synthesised that contain a quaternary a-anomeric carbon 
centre with a vinyl group that can then be further elaborated. Glycosylation of either 
protected serine 2.7a or threonine 2.7b with 2.8 in the presence of boron trifluoroetherate 
proceeds via an allylic rearrangement to give exclusively the a-glycoamino acid products 
2.9a or 2.9b (Scheme 2.2).12 
Scheme 2.2. 
2.7a, R= H 
2.7b, R= Me 
::~OAc::~ 
2.8 0 R 
BF3 'OEtz, molecular sieves .. Fmoc'-NXCOZMe 
H 
2.9a, 83% 
2.9b,70% 
There are some problems associated with O-linked glycoamino acids and peptides despite 
that fact they are effective therapeutic agents as they resemble the naturally occurring 0-
glycoside linkages so closely. Serine and threonine glycopeptides such as 2.6 are 
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susceptible to cleavage in biological systems through acid, base, or enzymatic hydrolysis 
of the O-linked tether that is in the same position as in naturally occurring glycopeptides. 
S-Linked glycopeptides 
Cysteine has been used to construct S-glycopeptides by linkage through the side chain thiol 
group, instead of the alcohol group in O-glycopeptides. One example of many is the 
coupling of activated hexane derivative 2.11 to Boc-L-Cys-OMe 2.10 to give S-glycoside 
derivative 2.12 (Scheme 2.3).13 Compound 2.12 is an example of a modified amino acid 
building block that could be incorporated into a peptide. The same methodology was also 
shown to be applicable to the conjugation of carbohydrate derivative 2.11 to the pre-
assembled peptide 2.13, to give glycopeptide 2.14 (Scheme 2.3). 
Scheme 2.3. 
2.10 
(SH 
N-Boc-Gly-Cys-Phe-OEt 
2.13 
OACI 1:::-
Aeo~OH 
OAc 
2.11 
2 steps 
OAe OAe A~~ 
S 
Boe'-Ni C02Me 
H 
2.12 
OAe OAe A~~ 
(8 
N-Boe-Gly-Cys-Phe-OEt 
2.14 
S-Glycopeptides are potentially unstable in biological systems due to the type and position 
of linking tether, as is the case for O-glycopeptides. This is a potential disadvantage for 
therapeutic applications, as for example conjugates could be broken down before reaching 
an intended biological target. 
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C-Linked glycopeptides 
C-Linked glycoamino acids and peptides have been synthesised that are more stable in 
biological systems towards acid, base, and enzymatic hydrolysis compared to 0- and S-
glycopeptides.14 The coupling reaction of a carbohydrate derivative to an amino acid or 
peptide to construct a C-glycoside requires the formation of a carbon-carbon bond. An 
example of a method used to achieve this is the synthesis of a C-linked homoserine 
conjugate by Linhardt and co-workers. 15 Here glycosyl donor 2.16 was coupled to 
aldehyde acceptor 2.15 in a samarium diiodide mediated reaction to give a-C-glycoside 
2.17 in moderate yield. This was then converted in two steps to C-linked glycoamino acid 
2.18 (Scheme 2.4). 
OAe 
LJAC y0 2Me 
o AeHN~S02Ph 
~ OAcOAe H 2~6 Cbz 'N OTHP ------l ..... 
H 1) Sm12, THF 
2.15 
Scheme 2.4. 
OAc 
OAc 
C-Linked glycopeptides synthesised using eM 
OAe 
OAe 
Cbz'N OTHP 2 steps CbZ'N 
H 
---l..... H 
2.17,45% 2.18 
CM has been used as the key coupling reaction to construct C-linked glycopeptides by a 
number of research groups in recent years. These systems have been keenly investigated 
as an effective way to access C-linked glycopeptides that are more biologically stable than 
their O-linked analogues. Some examples of the CM of derivatised amino acids with 
carbohydrates were outlined in Chapter One, Schemes 1.5-1.9. The application of olefin 
metathesis to glycobiology has also been reviewed by Overkleeft et al. 16 
Two different synthetic strategies can be used in the construction of a glycopeptide. A 
modified carbohydrate can be conjugated to an amino acid to form a glycoamino acid 
building block, which can then incorporated into a peptide (e.g. 2.12, Scheme 2.3, or 
Schemes 1.5 - 1.9). Alternatively a carbohydrate can be conjugated to an already 
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assembled peptide (for example 2.14, Scheme 2.3). Very recently in January 2005 a patent 
was published by Davis and Kramer describing the preparation of glycosylated amino 
acids, proteins, and peptides via CM.17 Some limitations of this patent in comparison to 
work carried out in this thesis are outlined in Section 2.4. 
One of the aims of this thesis was to develop a CM method to link a modified carbohydrate 
to an amino acid or peptide through an alkene side chain tether of variable length. This 
allowed for control over the alkene tether length, leading to a very versatile general 
method. Variable tether lengths in peptide conjugates are known to be important in 
monoclonal antibody production. With this methodology in hand, a protein could 
potentially be conjugated to an olefin-containing organic molecule, leading to a very 
powerful and general technique for the synthesis of useful biological conjugates such as 
glycopeptides (Figure 2.2). The amino acids used in this project were lysine, serine, and 
cysteine. These were selected based on previous examples that showed the importance of 
glyco- and lipoamino acids of these types and because they contained a side-chain 
functional group that could be easily modified. The use of lysine may be particularly 
advantageous as it is often found on the hydrophilic surface of proteins, thus side-chain 
modification and conjugation could be envisioned to have little effect on the overall 
protein shape that may be crucial for biological activity. A lysine-rich protein (e.g. 
lysozyme) could potentially be linked to several organic molecules through the many 
different lysine side chain residues on the protein surface. 
o 
[ 
~ HO~n~ PROTEIN J YH ______ _ o [ PROTEIN rY~ 
eM 1 ~: 
[ PROTEIN rY~: 
Figure 2.2. General methodology of attachment of target molecule X to amino acid side 
chain Y of a protein using CM. 
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2.1.2 Applications and Synthesis of Lipopeptides 
The conjugation of a lipid or fatty acid moiety to an amino acid or peptide can greatly 
change the physical properties and biological behaviour of the parent peptide. Synthetic 
lipopeptides can be modified to fmely tune desired properties, for example the type and/or 
chain length of the lipid moiety, the amino acid spacer, and/or the peptide backbone can be 
varied. Peptides that are unable to cross intestinal mucosal membranes or the blood-brain 
barrier can be conjugated to fatty acids to increase bioavailability and passive transport 
membrane permeability.1S Lipopeptides have been used in the construction of vaccines as 
membrane delivery agents, and can be very effective at generating a comprehensive 
immune response. For a comprehensive review of lipopeptide vaccines for diseases such 
as mv, malaria, and herpes, see Nesbum et al. 19 
Lipopeptides have also been used as antibiotics, for example daptomycin 2.19 (Figure 2.3) 
that is used to treat Gram-positive infections. Daptomycin 2.19 consists of a cyclic peptide 
with a lipophilic tail that ends with a decanoyl side-chain. Its proposed biological 
mechanism of action is facilitated by the insertion of the lipophilic tail into the bacteria cell 
membrane?O Lipoamino acids have also found use in non medicinal chemistry 
applications, for example as lubricants, polishes, cosmetics, and as surface weatherproof 
coatings for ceramics. 
Lipophilic tail 
2.19 
Figure 2.3. Structure of daptomycin lipopeptide antibiotic. 
The following section outlines the importance of synthetic lipopeptides and discusses some 
existing methodologies employed to link an amino acid to a fatty acid derivative. 
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Fatty acid chains have been directly coupled to the a-carbon of an amino acid in a carbon-
carbon bond forming reaction. For example Boc-protected 2-amino-D,L-dodecanoic 
lipoamino acid 2.22 was synthesised as a mixture of enantiomers in three steps from 
diethyl acetamido malonate 2.20 and I-bromodecane 2.21 (Scheme 2.5).21 Lipoamino acid 
2.22 was then incorporated into a peptide at varying positions to give either 2.23a or 2.23b. 
These peptides are cell-permeable analogues of a-conotoxin MIl, a potent and highly 
selective inhibitor of neuronal nicotinic acetylcholine receptors implicated in several 
disease states including Alzheimer's, Tourette's, and Parkinson's disease. 
C02Et ACO'N~C02Et 
H 
2.20 
Scheme 2.5. 
Br~ 1)8 
2.21 
-----~ ..... Boc'N C02H 
3 steps H 
2.22,70% 
SSPS 
-
))8 
H
2
NAyGCCSNPVCHLEHSNLC 
o 
2.23a 
))8 
GCCS'N~PVCHLEHSNLC 
H 0 
2.23b 
Enantiomerically pure a-lipoamino acids 2.25 have been synthesised in a stepwise fashion 
by gradually building up the amino acid functionality from 2.24 (Scheme 2.6).22 
Lipoamino acids have also been synthesised using Wittig chemistry, for example the 
aldehyde of S-glutamic acid 2.26 was reacted with ylide 2.27 to give a Z-alkene in 92% 
yield, which was then deprotected to give 2.28 as a pure enantiomer (Scheme 2.6)?3 
Scheme 2.6. 
10 < n > 20 
~OH 
n 
2.24 
H 0 
Boo y(:,,,, 
I 
Boc 
2.26 
CB e 
~PPH21 
13 
2.27 
2.28 
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Synthetic lipoamino acids have been constructed where the fatty acid moiety is instead 
linked through the amino acid side chain functionality. For example both isoprenyl and 
palmitoyl functionalities have been installed as thioether (2.30) or thioester (2.31) 
functionalities on the side chain of solid-phase trityl-protected cysteine derivative 2.29 
(Scheme 2.7)?4 Lipoamino acid building blocks 2.30 and 2.31 were then incorporated into 
a human Ras protein synthetic analogue and used as a mechanistic probe, as lipidation of 
Ras proteins is known to be essential for biological activity. There are also examples 
where various types and lengths of fatty acid chains have been attached to peptides via an 
N-terminallinkage to the peptide backbone.25-27 
Famesyl bromide fS~ 
Trt 
I 3 steps S Fmoc'N~~'N~ 
H 0 H 
Fmoc'NA co2Me 
H 
2.30,55% 
o 
sJ 
,. f 2.29 
Palmitoyl chloride Fmoc'NACO Me 
3 steps H 2 
2.31,56% 
Scheme 2.7. 
Part of this thesis, as illustrated in Figure 2.2 where 'X' is a fatty acid, investigates the 
coupling of amino acids to fatty acid derivatives using a CM coupling reaction. Currently 
there are no literature reports detailing the application of eM to the construction of 
lipoamino acids. The synthesis of side-chain cysteine tethered fatty acids described in this 
thesis has advantages over other cysteine side-chain attachment methods such as shown in 
Scheme 2.7. These are discussed in this chapter at the end of Section 2.4. 
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2.2 SYNTHESIS OF MODIFIED AMINO ACIDS 
The side-chains of lysine, serine, and cysteine were acy lated with an alkene containing 
carboxylic acid to give amino acid-based substrates that were suitable for CM. This 
methodology allows for attachment of a variable and controlled alkene tether length. The 
following section outlines the synthesis of these types of modified amino acids and 
peptides. 
2.2.1 Synthesis of Modified Lysine Compounds 
Four different lysine-based CM precursors with different alkene chain lengths were 
synthesised from common precursor Na-Boc-L-Lys-OMe 2.33 (Scheme 2.8). N- And C-
backbone protected lysine 2.33 was initially purchased from a commercial source and used 
directly but the quality was dubious, so instead 2.33 was synthesised from commercially 
available NE-Cbz-L-Lys-OMe hydrochloride salt 2.32a. Amine salt 2.32a was Boc-
protected using Boc-anhydride to give fully protected 2.32b in quantitative yield. The Cbz 
amino-side chain protecting group of 2.32b was cleaved by hydrogenation over palladium 
on carbon to afford common precursor 2.33. Na-Boc-L-Lys-OMe 2.33 was then coupled to 
IO-decenoic acid using a standard EDCIIHOBt coupling strategy to give long chain NE-
decenoyllysine 2.34 in 58% yield. 4-Pentenoic acid was reacted with 2.33 under the same 
coupling conditions to give NE-pentenoyl lysine 2.35 in a slightly higher yield of 71 %. 
Vinyl acetic acid was also coupled to 2.33 to give NE-propenoyllysine 2.36 in 77% yield, 
as an example of a intermediate tether length. 
An Ne-acryloyl lysine analogue was also synthesised as a,p-unsaturated amides have 
previously been effective in CM reactions?8 Coupling of acrylic acid to common 
precursor 2.33 was attempted using EDCIIHOBt but the Ne-acryloyllysine product could 
not be isolated, perhaps since acrylic acid readily forms polymers that could interfere with 
the coupling reaction. Acryloyl chloride was instead coupled to 2.33 to afford the desired 
a,p-unsaturated amide 2.37 in 78% yield (Scheme 2.8). Ne-Acryloyllysine 2.37 was a 
sticky oil that was sparingly soluble in DCM. After a few months of storage in a freezer 
samples of 2.37 resembled hard, treacle-like gum that would not dissolve in DCM or any 
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other solvents. It was assumed due to the nature of the N-acryloyl group that the 
compound polymerised over time, therefore samples of 2.37 were prepared within a month 
of use. 
(ii) LNH2 Boc'N C02Me 
H 
r--- 2.32a, R = H'HCI 2.33 
(I) (iii) 
(iii) 
~ N]v B"'N~: 
~- 2.32b, R = Boc 
(iii) 
H 
2.37 
2.34 LN~ . H BOC'N C02Me 
H 
LN~ BOC'N CO,M: 
H 
2.35 2.36 
Scheme 2.8. Reagents and conditions: (i) BOC20, TEA, CH3CN, rt, 16 h (99%). (ii) 10% 
Pd/C, H2, MeOH, rt, 16 h (98%). (iii) EDCI, HOBt, DIPEA, DCM, rt, 16 h, lO-decenoic 
acid (2.34, 58%) or 4-pentenoic acid (2.35, 71 %) or vinyl acetic acid (2.36, 77%). (iv) 
DIPEA, acryloyl chloride, DCM, O°C, then rt, 16 h (78%). 
~-Amino acids are a variation of the more abundant a-amino acids, where the amino acid 
backbone is extended by one sp3 carbon unit. Research into ~-amino acids and their 
corresponding peptides is of interest for a number of reasons, for example as they are 
found in a variety of biologically active natural products such as Taxol®.29 ~-Peptides 
have also shown promising results as therapeutics due to their increased metabolic stability 
towards protease cleavage and interesting structural properties such as well-defIned three-
dimensional shapes. A ~-amino acid was synthesised (2.43) as an example of how a side-
chain olefIn tethered a-amino acid could be converted into a ~-amino acid framework. 
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The synthesis of p-amino acid 2.43 began with the preparation of key precursor 2.41 
(Scheme 2.9). 4-Pentenoic acid 2.38 was reacted with oxalyl chloride in dry ether with a 
catalytic amount ofDMF to give 4-pentenoyl chloride 2.39. Commercially available Boc-
L-Iysine hydrochloric salt 2.40 was acylated at the side chain amine with 4-pentenoyl 
chloride 2.39 in aqueous conditions to afford Nct-Boc-Ne-pentenoyl-a-lysine 204.1 in 68% 
yield. a-Amino acid 2.41 was converted to the Nct-Boc-NE-pentenoyl-p-lysine methyl ester 
2.43 in two steps. Carboxylic acid 2.41 was treated with TEA and ethyl chloroformate to 
form the mixed anhydride, followed by dropwise addition of diazomethane in ether to give 
diazoketone 2.42. This transformation is known as the Arndt-Eistert synthesis.30,3! 
Diazoketone 2.42 then underwent a Wolff rearrangement in the presence of silver benzoate 
and methanol to give p-Iysine methyl ester 2.43. The Wolff rearrangement mechanism is 
believed to involve the loss of nitrogen gas to give a carboanion that rearranges via 
intramolecular attack to give a ketene, which then reacts with methanol to give 2.43. 
HOOC~ 
2.38 
(iv) 2.43 
+ 
2.35 2.35 
Scheme 2.9. Reagents and conditions: (i) Oxalyl chloride, DMF, ether, OOC then rt, 16 h 
(81 % after distillation). (ii) 2.39, NaOH, CH3CN, rt, 2 h (68%). (iii) TEA, CIC02Et, THF, 
-15°C, 15 min, warm to O°C, then CH2N2/ether, warm to rt, 3 h. (iv) AgOBn, TEA, 
MeOH, -25°C, 3 h (73% yield of 2.43 over 2 steps). 
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The crude reaction mixture following Wolff rearrangement gave a mixture of p-Iysine 
methyl ester 2.43 and a-lysine methyl ester 2.35 (Scheme 2.9). The formation of 2.35 is 
presumably due to the non-quantitative reaction of ethyl chloroformate with 2.41 to form 
the mixed anhydride in the preceding Arndt-Eistert step. Any umeacted carboxylic acid 
2.41 would be methylated upon treatment with diazomethane to give a-lysine methyl ester 
2.35. Diazoketone 2.42 was not purified, so presumably both 2.42 and 2.35 were present 
in the Wolff rearrangement step, with only diazoketone 2.42 reacting to give 2.43. A pure 
sample of p-amino acid 2.43 was eventually obtained from the crude mixture also 
containing 2.35 by purification using silica gel-based column chromatography. This was 
difficult as the compounds 2.43 and 2.35 have very similar polarities as they differ by only 
one methylene group. 
2.2.2 Synthesis of Modified Serine and Cysteine Compounds 
Two modified serine-based compounds were synthesised with different side-chain tether 
lengths. Commercially available Boc-L-Ser-OMe 2.44 was acylated with 4-pentenoic acid 
in the presence of EDCIIDMAP to afford O-pentenoyl serine 2.45 in 89% yield (Scheme 
2.10). The same coupling conditions were used to attach 10-decenoic acid to 2.44, to give 
O-decenoyl serine 2.46 in 84% yield as an example with an extended tether. 
OH 
BOC'-NfCOzMe 
H 
2.44 
llQ 0 
(i) 
-_ .._ .. ---
O~ 
BOC'-Ni C02Me 
H 
2.46 
o 
O~ BOC'-N~COzMe 
H 
2.45 
Scheme 2.10. Reagents and conditions: (i) EDCI, DMAP, DCM, rt, 16 h, 4-pentenoic acid 
(2.4589%) or IO-decenoic acid (2.46,84%). 
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The amino acid cysteine was also modified to contain an olefin tether, which was installed 
by reaction of the side-chain thiol group. Boc-L-Cys-OMe 2.47 was coupled to 10-
decenoic acid using BOP-CI to give S-decenoyl cysteine 2.48 in 82% yield (Scheme 2.11). 
Cysteine 2.47 was also coupled to 4-pentenoic acid to afford fully protected S-pentenoyl 
cysteine 2.49a in slightly a higher yield of 93%. 
S-Pentenoyl-~-cysteine cysteine 2.51 that contained a side-chain substituted olefin tether 
suitable for CM elaboration was also prepared. a-Cysteine 2.49a was treated with lithium 
hydroxide in a THF/water mixture to hydrolyse the methyl ester and give carboxylic acid 
2.49b (Scheme 2.11). The stability of the pentenoyl thioester group of 2.49a under these 
conditions was of concern, but subsequent Arndt-Eistert synthesis proceeded in high yield, 
indicating that cleavage of the thio ester of 2.49a was minimal. Treatment of carboxylic 
acid 2.49b with TEA and ethyl chloroformate, followed by addition of diazomethane 
afforded a mixture of diazoketone 2.50 and a small amount of a-cysteine methyl ester 
2.49a. Because of the problems encountered isolating ~-lysine 2.43 from a-lysine 2.35 
(Scheme 2.9), diazoketone 2.50 was purified by silica gel-based chromatography as it was 
anticipated that separation of a mixture of 2.50 and 2.49a would be easier than a mixture of 
2.51 and 2.49a following Wolff rearrangement. 
SH 
BOC'Ni C02Me 
H 
2.47 
(0 
Oi) 
2.49a, R = Me 
'------i~ 2.49b R = H 
+ 2.49a 2.51 
Scheme 2.11. Reagents and conditions: (i) BOP-Cl, TEA, DCM, O°C then rt, 4 h, 10-
decenoic acid (2.48, 82%) or 4-pentenoic acid (2.49a, 93%). (ii) LiOHaq (O.2M), THF, 
O°C, 30 min. (iii) TEA, C1C02Et, THF, -15°C 15 min, warm to O°C, then CH2N2/ether, 
warm to rt, 3 h (82% yield of 2.50 over 2 steps). (iv) AgOBn, TEA, MeOH, -25°C, 3 h 
(51 %). 
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Diazoketone 2.50 was treated with silver benzoate, TEA, and methanol to give p-cysteine 
methyl ester 2.51 in 51 %. Synthesis of the corresponding p-serine was not carried out, 
since it was considered that the general method of p-amino acid formation from olefinic 
side chain-derivatised a-amino acids had adequately been demonstrated. 
2.2.3 Synthesis of Modified Dipeptide Compounds 
As an extension of amino acid-based CM precursors in sections 2.2.1 and 2.2.2, dipeptides 
were synthesised in a step towards using larger peptides and eventually proteins for these 
types of studies. Ns-Pentenoyllysine 2.35 was Boc-deprotected by bubbling hydrochloric 
gas through an ethyl acetate solution to give hydrochloride salt 2.52 (Scheme 2.12). Boc-
L-Phe-OH 2.53 was coupled to hydrochloric salt 2.52 using EDCIIHOBt coupling 
conditions to afford Ns-pentenoyl-Lys-Phe dipeptide 2.54 in 63% yield. An example of a 
dipeptide containing an S-acyl olefin linkage was also synthesised. The methyl ester of 
2.48 was hydrolysed with aqueous lithium hydroxide to give carboxylic acid 2.55, which 
was then coupled to proline benzyl ester 2.56 using EDCI/HOBt to afford S-decenoyl 
substituted dipeptide 2.57 in 72% yield. 
The dipeptides 2.54 and 2.57 were synthesised by the peptide coupling of an amino acid 
pre-installed with an olefm tether to a second amino acid. An example involving the 
substitution of an olefin tether to a pre-assembled dipeptide was demonstrated with the 
synthesis of dipeptide 2.59. Commercially available N-acetyl-L-Gly-L-Lys-OMe 2.58 was 
reacted with 4-pentenoic acid in the presence of EDCIIHOBt to give Ns-pentenoyl peptide 
2.59 in excellent yield (Scheme 2.12). Dipeptide 2.59 was isolated as a fine, white solid 
that was very sparingly soluble in DCM, likely due to the polar acetate protecting group. 
Attempts to synthesise and isolate the corresponding N-acryloyl a,p-unsaturated derivative 
by reaction of 2.58 with either acrylic acid or acryloyl chloride were unsuccessful, 
presumably due to insolubility issues. 
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2.35, R = Boc -~ 
2.53 V 
(i) 
L---- 2.52, R H'HCI 2.54 
o 
(ii) S)~ 
~ BOC'N~N~ 
H 0 C02Bn 
2.57 
2.48, R = Me 
(iii) 
2.55, R H 
(iv) 
2.59 
Scheme 2.12. Reagents and conditions: (i) HCI gas, ethyl acetate, rt, 4 h (99%). (ii) EDCI, 
HOBt, DIPEA, DCM, rt, 16 h, Boc-L-Phe-OH (2.54,63% ) or L-Pro-OBn (2.57, 72% over 
2 steps). (iii) LiOHaq (O.2M), THF, OoC, 30 min. (iv) EDCI, HOBt, DIPEA, DCM, 4-
pentenoic acid, rt, 16 h (93%). 
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2.3 MODEL STUDY: CONJUGATION OF AMINO ACIDS TO 
TERMINAL ALKENES 
A model study was carried out in which terminal protected alcohols were coupled to 
derivatised amino acids synthesised in Section 2.2. This was undertaken to ascertain the 
effectiveness of eM with these amino acid substrates before conjugation to the more 
complex carbohydrates or fatty acids was attempted. The choice of coupling partner was 
based upon an earlier study by Grubbs and colleagues28 that showed CM between 
protected terminal alkene 2.61 and a,p-unsaturated amides 2.60a-e proceeded effectively 
to give products 2.62a-e (Scheme 2.13). 
(i ~o/'-...o~ 
o 2.61 R~ ----~-------.~ 
1.17, oeM, reflux 
2.60a ·e 2.62a - e 
Alkene 
R Product CMyield 
substrate 
2.60a ~N/ 2.62a 80% 
H 
2.60b /o"N/ 2.62b 89% I 
2.60c Ph"N/ 2.62c 90% H 
2.60d Ph"N/ 2.62d 97% I 
2.60e Ph2"N/ 2.62e 100% H 
Scheme 2.13. 
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2.3.1 Synthesis of protected terminal alkene 
The required protected tenninal alkenes were prepared as outlined in Scheme 2.14. 
Hexen-l-01 2.63 was treated with dihydropyran in the presence of p-toluene sulfonic acid 
monohydrate to give protected tenninal alkene 2.61 in quantitative yield. Similarly decen-
1-01 2.64 was converted into protected 2.65 in 90% yield. Both 2.61 and 2.65 were 
isolated after silica gel-based column chromatography as racemic mixtures. 
~OH 
m 
(i) D 
------1,.... ~O 0 
m 
2.63, m = 1 
2.64, m = 5 
2.61, m = 1 
2.65, m '" 5 
Scheme 2.14. Reagents and conditions: (i) Dihydropyran, p-TsOH, DCM, 18 h (2.61, 
99%), (2.65,90%). 
2.3.2 Cross metathesis reactions 
CM reactions between modified amino acids (2.34-2.37, 2.48, 2.54) and terminal alkenes 
(2.61, 2.65) were carried out in refluxing DCM using 20 mol% of Grubbs second 
generation catalyst 1.17 (Scheme 2.15). A flow of nitrogen was used to remove the 
ethylene gas side product, with DCM periodically added due to evaporation in order to 
maintain the approximate starting substrate concentration (refer to section 1.4, Chapter 1). 
One equivalent of the amino acid coupling partner and three equivalents of the other 
tenninal alkene coupling partner were used to optimise the cross-coupled product yield 
(see Chapter 1, Figure 1.5). The protected alcohol tenninal alkene CM homodimer was 
also isolated in all cases. CM reactions were worked up by adding fifty equivalents of 
DMSO (relative to catalyst) to assist the removal of coloured ruthenium by-products.32 
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Despite several purification attempts the eM products shown in Scheme 2.15 were isolated 
as an inseparable mixture containing traces of isomers. These trace isomers were only 
assigned if distinguishable peaks were observed in 1 H NMR spectra that could be 
unequivocally assigned to a particular isomer structure. This was possible for isomer 
products 2.68a - 2.70a, 2.71a - b, and 2.74a (Scheme 2.15) that contained an a,y-
unsaturated amide functionality, formed as a result of chain contraction andlor double bond 
migration as discussed in section 2.3.3. The precise structures of these isomers in relation 
to the chain length 'y' was not determined, also as discussed in section 2.3.3. Traces of 
compounds other than shown in Scheme 2.15 were likely also produced due to bond 
migration, but were not assigned due to the lack of a distinctive resonance in 1 H NMR 
spectra. All eM products shown in Scheme 2.15 were assigned as E, reasons for which are 
discussed later in this section. The yields of eM reactions were calculated using the total 
mass of the isolated cross-coupled sample following silica gel-based column 
chromatography and assumed the mass of the maj or eM product. 
a,~-Unsaturated amide 2.37 was coupled to hexen-l-012.61 and decen-l-01 2.65 terminal 
alkenes in separate reactions to give eM products 2.66 (91 %, entry 1) and 2.67 (75%, 
entry 2) (Scheme 2.15). N-Propenoyllysine 2.36 was coupled to terminal alkene 2.61 to 
afford a mixture containing major eM product 2.68 and isomer 2.68a (3: 1 2.68/2.68a, 
57%, entry 3). Isomer 2.68a was presumed to be formed due to chain contraction (i.e. y 
m-l) as the major eM product 2.68 (y = m) also contains an a,y-unsaturated amide. eM 
between N-propenoyl lysine 2.36 and terminal alkene 2.65 was carried out to give a 
mixture of 2.69 and 2.69a (3: 1 2.69/2.69a, 56%, entry 4) in slightly lower yield. Relative 
amounts of isomers were determined using IH NMR integral ratios. 
N-Pentenoyl lysine 2.35 was reacted with 2.61 to give 2.70 and traces of 2.70a (6:1 
2.70/2.70a, 54%, entry 5). N-Pentenoyl lysine 2.35 was also coupled to terminal alkene 
2.65 to afford major eM product 2.71 along with traces of 2.71a and 2.71b (23:4:1 
2.7112.71a/2.71b, 51%, entry 6), which were formed as a result of ring contraction andlor 
double bond migration. The longer chain N-decenoyllysine 2.34 was coupled to protected 
hexen-l-012.61 to afford eM product 2.72 (67% yield, entry 7). 
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LN~ H n BOC'N C02Me 
H 
2.34·2.37 
~OyO 
;61,2.65 0 
----------------~. 
(i) 
Amino Coupling CM 
Entry n m 
acid partner Product 
1 0 2.37 1 2.61 2.66 
2 0 2.37 5 2.65 2.67 
3 1 2.36 1 2.61 2.68 
4 1 2.36 5 2.65 2.69 
5 2 2.35 1 2.61 2.70 
6 2 2.35 5 2.65 2.71 
7 8 2.34 1 2.61 2.72 
2.68a· 2.70a, 2.71a, b 
Yield 
91% 
75% 
57% 
56% 
54% 
51% 
67% 
a,y-unsat. 
amide isomel 
2.68a 
2.69a 
2.70a 
2.71a, b 
64 
Ratio * 
3:1 
3:1 
6:1 
23:4:1 
* Ratio ofCM product/a,y-unsaturated isomer. # Not isolated, present as a mixture. 
2.48 
y = 5 and/or 4 
2.54 2.74 
Scheme 2.15. Reagents and conditions: (i) Grubbs second generation catalyst 1.17 (20 
mol%), 2.61 or 2.65 (3 equiv), DCM, argon flow, reflux 6 h, then DMSO (50 equiv 
relative to 1.17), rt, 12 h (2.73, 36%), (2.74/2.74a 5:1,56%). 
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Analysis of the table shown in Scheme 2.15 reveals that N-acryloyl products 2.66 (entry 1) 
and 2.67 (entry 2) were isolated in the highest yield (compare entries 1 and 3, 2 and 4). An 
explanation for the high CM yields when using a,~-unsaturated amide 2.37 could be due to 
its olefm Type, as detlned in Table 1.1, Chapter One. a,~-Unsaturated amide 2.37 is 
defined as a Type II olefin, while protected alcohols 2.61 and 2.65 and amino acid-based 
substrates 2.34 - 2.36 are more characteristic of Type Iolefins. Chaterjee and Grubbs have 
suggested that CM between a Type I (e.g. 2.61, 2.65) and Type II (e.g. 2.37) olefin is 
selective and gives the cross-coupled product in higher yield, compared to CM between 
two Type I olefins that gives a lower, statistical yield of the cross-coupled product.33 The 
higher yields of CM products using substrate 2.37 compared to 2.34 2.36 was also in line 
with a study by Grubbs et aP8 that showed a,~-unsaturated olefins are particularly 
effective CM substrates (Scheme 2.13). 
The longer Ns-decenoyl olefin tether length of 2.34 (entry 7) would also appear to be 
favourable for CM, as although 2.34 gave lower CM yields compared to a,~-unsaturated 
amide 2.37 (entries 1,2), it gave higher CM yields compared to both Ns-pentenoyllysine 
2.35 (entries 5, 6) and Ns-propenoyllysine 2.36 (entries 3,4). This may have been due to 
reduced steric clashing between the catalyst and amino acid backbone for the longer olefin 
tether length of 2.34, compared to the shorter side-chain tethers of lysine 2.35 and 2.34. 
This trend was in agreement with other studies, for example as shown in Scheme 1.1, 
Chapter 1, where amino acid a-carbon substituted olefin tethers of longer lengths gave 
higher CM yields compared to shorter olefin tether lengths.34 Longer length olefin tethers 
substituted at the N-terminus position of amino acids have also been shown to give higher 
CM yields than shorter olefin tether lengths (Scheme 1.13, Chapter 1).35 Comparison of 
the CM product yields for terminal alkene coupling partners 2.61 and 2.65 reveals that 2.61 
gave slightly higher but comparable yields when coupled to analogous modified amino 
acid substrates (compare entries 1 and 2,3 and 4, 5 and 6). 
S-Decenoyl cysteine 2.48 was coupled to terminal alkene 2.61 to give CM product 2.73 in 
36% yield (Scheme 2.15), which is significantly lower than was observed for the 
corresponding Ns-decenoyllysine 2.72 (67%, entry 7). An IH NMR spectrum of each of 
the crude CM products 2.72 and 2.73 showed only evidence of HRC=CRH coupled 
products, and in both cases the only compounds isolated following silica gel-based 
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chromatography were the eM product (2.72 or 2.73) and the terminal alkene homodimer. 
This suggested that in each case eM was equally as efficient despite the difference in eM 
yield. Therefore the difference in product yield was likely due to isolation issues, although 
it would be anticipated that the opposite would apply, Le. that the more non-polar cysteine-
based 2.73 would be more easily purified using silica gel-based chromatography than the 
more polar lysine-based 2.72. eM reactions to give 2.72 and 2.73 were repeated, and gave 
the same difference in eM yields between the two products. 
Dipeptide 2.54 was coupled to the protected terminal alkene 2.65 under eM conditions to 
give a 5:1 mixture of eM product 2.74 and isomer 2.74a respectively in 56% yield 
(Scheme 2.15). This was a promising result as N-pentenoyl single amino acid eM product 
2.71 was produced in a comparable yield of 51 % (entry 6), indicating that the method is 
equally applicable to larger molecular architectures. 
It is important to note that all eM products shown in Scheme 2.15 are presumed to be a 1: 1 
mixture of epimers since the terminal alkenes 2.61 and 2.65 are racemic. Surprisingly the 
IH and l3e NMR spectra of eM products shown in Scheme 2.15 did not reveal any 
evidenee of diastereoisomers, as only a single resonance at approximately DB 4.5 ppm and 
Dc 99 ppm for the OCHO tetrahydropyran atoms, and one set of peaks at Dc 62 and 67 ppm 
for the OCH2 atoms was observed. Presumably this was because the OCHO atoms in the 
diastercoisomers were in chemically equivalent environments, perhaps due to the distance 
away from the chiral amino acid stereocentre. 
The configuration of the double bond formed during olefin metathesis can be E or Z. 
Studies have shown that olefin metathesis using catalyst 1.17 is under thermodynamic 
control, and preferentially gives the most thermodynamically stable double bond 
configuration in excess.36,37 The eM products shown in Scheme 2.15 were all assigned as 
E. This was determined on the basis of the vicinal coupling constant across the double 
bond for 2.66 2.70, and 2.74, and where the measurement of this coupling eonstant was 
not possible the eM product was assumed E for thermodynamic reasons. It was possible 
that traees of the corresponding Z isomers were present in eM products E-2.66 2.74, 
however distinguishable peaks were not observed in the IH and l3e NMR spectra of 2.66 -
2.74 that could be assigned as sueh. 
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23.3 Double bond migration during cross metathesis 
Double bond migration can occur in metathesis substrates prior to eM coupling andlor in 
the coupled product following eM, which gives rise to isomers which are chain contracted 
andlor contain a double bond in a different position compared to the major eM product. 
Migration is believed to be catalysed by a ruthenium hydride species produced as a result 
of catalyst breakdown over time.38 Ruthenium hydride species are in fact used in organic 
synthesis for intentional double bond isomerization reactions.39 
[Ru]-H 
o 
R1 II ~ j ~R2 ~ 0 
CM 
C loss of CH2=CH2 
[RuJ-H 
B 
o 
R1)~ 
o ) CM 
loss of CH3CH2=CHz 
CM) loss of CH3CH2=CH2 E 
o 0 
Rl~R2 G j [Ru]-H 
---------------~ -
t 
[Ru1-H F 
Scheme 2.16. Example of isomers that could be produced due to ruthenium hydride 
catalysed double bond migration during eM between two pentenoyl substrates. 
As an example, Scheme 2.16 illustrates double bond migrated isomers that could be 
formed during eM between two pentenoyl alkenes. eM without double bond migration 
(Step C) gives the expected cross-coupled product. Depending on the rate of this reaction, 
some ruthenium hydride species may form in situ that could catalyse double bond 
migration in either eM substrate (Step A or B), the products of which could then undergo 
eM (Step D or E) to produce chain-contracted products.4o These contracted products 
would in fact also be convertible after eM had occurred via double bond migration (Step 
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F). Double bond migration is also possible after CM (Step G),41 and gives rise to CM 
products of the same chain length as the CM product in Step C but containing a double 
bond in a different position. 
Double bond migrated compounds 2.68a-2.70a, 2.71a-b, and 2.74a were assigned as such 
by the observation of a small doublet at approximately 8H 2.9 - 3.0 ppm in the IH NMR 
spectra of the respective CM products 2.68-2.71 and 2.74 that did not correspond to the 
expected non-double bond migrated CM product. This doublet is due to the a,y-
unsaturated amide of the double bond migrated isomers, confirmed by COSY spectrum 
that revealed coupling of this doublet to a small resonance at approximately 8H 5.3 5.5 
ppm in the olefinic proton region. 
2.71 
3.050 3.000 2.950 2.900 2.850 
ppm (f1) 
5.50 5.00 
ppm (f1) 
4.50 
LH1N~ODO H3 Y H 2 Soc, H Y = 5 and/or 4 N C02Me 
H 
2.71a, b 
4.00 3.50 3.00 
Figure 2.4. IH NMR (CDCh, 500 MHz) of 2.71, with resonances due to double bond 
migrated a,y-unsaturated isomers 2.71a - b circled. 
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Figure 2.4 shows the 1 H NMR spectrum of 2.71, which contains two double bond migrated 
isomers (2.71a and 2.71b), assigned by the presence of two distinguishable doublets 
between DR 2.9 - 3 ppm. A small peak in the HRMS corresponding to a chain contracted 
product containing one less methylene unit compared to the major eM product was 
observed in all products shown in Scheme 2.15 apart from 2.66 and 2.67. These traces of 
chain contracted products could not be purified from the reaction mixture, and as such their 
entire structure was not assigned. For example although 2.68a-2.70a, 2.71a-b, and 2.74a 
can be identified as double bond migrated isomers by the presence of a doublet at 
approximately DR 2.9 ppm, the entire structure, or in other words the 'y' in structures 
2.68a-2.70a, 2.71a-b, and 2.74a, was not determined. Double bond migrated products can 
be chain contracted compounds (e.g. step D or E, Scheme 2.16) or a result of double bond 
migration after eM (e.g. step G, Scheme 2.16). 
This model study demonstrated that the side-chain modified amino acids synthesised in 
Section 2.2 could be successfully coupled in eM reactions to alcohol-protected terminal 
alkenes. This then set the stage for conjugation of the amino acid substrates to biologically 
relevant molecules such as modified sugars and fatty acids. 
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2.4 CROSS METATHESIS OF MODIFIED AMINO ACIDS TO 
A FATTY ACID OR CARBOHYDRATE COMPOUND 
2.4.1 Synthesis of protected fatty acid and carbohydrate 
Fatty acid and carbohydrate coupling partners containing an olefm were synthesised for 
use in CM reactions. 10-Decenoic fatty acid 2.75 was esterified using Amberlyst 15 ion-
exchange resin to give fatty acid methyl ester 2.76 as a pure colourless liquid (Scheme 
2.17). Carboxylic acid protection of 2.75 was carried out as in some CM studies with 
catalyst 1.17 olefinic compounds containing this functional group were not tolerated.34 
OH 
Ho""Q""OM' 
HO OH 
2.77 
OBn 
(ii) ~~ 
.. BnO"">-_t"OH 
BnO OBn 
2.78 
(i) 
OBn 
(iii) ~~ 
~C02Me 
2.76 
OBn 
.. BnO"">--(OAC 
BnO OBn 
(iv) Q 
.-.~ BnO'!!! IIIII~ 
< 
BnO bBn 
2.79 1.51b 
Scheme 2.17. Reagents and conditions: (i) Amberlyst 15 ion-exchange resin, MeOH, rt, 7 
h (75%). (ii) Benzyl chloride, KOH, dioxane, reflux, 3 h (30%). (iii) Pyridine, acetic 
anhydride, rt, 16 h (97%). (iv) Allyltrimethylsilane, boron trifluoroetherate, CH3CN, 4°C, 
24 h (50%). 
The carbohydrate scaffold 1.51b based on tetra-benzyl a-D-glucopyranose was also 
prepared (see Chapter 1, Scheme 1.7).42 Commercially available methyl a-D-
glucopyranoside 2.77 was protected by reaction with benzyl chloride in alkaline conditions 
that also cleaved the methyl group of 2.77 to give 2.78 in a notoriously low yielding 
reaction. However the benzyl protecting group has the advantage that it imparts improved 
solubility in DCM, the solvent used for CM reactions with catalyst 1.17. The anomeric 
hydroxyl group of 2.78 was acylated on treatment with acetic anhydride and pyridine to 
afford acetyl 2.79 as a mixture of anomers at the anomeric carbon centre. Treatment of 
acetyl 2.79 with allyltrimethylsilane in acetonitrile in the presence of boron 
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trifluoroetherate gave a-anomer vinyl carbohydrate derivative 1.51b. The reaction 
proceeds via nucleophilic attack of the oxonium ion from the preferred axial face. 43,44 
2.4.2 Cross metathesis of amino acids to carbohydrate compound 
Protected a-glycopyransose carbohydrate 1.51b was coupled to the three modified lysine 
amino acids 2.37, 2.35, and 2.34, each of which contains a different acyl chain length 
(Scheme 2.18). All reactions shown in Scheme 2.18 were carried out with three 
equivalents of carbohydrate 1.51b relative to one equivalent of the amino acid-based 
coupling partner. Consequently the carbohydrate homodimer of 1.51 b was isolated in all 
reactions. All CM products isolated (Scheme 2.18) were assigned as the E configuration, 
on the basis of the vicinal coupling constant across the double bond (for 2.80, 2.82, 2.84) 
or on the assumption that E is more thermodynamically stable than Z (for 2.81, 2.75). CM 
products contained traces of inseparable isomers that were only assigned when minor 
resonances in the IH NMR spectra of CM products could be assigned to a specific type of 
trace isomer structure.* This was possible for isomers containing an a,y-unsaturated 
amide, the structures of which (2.81a, 2.84a, 2.85a) are shown in Scheme 2.18. 
a,p-Unsaturated amide 2.37 was reacted with carbohydrate 1.51b to give cross coupled 
product 2.80 in 55% yield. N-PentenoyI2.35 was coupled to 1.51b to give an inseparable 
mixture of2.81 and 2.81a (6:1 2.81/2.81a) in 43% yield. Longer chain N-decenoyllysine 
2.34 was also conjugated to 1.51 b to afford 2.82 in a higher yield of 65%. Compound 2.82 
can also be regarded as a glycolipoamino acid, as contains both a carbohydrate moiety and 
a long alkyl chain. Glycoamino acid 2.82 was treated with palladium on carbon under an 
atmosphere of 74 psi hydrogen gas to give carbohydrate-deprotected and side chain 
reduced analogue 2.83. Glycoamino acid 2.83 provides an example of an unprotected 
carbohydrate linked to the side chain of lysine through a Cl2 chain. 
• Refer to section 2.3.3 for an explanation of isomers that can form during CM due to double bond migration 
and ring contraction. 
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Scheme 2.18. Reagents and conditions: (i) Grubbs second generation catalyst 1.17 (20 
mol%), 1.51b (3 equiv), DCM, argon flow, reflux, 6 h, then DMSO (50 equiv reI. to 1.17), 
rt, 12 h (2.84/2.84a 3:1, 35%), (2.85/2.85a, 4:1, 43%). (ii) 10% Pd/C, H2 (74 psi), EtOH, 
24 h (quantitative). # Isolated as a mixture of2.8112.81a 6:1. 
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N-Decenoyllysine 2.34 was reacted with carbohydrate 1.51b to give CM product 2.82 in a 
higher yield (65%) compared to when lysine substrates 2.35 (43%) or 2.37 (55%) were 
coupled to 1.51 b. This result differs to the terminal alkene model study (Section 2.3), 
where a,p-unsaturated amide 2.37 gave CM products in the highest yields, likely due to a 
selective CM reaction between Type II olefin 2.37 (as defined in Table 1.1, Chapter 1) and 
Type I olefms 2.61 or 2.65. The observation that CM between carbohydrate 1.51b and 
2.34 gave a higher CM yield than between 1.51 band 2.37 (Type II olefin) suggested that 
steric factors were more influential then selectivity issues in this instance. This may be due 
to the shorter olefin tether length of carbohydrate 1.51b compared to the longer olefin 
tethers of 2.61 and 2.65. The trend of higher CM yields for substrates containing longer 
olefm tether lengths are used has previously been reported, for example see Schemes 1.1 
and 1.13, Chapter 1. 
NE-Pentenoyl p-Iysine 2.43 was coupled to carbohydrate 1.51b, to give a mixture of 
glycoamino acids 2.84 and 2.84a (3: 1 ratio respectively) in 35% yield (Scheme 2.18). This 
demonstrated the applicability of CM methods to p-amino acids, which are important 
variations of natural a-amino acids. Modified S-pentenoyl cysteine 2.49a was also reacted 
with 1.51b in a CM reaction to afford coupled products 2.85 and 2.85a (4:1 ratio 
respectively) in 43% yield, the same yield as was observed in the CM reaction of2.35 with 
1.51b. Carbohydrate 1.51b was reacted with O-decenoyl serine 2.46 under CM coupling 
conditions to give a crude reaction mixture that contained evidence of only coupled 
RHC=CHR resonances in the lH NMR spectrum, indicating an efficient CM coupling had 
occurred. However the cross-coupled product could not be purified from the carbohydrate 
homodimer using silica gel-based column chromatography. 
The lH, 13C, andlor HRMS spectra of CM products in Scheme 2.18 showed evidence of 
trace isomers as an inseparable mixture following chromatography. These isomers were 
only assigned if a distinguishable doublet at approximately 8H 2.9 ppm corresponding to an 
a,y-unsaturated amide could be observed in the IH NMR spectra of CM products, for 
example in the cases of2.81a, 2.84a, and 2.85a. These isomers were assigned on the basis 
that they contained an a,y-unsaturated amide functional group as a result of double bond 
migration, but it was not determined if the observed isomer also corresponded to a chain 
contracted product. However small peaks corresponding to a compound of one less 
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methylene unit compared to the major CM product were observed in each of the HRMS of 
products shown in Scheme 2.15, apart from 2.80. This indicated that traces of chain 
contracted compounds were present along with the major CM product. 
CM products shown in Scheme 2.18 represent examples of glycoamino acids in which the 
amino acid side-chain is linked to the anomeric position of a carbohydrate by a carbon 
chain. This project is the first example of an acyl tether containing an olefin attached to 
the side-chain of an amino acid being linked via CM to a carbohydrate to give a 
glycoamino . acid. This methodology has some advantages over previously reported 
methods discussed in Sections 2.1 and 1.5.1. The synthesis of a-carbon substituted amino 
acids such as allylglycine invariably creates a new stereocentre, the chirality of which must 
be controlled to produce one enantiomer. The acyl side-chain approach used in this study 
to install the double bond tether does not form a new stereocentre, so the chirality at the 
natural amino acid a-carbon centre is not an issue. 
Another advantage of carrying out CM on an amino acid acylated with an olefin tether as 
described in this study is the ability to control the tether length. This was demonstrated in 
Scheme 2.18 where three different acyl tether lengths of 2.37,2.35, and 2.34 all underwent 
CM with carbohydrate 1.51b in similar yields. Other types of alkene attachments, for 
example a-carbon substituted attachments such as in allylglycine, have limited tether 
lengths and often rely on the defined three carbon conjugated system of allyl bromide to 
install the double bond tether. 
A patent was published by Davis and Kramer in January 2005 describing a general method 
for the attachment of amino acids or peptides to unprotected carbohydrates using CM.17 
Amino acids substituted with an olefin tether at the a-carbon position are preferably used 
in this patent, for example commercially available vinyl glycine. In particular this patent 
focuses on the oxidation of a methionine or selenomethionine side chain 2.86 to the 
corresponding sulfoxide or selenoxide 2.87, followed by elimination at an elevated 
temperature/pressure to give vinyl amino acid 2.88 (Scheme 2.19). The elimination 
reaction also produced approximately the same amount of a,~-dehydro side product 2.89. 
The modification of methionine or selenomethionine to contain a double bond can also be 
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carried out in pre-assembled peptides, for example peptide 2.90 can be modified in two 
steps by oxidation and elimination to give 2.91. 
The modified vinyl amino acids or peptides (e.g. 2.91) were coupled to unprotected 
carbohydrates such as 2.92 by treatment with second generation recyclable catalyst 1.20 in 
methanol with microwave heating to give glycopeptide products (e.g. 2.93). The CM 
method shown in Scheme 2.19 does not overlap with the work carried out in this thesis, as 
only unprotected carbohydrates are covered under the Davis et al patent. I7 
./ 
Z= S, Se t 
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Scheme 2.19. 
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There are drawbacks to the method shown in Scheme 2.19. Firstly the preparation of 2.88 
also gives a,p-dehydro 2.89 as a by-product that will not react under CM conditions. 
Secondly a peptide must contain a methionine or se1enomethionine to enable the 
introduction of the double bond functionality. The authors use peptides and proteins that 
contain one or more methionine residues, or alternatively a methionine or 
selenomethionine residue was installed via site-directed mutagenesis or a SetMet culture 
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medium during peptide synthesis. These extra steps add complexity, compared to the 
methodology used in this thesis for alkene attachment that required only one mild and 
reliable reaction to install the double bond moiety onto the side chain of natural amino 
acids more commonly found in many peptides. Thirdly the elimination reaction to give 
2.88 or 2.91 shown in Scheme 2.19 requires high temperature/pressure conditions that 
could degrade some peptides. 
The method shown in Scheme 2.19 is not as versatile as the methodology described in this 
thesis since a methionine or selenomethionine residue is required, and the olefin tether 
length that is substituted at the amino acid a-carbon can only be a vinyl tether of non-
variable length. In this thesis, different tether lengths in glycoamino acids between the 
amino acid and carbohydrate component can be achieved, simply by side chain acylation 
using different lengths of alkene acids. The method described in this thesis also allows for 
olefin tether lengths to be installed into many types of natural amino acids, for example 
lysine, serine, and cysteine. 
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2.4.3 Cross metathesis of amino acids to fatty acid compound 
Three lysine-based amino acids 2.37, 2.35, and 2.34, each containing a different olefin 
tether length, were coupled to protected fatty acid 2.76 using CM (Scheme 2.20). Fatty 
acid 2.76 was used in three fold excess and the corresponding homodimer of 2.76 was also 
isolated. a,p-Unsaturated amide 2.37 was reacted with fatty acid 2.76 to give lipoamino 
acid 2.94 in 68% yield. CM product 2.94 also contained trace isomers (2.94/2.94a 12: 1), 
presumably due to double bond migration of CM product 2.94. N-Pentenoyllysine 2.35 
was also coupled to 2.76 to give an inseparable mixture of 2.95 and traces of double bond 
migrated products 2.95a-b (34:4:1 2.95/2.95a/2.95b) in 48% yield. N-Decenoyl 2.34, 
containing a longer olefin tether, was coupled to 2.76 to afford 2.96 in 64% yield. CM 
product 2.94, which contains an a,p-unsaturated amide, was formed in higher yield 
compared to both 2.95 and 2.96. The same trend was observed in the terminal alkene 
model study (Section 2.3), thought to be a due to a selective CM reaction between two 
olefins of different Types, as defined in Table 1.1, Chapter 1. N-Decenoyl 2.96 was 
formed in slightly lower yield than 2.94 but still higher than for 2.95, presumably due to 
steric reasons. 
N-Pentenoyl dipeptide 2.54 was conjugated to fatty acid 2.76 to afford a mixture of 2.97 
and 2.97a (4:1 2.97/2.97a) in 41 % yield, a result comparable to the 48% yield obtained for 
single amino acid N-pentenoyl 2.95 (Scheme 2.20). This demonstrates the applicability of 
this methodology to larger molecular architectures. CM of S-decenoyl cysteine 2.48 to 
2.76 was carried out to give lipoamino acid 2.98 in 61 % yield, a result comparable result to 
the 64% yield for N-decenoyl lysine product 2.96. p-Cysteine derivative 2.51 was 
successfully coupled to fatty acid 2.76 to afford 2.99 in 59% yield. Conjugate 2.99 is an 
example of a p-lipoamino acid (a p-arnino acid linked to a fatty acid), the basis of which 
could be a useful synthetic conjugate in biological systems as p-arnino acids are 
hydrolytic ally more stable than a-amino acid analogues,45 and are becoming important 
peptidomimetic stmctures for therapeutic applications. S-Decenoyl cys-pro dipeptide 2.57 
was coupled to 2.76 via CM to give lipopeptide 2.101 in 43% yield. O-Decenoyl serine 
2.46 was also reacted with 2.76 to afford CM product 2.100 in 73% yield, the highest yield 
for all reactions shown in Scheme 2.20. 
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Scheme 2.20. Reagents and conditions: (i) Catalyst 1.17 (20 mol%), 2.76 (3 equiv), DCM, 
argon flow, reflux, 6 h, then DMSO (50 equiv reI. to 1.17), rt, 12 h (2.97/2.97a 4:1, 41%), 
(2.98, 61%), (2.99, 59%), (2.100, 73%), (2.101, 43%). # Isolated as a mixture of 
2.95/2.95a/2.95b 34:4: 1. 
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The reaction of acetyl dipeptide 2.59 with 2.76 did not give rise to the CM product, 
presumably because the dipeptide was only sparingly soluble in DCM. Further reactions 
with 2.59 were not attempted as available catalyst 1.17 was only soluble in solvents such 
as DCM. 
CM products shown in Scheme 2.20 were all assigned as E. This was detennined on the 
basis of the vicinal coupling constant across the double bond for 2.94, 2.95, 2.97 and 2.99, 
or was assumed for thermodynamic reasons. Small resonances due to trace isomers were 
observed in the IH NMR spectra of 2.94 - 2.101. The only isomers that could be assigned 
were 2.94a, 2.95a-b, and 2.97a, which contain an a,y-unsaturated amide as a result of 
double bond migration. Analysis of CM products 2.95-2.101 by mass spectrometry 
revealed small peaks that corresponded to species with one less methylene unit compared 
to the major CM products, consistent with alkyl chain contracted products. 
The lipoamino acid and lipopeptides shown in Scheme 2.20 are all novel structures. This 
is the first report of the use of side-chain acylation followed by CM to attach lysine, serine, 
and cysteine to a fatty acid. The only other example of attachment of a fatty acid to an 
amino acid side-chain via CM is to allyl-serine compounds, for example 1.65, Scheme 
1.10. Previous literature methods for lipoamino acid and lipopeptide synthesis include 
attachment of a fatty acid chain to the amino acid a-carbon (e.g. see Scheme 2.5)?1 
Advantages of the methodology developed in this thesis include the attachment of a fatty 
acid without creating a stereocentre, and the ability to install the fatty acid group either pre-
or post-peptide synthesis. Installing a fatty acid onto an olefinic side chain of an amino 
acid after peptide synthesis could be an advantage, for example to prevent the fatty acid 
group interfering with standard SPPS techniques. 
In summary, a new and important method that allows conjugation of a suitably 
functionalised fatty acid or carbohydrate to the acylated side chain of the natural amino 
acids lysine, cysteine, or serine has been identified. This methodology should be amenable 
to a wide range of other biologically important olefins. The ability to couple these 
modified amino acids to carbohydrates is particularly significant since it paves the way for 
the preparation of important peptide-carbohydrate complexes. 
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2.5 APPLICATION OF CROSS METATHESIS TO SOLID-
PHASE CHEMSITRY 
2.5.1 Attempted solid-phase cross metathesis 
CM of modified amino acids to terminal alkene 2.65 on solid phase was attempted as an 
alternative to solution phase reactions. This offers the advantage of easier and more 
thorough purification, as CM products attached to the resin could be vigorously washed 
before cleavage and isolation. The Fmoc group was selected for protection of the 
backbone amine for use in solid-phase peptide synthesis (SPPS),46 rather than a Boc group 
as was used in solution-phase CM. 
Fmoc-protected 2.105 and 2.106 were prepared as substrates for solid-phase CM reactions 
(Scheme 2.21). Commercially available Fmoc-L-Lys-COOH 2.102a was reacted with 
methanol in the presence of Amberlyst 15 ion exchange resin to give methyl ester 2.102b 
in quantitative yield. The side-chain amine of 2.102b was coupled to 4-pentenoic or 10-
decenoic acid by treatment with EDCI and HOBt to give N-pentenoyI2.103 or N-decenoyl 
2.104 respectively. The methyl esters of 2.103 and 2.104 were hydrolysed with aqueous 
lithium hydroxide to give the desired Na;-Fmoc-protected carboxylic acids 2.105 and 2.106, 
which posses the required side-chain olefin tether. 
2.102a, R = H 
(0 
2.102b, R = Me 
2.103, n = 2 
2.104, n = 8, 
2.105, n = 2 
2.106, n = 8, 
Scheme 2.21. Reagents and Conditions: (i) Amberlyst 15 ion exchange resin, MeOH, rt, 
24 h (99%). (ii) EDCI, HOBt, DIPEA, DCM, rt, 16 h, 4-pentenoic acid (2.103, 66%), or 
lO-decenoic acid (2.104, 60%). (iii) LiOH(aq), THF, O°C, 40 min (2.106,96%). 
Na-Fmoc-N8-pentenoyl-Lys-OH 2.105 was unfortunately completely insoluble in 
petroleum ether, ethyl acetate, DCM, THF, DMF, water, and only sparingly soluble in 
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methanol, all at both rt and reflux. Carboxylic acid derivative 2.105 was not characterised 
due to insolubility, but was presumed to be the structure present following treatment of 
2.103 with lithium hydroxide. A solvent often used in SPPS is N-methylpyrrolidone 
(NMP) - even this did not solubilise 2.105. Therefore N-pentenoyllysine 2.105 was not 
suitable for solid-phase chemistry due to its insolubility. Longer chain N-decenoyl 
carboxylic acid 2.106 was sparingly soluble in DCM and DMF so solid-phase chemistry 
with this derivative was attempted. 
Solid phase metathesis reactions can be carried out using either resin-bound substrates or a 
resin-bound catalyst. A CM method that entailed reaction of a resin-bound olefin substrate 
with a solution containing the other olefm substrate and Grubbs second generation catalyst 
1.17 was selected for this project. Solid-phase CM carried out in this way requires a low 
loaded concentration of the resin-bound olefin to avoid the competing homodimerisation 
(or pseudo-ReM) reaction. This was achieved by capping a large portion of the resin 
binding sites before loading the CM olefin substrate onto the remaining sites. 
The solid-phase metathesis procedures used were based upon work carried out by Gibson 
and co-workers.34 Wang resin 2.107 was treated with 0.9 equivalents of tertiary butyl 
dimethyl silyl chloride to give resin 2.108, that was presumed to contain 90% capped and 
10% free alcohol binding sites (Scheme 2.22). Resin 2.108 was reacted with Fmoc-L-Lys-
OR 2.106, EDCI, and DMAP in an effort to give resin-bound lysine derivative 2.109, 
which was treated with a solution of terminal alkene 2.65 and catalyst 1.17 in an effort to 
produce the resin-bound CM product 2.110. Resin 2.110 was then thoroughly washed, 
treated with TF A, and the filtrate and washings collected, however CM product 2.111 was 
not isolated. The entire sequence of reactions shown in Scheme 2.22 was repeated twice 
more to give the same end result. The lR NMR spectrum of the filtrate following TF A 
treatment of resin 2.110 was complex, and resonances corresponding to either 2.111 or 
starting material 2.106 were not observed. This was not helped by the fact the reaction 
sequence shown in Scheme 2.22 was carried out on a small scale relative to the amounts of 
olefin substrates used as resin 2.108 had only 10% of available binding sites. The scale-up 
of the reaction was limited due to equipment restrictions and the amount of Wang resin 
available. 
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Scheme 2.22. Reagents and Conditions: (i) 0.9 eq tBuMe2SiCI, Et3N, DCM, shake, rt, 24 
h. (ii) 2.106, EDCI, DMAP, DCM, shake, rt, 24 h. (iii) Catalyst 1.17,2.65, reflux, 24 h. 
(iv) TFA, DCM. Wang resin 2.107 (Novabiochem, 200-400 mesh, loading 0.60 mmole/g 
resin). 
Studies were next carried out to determine whether or not 2.106 was binding to the Wang 
resin, as 2.106 was only sparingly soluble in DCM. The coupling of 2.106 directly to an 
uncapped sample of Wang resin 2.107 was attempted following standard SPPS protoco1.46 
Na-Fmoc-Ns-decenoyl-Iysine 2.106 was only sparingly soluble in various combinations of 
DCM, DMF, and NMP however it was hoped that solubility in 1:1 DMFIDCM was 
sufficient to enable some binding of 2.106 to resin 2.107. After treatment of 2.107 with 
2.106, EDCI, and DMAP the resin was treated with TF A, but lH NMR spectra (CDCh) of 
the resulting filtrate did not contain any type of lysine-based compound, indicating that 
2.106 was not binding on to resin 2.107. Therefore it was assumed that CM product 2.111 
was not isolated for this reason. 
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2.5.2 Synthesis of solid phase peptide synthesis building blocks 
The development of a glycoamino acid building block for use in SPPS of glycopeptides 
was another aim of this project. Attempts at solid-phase CM discussed in section 2.5.1 
suggested that Fmoc protected lysine-based amino acids such as 2.105 and 2.106 were not 
suitable for SPPS application due to insolubility. Instead the more non-polar serine-based 
modified amino acid 2.115 was prepared, again with the Fmoc amine protecting group that 
is commonly used in SPPS. The synthesis of Fmoc-L-Ser-OBn 2.114 was initially 
attempted by reaction of commercially available Fmoc-L-Ser-OH 2.112 with benzyl 
alcohol in the presence of p-toluene sulfonic acid monohydrate (Scheme 2.23), but this 
gave complex mixtures of inseparable products. Instead commercially available L-Ser-
OBn 2.113 was reacted with Fmoc-chloride to give 2.114 in 90% yield. 
2.113 2.114 
o Haq, OH O~"'" ""OH (' 2 0 
Fmoc'NA C02H HO 
H 
(v) 
'" >< 
2.117 
(iii) 
o 
o~ 
Fmoc'-Ni C0
2
Bn 2 
H 
2.115 
(iv) ~ BOOB ,o~":'0':B" 
Fmoc'NA C02Bn ~~ H BnO BnQ OBn 
2.116 t,/O~~H"q' ""OBn 
"i y 0-
2.116a Y = 1 and/or 2 BnO 
Scheme 2.23. Reagents and Conditions: (i) Benzyl alcohol, p-toluene sulfonic acid 
monohydrate, CHCh, reflux, 24 h. (ii) Fmoc-CI, DIPEA, DCM, 1 h (90%). (iii) EDCI, 
HOBt, DIPEA, DCM, 18 h (94%). (iv) Catalyst 1.17 (20 mol%), l.S1b (3 equiv), DCM, 
nitrogen flow, reflux 6 h, then DMSO (50 equiv reI. to 1.17), rt, 12 h (36%). (v) 10% 
PdlC, H2, MeOH/ethyl acetate. 
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The side-chain alcohol of 2.114 was acylated using 4-pentenoic with EDCI and HOBt to 
give 2.115 in 94% yield. The CM substrate 2.115 was then reacted with 1.51b in the 
presence of catalyst 1.17 to give an inseparable 12:1 mixture of 2.116 and 2.116a 
respectively in 36% yield. The preparation of glycoamino acid 2.116 demonstrates that the 
CM methods used in this thesis are amenable to the Fmoc protecting group, which is an 
important and useful functional group for use in SPPS. Compound 2.116 was submitted to 
hydrogenation conditions using palladium on carbon under an atmosphere of hydrogen in 
an effort to produce the benzyl deprotected and double bond reduced product 2.117, but 
this gave a complex mixture of products that could not be elucidated. It is possible that the 
hydrogenation conditions also cleaved the N-Fmoc protecting group, as has been reported 
in some instances.47 Therefore the synthesis of an Na-Fmoc protected carboxylic acid 
SPPS building block requires the use of a different C-terminal protecting group that can be 
cleaved under conditions where the N-Fmoc group is stable. Due to time constraints the 
synthesis of other glycoamino acid SPPS building blocks was not attempted. 
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2.6 CONCLUSION AND FUTURE WORK 
The side chains of lysine, serine, and cysteine amino acids were acylated with either 10-
decenoic acid, 4-pentenoic acid, vinyl acetic acid, or acryloyl chloride to give substrates 
suitable for CM elaboration. These included those based on lysine (2.34 2.37), p-Iysine 
(2.43), serine (2.45, 2.46), cysteine (2.48, 2.49a), p-cysteine (2.51), as well as dipeptides 
based on Phe~Lys (2.54) and Cys-Pro (2.57) scaffolds. This approach is versatile in that a 
range of olefin tether lengths from C3 to Cll can be controllably introduced using a mild 
acylation reaction. A model study of the CM between amino acid-based substrates (2.34 -
2.37, 2.48, 2.54) and terminal alkenes (2.61 and 2.65) was carried out, to give CM products 
(2.66 - 2.74) in yields of 36% - 91%. This demonstrated that CM between side-chain 
acylated amino acids with a controllable olefin tether length and target compounds was a 
viable and versatile general method. 
Side chain acylated amino acids 2.34 2.37, 2.43, 2.49a that contain a suitable olefin 
tether were then each coupled to carbohydrate 1.51b using catalyst 1.17 to give 
glycoamino acids 2.80 - 2.85 as the CM products. Amino acid-based substrates 2.34 -
2.37, 2.54, 2.48, 2.51, 2.46 and 2.57 were coupled to fatty acid derivative 2.76 using 
catalyst 1.17 to give lipoamino acids 2.94 - 2.101 as the CM products. The preparation of 
these glyco- and lipoamino acids again demonstrated the versatility of this general 
methodology, in that amino acids of different types and with variable but controllable 
olefin tether lengths can be coupled via CM to suitably modified target biological 
molecules. Synthesis oflarger molecular architectures such as Phe-Lys lipopeptide 2.97 in 
a similar yield to single amino acid lysine lip 0 amino acid 2.95 demonstrated that this 
method is applicable to larger molecular architectures. Solid phase CM was attempted 
between Na-Fmoc-N,,-decenoyl-Iysine substrate 2.106 and terminal alkene 2.65, but no 
coupled product could be isolated due the insolubility of2.106 in DCMlDMF. 
Future work in this area could involve applying the general methodology developed for 
amino acid- and dipeptide-based CM substrates to larger peptides and eventually proteins. 
This could be achieved using reaction conditions such as catalyst 1.20 in methanol. In 
principle any amino acid, peptide, or protein with a side-chain that can be derivatised to 
contain an olefin could be linked using CM to any target molecule (e.g. a hormone or 
complex natural product) that is also suitably modified to contain an olefin. 
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3.1 INTRODUCTION 
Cross linking in peptides is widespread and has many important implications. It can result 
in structural changes that impart modified biological function, for example in blood 
clotting and collagen. Nature has evolved a number of general methods for the fOlmation 
of these linkages, for example the cross-linking of lysine residues in the Maillard reaction,! 
and the formation of disulfide bonds in the case of cysteine. Synthetic mimics of natural 
protein cross-links are of interest for many reasons, including the probing of biological 
structure/function relationships or the development of therapeutics. Section 3.2 describes 
the preparation of a novel series of homo- and hetero-amino acid dimers via CM coupling. 
These dimers were synthesised to expand the scope of the general CM coupling strategy 
described in Chapter 2, which is a versatile method involving side-chain acylation with 
varying carboxylic acids to install the olefm tether. The following section outlines the 
synthesis of selected amino acid and peptide cross-linked dimers and the coupling 
reactions that have been used for dimerisation. 
Dityrosines such as 3.2 are naturally occurring biaryl cross-links that result from the ortho 
coupling of two tyrosyl radicals, and are found in proteins such as RNase A enzyme and in 
the eye lens a,- and y B-crystallins? Synthetic cross linking of tyrosine residues is also of 
interest as tyrosine-like dimers are often found as part of natural product scaffolds that 
have potent biological activities? 
x 
Figure 3.1. 
II N Boc 
o H 
MeOZCY~07° ~, 
NHz 3.2 
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Carbon-carbon cross linked dityrosine compounds such as 3.1 have been synthesised using 
Stille coupling conditions (Figure 3.1).4 Dityrosine cross-linked peptide 3.2 was 
synthesized using a Miyaura-Suzuki coupling reaction.s Tyrosine dimers have also been 
synthesised using a phenol oxidation approach.6 
Side-chain cross-linked amino acids have been synthesised by nucleophilic attack of thiol 
(3.4a), imidazole (3.4b) or amine (3.4c) side chain functional groups to dehydroalanine 3.3 
to give 3.Sa-c respectively (Scheme 3.1).7 
3.5a 
Scheme 3.1. 
BOC'NJlC02Me I 
3.5b 
Tos 
3.3 
j Boc-Cys-OMe, 3.4a Boc-His-OMe, 3.4b Z-Lys-OMe, 3.4e 
3.5e 
Ligand.;.induced receptor and protein dimerisation or oligomerization has been identified as 
a general mechanism for signal transduction in proteins such as tyrosine kinase, 
serine/threonine kinase, and class I cytokine receptors.8 Compounds that mimic this 
natural dimer structure have been synthesized as effective enzyme inhibitors, for example 
HIV-1 integrase inhibitor 3.8 (Scheme 3.2).9 Hexapeptide dimer 3.8 was constructed by 
linking peptide 3.6 with cysteine dimer 3.7, synthesized itself from Boc2-L-homocysteine 
by a sulfur extrusion reaction. The inhibitor 3.8 is more potent than monomeric 3.6, 
presumably because the bivalent inhibitor simultaneously occupies two neighboring 
catalytic sites in the HIV-1 integrase 0ligomer.9 Dimeric HIV-1 integrase inhibitors have 
also been linked using a lysine residue, for example resin-bound 3.9 was coupled to HIV-1 
integrase peptide inhibitor 3.10 to give dimeric 3.11, which showed higher biological 
activity compared to the monomer (Scheme 3.3).10 
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Scheme 3.2. 
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Scheme 3.3. 
Peptides have been dimerized by linking the side chains of tenninal lysine residues. For 
example resin bound peptide 3.12 was dimerized using different types of linkers (3.13a-b) 
to give dimers 3.14a-b (Scheme 3.4).11 Side chain dimerisation leaves both N- and C-
tennini unsubstituted, which can be advantageous as these groups can be involved in 
important interactions with biological targets.12 
o 
NH HO~O~O~OH 
000 0 ! 2 3.13a 0 ~ VT(O'.")ALGK(.OOi HO~~~~~OH 
VT(OtBu)ALGK(Boc) 3.13b 
o 
Ij I' 
3.12 \ VTALGK 
NH2 
Scheme 3.4. 
LINKER 
3.14a, b 
o 
II 
'\ 
VTALGK 
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3.1.1 Formation of amino acid and peptide dimers using cross metathesis 
The first reported example of an amino acid dimer synthesised using CM was in 1997, 
where dimers 1.34b-c were reported as side product homodimers in the CM of two 
different alkenes (Chapter One, Scheme 1.1)Y There are also examples where the CM 
dimer is the intended product, for example in the synthesis of 1.63a, 1.77, 1.72 and 1.67 
(Figure 3.2) that were discussed in Chapter One (Schemes 1.10, 1.12, 1.14).14 These 
symmetrical dimers were cross linked through a serine or tyrosine side-chain O-allyl 
tether. The synthesis of pentapeptide 1.67 demonstrates the use of CM homodimerisation 
for the construction of highly functionalized, large peptide dimers. 
1.77 
r='l 
o 0 
BOC'-.N<02Me Me02)N/BOC 
H H 
1.63a 
1.67 
Figure 3.2. 
Libraries of peptide dimers have been constructed using solution-phase combinatorial 
CM. 15,16 For example peptides 3.15 were coupled to an alkyl carboxylic acid through an 
N-peptide backbone linkage to give 3.16, which were then dimerized to produce cross-
linked dimers 3.17 (Scheme 3.5). Dimeric peptides have also been synthesised using an N-
terminal linkage. The free amines of resin bound peptides 3.18 were acylated with a range 
of olefin-containing carboxylic acids to give 3.19, which were dimerized using CM to give 
coupled products 3.20 (Scheme 3.6).17 Similar backbone-tethered compounds such as 3.21 
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have also been constructed, in studies directed towards the use of CM for the· construction 
of dynamic combinatorial libraries. 18 
o H 0 pePtide'N~N~wpePtide 
o ,(n 
0, yrp 
-----.; .. -- pePtide'N~N~N~pePtide 
H H H H 
3.15 3.16 
j 
H H 
peptide/xNr;::rN,p,Pijd, 
n = 1, 2, 3,4,7, or 8 // 
o )n 
o 0 
pePt~de'N~NJlN~pePtide 
H H 
3.17 
Scheme 3.5. 
o 
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• 0 n N-Peptide -N, A..;::? 
HIT' 'n~ 
H 
Q):'N-peptide-NHz _ 
N-Peptide-NH2 
H 
3.18 3.19 0 3.20 
n = 1, 2, 3, 4, or 8 
Scheme 3.6. 
Chapter 2 demonstrated that CM using amino acid-based substrates that contain an acyl 
side-chain tether of variable length was a highly versatile and useful procedure. These 
side-chain acylated amino acid substrates were also utilized for the synthesis of CM homo-
and heterodimers, as is outlined in section 3.2, to further extend the scope of this general 
methodology. Comparisons between the strategy used in this thesis and literature 
examples discussed in section 3.1 are outlined at the end of section 3.2. 
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3.2 CROSS METATHESIS DIMERS 
3.2.1 Symmetrical Dimers 
Symmetrical dimers were constructed by the self-metathesis or homodimerisation CM 
coupling of amino acid-based substrates (e.g. 2.45, 2.46) that contain an acyl side-chain 
olefin tether. These included two serine symmetrical dimers, each with a different cross-
linked tether length (3.22 and 3.23, Scheme 3.7). O-Pentenoyl serine 2.45, prepared as in 
Scheme 2.10, Chapter 2, was treated with Grubbs second generation catalyst 1.17 to give 
homodimer 3.22 (86% yield) which contained traces of two double bond migrated products 
(3.22a and b) (20:4:1 by IH NMR) following silica gel-based column chromatography. 
These trace isomers (3.22a and b) were assigned by the presence of minor doublets at OR 
3.01 ppm and 3.09 ppm in the IH NMR spectrum of the product mixture, that were 
presumably due to double bond migrated compounds that contain an a,y-unsaturated 
amide. * Catalyst 1.17 was used in 20 mol% relative to two equivalents of the amino acid 
monomer in all CM dimerisation reactions shown in Schemes 3.7 3.10. 
H 
(i) 
MeozcyN'BOC 0 
1 /'--~ ~ ,,0) o~' O/~#~lf i' 
B" 0 3.22a, 3.22b OC'N"~C02Me 
H 
2.45 3.22 
o 0 
~ 0 
.. (i) .. 
Boc, A )00 Boc'NACO M N C02Me 2 e H H 
2.46 3.23 
o 
Scheme 3.7. Reagents and Conditions: (i) Amino acid alkene (2 equiv), Grubbs second 
generation catalyst 1.17 (20 mol%), DCM, argon flow, reflux 6 h, then DMSO (50 equiv 
relative to 1.17), rt, 12 h (3.22/3.22a/3.22b, 20:4: 1, 86%), (3.23, 62%). 
The entire structure of the trace isomers (3.22a, b) was not assigned as these compounds 
could not be purified from the product mixture. However, the HRMS of the 3.22/3.22a-b 
• Refer to section 2.3.3 for a discussion on double bond migrated product in CM 
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product mixture contained a minor M+H peak corresponding to one less methylene unit 
compared to 3.22, indicting the presence of a chain contracted product, likely as result of 
double bond migration in substrate 2.45 prior to CM. 
O-Decenoyl serine 2.46, prepared as in Scheme 2.10, was also dimerized by treatment with 
catalyst 1.17, to give 3.23 in 62% yield, which is an example of a longer cross-linked tether 
length compared to 3.22. The IH NMR spectrum of 3.23 showed evidence of only one 
compound, however the HRMS revealed two minor M+H peaks that corresponded to one 
and two less methylene units compared to 3.23, indicating that traces of chain contracted 
CM products were present. 
The symmetrical dimers 3.24 and 3.25 were similarly prepared but from modified cysteine 
amino acids. N-Boc-S-pentenoyl-Cys-OMe 2.49a, prepared as in Scheme 2.11, Chapter 2, 
was dimerized by treatment with catalyst 1.17 to afford cysteine dimer 3.24 in 4S% yield 
(Scheme 3.8). Substrate 2.48, containing an S-decenoyl tether length (Scheme 2.11), was 
also treated with catalyst 1.17 to give symmetrical dimer 3.25 (7S%) as a mixture which 
contained traces of chain contracted isomers. The presence of these isomers was observed 
by two minor peaks in the HRMS of 3.25 that corresponded to one and two less methylene 
units compared to 3.25. 
2.49a 3.24 
2.48 3.25 
Scheme 3.8. Reagents and Conditions: (i) Amino acid alkene (2 equiv), Grubbs second 
generation catalyst 1.17 (20 mol%), DCM, argon flow, reflux 6 h, then DMSO (SO equiv 
relative to 1.17), rt, 12 h (3.24, 4S%), (3.25, 73%). 
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The serine and cysteine symmetrical dimers shown in Schemes 3.7 and 3.8 were all 
isolated in moderate to good yields. Dimers 3.22 - 3.25 were assigned as the more 
thermodynamically stable E configuration, since olefin metathesis reactions with catalyst 
1.17 are presumed to be under thermodynamic control. The IH and BC NMR spectra of 
symmetrical dimers 3.22 - 3.25 showed the protons and carbons on each side of the double 
bond to have equivalent resonances. 
Both 3.22 and 3.23 represent examples of novel side-chain to side-chain cross-linked 
serine amino acids. The methodology used to prepare 3.22 and 3.23 is amenable to variety 
of acyl tethers appended to the side chain of serine. These variable tethers can be installed 
using the same general acylation reaction, compared to O-allyl tethers of dimers such as 
1.63a (Figure 3.2) that can not so easily be varied. Symmetrical dimers 3.24 and 3.25 
represent novel cysteine side-chain to side-chain tethered amino acids. Cysteine 
commonly forms disulfide bonds in biological systems via the side-chain thiol group. 
Dimers such as 3.24 and 3.25 can be considered disulfide mimics, although they are of 
longer tether length than native disulfide linkages. The C-C linkage used in this study to 
dimerise modified cysteine amino acids would be more stable in biological systems than a 
disulfide bond that can be readily reduced and cleaved. 
3.2.2 Unsymmetrical Dimers 
Unsymmetrical dimers were also synthesised via CM, by the coupling of two different 
amino acid-based substrates that were suitably functionalised with an olefin group. 0-
Decenoyl serine 2.46 was coupled to S-decenoyl cysteine 2.48 upon treatment with catalyst 
1.17 to give heterodimer 3.26 in 66% yield (Scheme 3.9). Cysteine 2.48 was used in two-
fold excess, and consequently homodimer 3.25 was also isolated from the reaction mixture. 
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H 
2.46 
Me02Cr N'BOC j ~S 2.48 ro H 
Me02CrN'BOC S 
o 
+ 3.25 
3.26 
Scheme 3.9. Reagents and Conditions: (i) Grubbs second generation catalyst 1.17 (20 
mol%), DeM, argon flow, reflux 6 h, then DMSO (50 equiv relative to 1.17), rt, 12 h 
(66%). 
An unsymmetrical dimer (3.27) was also synthesised, by the CM coupling between two 
substrates that each contained a different olefin tether length. O-Decenoyl serine 2.46 was 
coupled to S-pentenoyl cysteine 2.49a to give dimer 3.27 in 51 % yield (Scheme 3.10). 
Cysteine-based 2.49a was used in two-fold excess, and consequently homodimer 3.24 was 
also isolated from the crude reaction mixture. 
o 
~ 
BOC'-Nf C02Me H . 
2.46 
(i) 
2.49a 
3.27 + 3.24 
Scheme 3.10. Reagents and Conditions: (i) Grubbs second generation catalyst 1.17 (20 
mol%), DCM, argon flow, reflux 6 h, then DMSO (50 equiv relative to 1.17), rt, 12 h 
(51%). 
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Unlike symmetrical dimers 3.22 - 3.25, the IH and l3e NMR spectra of unsymmetrical 
dimers 3.26 and 3.27 showed non-equivalent resonances for the protons and carbons on 
each side of the double bond. Dimers 3.26 and 3.27 were assigned as the E configuration 
for thermodynamic reasons. A vicinal coupling constant of 15.2 Hz across the double 
bond was measured in the IH NMR spectrum of 3.27, confirming the E configuration. The 
HRMS of both 3.26 and 3.27 showed minor M+H peaks that corresponded to one less 
methylene unit compared to the respective major eM product, indicating traces of chain 
contracted isomers were present in the product mixtures. The synthesis of unsymmetrical 
tether length dimers of the same type of amino acid was not attempted, as it was 
anticipated that separation of the eM and homodimer products would be problematic. 
The preparation of unsymmetrical dimers 3.26 and 3.27 further demonstrates the versatility 
ofthe eM method developed in this thesis, and shows it is applicable for different types of 
amino acids. The general approach of amino acid side-chain acylation to install an olefin 
tether followed by dimerisation via eM could be also applied to other amino acids, for 
example tyrosine, aspartic acid, glutamic acid, or threonine. 
Amino acid dimers such as 3.20 have previously been prepared by eM of acyclic 
precursors 3.19, which were synthesised by acylation of the N-terminal amine with 
carboxylic acids of varying olefin tether lengths (Scheme 3.6). Some advantages of the 
side-chain acylation strategy used in this thesis over this N-terminus method include the 
ability to install the olefin tether at· any position along a peptide that contains an 
appropriate amino acid, for example serine or cysteine. N-Backbone amides have also 
been acylated with carboxylic acids containing different olefin tether lengths (3.16), to give 
dimers such as 3.17 (Scheme 3.5). Some disadvantages of this method may include 
disruption to the peptide secondary structure, and that acylation of a backbone amide in a 
pre-assembled peptide is likely not as efficient compared to a side-chain acylation strategy. 
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3.2.3 Lysine Dimers 
The use of modified lysine substrates 2.37, 2.35, and 2.34 in CM dimerisation reactions 
was attempted, however in all cases only the unreacted lysine substrates were recovered 
from the reaction. The attempted CM reactions of lysine-based substrates are outlined in 
Table 3.1. Initially CM reaction conditions involving a 6 h reflux period were used, but as 
CM coupling did not occur the reflux time was increased to 18 h in an effort to give the 
cross-coupled product. N-Pentenoyl lysine 2.35 was reacted with catalyst 1.17 under a 
range of reaction conditions (see Table 3.1) but an IH NMR spectrum of each crude 
reaction mixture showed only uncoupled CM substrate 2.35 (Table 3.1, entries 1,2, and 3). 
The lack of dimerisation of N-pentenoyl lysine 2.35 was surprising given the successful 
RCM between the two N-pentenoyl tethers of both acyclic dipeptides 4.15 and 4.26 
(Schemes 4.4 and 4.6, Chapter 4). Homodimer formation was then attempted with N-
acryloyllysine 2.37 (entry 4), but again homodimer products were not detected. 
N-Acryloyllysine 2.37 was shown in Chapter 2 to be an excellent CM substrate, and gave 
glyco- and lipoamino acid CM products in high yields (see Schemes 2.18, 2.20). This is 
thought to be because Ne-acryloyllysine 2.37 is a Type II olefin while olefins 1.51b and 
2.76 are Type I olefins, as defined in Table 1.1, Chapter 1. CM between two olefins of 
different Types is thought to be selective, and give higher cross-coupled product yields. 
Dimerisation reactions were attempted between olefin 2.37 and other lysine-based olefins 
such as 2.35 and 2.34. However reaction of N-acryloyl 2.37 with N-pentenoyllysine 2.35 
(entry 5) gave only starting materials. a,p-Unsaturated amide 2.37 was also reacted with 
N-decenoyllysine 2.34 (entry 6) but again only unreacted monomer starting materials were 
present in the crude reaction mixture. 
THE LIBRARY 
lINIVERSllY OF CANTERBURY 
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o 
LNj~ ~ ~ ~ I H n o s Soc" SOC'-NfCO M BOC"NLCO M N COzMe 2 e 2 e 
H H H 
2.34, 2.35, 2.37 2.46 2.48 
Entry Alkene One (1 equiv) Alkene Two (2 equiv) 
Reaction Conditions 
Compound n Compound n 
I Reflux, 6 h 
2 2.35 2 - - Reflux, 18 h 
3 Microwave, 6 min * 
4 2.37 0 - - Reflux, 18 h 
5 2.37 0 2.35 2 Reflux, 18 h 
6 2.37 0 2.34 8 Reflux, 18 h 
7 2.35 2 2.48 - Reflux, 18 h 
8 2.48 - 2.35 2 Reflux, 18 h 
9 2.34 8 2.46 - Reflux, 18 h 
10 2.34 8 2.48 - Reflux, 18 h 
Table 3.1. Attempted CM dimer reactions with lysine-based substrates. Reaction 
conditions - Grubbs second generation catalyst 1.17 (20 mol%), DCM, argon flow, reflux 
(time period shown in table), then DMSO (50 equiv relative to 1.17), rt, 12 h. * Reaction 
carried out under air atmosphere, catalyst 1.17 (20 mol%), DCM, 6 min in 800W 
microwave, then DMSO (50 equiv relative to 1.17), rt, 12 h. 
Dimer formation between lysine substrates 2.35 or 2.34 and a serine or cysteine amino acid 
bearing a side-chain olefin tether was then attempted. N-Pentenoyllysine 2.35 was reacted 
with S-decenoyl cysteine 2.48 (entry 7) to give a mixture of 2.35 starting material and 
cysteine symmetrical homodimer 3.25. CM between 2.35 and 2.48 in the opposite 
equivalent amounts was also attempted (entry 8), but again gave no CM cross-coupled 
product. Dimer formation between Ne-decenoyl lysine 2.34 and another amino acid also 
containing an extended N-decenoyl tether length was attempted, to see if perhaps reduced 
steric clashes between the catalyst and amino acid backbone would result in cross-coupled 
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product formation. In separate reactions N-decenoyllysine 2.34 was treated with either 0-
decenoyl serine 2.46 (entry 9) or S-decenoyl cysteine 2.48 (entry 10) in the presence of 
catalyst 1.17, but in both cases only symmetrical serine (3.23) or cysteine (3.25) 
homodimers were obtained along with starting material 2.34. 
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3.3 CONCLUSION AND FUTURE WORK 
Amino acid dimers were prepared by CM of serine or cysteine-based substrates that 
contain acyl olefin tethers substituted at the side-chain. Two symmetrical serine-based-
(3.22 and 3.23) and two cysteine-based (3.24 and 3.25) dimers were synthesised via CM 
coupling of their corresponding monomer substrates. Dimers 3.22 and 3.24 were 
synthesised from substrates with side-chain pentenoyl tethers, while dimers 3.23 and 3.25 
were synthesised from· substrates containing side-chain decenoyl tethers. Two 
unsymmetrical dimers (3.26 and 3.27) were prepared via CM coupling between a serine-
and a cysteine-based substrate. 
The preparation of cross-linked amino acid dimers 3.22 - 3.27 further demonstrates the 
versatility of the general CM methodology developed in Chapter 2. This allows for 
acylation of natural amino acid residues, in this case the side chains of serine and cysteine, 
using carboxylic acids that are of varying olefin tether length, which can be coupled via 
CM to give cross-linked dimeric products. 
Future work could involve application of this general methodology to the preparation of 
target dimers designed specifically for intended biological uses. Dimers such as 3.22 
3.27 could be used as templates to link together two bioactive peptides, resulting in an 
even more potent peptide dimer structure, for example as discussed in Section 3.1, Scheme 
3.2. Alternatively the general methodology established in this chapter could be applied to 
the dimerisation of larger peptides, to create a stable C-C cross-link of desired length 
between two side-chain acylated amino acids, for example serine or cy~teine, that contain 
the requisite olefin tether. 
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4.1 INTRODUCTION 
RCM is now a firmly established reaction in organic synthesis. The reliability and 
functional group tolerance of this reaction, along with the commercial availability of 
catalysts such as 1.17, has resulted in the use of RCM among organic chemists for a 
myriad of different applications. Some examples outlining the application of RCM to 
modified amino acids and peptides were discussed in Chapter 1, Section 1.6. 
The application ofRCM to the construction of constrained peptidomimetics can be broadly 
grouped into three different categories: 
1) The macrocyclisation of large, acyclic pre-assembled peptides that contain 
two suitably substituted olefin groups. 
2) The rational design and synthesis of low molecular weight bioactive, cyclic 
peptidomimetic compounds specific for certain biological targets. 
3) The synthesis of cyclic amino acid-type building blocks, which can 
subsequently be introduced into peptides to alter stability and/or 
conformational properties in a predictable way. 
RCM can be carried out on pre-assembled acyclic peptides that are suitably functionalised 
with two olefm substituents. The requisite double bonds can be introduced after peptide 
synthesis or alternatively in a step-wise fashion using acyclic olefinic amino acid building 
blocks. RCM of suitably modified pre-assembled peptides has been used to construct fJ-
tum mimetics, for example to generate fJ-tum motifs as a basis of HIV -I protease inhibition 
(Scheme 1.16, Chapter 1 ).1 Disulfide bond mimics have been synthesised using RCM, to 
provide a stable cyclic structural analogue of the natural disulfide-linked cyclic peptide. 
For example both single disulfide bonds (Scheme 1.27i and thio ether 'knots' of more 
than one disulfide bond (Scheme 1.26)3 have been replaced with carbon-carbon linkages 
using RCM carried out on large peptide substrates. 
RCM has also found wide application in drug discovery where cyclic, conformationally 
constrained compounds prepared using this methodology have been shown to have 
enhanced potency relative to the corresponding acyclic analogues. This is likely due to 
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increased metabolic stability and structural pre-organisation into a favourable binding 
conformation. This work has found application in inhibition of enzymes such as HIV 
protease,4 hepatitis C virus NS3 protease,S Grb2 SH2 domain-binding peptides,6 thrombin,7 
and peptide deformylase.8,9 Constrained cyclic enzyme inhibitors provide a basis for 
biomeehanistic investigation as well as probing struetural requirements for efficient ligand-
receptor interactions. 
The synthesis of cyclic amino acid building blocks has attracted much attention over the 
years for a number of reasons. Structural motifs of this type are often found in complex 
natural products and peptides. For example the synthesis of small cyclic ~-amino acid 
subunits has been studied with this application in mind (e.g. Scheme 1.19, Section 1.6).10 
The incorporation of larger cyclic amino acid building blocks into peptides or 
peptidomimetics can induce conformational restrictions and provide important structural 
effects, for example a,a-disubstituted cyclic glycine derivatives have been incorporated 
into helical peptides (Scheme 1.22, Chapter 1). 11 
The short, versatile, and reliable synthesis of novel, cyclic constrained amino acids-based 
compounds that can be used as building blocks in peptide synthesis is of ongoing interest 
and importance. In this thesis cyclic compounds based on lysine, serine, and cysteine 
amino acids and dipeptides were synthesised, resulting in a series of novel RCM products, 
as summarised in Figure 4.1. C-Terminal protected natural amino acids (A) were modified 
to contain side-chain and N-terminus olefin tethers by acylation with carboxylic acids (B) 
to give acyclic amino acid-based RCM precursors (C). The modified amino acids 
containing two substituted olefin tethers (C) were then cyelised via RCM with Grubbs 
second generation catalyst 1.17 to give cyclic compounds (D) of varying ring sizes. Cyclic 
eompounds based on dipeptide scaffolds (H) were also synthesised. Here backbone 
protected natural amino acids (E) were side-chain acylated with a carboxylic acid of 
variable C-chain length (B) to give an amino acid that is substituted with one olefin tether 
(F). Compounds such as F were used as CM substrates in Chapters 2 and 3. The Boc and 
methyl ester group of F were each removed in separate reactions and the resulting free 
amine and the carboxylic acid were coupled to give dipeptides containing two side-chain 
olefin tethers (G). The acyclic dipeptides (G) were cyclised via RCM with 1.17 to give 
cyclic dipeptide-based compounds (H) of varying ring sizes. The olefin tether length and 
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hence ring size of D and H can be controlled by use of different lengths of carboxylic acids 
(B), resulting in a versatile general method. 
o 
o (r1rX~ 
~ U ~ ~~"N C02Me ----.... 
H 
RCM 
C 
D 
RCM 
H 
E 
Amino acid or dipeptide n X m 
Lysine 4 NH2 2,8 
Serine 1 OH 2,8 
Cysteine 1 SH 2,8 
Figure 4.1. 
The general methodology presented here is not limited to a specific amino acid, as is 
demonstrated by the synthesis of cyclic, amino acid building blocks from different natural 
amino acids (A and E). This study was carried out to further explore the versatility, 
reliability, and efficiency of RCM as applied to amino acid and peptide systems. This 
chapter is divided into the type of amino acid used, and then further into the ring size of the 
RCM product. 
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4.2 LYSINE-BASED CYCLIC COMPOUNDS 
Single amino acid-based cyclic compounds 4.6 and 4.13 were synthesised from their 
respective acyclic precursors 4.5 and 4.12, which consisted of a side-chain and amino-
terminus acylated lysine residue. Dipeptide-based cyclic compounds 4.16 and 4.21 were 
synthesised from side-chain acylated acyclic dipeptide precursors 4.15 and 4.20. One 
example of a lysine-based cyclic dipeptide (4.27) was also synthesised via ReM of acyclic 
4.26, which .contained side-chain and amino-terminus substituted olefin tethers as in 4.6 
and 4.13. The synthesis of this novel series of compounds was carried out to demonstrate 
the versatility of the general methodology shown in Figure 4.1, section 4.1, whereby the 
olefin tether length can easily be controlled to give cyclic products containing different 
ring sizes. These studies were also carried out to further explore ReM reactions with 
amino acid and peptide-based substrates. The following section is divided into single 
amino acid and dipeptide compounds. 
4.2.1 Lysine-based single amino acid cyclic compounds 
The synthesis of three lysine-based cyclic amino acid compounds (4.4, 4.6, 4.13) was 
attempted by ReM of precursors containing N-terminus and N-side chain substituted olefin 
tethers. 
Attempted synthesis of ll-membered lysine-based cyclic compound (4.4) 
The synthesis of cyclic compound 4.4 via ReM of acyclic precursor 4.3, which contains an 
a,~-unsaturated amide at both the side chain and the N-terminus, was attempted (Scheme 
4.1). L-Lysine hydrochloride salt 4.1 was esterified by treatment with 2,2-
dimethoxypropane and concentrated hydrochloric acid to give lysine methyl ester 
dihydrochloride salt 4.2. This was then acylated upon reaction with acryloyl chloride in 
alkaline conditions to give N,N-diacryloyl 4.3 in 14% yield after silica gel-based column 
chromatography. The poor isolated yield of 4.3 is likely due to its relative insolubility and 
polymerization of its constituent a,~-unsaturated amide. N,N-Diacryloyl 4.3 was only 
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sparingly soluble in DCM, sufficient to allow characterisation by NMR spectroscopy in 
CDCb. RCM of 4.3 using catalyst 1.17 was not attempted, as other metathesis reactions 
with substrates that were also only sparingly soluble in DCM, for example dipeptide-based 
CM substrate 2.59, were unsuccessful. RCM was not attempted under microwave 
conditions due to insolubility in TCE, nor in a more polar solvent as appropriate catalysts, 
for example 1.20 that can be used in methanol, were not accessible. N,N-Diacryloyl 4.3 
formed a hard, sticky solid over time, in much the same way as Ns-acryloyl lysine CM 
substrate 2.37. 
4,1,R=H 
(i) I 
'----.... 4,2. R = Me 
4,3 4,4 
Scheme 4.1. Reagents and conditions: (i) 2,2-Dimethoxypropane, HCI, MeOH, reflux 2 h, 
then rt, 18 h (84%). (ii) Acryloyl chloride, DIPEA, DCM, O°C, then rt, 16 h (14%). 
Synthesis of 15-membered lysine-based cyclic compound (4.6) 
A I5-membered lysine-based cyclic compound (4.6) was synthesised from Na"Na-
dipentenoyl lysine 4.5, a suitable acyclic precursor for RCM (Scheme 4.2). L-Lysine 
methyl ester dihydrochloride salt 4.2 was acylated by treatment with 4-pentenoic acid and 
EDCIIHOBt to afford Na"Ng-dipentenoyl lysine methyl ester 4.5 in 74% yield. RCM 
precursor 4.5 was then cyclised using Grubbs second generation catalyst (1.17), in 
refluxing DCM, to give an inseparable mixture of cyclic products (73%), containing the E-
I5-membered 4.6 and Z-14-membered ring contracted compound 4.7a or 4.7b as a 3:1 
mixture respectively. The ring-contracted product 4.7a/b is presumed to form by double 
bond migration in either the Ng-side chain (4.7a) or Na,-terminus (4.7b) pentenoyl tether of 
acyclic precursor 4.5. 
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The mixture of the cyclic compounds 4.6 and 4.7a/b (3:1) was hydrogenated using 
palladium on carbon under an atmosphere of hydrogen gas to give 15-membered 4.8 and 
14-membered 4.9 in the same 3:1 ratio. This mixture was then separated by semi-
preparative HPLC to give pure samples of 4.8 and 4.9. 
ENH,.HCI 
HCI.H2N C02Me 
4.2 
4.8 
(iii) 
4.7a 4.7b 4.9 
Scheme 4.2. Reagents and conditions: (i) 4-Pentenoic acid, EDCI, HOBt, DIPEA, DCM, 
rt, 16 h (74%). (ii) Grubbs second generation catalyst 1.17 (20 mol%), DCM, argon flow, 
reflux 6 h, then DMSO (50 equiv relative to 1.17), rt, 12 h (73%, 4.6/4.7a or b, 3:1). (iii) 
H2, 10% PdlC, MeOH, 18 h (quantitative, 4.8/4.9, 3:1). 
The structures of the RCM products 4.6 and 4.7alb, and the saturated analogues 4.8 and 
4.9, were elucidated by NMR and mass spectrometry. An HRMS of 4.8 gave an M+H 
parent ion peak at 299, while the 13C NMR spectrum of 4.8 showed fifteen distinctive 
peaks, both of which are in agreement with the 15-membered ring structure. An HRMS of 
4.9 gave an M+H parent ion peak at 285, and fourteen distinctive resonances in the l3C 
NMR spectrum, with one less carbon between Dc 30 - 40 ppm as compared to 4.8, results 
that are consistent with the 14-membered ring contracted product (4. 7a or b ). 
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Figure 4.2. III NMR spectra (500 MHz, CDCb) of (a) Mixture of 4.6 and 4.7a/b*, 3:1; 
(b) Mixture of 4.8 and 4.9*, 3: 1 ; (c) 4.8 pure sample; (d) 4.9* pure sample. NB. Pure 
samples of 4.8 and 4.9 were only sparingly soluble in CDCb. 
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IH NMR spectra of the mixtures of 4.6/4.7a/b and 4.8/4.9 are shown in Figure 4.2, along 
with those of the pure samples of 4.8 and 4.9 for comparison. The integrals of the 
observed resonances that correspond to the major and minor isomers of both (a) and (b) 
were found to be in a 3:1 ratio. It is assumed that either 4.7a or 4.7b was present in the 
mixture and not both, as there was evidence of only two compounds in 1 H NMR spectrum 
(a), Figure 4.2, and one of these was assigned as IS-membered 4.6. 
Hydrogenation of the mixture containing 4.6/4.7a/b gave 4.8 and 4.9 in a similar 3:1 ratio, 
a result which excluded the possibility of the original 3: 1 mixture being due to E and Z 
isomerism. Peak coalescence was not observed in the high temperature NMR spectrum of 
4.6/4.7alb, indicating the isomer mixture was not due to rotamers. A mass spectrum of the 
4.6 and 4.7a/b mixture showed M+H parent ion peaks at 297 and 283. Thus the isolated 
mixture of products following RCM of acyclic 4.5 was assigned as the IS-membered 4.6 
and 14-membered 4.7a/b. 
The ring contracted compound 4.7alb differs from 4.6 in that it contains an a,y-unsaturated 
amide, the presence of which can be observed by a distinctive doublet at approximately OR 
3.0 ppm! in IH NMR spectra. This doublet, however, was not observed in the NMR 
spectrum of the mixture of 4.6/4.7alb, due to overlapping signals. It was presumed that the 
resonance corresponding to the a,y-unsaturated amide of 4.7a/b was hidden underneath a 
broad multiplet pertaining to the CH2-NH protons at OR 2.95 - 3.00 ppm. A COSY of the 
4.6/4.7alb mixture revealed coupling between this multiplet and the minor olefinic proton 
resonance, consistent with the presence of an a,y-unsaturated amide. 
There is strong experimental evidence to suggest that RCM using catalyst 1.17 occurs 
under thermodynamic control.12,13 Molecular modeling was carried in order to identify the 
most thermodynamically stable configurations of the RCM products shown in Scheme 4.3, 
and hence assign their double bond configuration. The assumption that E is more stable 
than Z, as was made for CM products in Chapters 2 and 3, was not appropriate for cyclic 
compounds as the most stable double bond configuration can also be greatly influenced by 
factors such as torsional strain andlor intramolecular hydrogen bonding. 
1 Refer to Section 2.3.3 for a discussion on double bond migrated products in olefin metathesis 
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(d) 
(e) 
Figure 4.3. Minimized energy structures in vacuo of (a) E-4.6, -62.59 kllmol; (b) Z-4.6, 
-56.13 kllmol; (c) E-4.7b, 32.56 kllmol; (d) Z-4.7b, 14.91 kllmol; (e) E-4.7a, 33.29 
kllmol; (f) Z-4.7a, 22.56 kllmol. For clarity only the amide and double bond hydrogens 
are shown. Boltzmann weighted average energies given. 
The E and Z configurations of 4.6, 4.7a, and 4.7b were each independently constructed in 
silico using Schr6dinger's Maestro build function and minimized using the MMFFs 
forcefield in vacuo, with conformations within 12 kl morl Ang-1 of the lowest energy 
conformation identified to generate a low energy ensemble for each of the six structures. 
These ensembles were then used to calculate the Boltzmann weighted average energy of 
each of the six configurations (E- and Z-4.6, 4.7a and b). These calculations gave E-4.6 to 
be lower in energy compared to Z-4.6, but E-4.7a and b to be higher in energy compared to 
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the corresponding Z configurations. Therefore the RCM products shown in Scheme 4.2 
were assignedE-4.6 and Z-4.7alb (Figure 4.3, lowest energy structures shown). 
A hydrogen bond that spanned the ring scaffold was observed in the lowest energy 
structures both E- and Z-4.6. The lowest energy structures of the Z configuration for both 
ring contracted compounds (4.7a and b) also exhibited a hydrogen bond between the same 
atoms, while E-4.7a and b lacked a hydrogen bond. This is likely the reason for the greater 
thermodynamic stability of Z-4.7a and b compared to the respective E configurations. 
RCM of acyclic diene 4.5 was also carried out under microwave conditions to provide a 
comparison to the standard refluxing DCM conditions discussed above. A solution of 
diene 4.5 and catalyst 1.17 (same molarity % as DCM conditions) in TCE was heated for 
six min at 800 W in a microwave. The higher boiling point of TCE (compared to DCM) 
makes this solvent better suited to microwave conditions. Purification of the crude 
reaction mixture by silica gel-based column chromatography gave an inseparable 4: 1 
mixture of 4.6/4.7a/b in a total yield of 70%. This mixture was then hydrogenated to give 
a product mixture containing 4.8/4.9 in the same 4:1 ratio. 
The formation of I4-membered ring-contracted product 4.7a/b presumably occurs due to 
double bond migration in acyclic 4.5 prior to RCM. The formation of a smaller proportion 
of 4.7a/b under microwave conditions, compared to DCM reflux conditions, suggests that 
in this case perhaps RCM of diene 4.5 occurred at a proportionally faster rate than double 
bond migration of 4.5, which may have been a reflection of less ruthenium hydride species 
present. These kinetic factors refer to the relative rate of the competing reactions of RCM 
and double bond migration, and must not be confused with the thermodynamically 
controlled product outcome ofthe RCM reaction. 
The structure of the minimum energy conformation of IS-membered E-4.6 closely 
resembles. that of cyclic dipeptide 4.10, based on a glutamine to lysine side-chain 
cyclisation, that is present at the terminus of renin enzyme inhibitor 4.11 (Figure 4.4).14 
The IS-membered cyclic compound 4.10 is an important component of inhibitor 4.11, 
evidenced by the fact that the analogues linear peptide with no cyclisation between 
glutamine and lysine showed a several fold lower inhibition compared to 4.11. 
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Figure 4.4. Comparison of E-4.6 to cyclic peptide 4.10, a component of renin inhibitor 
4.11. Representation of 4.10 shows superimposed minimum energy structures of various 
conformations (taken from Kunwar et al).14 Ring systems are numbered according to 
IUP AC naming system for 4.6. 
In addition to having the same ring size, E-4.6 and 4.10 both contain amide groups at ring 
positions 7 and 16, and carbonyl groups at ring positions 8 and 15. These two exposed 
carbonyl groups of 4.10 are thought to hydrogen bond to residues in the renin enzyme 
active site. BothE-4.6 and 4.10 show a similar intramolecular hydrogen bond between the 
amide hydrogen at position 16 and the carbonyl at position 8, resulting in a lO-membered 
pseudo fJ-tum-Hke cyclic structure. These similarities demonstrate that con.<;trained, cyclic 
amino acid-based scaffolds such as E-4.6 could be incorporated into peptides to impart 
enhanced biological activities specific for certain therapeutic targets. 
Synthesis of 27-membered lysine-based cyclic compound (4.13) 
The synthesis of a 27-membered lysine-based cyclic compound (4.13) was also carried out 
to further demonstrate the versatility of the general RCM methodology developed in this 
chapter (refer to Figure 4.1, section 4.1). L-Lysine methyl ester dihydrochloride salt 4.2 
Chapter Four Ring Closing Metathesis 115 
was acylated upon treatment with 10-decenoic and EDCIIHOBt to give Na ,N6-didecenoyl 
lysine methyl ester 4.12 in an excellent yield of 92% (Scheme 4.3). Acyclic RCM 
precursor 4.12 was treated with Grubbs second generation catalyst 1.17 and the product 
purified by silica gel-based chromatography to give the 27-membered cyclic compound E-
4.13 (20%), which contained traces of isomers, including two ring-contracted products. 
LN~ H 7 o (ii) ~ ~, ,il II> ~~'N C02Me 
H 
~~il N C02Me 
H 
4.2 4.12 4.13 
Scheme 4.3. Reagents and conditions: (i) 10-Decenoic acid, EDCI, HOBt, DIPEA, DCM, 
rt, 16 h (92%). (ii) Grubbs second generation catalyst 1.17, DCM, argon flow, reflux 6 h, 
then DMSO (50 equiv relative to 1.17), rt, 12 h (20%). 
Molecular modeling was carried out to identify which double bond configuration of 4.13 
was more thermodynamically stable. Cyclic E-4.13 and Z-4.13 were constructed 
separately in silico using Schrodinger's Maestro build function and minimized using the 
MMFFs forcefield in vacuo, to generate a low energy ensemble for each of the two 
structures. These ensembles were then used to calculate a Boltzmann weighted average 
energy for each of E-4.13 and Z-4.13, which revealed E-4.13 to be lower than Z-4.13 
(Figure 4.5, lowest energy structures shown), therefore the double bond configuration of 
RCM product 4.13 was assigned as E. A hydrogen bond was observed in the energy 
minimized structures of both and Z-4.13, however it was between different sets ofNH-
OC atoms, as shown in Figure 4.5. Structure E-4.13 was hydrogen bonded through the N-
terminus amide and side-chain carbonyl, while Z-4.13 between the N-terminus carbonyl 
and side-chain amide group. The structure of E-4.13 has a comparatively planar ring 
structure with less torsional strain compared to the twisted ring structure of Z-4.13. 
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(a) (b) 
Figure 4.5. Minimized energy structures in vacuo of 4.13 (a) E, -78.78 kJ/mol, and 
(b) Z, -68.67 kJ/mot Boltzmann weighted average energies given. 
The trace isomers could not be purified from the product mixture by silica gel-based 
column chromatography, and as such their precise structure was not determined. The 
HRMS of 4.13 containing these isomers did, however, show two minor peaks, 
corresponding to a molecular mass with one and two less methylene units compared to 
4.13. This indicates that these structures are likely to be 26- and 25-membered ring 
contracted products, presumably formed as a result of double bond migration in the 
acyclic RCM precursor 4.12. 
Amino acid building blocks with large hydrophobic rings have been coupled to the 
backbone terminus of peptides to alter the structural properties of the parent peptide, as 
discussed in Chapter 1, Scheme 1.23. 11 Lysine-based 4.13 also contains a large, 
hydrophobic ring, and could be incorporated to the N-terminus of a peptide to study the 
changes in structural properties ofthe parent peptide. 
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4.2.2 Lysine-based dipeptide cyclic compounds 
Lysine-based cyclic dipeptides 4.16, 4.21, and 4.27 were synthesised to extend the scope of 
this general methodology beyond that of single amino acid-based compounds (refer to 
Figure 4.1, section 4.1). 
Synthesis of22-membered lysine-based cyclic compound (4.16) 
Na-Boc-Ns-pentenoyl-L-Iysine methyl ester 2.35 (Section 2.2, Scheme 2.8) was used as the 
starting material for the synthesis of 22-membered lysine-based cyclic compound 4.16. 
Lysine derivative 2.35 was treated with TFA in DCM to give Boc-deprotected amine salt 
4.14 (Scheme 4.4). C-Teffilinal deprotection of 2.35 was also carried out, where the 
methyl ester of 2.35 was hydrolysed upon treatment with aqueous lithium hydroxide to 
afford carboxylic acid 2.41. The amine salt 4.14 and the carboxylic acid 2.41 were then 
coupled using HATU to give dipeptide 4.15 in 54% yield over 3 steps from 2.35. RCM of 
diene 4.15 by treatment with Grubbs second generation catalyst 1.17 followed by product 
purification using silica gel-based column chromatography gave an inseparable mixture 
(30%) of E-4.16 and a double bond migrated isomer (4.16a) (9:1 by IH NMR). Dipeptide-
based E-4.16 was isolated in 30% yield, despite the presence of only coupled CHR=CHR 
olefinic signals in an IH NMR spectrum of the crude reaction mixture following RCM. 
This low yield is likely the result of difficulties in isolation of the relatively polar E-4.16 
by silica gel-based column chromatography. 
Molecular modeling of E-4.16 and Z-4.16 was again carried out using Schrodinger's 
Maestro, and revealed E-4.16 to have a lower Boltzmann weighted average energy than Z-
4.16 (Figure 4.6, lowest energy structures shown), therefore the RCM product was 
assigned as E-4.16. The lowest energy structures of both and Z-4.16 showed two 
hydrogen bonds, but in different positions the E structure showed two hydrogen bonds 
spanning the ring structure, while the Z structure showed one hydrogen bond spanning the 
ring and one not across the ring between two atoms of the peptide backbone. 
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0 (i) LN~ .. 4.14, R1 = H.TFA 
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Scheme 4.4. (i) TFA, DCM, rt, 12 h. (ii) LiOH, THF, O°C, 30 min. (iii) HATU, DIPEA, 
DMF, rt, 18 h (54%, 3 steps). (iv) Grubbs second generation catalyst 1.17, DCM, argon 
flow, reflux 6 h, then DMSO (50 equiv relative to 1.17), rt, 12 h (4.16/4.16a 9:1,30%). 
(a) 
Figure 4.6. Minimized energy structures in vacuo of 4.16 (a) -302.08 kJ/mol; and 
(b) Z, -299.77 kJ/mo!. Boltzmann weighted average energies given. 
The trace isomers could not be purified by silica gel-based column chromatography, and as 
such their exact structure was not determined. However the IH NMR spectrum of 4.16 
containing these isomers showed a minor doublet at (5H 2.8 ppm that is consistent with an 
a,y-unsaturated amide, which is presumably contained within a double bond migrated 
structure (4.16a). Isomer 4.16a could be a ring contracted structure resulting from double 
bond migration in either pentenoyl tether of acyclic 4.15, or a structure resulting from 
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double bond migration in 22-membered cyclic 4.16. The HRMS of 4.16 containing traces 
of isomers showed a minor peak corresponding to one less methylene unit compared to 
4.16, consistent with the presence of a ring contracted product. 
Compound E-4.16 is an example of a cyclic, constrained amino acid building block, in that 
the pre-cyclised structure could be incorporated into the step-wise synthesis of a target 
peptide sequence, to give a modified peptide that contains a cyclic structure. 
Synthesis of 34-membered lysine-based cyclic compound (4.21) 
A 34-memebered cyclic compound (4.21) was also prepared by RCM of an acyclic lysine-
based dipeptide (4.20), containing two side-chain substituted N-decenoyl tethers (Scheme 
4.5). 
4.17 4.18 
o 
J:'~ H Boc"N~~~N 
H 0 COzMe 0 
4.21 
(iii) 
~. - R = Boc, 2.34 
(Ii) RHN~C02Me • ~ '------JOo- R = H.TFA, 4.19 
~~~ 
o 
Scheme 4.5. (i) 10-Decenoyl chloride, NaOH, acetonitrile (64%). (ii) TFA, DCM, rt, 12 h. 
(iii) HATU, DIPEA, DMF, rt (87%, 2 steps). (iv) Grubbs second generation catalyst 1.17, 
DCM, argon flow, reflux 6 h, then DMSO (50 equiv relative to 1.17), rt, 12 h (28%). 
Models of both E-4.21 and Z-4.21 were constructed using Schrodinger's Maestro build 
function and minimized to generate a low energy ensemble for each configuration, in 
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which E-4.21 was found to have a lower Boltzmann weighted average energy than that of 
Z-4.21 (Figure 4.7, lowest energy strm"iures shown). On this basis cyclic compound 4.21 
was assigned as the E configuration. The lowest energy structures of both E- and Z-4.21 
(Figure 4.7) each showed two hydrogen bonds, but in different positions. 
The trace isomers present as a mixture along with E-4.21 could not be purified by silica 
gel-based column chromatography, and as such their precise structure was not determined. 
However the HRMS 0 f 4.21 containing these isomers showed a minor M+H peak: 
corresponding to one less methylene unit compared to 4.21, indicating the presence of a 
33-membered ring contracted product. 
Figure 4.7. Minimized energy structures in vacuo of 4.21 (a) E, -310.38 kJ/mol, and 
(b) Z, -297.53 kJ/mol. Boltzmann weighted average energies given. 
Synthesis of IS-membered lysine-based cyclic compound (4.27) 
Cyclic dipeptide-based compounds 4.16 and 4.21 are both examples of side-chain to side-
chain cyc1isation products. An example of a dipeptide-based side-chain to N-terminus 
cyclic compound (4.27) was also constructed, via RCM of acyclic precursor 4.26 (Scheme 
4.6). 
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Scheme 4.6. (i) 4-Pentenoyl chloride 4.24, NaOH, acetonitrile (63%). (ii) HATU, 
DIPEA, DMF, rt (77%). (iii) Grubbs second generation catalyst 1.17, DCM, argon flow, 
reflux 6 h, then DMSO (50 equiv relative to 1.17), rt, 12 h (4.27/4.27a 8:1, 27%). 
Commercially available NB-Cbz-L-Lys hydrochloride salt 4.22 was acylated by treatment 
with 4-pentenoyl chloride 2.39 (see Scheme 2.9) to give Na.-pentenoyl substituted lysine 
4.25 in 63% yield. The carboxylic acid 4.25 and the amine salt 4.14 (see Scheme 4.4) were 
then coupled using HA TU to afford dipeptide diene 4.26 in 77% yield. RCM of 4.26 was 
carried out using Grubbs second generation catalyst 1.17 and the product purified to give 
the 18-membered cyclic compound E-4.27 (27%) which contained traces of isomers, 
including a double bond migrated isomer (4.27a) (8:1 by IH NMR). 
Molecular modeling of E-4.27 and Z-4.27 was carried out using Schrodinger's Maestro and 
the Boltzmann weighted average energy was calculated for each configuration. This 
revealed E-4.27 to be more thermodynamically stable than Z-4.27 (Figure 4.8, lowest 
energy structures shown), therefore the RCM product 4.27 was assigned as E. A hydrogen 
bond was observed in both E and Z minimized energy structures shown in Figure 4.8, but 
in different positions - the E structure showed a hydrogen bond spanning the ring while the 
Z structure revealed weak hydrogen bonding between 3 atoms that spanned the ring. 
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The trace isomers could not be purified by silica gel-based chromatography) and as such 
their precise structure was not determined. However a minor doublet at (ill 2.9 ppm was 
observed in the IH NMR spectrum of 4.27 that is consistent with a structure that contains 
an u)y-unsaturated amide (4.27a)) presumably formed due to a ring contraction andlor 
double bond migration. The HRMS of 4.27 containing trace isomers showed a minor 
M+H peak corresponding to one less methylene unit compared to 4.27) consistent with the 
presence of a 17-memebered ring contracted product. 
(a) (b) 
Figure 4.8. Minimized energy structures in vacuo of 4.27 (a) E) -257.45 kJ/mol, and 
(b) Z) -249.19 kJ/mol. Boltzmann weighted average energies given. 
In summary) three lysine-based constrained dipeptides were synthesised - two via side-
chain to side-chain cyclisation (4.16 and 4.21) and one via N-terminus to side-chain 
cyclisation (4.27). Molecular modeling of both the E and Z configurations of these cyclic 
structures revealed E to be more thermodynamically stable than Z) thus compounds 4.16, 
4.21) and 4.27 were all assigned as E. Trace isomers were present as an inseparable 
mixture along with ReM products 4.16,4.21) and 4.27) of which were only assigned when 
they contained an u)y-unsaturated amide (4.16a and 4.27a). 
The synthesis of lysine-based cyclic compounds 4.6, 4.13) 4.16) 4.21 and 4.27 with varied 
ring size and site of olefm tether attachment was achieved using the same versatile general 
methodology as shown in Figure 4.1) section 4.1. 
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4.3 SERINE- AND CYSTEINE-BASED CYCLIC 
COMPOUNDS 
123 
Cyclic serine and cysteine single amino acid and dipeptide-based compounds were also 
synthesised in addition to the lysine-based compounds discussed in section 4.2. This was 
carried out to demonstrate the generality of the approach to different types of amino acids. 
These included three serine-based cyclic compounds (4.31, 4.33, 4.37) and four cysteine-
based cyclic compounds (4.40, 4.42, 4.45, 4.46) that were all synthesised by RCM of the 
corresponding acyclic diene. 
4.3.1 Serine-based cyclic compounds 
Synthesis of 12-membered serine-based cyclic compound (4.31) 
Serine-based cyclic compound 4.31 was synthesised by RCM ofthe acyclic precursor 4.30, 
which contained pentenoyl tethers substituted at the N-tel1ninus and side-chain positions of 
serine (Scheme 4.7). L-Serine 4.28 was esterified by treatment with 2,2-dimethoxypropane 
and concentrated hydrochloric acid to give serine methyl ester hydrochloride salt 4.29. 
This was then acylated by treatment with 4-pentenoic acid and HATU to give N,D-
dipentenoyl serine 4.30 in one step and in 59% yield. RCM of acyclic diene 4.30 was 
carried out using Grubbs second generation catalyst 1.17 to afford 12-membered serine-
based cyclic E-4.31, the structure of which was detennined by x-ray crystallography. 
(ii) 
,--- 4.28, R1 = H, R2 = H 
(i) 
'-----..... 4.29, R1 = H.HCI, R2 = Me 
o 
o~ ~Nic02Me 
H 
4.30 
(iii) 
4.31 
Scheme 4.7. Reagents and conditions: (i) 2,2-Dimethoxypropane, HCI, MeOH, reflux 2 h, 
then rt, 18 h (80%). (ii) 4-Pentenoic acid, HATU, DIPEA, DMF, rt, 16 h (59%). (iii) 
Grubbs second generation catalyst 1.17, DCM, argon flow, reflux 6 h, then DMSO (50 
equiv relative to 1.17), rt, 12 h (45%). 
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The x-ray crystal structure of 4.31 revealed an E configuration. Molecular modeling of 
both E- and Z-4.31 was carried out and compared to the x-ray crystal structure of 4.31, as 
is discussed in section 4.3.4. Molecular modeling showed E-4.31 to be more 
thermodynamically stable than the Z, which is in agreement with the observed E 
configuration in the x-ray crystal structure. This also validates the assignment of RCM 
product configurations made for other compounds in this thesis. The IH NMR spectrum of 
E-4.31 showed evidence of only one compound, and the HRMS of 4.31 showed only one 
M+H peak: at 284, indicating a lack of trace isomers. Cyclic compound 4.31 has 
previously been reported,15 as discussed at the end of section 4.3.4. 
Synthesis of 24-membered serine-based cyclic compound (4.33) 
24-Membered cyclic compound 4.33 was synthesised by RCM of serine-based acyclic 
precursor 4.32 (Scheme 4.8), which contains olefin tethers substituted at the same side-
chain and N-terminal positions as 4.30. 
(i) 
4.29 
o 
Jl /'-.. /'-. /'. /'-. ~ o 0 "-/ "-/ "-/ "-/ ~ ~NJ:C02Me 
H 
j 
4.32 
(ii) 
o 
~l N COzMe 
H 
4.33 
Scheme 4.8. Reagents and conditions: (i) 10-Decenoic acid, HATU, DIPEA, DMF, rt, 16 
h (54%). (ii) Grubbs second generation catalyst 1.17, DCM, argon flow, reflux 6 h, then 
DMSO (50 equiv relative to 1.17), rt, 12 h (15%). 
Serine methyl ester hydrochloride salt 4.29 was acylated by treatment with 10-decenoic 
acid and HATU to give N,O-didecenoyl serine 4.32 in one step (54% yield). Acyclic 
precursor 4.32 was then cyclised using Grubbs second generation catalyst 1.17 and the 
crude product purified by silica gel-based chromatography to give 24-membered cyclic 
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compound E-4.33 (15%), which contained traces of isomers, including a ring contracted 
product. 
The isolated yield of E-4.33 (15%) was much lower than that of E-4.31 (45%), even 
though IH NMR spectra of the crude reaction mixture in each case showed evidence of 
only RCH=CHR coupled olefin protons. Compound 4.33 is more non-polar compared 
than 4.31, therefore isolation issues related to purification by silica gel-based column 
chromatography are presumably not a large contributing factor to the difference in isolated 
yields. The lower isolated yield of 4.33 could be due to substituted double bond isomers 
that have similar IH NMR resonances to product 4.33, but were not isolated from the crude 
reaction mixture. The yield of 4.31 may also be a reflection of comparatively less 
structural pre-organisation of the decenoyl tethers of acyclic 4.32 into a favourable 
orientation for RCM, compared to the pentenoyl tethers of acyclic 4.30. 
Molecular modeling of E- and Z-4.33 was independently carried out using Schrodinger's 
Maestro to calculate the Boltzmann weighted average energy for each configuration 
(Figure 4.9, lowest energy structure shown). 
(a) 
Figure 4.9. Minimized energy structures in vacuo of 4.33 (a) E, 37.14 kJ/mol, and (b) Z, 
38.00 kJ/mol. Boltzmann weighted average energies given. 
This revealed E-4.33 to have a lower Boltzmann weighted average energy than that of Z-
4.33. On this basis the RCM product 4.33 was assigned as the E configuration. Hydrogen 
bond interactions were not observed in the minimized energy structures of either E- or Z-
4.33. The trace isomers could not be purified using silica gel-based column 
chromatography, and as such their precise structure was not determined. However the 
HRMS of 4.33 containing these isomers showed major M+H peak at 424 and a minor 
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M+H peak at 410, indicating the presence of a structure that contains one less methylene 
unit compared to 4.33. This observed isomer was presumed to be a 23-memebered ring-
contracted product, resulting from double bond migration in acyclic RCM precursor 4.32. 
Synthesis of 16-membered serine-based cyclic compound (4.37) 
Both 12-membered E-4.31 and 24-membered E-4.33 are examples of cyclic compounds 
based on a single serine residue. A cyclic compound (4.37), based on a serine dipeptide 
framework, was also synthesised via RCM of acyclic precursor 4.36 (Scheme 4.9). 0-
Pentenoyl serine 2.45, synthesised for CM studies discussed in Chapter 2 (Scheme 2.10), 
was used as the starting material for the synthesis of 4.37. 
(iii) 
o 
o~ (iv) 
BOC'N~~'T'O~ 
H 0 C02Me 
Oi) 4.34, R1 = Boc, R2 = H 
4.35, R1 = H.TFA, R2 = Me 
4.36 
o 
o~ 
i 4.37a-b 
o 
O~-B:'Y(~Y-O~ 
H 0 C02Me 
4.37 
Scheme 4.0. (i) TF A, DCM, rt, 12 h. (ii) LiOH, THF, O°C, 30 mins. (iii) EDCI, HOBt, 
DIPEA, DCM, rt, 18 h (13%, over 3 steps). (iv) Grubbs second generation catalyst 1.17, 
DCM, argon flow, reflux 6 h, then DMSO (50 equiv relative to 1.17), rt, 12 h 
(4.37/4.37a/4.37b 23:1:1, 45%). 
Serine-based 2.45 was treated with TFA in DCM to give the Boc-deprotected amine salt 
4.35. The methyl ester of 2.45 was hydrolysed by treatment with aqueous lithium 
hydroxide to afford carboxylic acid 4.34, and this was coupled to the amine salt 4.35 on 
treatment with EDCIIHOBt to give acyclic RCM precursor 4.36. This was then cyclised 
using Grubbs second generation catalyst 1.17 and the product purified by silica gel-based 
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column chromatography to afford an inseparable mixture (45%) of l6-membered cyclic E-
4.37 and two double bond migrated isomers (4.37a and b) (23:1:1 by IH NMR). 
The formation of dipeptide 4.36 in low yield (13% over 3 steps) was likely due to 
pentenoyl ester cleavage of 2.45 during treatment with aqueous lithium hydroxide. The 
duration of this reaction was shortened from 30 min to 10 min, but even this produced a 
mixture of products resulting from ester hydrolysis. A C-terrninal protecting group that is 
labile under conditions in which the pentenoyl ester and amine protecting groups of 2.45 
are not would potentially overcome this problem. Alternatively, a method selective for 
hydrolysis of the methyl ester over the pentenoyl ester would suffice. Methyl ester 
hydrolysis of 2.45 was attempted using milder conditions by treatment with 2% aqueous 
sodium carbonate in I: I THF/methanol, however this still gave a mixture of products. 
Other methods selective for the methyl ester of 2.45 were not attempted due to time 
constraints. 
(a) 
Figure 4.10. Minimized energy structures in vacuo of 4.37 (a) E, -10.04 kJ/mo~ and (b) Z, 
-9.55 kJ/mol. Boltzmann weighted average energies given. 
Molecular modeling of both E- and Z-4.37 was carried out using Schrodinger's Maestro 
and minimized using the MMFFs forcefield in vacuo to generate a low energy ensemble 
for each configuration. From this the Boltzmann weighted average energies of E and Z 
were calculated, revealing E-4.37 to be more thermodynamically stable than Z-4.37 (Figure 
4.10, lowest energy structures shown). The cyclic ReM product 4.37 was assigned as the 
E configuration on this basis. Hydrogen bonds were not observed in the lowest energy 
structures of E- or Z-4.37. 
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The trace isomers (4.37a, b) present as a mixture along with 4.37 could not be purified by 
silica gel-based column chromatography, and as such their entire structure was not 
determined. Two minor doublets at 8H 2.97 and 3.03 ppm were, however, observed in the 
IH NMR spectrum of the 4.37 product mixture, consistent with isomers containing an a,Y-
unsaturated amide. These are likely formed as a result of double bond migration in acyclic 
4.36 andlor RCM product 4.37. Isomer structures containing an a,y-unsaturated amide 
were present along with lysine-based dipeptides 4.16 (4.16a) and 4.27 (4.27a), that were 
also formed during RCM of an acyclic precursor with pentenoyl tethers. The HRMS of 
4.37 was consistent with these isomers (4.37a, b) with a minor ion corresponding to one 
less methylene unit compared to 4.37, indicating the presence of a 21-membered ring 
contracted product. 
The same isolated yields (45%) obtained for the dipeptide-based product 4.37 and single 
amino acid-based 4.31, both synthesised from acyclic precursors that contained the same 
N-pentenoyl tethers, demonstrates that this general methodology (see Figure 4.1, section 
4.1) is equally applicable to larger molecular architectures. 
4.3.2 Cysteine-based cyclic compounds 
Synthesis of 12-membered cysteine-based cyclic compound (4.40) 
A cysteine-based cyclic amino acid (4.40) was synthesised via RCM from an acyclic 
cysteine-based diene (4.39) that contains S-side chain and N-terminus olefin tethers, to 
further demonstrate the generality of this methodology (Scheme 4.1, section 4.1) to other 
amino acids. Commercially available L-cysteine methyl ester hydrochloride salt 4.38 was 
acylated by reaction with 4-pentenoic acid and BOP-CI to give N,S-dipentenoyl cysteine 
methyl ester 4.39 in one step and 88% yield. 
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Scheme 4.10. Reagents and conditions: (i) 4-Pentenoic acid, BOP-CI, TEA, DCM, OoC, 
then rt; 18 h (85%). (ii) Grubbs second generation catalyst 1.17, DCM, argon flow, reflux 
6 h, then DMSO (50 equiv relative to 1.17), rt, 12 h (74%). 
RCM was carried out by treatment of 4.39 with Grubbs second generation catalyst 1.17, to 
afford 12-membered cysteine-based cyclic compound E-4.40 in 74% yield. RCM product 
4.40 was analysed x-ray crystallography, which revealed the double configuration to be E. 
Cysteine-based E-4.40 differs from serine-based E-4.31 (see Scheme 4.7) by the presence 
of a sulfur atom derived from cysteine instead of an oxygen atom derived from serine. 
Molecular modeling of both . and Z-4.40 was carried out, and these results are discussed 
and compared to the crystal structure of E-4.40 in section 4.3.4. As was the case for 
serine-based E-4.31, the molecular modeling results showed the E configuration to be more 
thermodynamically stable than Z, in agreement with the observed configuration x-ray 
crystal structure, and also further validating other molecular modeling results. 
Synthesis of 24-membered cysteine-based cyclic compound (4.42) 
In a likewise fashion to the synthesis of 24-membered serine-based cyclic compound 4.33, 
cysteine-based 4.42 was synthesised via RCM from an acyclic precursor (4.41) that 
contains N-terminus and side-chain decenoyl tethers (Scheme 4.11). L-Cysteine methyl 
ester hydrochloride salt 4.38 was acylated by treatment with 10-decenoic acid and BOP-CI 
to afford N,S-didecenoyl acyclic RCM precursor 4.41 in one step (48% yield). RCM of 
4.103-2.1 was carried out using Grubbs second generation catalyst 1.17 and the product 
purified by silica gel-based column chromatography to give an inseparable mixture (43%) 
of E-4.42 and trace isomers, including a ring-contracted product. 
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Scheme 4.11. Reagents and conditions: (i) lO-Decenoic acid, BOP-CI, TEA, DCM, O°C, 
then rt, 18 h (44%). (ii) Grubbs second generation catalyst 1.17, DCM, argon flow, reflux 
611, then DMSO (50 equiv relative to 1.17), rt, 12 h (43%). 
Molecular modeling of both E- and Z-4.42 was independently carried out usmg 
Schrodinger's Maestro, and from the lowest energy ensembles that were generated the 
Boltzmann weighted average energy of each configuration was calculated (Figure 4.11, 
lowest energy structures shown). This revealed E-4.42 to be lower in energy than Z-4.42, 
and as such the configuration ofRCM product 4.42 was assigned as E. The lowest energy 
structures of E- and Z-4.42 both showed evidence of a hydrogen bond between the thio 
ester carbonyl and the amide hydrogen. 
(a) 
Figure 4.11. Minimized energy structures in vacuo of 4.42 (a) E, 9.65 kJ/mol, and (b) Z, 
15.82 kJ/mo!. Boltzmann weighted average energies given. 
The trace isomers present in the sample of E-4.42 could not be purified by silica gel-based 
column chromatography, and as such their precise structures were not determined. The 
HRMS of 4.42 that contained these isomers did, however, show a minor peak that 
corresponded to one less methylene unit compared to 4.42, presumably due to the presence 
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of a 23-membered ring contracted product formed due to double bond migration of acyclic 
precursor 4.41. 
Synthesis of 16-membered cysteine-based dipeptide cyclic compound (4.45) 
Cysteine-based cyclic dipeptide 4.45 was synthesised from acyclic dipeptide precursor 
4.44, using the same general methodology employed for the synthesis of 16-membered 
serine-based 4.37, but instead using 2.49a as the starting material. S-Pentenoyl cysteine 
2.49a (Scheme 2.11, Chapter 2) was treated with TF A in DCM to afford the Boc-
deprotected amine salt 4.43 (Scheme 4.12). The methyl ester of 2.49a was hydrolysed by 
treatment with aqueous lithium hydroxide to give carboxylic acid 2.49b, which was then 
coupled to the amine salt 4.43 using HATU to give dipeptide-based RCM precursor 4.44 
(11 % yield over 3 steps). Diene 4.44 was cyclised via RCM using with Grubbs second 
generation catalyst 1.17 and the product purified by silica gel-based chromatography to 
give Z-4.45 (36%) that contained traces of isomers, including the double bond migrated 
isomer 4.45a (10:1 by IH NMR). 
2.49a, R 1 = Boc, R2 = Me 
(ii) 
! (I) 4.45a 
2.49b, R 1 = Boc, R2 = H 
(iii) 
4.43, Rl = H.TFA, R2 = Me 
Scheme 4.12. (i) LiOR, THF, O°C, 30 min. (ii) TF A, DCM, rt, 12 h. (iii) HATU, DIPEA, 
DMF, rt, 18 h (11 %, over 3 steps). (iv) Grubbs second generation catalyst 1.17, DCM, 
argon flow, reflux 6 h, then DMSO (50 equiv relative to 1.17), rt, 12 h (4.45/4.45a 10:1, 
36%). 
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The low yield (11%) of dipeptide 4.44 could have been due to thio ester cleavage of2.49a 
during treatment with lithium hydroxide. However, preparation of S-pentenoyl-~-cysteine 
2.51 (Chapter 2, Scheme 2.11) that also involved treatment of 2.49a with aqueous lithium 
hydroxide, followed by further elaboration, proceeded efficiently. This indicates that 
minimal S-pentenoyl ester cleavage occurs under these conditions. As is in the case for 
serine dipeptide 4.36, a different C-terminal protecting group strategy may be required to 
improve the yield of dipeptide 4.44. Due to time constraints this was not investigated. The 
emphasis in this thesis was on the subsequent RCM of acyclic dipeptide-based 4.44 to give 
cyclic product 4.45. 
Molecular modeling using Schrodinger's Maestro and Boltzmann weighted average energy 
calculations was carried out independently for both E- and Z-4.45, which showed the Z 
configuration to be more thermodynamically stable than E (Figure 4.12, minimum energy 
structures shown). The RCM product 4.45 was therefore assigned as Z. This is the only 
dipeptide-based compound synthesised in this thesis where the Z configuration was s~own 
to be more thermodynamically stable than E. The minimum energy structure of E-4.45 did 
not show any hydrogen bonding, while Z-4.45 showed a hydrogen bond between the Boc 
group carbonyl and amide hydrogen of the adjacent cysteine residue, perhaps a reason for 
the lower energy of the Z configuration. 
The exact structure of the trace isomer (4.45a) present as a mixture with Z-4.45 was not 
assigned since it could not be separated by silica gel-based column chromatography. 
However, the a,y-unsaturated amide of isomer 4.45a could be assigned, as a minor doublet 
at OH 3.0 ppm was observed in the lH NMR spectrum of the product mixture. This trace 
isomer (4.45a) is presumably formed due to double bond migration in either of the 0-
pentenoyl tethers. An HRMS showed a minor M+H peak corresponding to one less 
methylene unit compared to 4.45, suggesting that isomer 4.45a is a IS-membered ring 
contracted product presumably formed by double bond migration in acyclic RCM 
precursor 4.44. The 16-membered serine-based compound 4.37 was also isolated along 
with traces of an isomer containing an a,y-unsaturated amide. 
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(a) 
Figure 4.12: Minimized energy structures in vacuo of 4.45 (a) E, -76.76 kJ/mol, and (b) Z, 
-77.89 kJ/mot Boltzmann weighted average energies given. 
To summarize, three serine-based (4.31, 4.33, 4.37) and three cysteine-based (4.40, 4.42, 
4.45) cyclic compounds were synthesised via RCM of an acyclic precursor. The acylation 
of natural amino acids and. dipeptides with olefin-containing carboxylic acids of 
controllable lengths, followed by RCM to give cyclic compounds of varied ring sizes has 
therefore been demonstrated as a viable general method. These constrained, cyclic amino 
acid building block-type compounds could be incorporated into peptides to potentially alter 
the biological or physical properties ofthe parent peptide in an intended manner. 
The 5 lysine-, 3 serine-, and 3 cysteine-based constrained, cyclic anuno acids and 
dipeptides described here are interesting molecular architectures in their own right. For 
example this array of 11 compounds could be added to an in-house library and tested in 
screening assays to identify potential biological activities against intended therapeutic 
targets. The double bond moiety of the cyclic compounds could also be elaborated, for 
example by epoxidation, dihydroxylation, or bromination, to produce a library of highly 
functionalised novel molecular architectures. 
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4.3.3 Synthesis of cysteine-tert-Ieucine-based dipeptide (4.46) 
The RCM products described in sections 4.1 and 4.2 are not specifically designed to target 
a particular biological receptor. Attempts to extend the general methodology outlined in 
Figure 4.1, section 4.1 to one such specific target, cyclic peptide deformylase (PDF), are 
described in the following section. PDF is an essential enzyme in the life cycle of all 
eubacteria, and thus has been identified as a therapeutic target for antibacterial drug 
design. 16-18 
A target compound (4.46) was synthesised based on the reported PDF inhibitor 4.47 
(Figure 4.13),9,19 also synthesised using RCM, that shows enhanced inhibition compared to 
the analogous acyclic compound. Some similarities between 4.46 and 4.47 include the 
same ring size, and a dipeptide-based scaffold containing a tert-leucine residue, known to 
be important in inhibitor binding. Compound 4.46 does differ from 4.47 in some respects, 
for example it lacks a metal chelating warhead, and contains a thio ester where inhibitor 
4.47 contains an unsubstituted hydrocarbon chain. The methyl ester of 4.46 could 
potentially be derivatised to contain a metal chelating warhead.8,20 In this thesis, cyclic 
4.46 was synthesised by the RCM of an acyclic dipeptide-based precursor (4.52) that has 
pentenoyl tethers substituted at the N-terminus and S-side chain positions. The olefin 
tethers of RCM precursor 4.52 can be installed via an acylation reaction with a carboxylic 
acid, thus demonstrating the general methodology described in this thesis to a target 
compound. 
0+ H C0(~AyN\C02Me HOI - S 1-+
0 
N~N 6 H 
4.46 0 4.47 
Figure 4.13. Comparison of 4.46 to PDF inhibitor 4.47.9 (Metal-chelating warhead 
circled). 
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Commercially available tert-L-Ieucine 4.48 was treated with Boc-anhydride in the presence 
of sodium hydroxide to give Boc-protected 4.49 in quantitative yield (Scheme 4.13). Boc-
L-tert-Leucine 4.49 and S-pentenoyl cysteine methyl ester amine salt 4.43 (see Scheme 
4.12) were treated with HATU in DMF, but the expected coupled dipeptide was not 
isolated. However reaction of 4.49 with 4.43 in the presence of EDCIIHOBt in DCM gave 
dipeptide 4.50 in a moderate yield of 46%. tert-Leucine-cysteine dipeptide 4.50 was then 
treated with TFA in DCM to give Boc-deprotected 4.51, and this was acylated with 4-
pentenoic using EDCI/HOBt to afford acyclic RCM precursor 4.52 in 72% yield over 2 
steps. Diene 4.52 was cyclised using Grubbs second generation catalyst 1.17 to give 15-
membered compound E-4.46 in 65% yield. 
(i) 
4.48 4.49 
(v) 
R,~~yC02Me 
H 0 .;; 
~s 
o 
4.50, R = Boc 
4.51, R = H.TFA 
J (iv) 
OYH ~N,~N.yC02Me 
H 0 ~ ~s 
o 
4.52 
Scheme 4.13. Reagents and Conditions: (i) Boc20, NaOH, waterltert-butyl alcohol, 18 h, 
rt (99%). (ii) EDCI, HOBt, DIPEA, DCM, 16 h (46%). (iii) TFA, DCM, rt, 18 h. (iv) 4-
Pentenoic acid, EDCI, HOBt, DIPEA, DCM, rt, 16 h (72%, over 2 steps). (v) Grubbs 
second generation catalyst 1.17, DCM, argon flow, reflux 6 h, then DMSO (50 equiv 
relative to 1.17), rt, 12 h (65%). 
Molecular modeling of 4.46 was· carried out to determine the most thermodynamically 
stable double bond configuration, and therefore enable assignment of the RCM product. 
Both and Z-4.46 were independently modeled using Schrodinger's Maestro, and the 
Boltzmann weighted average energy for each configuration was calculated from the 
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minimized energy ensemble (Figure 4.14, lowest energy structures shown). These results 
showed E-4.46 to be more thermodynamically stable than Z-4.46, therefore the RCM 
product was assigned as E-4.46. 
(a) (b) 
Figure 4.14. Minimized energy structures in vacuo of 4.46 (a) E, 113.26 kJ/mol, and (b) 
Z, 116.65 kJ/mol. Boltzmann weighted average energies given. 
The minimized energy structures of E- and Z-4.46 both revealed a hydrogen bond, but in 
the lower energy E confonnation between the N-pentenoyl carbonyl and cysteine amide, 
and in the Z configuration between the thio ester carbonyl and the tert-Ieucine anude. 
The synthesis of cyclic dipeptide-based 4.46 was carried to demonstrate that the general 
methodology involving acylation of natural amino acid functional groups followed by 
RCM is a viable route to the core of compounds of the type 4.47. The versatility and 
control over olefm tether length discussed in this thesis is also applicable in this case, 
where for example cyclic compounds based on 4.46 with different ring sizes could be 
synthesised. This approach can be useful in the design-based synthesis of therapeutic 
compounds, where the optimum ring size for ligand-receptor binding can be determined 
through structure-activity relationships. 
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4.3.4 Structural analysis of 12-membered cysteine- and serine-based 
cyclic compounds (4.40 and 4.31) 
X-Ray crystal structures 
Crystal structures of cysteine-based 4.40 and serine-based 4.31 cyclic compounds were 
obtained to determine their structure and configuration, and were both found to be the E 
configuration (Figure 4.15). 
(a) 01 (b) 
(c) 
Figure 4.15. X-ray crystal structures of E-4.40 (a, b) and E-4.31 (c, d). 
Cyclic compound E-4.31 has been reported previously,15 as outlined later in this section, 
while E-4.40 is presented for the fIrst time in this thesis. The structures of E-4.40 and E-
4.31 both reveal a low trans-annular and torsional strain, which can be likened to the 
insertion of planar, Sp2 -hybridised two-atom elements with trans geometry into the ring 
bonds of a fully hybridized six-membered ring (Figure 4.16). The ring-forming reaction in 
the synthesis of 4.40 and 4.31 was RCM, which installed the E double bond as the last 
trans element. This alternating pattern of Sp2 and Sp3 hybridized two-atom elements results 
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in a hexagonal shaped ring structure, which is observed in the x-ray crystal structures E-
4.40 and E-4.31, as shown in Figure 4.15, (b) and (d). An intennolecular hydrogen bond 
was observed between the amide hydrogen and 02 oxygen of different molecules in both 
E-4.40 (2.82 A) and E-4.31 (2.83 A). 
amide bond !'00~i trans double 
~' l}J':U~l '\, bond 
Me02C '0' ---"'.... Me02c~x ___ ='-' 
, , , X S, 4.40 
insert 1 ___ Q,: =0,4.31 
ester bond 
Figure 4.16. Illustration of the ideal hexagonal shaped ring structure with low torsional 
and trans-annular strain. Adapted fann Schreiber et aI. I5 
Superposition of the x-ray crystal structures E-4.40 and E-4.31 reveals some structural 
differences (Figure 4.17). The cyclic scaffold of each structure is very similar, with the 
ring portion of C9, N to C4, C3 in each case almost completely overlapping. The only 
difference in chemical composition between the two compounds is the presence of a sulfur 
atom (E-4.40) or oxygen (E-4.31). Consequently the portion of the ring containing the 
corresponding ester bond is slightly different in each structure, due to the different bond 
lengths and angles of the ester of 4.31 compared to thio ester of E-4.40 (refer to Table 4.1 
for ester bond lengths and angles). 
Another difference between the two structures, as shown in Figure 4.17, is the position of 
the exocyclic methyl ester, where the C11-04 carbonyl is almost at right angles in each 
case (refer to Table 4.1 for torsion angles of ClO - C9 - C11 - 04/03). This is the result 
of the different cell constants in each crystal structure. Both crystalline compounds had an 
orthorhombic P2(1 )2(1)2(1) space group, but serine-based E-4.31 had unit cell constants of 
8.13,9.05, and 16.93 A, while cysteine-based E-4.40 had unit cell constants of 4.96, 15.60, 
and 16.71 A. In other words the crystals of E-4.31 and E-4.40 were not isomorphous, i.e. 
despite their very similar chemical composition they did not have the same unit cell 
constants. The different packing in each crystal structure was a result of free rotation about 
the C9 - C 11 bond, thus the exocyclic methyl ester adopted the most thennodynamically 
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favourable orientation in the unit cell of the crystal structures, which happened to be 
mutually at right angles in each case. 
Figure 4.17. Superposition of crystal structure E-4.31 (solid line) and E-4.40 (dashed 
line). 
Serine-based E-4.31 Cysteine-based E-4.40 
Bond length (A) Bond length (A) 
CI 05 1.34 (16) C1 S 1.77 (2) 
05 - CIa 1.42 (16) S CIa 1.80 (18) 
Bond angle Bond angle 
C2 C1-05 111.33 (11) C2 C1-S 113.37 (14) 
Cl- 05 - CIa 117.40 (11) C1 S-ClO 100.63 (9) 
05 - CIa C9 109.02 (11) S-C10-C9 112.43 (13) 
Torsion Angle Torsion Angle 
CIa C9- C11 04 -92.58 (15) ! CIa C9- Cll 04 -0.3 (3) 
ClO- C9 - C11 03 85.37 (13) I C10-C9-Cll 03 -179.34 (16) 
Table 4.1. Comparison of the x-ray crystal structures of E-4.31 and E-4.40. Standard 
deviations given in brackets. 
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Molecular modeling 
Molecular modeling of 4.40 and 4.31 was carried out to compare to the x-ray crystal 
structures shown in Figure 4.15. The E- and Z-configurations of both 4.40 and 4.31 were 
constructed in silico using Schr6dinger's Maestro build function and minimized using the 
MMFFs forcefield in vacuo, which is reputed to be the best for comparison to x-ray crystal 
structures.21 ,22 A low energy ensemble was generated for each configuration, that was then 
used to calculate a Boltzmann weighted average energy (Figure 4.18). 
(a) (b) 
(d) 
Figure 4.18. Minimized energy structures of (a) E-4.40, 12.81 kJ/mol; (b) Z-4.40, 16.99 
kJ/m01; (c) E-4.31, 0.6 kJ/mol; (d) Z-4.31, 50.5 kJ/mol. Boltzmann weighted average 
energies given. 
The E configuration ofboth 4.40 and 4.31 were shown by molecular modeling to be lower 
in energy than the corresponding Z configuration. This is in line with the E configuration 
of both the x-ray crystal structures of 4.40 and 4.31, and confrrms that the RCM reactions 
were under thermodynamic control. This result also validates the assignment of the 
configuration of other RCM products that was based on molecular modeling results. The 
lowest energy structures of E-4.40 and E-4.31 adopt the same hexagonal ring shape (see 
Figure 4.16) as observed for the crystals structures (Figure 4.15). The Z minimized 
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structures of 4.40 and 4.31 can not adopt the more favourable hexagonal shape as they 
contain a cis two-atom element, disrupting the stable pattern of alternating two-atom trans 
elements around the ring. 
The minimized structures of E-4.40 and E-4.31 revealed an intramolecular hydrogen bond 
between the amide hydrogen and carbonyl oxygen of the pentenoyl ester. The crystal 
structures of E-4.40 and E-4.31 contained only an intermolecular hydrogen bond. These 
different types (intra vs. inter) of hydrogen bonds were a result of the molecular modeling 
conditions, where each structure was analysed as one isolated molecule, and as such could 
not contain any intermolecular interactions. The intramolecular hydrogen bond observed 
for E-4.40 and E-4.31 is presumably a reason for the slightly distorted hexagonal shape in 
comparison to the corresponding crystal structures. 
The synthesis and x-ray crystal structure of 12-membered serine-base cyclic compound 
4.31 has previously been reported by Schreiber and colleges (Scheme 4.14),15 in a study 
directed towards establishing the suitability of split-pool syntheses to ReM reactions. 
4.54 
R1 = H, Ph, Me 
RZ = C02H, Me, CHzOMe 
R3, R4, R5 = H, Me 
4.55 
Scheme 4.14. Series of 12-membered compounds synthesis by Schreiber et al. i5 
Stereochemistry not shown. 
The general methodology used to generate the senes of structurally diverse cyclic 
compounds of the same ring size (4.56) shown in Scheme 4.14 involved using differently 
substituted starting materials 4.53 and 4.54. The study presented in this thesis differs from 
that shown in Scheme 4.14 in that it focuses on the synthesis of compounds with varying 
ring sizes via controlled acylation of natural amino acid residues with variable lengths of 
carboxylic acids. The structure of compounds 4.56 were purposely chosen by Schreiber et 
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al as they contained the hexagonal-shaped 12-membered ring scaffold with low trans-
annular and torsional strain, as discussed in Figure 4.16. Serine-based 4.31 was 
synthesised in this thesis, despite being a reported compound, to enable x-ray 
crystallography data to be collected at cryogenic 92 F, which were the running conditions 
of the in-house defractometer. The Schreiber et al crystal structure of E-4.31 was collected 
at 213 F, so was not suitable for direct comparison to the crystal structure of E-4.40 
obtained at 92 F in this thesis. Crystal structures obtained at these two temperatures would 
have significantly different unit cell constants. 
A cyclic compound (4.58) similar in structure to E-4.31 has also been reported in a patent 
by Grubbs and colleges23 that covers the application of RCM for the construction of 
constrained peptides (Scheme 4.15). Serine-glycine-based RCM precursor 4.57 was 
cyclised using Grubbs first generation catalyst 1.10 to give 12-membered cyclic 4.58. 
RCM product 4.58 has the same core ring structure as 4.31 but contained an additional 
exocyclic NHBoc group substituted in the ring scaffold, which is derived from the amino 
terminus of the allyl glycine residue in dipeptide-based 4.57. 
) )~ BOC'N~(~J __ 1._10_,_D_cM_._re_fl_ux_ ..... 
H 0 C02Me 
4.57 
Scheme 4.15 
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4.4 CONCLUSION AND FUTURE WORK 
The synthesis of 5 lysine- (4.6, 4.13, 4.16, 4.21, 4.27), 3 serine- (4.31, 4.33, 4.37), and 3 
cysteine-based (4.40, 4.42, 4.45, 4.46) cyclic amino acid and dipeptide compounds was 
carried out by RCM from the corresponding acyclic precursors. The I5-membered 4.6 and 
27-membered 4.13 cyclic compounds were prepared by RCM of lysine-based acyclic 
precursors 4.5 and 4.12 respectively. These precursors were synthesised by side chain and 
N-terminus acylation of a single lysine residue with 4-pentenoic acid or IO-decenoic acid 
to install the different olefin tether lengths and therefore give cyclic compounds of 
different ring sizes. Lysine-based 4.6 was isolated as a mixture containing a ring-
contracted product (4.7a/b), which was separated by semi-preparative HPLC and 
characterised. 
Three lysine dipeptide-based cyclic compounds (4.16, 4.21, 4.27) were prepared via RCM 
of acyclic precursors (4.15, 4.20, 4.26) 4.16 and 4.21 via a side-chain to side-chain 
cyclisation and 4.27 via a side-chain to N-terminus cyclisation. Acyclic dipeptide-based 
precursors 4.15, 4.20, 4.46 were synthesied using the same general methodology of 
acylation with carboxylic acids of controllable olefin tether lengths, providing the ability to 
easily produce an array of cyclic compounds with readily adjustable ring sizes. 
Cyclic compounds containing a I2-membered (4.31) and 24-membered (4.33) ring, based 
on a single serine residue, were prepared via RCM of acyclic precursors 4.30 and 4.32. A 
serine dipeptide-based cyclic compound, the I6-membered 4.37, was prepared by RCM of 
a side-chain acylated serine dipeptide acyclic precursor (4.36). The analogous cyclic 
compounds based on a cysteine scaffold were also prepared (4.40, 4.42, 4.45). 
The configuration of cyclic RCM products was assigned as the most thermodynamically 
stable isomer as shown by molecular modeling. Cysteine dipeptide-based cyclic Z-4.45 
and ring contracted RCM product 4.7a/b were the only compounds assigned as the Z 
configuration. X-Ray crystal structures of 4.31 and 4.40 were obtained, and showed the 
same core ring structure. The observed E configuration in both x-ray crystal structures 
(4.31, 4.40) was also the most thermodynamically stable configuration determined by 
molecular modeling, thus validating the modeling results. 
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The synthesis of dipeptide-based cyclic compound 4.46 demonstrates that the general 
methodology involving acylation of natural amino acid functional groups followed by 
ReM is a viable route to the core of PDF inhibitor 4.47. 
Future work could involve the application of this general methodology to the synthesis of 
other amino acid and dipeptide-based cyclic compounds that can be suitably acylated with 
a carboxylic acid, to give cyclic compounds with variable ring sizes. Target compounds 
could be prepared in this way, designed with a specific biological role in mind. In addition 
to application of this general methodology, the cyclic compounds prepared in this thesis 
could be used as cyclic amino acid building blocks, in that they could be incorporated into 
peptides to potentially alter the biological or physical properties of the parent peptide in an 
intended manner. They could be added to an in-house library of compounds and screened 
against specific biological targets. 
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5.1 GENERAL METHODS AND EXPERIMENTAL 
PROCEDURES 
Melting Points 
All melting points were obtained on an Electrothermal apparatus and are uncorrected. 
Nuclear Magnetic Resonance 
Proton NMR spectra were obtained on a Varian Inova spectrometer, operating at 500 MHz. 
Carbon NMR were obtained on a Varian Inova Unity 300 spectrometer, operating at 75 
MHz, with a delay (D}) of 1 second. All spectra, unless specified, were obtained at 23°C. 
Chemical shifts are reported in parts per million (ppm) on the D scale. Solvents used for 
NMR analysis (reference peaks listed) included: DMSO-d6 (CHD2SOCD3 at DR 2.60 ppm, 
(CD3)2S0 at Dc 39.6 ppm); CDCh (CHCh at DR 7.25 ppm, CDCh at Dc 77.0 ppm); CD30D 
(CHD20D at DR 3.30 ppm, CD30D at Dc 49.3 ppm). Two-dimensional NMR experiments 
included COSY, HSQC, HMBC and CIGAR, and all were obtained on the Varian Inova 
spectrometer operating at 500 MHz. 
Small Molecule Mass Spectrometry 
Electron impact mass spectra were detected on a Kratos MS80 RF A mass spectrometer 
operating at 4000 V (accelerating potential) and 70 eV (ionization energy) and using a 
source temperature of 200 - 250°C. Electrospray ionization mass spectra were detected on 
a micromass LCT TOF mass spectrometer, with a probe voltage of 3200 V, temperature of 
150°C and a source temperature of 80°C. Direct ionization used 1 0 ~L of a 1 0 ~g/mL 
solution, using a carrier solvent of 50% acetonitrile/H20 at a flow rate of 20 uL/min. 
Ionisation was assisted by the addition of 0.5% formic acid. 
High Pressure Liquid Chromatography 
Analytical HPLC was performed on a Shimadzu LC-IOAD VP liquid chromatograph 
coupled to a SIL-IOA VP autoinjector, a CTO-IOA VP column oven set to 40°C and a 
SPD-MIOA VP photodiode array detector. The system was controlled by a Shimadzu 
CLASS-VP (Version 5.02) software. For reverse phase HPLC a Phenomenex Prodigy CI8 
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5-0DS (3 )l, 250 x 4.6 mm) column was used with a flow rate of 1 mUmin with a standard 
HPLC solvent gradient system that comprised of variable concentration of water (Milli-Q) 
containing 0.05% TFA and acetonitrile (HPLC grade). Isocratic systems consisted of a 20 
min run with 20% acetonitrile in water (0.05% TF A). Preparative HPLC was performed 
on a Shimadzu LC-4A instrument equipped with a UV Spectrophotometric Detector SPD-
2AS (wavelength 'A = 206 nm). A Phenomenex Jupoter C18 Proteo 90A (10 )l, 250 x 10 
mm) was used with a flow rate of 16 mUmin. An isocratic solvent system of 20% 
acetonitrile in water (0.05 % TF A) was used. 
X-ray Crystallography 
All measurements were made with a Seimens CCD area detector usmg graphite 
monochromised Mo Ka ('A = 0.71073 AO) radiation at 92 F. The data reduction was 
performed using SAINT.l Intensities were corrected for Lorentz and polarization effects 
and for absorption using SADABS. Space groups were determined from systematic 
absences and checked for higher symmetry. The structures were solved by direct methods2 
using SHELXS, and refined on F3 with all data using full-matrix least squares procedures 
with SHELXL-97. All non-hydrogen atoms were refined with anisotropic displacement 
parameters. All hydrogen atoms were fixed in idealised positions. Absolute structure 
determinations were based on the Flack parameter. In all cases, final Fourier syntheses 
showed no significant residual electron density in chemical sensible positions. 
Molecular Modeling 
E- And Z- configurations of cyclic compounds were constructed in silico using 
Schrodinger's Maestro build function and minimized using the MMFFs forcefield in 
vacuo, which is reputed to be best for comparing with crystal structures.4,5 The same 
forcefield was then used to perform a conformational search on each structure. 
Conformations within 12 kJ morl Ang-l of the lowest energy conformation were saved to 
generate a low energy ensemble for each structure. Each ensemble was then used to 
calculate the Boltzmann weighted average energy of each compound allowing the most 
thermodynamically stable double bond configuration of each compound to be identified. 
Molecular modeling was carried out by Blair Stewart, Department of Chemistry, 
University of Canterbury. 
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Microanalysis 
Microanalysis was performed at the University of Otago Microanalytical Laboratory. 
Reagents, solvents and laboratory methodology 
Oven-dried glassware was used in all reactions carried out under an inert atmosphere 
(refers to either dry argon or dry nitrogen). All starting materials and reagents were 
obtained commercially unless otherwise stated. "Removal of the solvent (or volatiles) by 
evaporation under reduced pressure" was carried out by rotary evaporation (low vacuum 
pump) followed by application of high vacuum (oil pump) for a minimum of one hour. 
Analytical TLC was performed on plastic-backed Merck Keiselgel KG60F254 silica plates, 
and visualised using ultraviolet light or potassium permanganate dip. Column 
chromatography was performed using 230-400 mesh Merck Silica Gel 60 under an 
atmospheric pressure unless stated. Flash column chromatography refers to the use of a 
positive pressure of nitrogen.6 THF and diethyl ether were distilled from sodium 
benzophenone ketyl under an inert atmosphere immediately prior to use. DCM, 
acetonitrile, and TEA were distilled from calcium hydride under an inert atmosphere 
immediately prior to use. Ethyl acetate and petroleum ether were distilled from calcium 
hydride prior to their use in chromatography. Petroleum ether refers to the fraction 
collected between 50 - 70°C. HPLC grade DMF was purchased commercially and stored 
over 4 A molecular sieves in an inert atmosphere. All other reagents and solvents were 
purified prior to use using literature procedures.7 
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General Procedure I: RCM 
To a solution of alkene (1 equiv) in dry DCM (~0.06 M) was added Grubbs second 
generation catalyst 1.17 (0.2 equiv). The solution was stirred at reflux under a flow of 
inert gas for 6 h, and DMSO added (50 equiv relative to catalyst) and stirring continued at 
rt overnight. The solvent was removed under reduced pressure to give the crude product. 
General Procedure II: Esterfication of carboxylic acids using 2,2-dimethoxypropane 
To a suspension of carboxylic acid (1 equiv) in 2,2-dimethoxypropane (~0.1 M) was added 
concentrated 12 M aqueous hydrochloric acid (~0.1 M) and the solution was stirred at 
reflux for 2 h and then overnight at rt. The solvent was removed by evaporation under 
reduced pressure and the residue dissolved in a minimal amount of methanol. See 
individual experiments for recrystalisation details. 
General Procedure III: Hydrogenation of olefins 
Olefm (1 equiv) was dissolved in methanol (typically 0.02 M) and 10% palladium on 
carbon was added (~ 20% w/w) and the solution stirred overnight under an atmosphere of 
hydrogen gas (hydrogen balloon). The solution was filtered through celite and the solvent 
removed by evaporation under reduced pressure. 
Modified General Procedure III: Hydrogenation of CBZ group 
The substrate (1 equiv) was dissolved in methanol (typically 0.02 M) and 10% palladium 
on carbon was added (~ 20% w/w) and the solution stirred overnight under an atmosphere 
of hydrogen (hydrogen balloon). The solution was filtered through celite and the solvent 
removed by evaporation under reduced pressure. 
General Procedure IV: Acylation of amines using acid chlorides8 
To a solution of amine (1 equiv, ~0.1 M) in 1 M sodium hydroxide/acetonitrile (1: 1 v/v) 
was added dropwise the acid chloride (1.1 equiv). The solution was stirred for 2 h, and 
then quenched with 1 M aqueous hydrochloric acid to give a pH of 5-6 (Universal 
indicator paper). The mixture was extracted twice with ethyl acetate, dried (Na2S04), and 
the solvent removed by evaporation under reduced pressure. 
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General Procedure V: HATU Peptide coupling9 
To a solution of the amine (1 equiv) and carboxylic acid (1 equiv) in DMF was added 
DIPEA (6 equiv). HATU was added (l.2 equiv) and the reaction stirred overnight. The 
reaction was quenched with water and the resulting solution extracted twice with ethyl 
acetate. The organic layer was washed twice with aqueous saturated sodium bicarbonate, 
saturated ammonium chloride, and saturated brine, then dried (MgS04), and the solvent 
removed by evaporation under reduced pressure. 
General Procedure VI: Boc-cleavage using TF A 
To a stirred solution of the Boc-protected compound (1 equiv) in DCM (~0.2 M) was 
added TF A (typically 40 equiv). The solution was stirred overnight, and then the solvent 
removed by evaporation under reduced pressure. The residue was re-dissolved in 
methanol and the solvent removed by evaporation under reduced pressure three times to 
remove any residual TF A. 
General Procedure VII: EDCI Peptide couplinglO 
To a stirred solution of the amine (1 equiv) and carboxylic acid (l.14 equiv) in DCM was 
added EDCI (l.3 equiv) and HOBt (l.5 equiv). DIPEA (l.14 equiv) was added and the 
reaction stirred overnight. The solution was diluted with DCM, and the organic layer 
washed twice with saturated brine. The combined aqueous layers were back extracted 
twice with DCM, and the combined organic layers were dried (MgS04), and the solvent 
removed by evaporation under reduced pressure. 
General Procedure VIII: Hydrolysis of methyl ester with lithium hydroxide 
To a stirred solution of methyl ester (1 equiv) in THF at O°C was added dropwise a 
solution of lithium hydroxide in water (0.2 M aqueous LiOH, 2 equiv). The solution was 
stirred at O°C for 40 min and then quenched by addition to a biphase of 0.2 M aqueous 
hydrochloric acid/ethyl acetate (1: 1 v/v). The aqueous layer was extracted with ethyl 
acetate, the organic layers combined and dried (MgS04), and the solvent removed by 
evaporation under reduced pressure. 
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General Procedure IX: CM Dimer formation 
To a solution of alkene (2 equiv) in dry DCM (~0.05 M) was added Grubbs second 
generation catalyst 1.17 (0.2 equiv). The solution was refluxed under a flow of inert gas 
for 6 h, and DMSO added (50 equiv relative to catalyst) and stirred at rt overnight. The 
solvent was removed by evaporation under reduced pressure to give the crude product. 
General Procedure X: CM 
To a solution of amino acid-based alkene substrate (1 equiv) and coupling partner alleene 
substrate (3 equiv) in dry DCM (~0.05 M) was added Grubbs second generation catalyst 
1.17 (0.2 equiv). The solution was stirred at reflux under a flow of inert gas for 6 h, and 
DMSO added (50 equiv relative to catalyst) and stirring continued at rt overnight. The 
solvent was removed by evaporation under reduced pressure to give the crude product. 
General Procedure XI: BOP-CI Acylation of a thiolll 
TEA (2.4 equiv) was added dropwise to a stirred solution of acid (1.1 equiv) in dry DCM 
(~0.09 M) under an inert atmosphere. After stirring for 20 min, this solution was added 
dropwise to a solution of BOP-Cl (1.2 equiv) in dry DCM (~0.09 M) at OoC. A solution of 
thiol (1 equiv) in dry DCM (~0.09 M) was then added dropwise at OoC. After 15 min the 
reaction was allowed to warm to rt and stirring continued overnight. The solvent was 
removed by evaporation under reduced pressure and the residue dissolved in ethyl acetate. 
The solution was washed twice with water, and the combined organic layers were washed 
with aqueous saturated sodium bicarbonate, water, and saturated brine solution 
sequentially. The combined organic layers were dried (MgS04), and the solvent removed 
by evaporation under reduced pressure. 
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General Procedure XII: Acylation of an alcohol using EDCIIDMAP12 
To a stirred solution of alcohol (1 equiv) and carboxylic acid (1.14 equiv) in DCM (~0.1 
M) was added DMAP (0.01 equiv) and the solution cooled to ODC. EDCI (1.09 equiv) was 
added, the solution was stirred at ODC for 2 h and then allowed to warm to rt with stirring 
overnight. The solvent was removed by evaporation under reduced pressure and the 
residue dissolved in ethyl acetate and water (1: 1 v/v). The organic layer was separated, 
washed with saturated aqueous bicarbonate and water, and the resulting organic layer was 
dried (MgS04), and the solvent removed by evaporation under reduced pressure. 
General Procedure XIV: Dihydropyran protection 
To a solution of alcohol (1 equiv) and dihydropyran (5 equiv) in DCM (~0.13 mM) was 
added p-toluene sulfonic acid monohydrate (10 equiv) at ODC. The solution was stirred for 
10 min at ODC then at rt for 2 h. Ether was added and the solution was washed with 
saturated brine, saturated aqueous sodium bicarbonate, and water. The resulting organic 
layer was dried (MgS04), and the solvent removed by evaporation under reduced pressure. 
General Procedure XV: Esterfication of carboxylic acid using Amberlyst 15 IER13 
To a stirred solution of carboxylic acid in methanol (~0.2 mM) was added Amberlyst 15 
Ion Exchange Resin (~1 70 mg/mmol carboxylic acid), and the suspension stirred at rt 
overnight. The Amberlyst IER was filtered off, and the resulting organic solvent removed 
by evaporation under reduced pressure. 
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5.2 EXPERIMENTAL WORK AS DESCRIBED IN CHAPTER 
TWO 
5.2.1 Synthesis of Amino Acid Cross-Metathesis Precursors 
Preparation of (2S)-2-tert-butoxycarbonylamino-6-( undec-l O-enoylamino )-hexanoic 
acid methyl ester (2.34) 
L N/CbZ ~ / H /'N_H2 ____ ~.~ L ~R'N C02Me -----BOC f" 
'NAcozMe B H H oC'N C02Me 
H 
-- 2.32a, R = H'HCI 2.33 2.34 
'------ 2.32b, R = Boc 
(2S)-2-tert-Butoxycarbonylamino-6-benzyloxycarbonylamino-hexanoic acid methyl ester 
(2.32b) To a stirred solution of Boc anhydride (1.32 g, 6.0 mmol, 1 equiv) and Ns-Cbz-L-
Lys-OMe.HCI2.32a (2 g, 6.0 mmol, 1 equiv) in acetonitrile (50 mL) was added TEA (2.6 
mL, 18.0 mmol, 3 equiv). The solution was stirred for 16 h, DCM (50 mL) was added and 
the organic phase extracted with 1 M aqueous hydrochloric acid (50 mL) and saturated 
aqueous sodium bicarbonate. The organic layer was dried (MgS04), and the solvent 
removed by evaporation under reduced pressure to give 2.32b (2.38 g) as a pale yellow oil 
which was not purified further. 
IH NMR (CDCh, 500 MHz) 0 1.23-1.60 (m, 4H, CH2), 1.40 (s, 9H, C(CH3)3), 1.62 (br m, 
1H, NHCHCHH), 1.75 (br m, 1H, NHCHCHH), 3.15 (m, 2H, NHCH2), 3.69 (s, 3H, 
OCH3), 4.24 (m, 1H, NHCH), 4.96 (br s, 1H, CHNH), 5.06 (s, 2H, OCH2), 5.13 (br d, J= 
7.9 Hz, 1H, CH2NH), 7.26-7.32 (m, 5H, ArH). 
6-Amino-2-tert-butoxycarbonylamino-hexenoic acid methyl ester (2.33) Na-Boc-Ns-Cbz-
L-Lys-OMe 2.32b (3.20 g, 8.10 mmol) was treated with 10% palladium on carbon (640 
mg) under a hydrogen atmosphere according to Modified General Procedure III, to give a 
yellow oil that was not characterised and used without purification. 
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(2S)-2-tert-Butoxycarbonylamino-6-(undec-l O-enoylamino)-hexanoic acid methyl ester 
(2.34) Boc-L-Lys-OMe.HCl 2.33 (500 mg, 1.68 mmol, 1 equiv) and 10-decenoic acid 
(353 mg, 1.92 mmol, 1.14 equiv) were treated with EDCI (417 mg, 2.18 mmol, 1.3 equiv) 
and HOBt (380 mg, 2.52 mmol, 1.5 equiv) according to General Procedure VII. The crude 
product was purified by flash chromatography on silica (petroleum ether/ethyl acetate, 3:7) 
to give 2.34 (418 mg, 58%) as a white solid. 
mp 63-65°C 
IH NMR (CDCh, 500 MHz) 0 1.24-1.79 (m, 18H, CH2), 1.42 (s, 9H, (CH3)3), 2.01 (m, 
2H, (CO(CHZ)7CH2), 2.13 (t, J= 7.6 Hz, 2H, COCH2), 3.21 (m, 2H, CH;zNH), 3.71 (s,3H, 
OCH3), 4.23 (m br, lH, NHCH), 4.90 (m, IH, CH=CHH), 4.96 (m, IH, CH=CHH), 5.08 
(d br, 7.8 Hz, IH, NHCH), 5.56 (s br, IH, CHzNH), 5.78 (m, IH, CH=CHz). 
13C NMR (CDCl), 75 MHz) 0 22.46, 25.67, 28.19, 28.74, 28.93, 29.18, 32.23, 33.64, 
36.64,38.84,52.15,53.04, 79.72, 114.02, 139.00, 155.43, 173.12, 173.23. 
HRMS (M+Na) Found 449.2982 (Calcd for C23lLuN20sNa 449.2991). 
Micro. Calcd for C23H42N20s: C, 64.79; H, 9.86; N, 6.57. Found: C, 64.96; 10.07; N, 
6.37. 
(2S)-2-tert-Butoxycarbonylamino-6-(pent-4-enoylamino )-hexanoic acid methyl ester 
(2.35) 
2.33 2.35 
Boc-L-Lys-OMe.HC12.33 (2.11 g, 8.10 mmol, 1 equiv) and 4-pentenoic acid (1.18 9.23 
mmol, 1.14 equiv) were treated withEDCI (2.01 g, 10.5 mmol, 1.3 equiv) and HOBt (1.83 
g, 12.2 mmol, 1.5 equiv) according to General Procedure VII. The crude product was 
purified by flash chromatography on silica (petroleum ether/ethyl acetate, 1 :4) to give 2.35 
(1.96 g, 71 %) as a colourless oiL 
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IH NMR (CDCh, 500 MHz) 0 1.31-1.60 (m, 4H, CH2CH2), 1.39 (s, 9H, (CH3)3), 1.62 (m, 
1H, NHCHCHH), 1.75 (m, 1H, NHCHCHH), 2.22 (m, 2H, COCH2CH2), 2.34 (m, 2H, 
COCH2), 3.19 (m, 2H, CH2NH), 3.69 (s, 3H, OCH3), 4.22 (m br, IH, NHCH), 4.95 (dd, J 
= 1.3, 10.3 Hz, 1H, =CHH), 5.01 (dd, J = 1.3, 17.1 Hz, 1H, =CHH), 5.14 (d br, J= 7.5 Hz, 
1H, NHCH), 5.74-5.83 (m, 2H, CH=CH2, CH2NH). 
13e NMR (CDCh, 75 MHz) 0 22.10, 27.70, 28.40, 29.15, 31.13, 34.92, 38.22, 51.53, 
52.89, 78.95, 114.64, 136.59, 155.19, 172.37, 172.79. 
HRMS (M+H) Found 343.2227 (Caled for C17H31N20S 343.2233). 
(2S)-2-tert-Butoxycarbonylamino-6-(but-3-enoylamino )-hexanoic acid methyl ester 
(2.36) 
2.33 2.36 
Boc-L-Lys-OMe.HCI2.33 (50 mg, 0.17 mmol, 1 equiv) and vinyl acetic acid (13 mg, 0.15 
mmol, 1.14 equiv) were treated with EDCI (42 mg, 0.22 mmol, 1.3 equiv) and HOBt (39 
mg, 0.26 mmol, 1.5 equiv) according to General Procedure VII. The crude product was 
purified by flash chromatography on silica (petroleum ether/ethyl acetate, 1 :4) to give 2.36 
(41 mg, 77%) as a colourless oil. 
IH NMR (CDCh, 500 MHz) 0 1.34 (m, 2H, CH2), 1.42 (s, 9H, C(CH3)3), 1.50 (m, 2H, 
CH2), 1.62 (m, 1H, NHCHCHH), 1.79 (m, 1H, NHCHCHH), 2.97 (d, J = 7.2 Hz, 2H, 
COCH2), 3.22 (m, 2H, CH2NH), 3.71 (s, 3H, OCH3), 4.25 (m, 1H, CHNH), 5.07 (d br, J= 
8.0 Hz, 1H, NHCH), 5.19 (m, 2H, CH=CH2), 5.71 (s br, 1H, NHCH2), 5.90 (m, IH, 
CH=CH2). 
13C NMR (CDCh, 75 MHz) 0 22.48, 28.23, 28.9, 32.28, 39.09, 41.55, 52.22, 53.08, 79.84, 
119.57, 131.42, 155.42, 170.59, 173.15. 
HRMS Found (M + Na) 351.1901 (Calcd for C16H2SN20sNa 351.1896). 
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(2S)-2-tert-Butoxycarbonylamino-6-acryloylamino-hexanoic acid methyl ester (2.37) 
o 
L NH2.HC' LNJV BOC .... N COzMe ---.. ~ .oe'N CO'M: 
H H 
2.33 2.37 
To a stirred solution of Boc-L-Lys-OMe.HCI 2.33 (1.5 g, 5.05 nunol, 1 equiv) in dry DCM 
(60 mL) under an inert atmosphere was added DIPEA at O°C to give a pH of 8 to 9 
(Universal indicator paper). Acryloyl chloride (842 mg, 9.30 nunol, 1.8 equiv) was added 
dropwise and the reaction was allowed to warm to rt with stirring overnight. The solution 
was washed successively with 1M aqueous hydrochloric acid (20 mL) and water (20 mL). 
The resulting organic layer was dried (MgS04), and the solvent removed by evaporation 
under reduced pressure. The crude product was purified by flash chromatography on silica 
(petroleum ether/ethyl acetate, 1 :4) to give 2.37 (1.42 g, 78%) as a pale yellow, sticky 
gum. 
IH NMR (CDCh, 500 MHz) (5 1.32 (m, 2H, CH2(CH2)2NH), 1.43 (s, 9H, (CH3)3), 1.54-
1.69 (m, 3H, CH2CH2NH, NHCHCHH), 1.79 (m, IH, NHCHCHH), 3.32 (q, J 6.5 Hz, 
2H, CH2NH), 3.72 (s, 3H, OCH3), 4.27 (m br, IH, NHCH), 5.11 (d br, J 7.8 Hz, IH, 
NHCH), 5.61 (dd, 1.2, 10.3 Hz, IH, CH=CHH), 5.78 (s br, IH, CH2NH), 6.08 (dd, J 
10.3,17.0 Hz, IH, COCH=), 6.27 (dd, J= 1.3, 17.0 Hz, IH, CH=CHH). 
l3C NMR (CDCh, 75 MHz) (5 22.50, 28.21, 28.75, 32.22, 38.97, 52.22, 53.07, 79.83, 
126.15, 130.81, 155.52, 165.72, 173.18. 
HRMS Found (M + Na) 337.1740 (Calcd for ClsH26N2051Na 337.1738). 
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Preparation of (3S)-3-tert-butoxycarbonylamino-7 -(pent-4-enoylamino )-heptanoic 
acid methyl ester (2.43) 
JNHiHCI 
BOC~Nfc02H 
H 
2.40 
HOOC~ 
2.38 
j 0 
CICC:;: J~~. 
BOC'N f C02H 
H 
2.41 
LN~ Boo'N C~Me 
H 
2.43 
4-Pentenoyl chloride (2.39) To a stirred solution of 4-pentenoic acid 2.38 (10 g, 0.1 mol, 
1 equiv) in dry ether (120 mL) under an inert atmosphere was added dropwise oxalyl 
chloride (13.96 g, 0.11 mol, 1.1 equiv) at O°C. After 10 min DMF (catalytic, a few drops), 
was added and the reaction was allowed to warm to rt and stirring continued overnight. 
The acid chloride product was purified via reduced pressure distillation to give 4-pentenoyl 
chloride 2.39 (9.65 g, 81 %) as a colourless liquid. 
(2S)-2-tert-Butoxycarbonylamino-6-(pent-4-enoylamino)-hexanoic acid (2.41) N-Boc-L-
Lys-OH.HCI 2.40 (2 g, 8.12 mmol, 1 equiv) was treated with 4-pentenoyl chloride 2.39 
(1.06 g, 8.93 mmol, 1.1 equiv) according to General Procedure IV. The crude product was 
recrystalised (petroleum ether/ethyl acetate) to give 2.41 (829 mg, 31 %) as a wax. 
lH NMR (CDCh, 500 MHz) 1.38 (m, 2H, NHCHCH2CH2), 1.43 (s, 9H, C(CH3)3), 1.52 
(m, 2H, NHCH2CH2), 1.70 (m, IH, NHCHCHH), 1.84 (m, IH, NHCHCHH), 2.28 (m, 2H, 
COCH2CH2), 2.36 (m, m,2H, COCH2), 3.23 (m, 2H, NHCH2), 4.26 (m, IH, NHCH), 
4.99 (d, J 10.1 Hz, IH, CH=CHH), 5.05 (d, J= 17.2 Hz, IH, CH=CHH), 5.30 (br d, 
7.8Hz, IH, CHNH), 5.79 (m, IH, CH=CH2), 5.97 (br s, IH, NHCH2). 
BC NMR (CDCb, 75 MHz) 28.11, 28.52, 29.51, 31.88, 35.34, 39.03, 53.01, 60.27, 79.66, 
115.39, 136.62, 155.67, 173.52, 174.92. 
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(3S)-3-tert-Butoxycarbonylamino-7-(pent-4-enoylamino)-heptanoic acid methyl ester 
(2.43) TEA (202 mg, 2 mmol, 1 equiv) and ethyl chloroformate (217 mg, 2 mmol, 1 
equiv) were added under an inert atmosphere to Na-Boc-NE-pentenoyl-L-Lys-OH 2.41 (655 
mg, 2 mmol, 1 equiv) in THF (10 mL) at -15°C. After 15 min the suspension was allowed 
to warm to O°C, whereupon an excess of diazomethane in ether (~ 0.2 M) was added until 
the. intensive yellow colour persisted over time. The mixture was allowed to warm to rt 
with stirring for 3 h. Excess diazomethane was destroyed by the addition of a few drops of 
acetic acid. The solution was washed with aqueous saturated sodium bicarbonate (10 mL), 
saturated ammonium chloride (10 mL), and saturated brine solution (10 mL), the organic 
layer dried (MgS04), and the solvent removed by evaporation under reduced pressure. The 
crude diazoketone was dissolved in dry methanol (8 mL) under an inert atmosphere at 
-25°C with the exclusion of light. Silver benzoate (51 mg, 0.22 mmol, 0.11 equiv), 
dissolved in TEA (5.8 mmol, 2.9 equiv) was added and the reaction was allowed to warm 
to rt with stirring for 3 h. The solvent was removed by evaporation under reduced pressure 
and the residue was taken up in ethyl acetate. The organic layer was washed with aqueous 
saturated sodium bicarbonate (10 mL), saturated ammonium chloride (10 mL), and 
saturated brine solution (10 mL), the organic layer dried (MgS04), and the solvent was 
removed by evaporation under reduced pressure. The crude product was purified twice by 
flash chromatography on silica (petroleum ether/ethyl acetate, 1:9, then methanol/DCM 
7.5:92.5) to give 2.43 (521 mg, 73%) as a pale yellow oil. 
IHNMR (CDCh, 500 MHz) 0 1.31 (s, 9H, C(CH3)3), 1.33 (m, 6H, CH(CH2)3), 2.15 (t, J= 
7.4 Hz, 2H, NHCOCH2), 2.26 (m, 2H, =CHCH2), 2.39 (d, J = 5.7 Hz, 2H, CHCH2CO), 
3.11 (m, 2H, CH2NH), 3.56 (s, 3H, OCH3), 3.77 (m, 1H, NHCH), 4.87 (dd, J= 1.0, 10.2 
Hz, 1H, CH=CHH), 4.93 (dd, J= 1.4,17.1 Hz, IH, CH=CHH), 5.07 (br d, J= 8.9 Hz, 1H, 
NHCH), 5.70 (m, 1H, CH=CH2)' 6.21 (br s, 1H, CH2NH). 
l3C NMR (CDCh, 75 MHz) 022.93,28.13,28.83,29.45,33.86,35.5,38.76,39.21,47.13, 
51.41, 78.94, 115.10, 136.92, 155.36, 171.81, 172.36. 
HRMS (M+H) Found 357.2389 (Caled for ClSH33N20S 357.2389). 
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(2S)-Pent-4-enoic acid-(2-tert-butoxycarbonylamino-2-methoxycarbonyl)-ethyI ester 
(2.45) 
2.44 2.45 
Boc-L-Ser-OMe 2.44 (2 g, 9.10 rnmol, 1 equiv) and 4-pentenoic acid (1.04 g, lOA rnmol, 
1.14 equiv) were treated with EDCI (1.89g, 9.92 rnmol, 1.09 equiv) and DMAP (11 mg, 
0.09 mmol, 0.01 equiv) according the General Procedure XII. The crude product was 
purified by flash chromatography on silica (ethyl acetate/petroleum ether, 3:7) to give 2.45 
(2.51 g, 89%) as a white solid. 
mp= 35-37°C 
IH NMR (CDCh, 500 MHz) 0 1042 (s, 9H, C(CH3)J), 2.32 (m, 2H, COCH2CH2), 2.39 (m, 
2H, COCH2), 3.73 (s, 3H, OCH3), 4.31 (dd, J = 3.6, 11.3 Hz, IH, OCHH), 4041 (dd, J = 
3.6, 11.3 Hz, IH, OCHH), 4.54 (m, 1H, NHCH), 4.98 (dd, IH, J lA, 10.3 Hz, 
CH=CHH), 5.02 (dd, 1H, J lA, 17.2 Hz, CH=CHH), 5.27 (br d, J 8.0 Hz, 1H, NH), 
5.77 (m, IH, CH=CH2)' 
13C NMR (CDCb, 75 MHz) 0 27.67, 28.13, 32.59, 51.98, 52.38, 63046, 79.34, 115.02, 
136.00, 154.67, 169.74, 171.79. 
HRMS (M+H) Found 302.1601 (Calcd for C14H24N06 302.l604). 
(2S)-U ndec-lO-enoic 
ester (2.46) 
2.44 
acid-(2-tert-butoxycarbonylamino-2-methoxycarbonyl)-ethyl 
Boc-L-Ser-OMe 2.44 (300 mg, 1.37 rnmol, 1 equiv) and 10-decenoic acid (287 mg, 1.56 
rnmol, 1.14 equiv) were treated with EDCI (285 mg, 1.49 rnmol, 1.09 equiv) and DMAP (2 
mg, 0.01 rnmol, 0.01 equiv) according the General Procedure XII. The crude product was 
purified by flash chromatography on silica (ethyl acetate/petroleum ether, 1 :4) to give 2.46 
(444 mg, 84%) as a colourless oil. 
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IH NMR (CDCh, 500 MHz) B 1.26-1.45 (m, lOH, CH2), 1.43 (s, 9H, (CH3)J), 1.57 (m, 
2H, COCH2CH2), 2.01 (m, 2H, CO(CH2)?CH2), 2.27 (t, J 7.6 2H, COCH2), 3.74 (s, 
3H, OCH3) , 4.29 (dd, IH, J = 3.5, 11.2 Hz, OCHH), 4.43 (dd, 1H, J = 3.5, 11.2 Hz, 
OCHH), 4.54 (m, 1H, NHCH), 4.90 (m, 1H, CH=CHH), 4.96 (m, 1H, CH=CHH), 5.27 (br 
d,J= 8.0 Hz, 1H, NH), 5.78 (m, lH, CH=CHH). 
13C NMR (CDCh, 75 MHz) B 24.47, 27.94, 28.54, 28.71, 28.86, 28.95, 33.45, 33.60, 
52.27,52,66,63.63, 79.74, 113.89, 138.67, 154.85, 169.99, 172.85. 
HRMS (M+Na) Found 408.2361 (Calcd for C2oH3SN06Na 408.2362). 
(2R)-2-tert-Butoxycarbonylamino-3-(undec-lO-enoylsulfanyI)-propionic acid methyl 
ester (2.48) 
2.47 2.48 
Boc-L-Cys-OMe 2.47 (598 mg, 2.54 mmol, 1 equiv) and lO-decenoic acid (516 mg, 2.80 
mmol, 1.1 equiv) were treated with BOP-CI (774 mg, 3.05 mmol, 1.2 equiv) according to 
General Procedure XI. The crude product was purified by flash chromatography on silica 
(ethyl acetate/petroleum ether, 1 :4) to give 2.48 (840 mg, 82%) as a colourless oil. 
1 . 
H NMR (CDCh, 500 MHz) B 1.26-1.47 (m, lOH, CH2), 1.42 (s, 9H, (CH3)3), 1.63 (m, 
2H, COCH2CH2), 2.01 (m, 2H, CO(CH2)7CH2), 2.53 (t, J = 7.6 Hz, 2H, COCH2), 3.32 (m, 
2H, CH2S), 3.73 (s, 3H, OCH3), 4.51 (m br, IH, NHCH), 4.91 (m, 1H, =CHH), 4.97 (m, 
1H, =CHH), 5.22 (d br, J 6.7 Hz, 1H, NH), 5.79 (m, 1H, CH=CH2). 
13C NMR (CDCh, 75 MHz) B 24.97, 27.67, 28.25, 28.29, 28.46, 28.62, 28.66, 30.25, 
33.19,43.28,51.85,52.56, 79.10, 113.70, 138.28, 154.49, 170.35, 197.44. 
HRMS (M+Na) Found 424.2119 (Calcd for C2oH3sNOsSNa 424.2134). 
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(2R)-2-tert-Butoxycarbonylamino-3-(pent-4-enoylsulfanyI)-propionic acid methyl 
ester (2.49a) 
2.47 2.49a 
Boc-L-Cys-OMe 2.47 (572 mg, 2.43 mmol, 1 equiv) and 4-pentenoic acid (267 mg, 2.67 
mmol, 1.1 equiv) were treated with BOP-C1 (741 mg, 2.92 mmol, 1.2 equiv) according to 
General Procedure XL The crude product was purified by flash chromatography on silica 
(ethyl acetate/petroleum ether, 1 :4) to give 2.49a (717 mg, 93%) as a white solid. 
mp = 33-35°C 
IH NMR (CDCh, 500 MHz) 0 1.42 (s, 9H, (CH3)3), 2.38 (m, 2H, COCH2CH2), 2.64 (t, J 
7.5 Hz, 2H, COCH2), 3.33 (m, 2H, CH2S), 3.73 (s, 3H, OCH3), 4.51 (m br, 1H, NHCH), 
5.00 (dd, J= 1.3, 10.3 1H, =CHH), 5.04 (m, 1H, =CHH), 5.21 (d br, J 7.5 Hz, 1H, 
NH), 5.76 (m, 1H, CH=CH2). 
l3C NMR (CDCh, 75 MHz) 0 27.54, 28.63, 30.10, 42.25, 51.79, 52.42, 79.01, 115.25, 
135.34, 154.43, 170.25, 196.64. 
HRMS (M+H) Found 318.1375 (Calcd for C14H2~05S 318.1375). 
Micro. Calcd for C14H23N05S: C, 53.00; H, 7.26; N, 4.42; S, 10.09. Found: C, 52.77; H, 
7.47; N, 4.41; S, 9.95. 
(3R)-3-tert-Butoxycarbonylamino-4-(pent-4-enoylsulfanyl)-butyric acid methyl ester 
(2.51) 
C 2.49a, R: Me 
2.49b, R - H 
2.50 2.51 
N-Boc-S-pentenoyl-L-Cys-OMe 2.49a (440 mg, 1.45 mmol, 1 equiv) was treated with 0.2 
M aqueous lithium hydroxide (2 equiv) according to General Procedure VIII to give 2.49b 
which was not characterised. The carboxylic acid product was dissolved in THF (10 mL), 
and TEA (153 mg, 1.52 mmol, 1.05 equiv) and ethyl chloroformate (165 mg, 1.52 mmol, 
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1.05 equiv) were added under an inert atmosphere at -15°C. After 15 min the suspension 
was allowed to warm to O°C, whereupon diazomethane in ether (~0.2 M) was added until 
the intensive yellow colour persisted over time. The mixture was allowed to warm to rt 
with stirring for 3 h. Excess diazomethane was destroyed by the addition of a few drops of 
acetic acid. The solution was washed with aqueous saturated sodium bicarbonate (10 mL), 
saturated ammonium chloride (10 mL), and saturated brine solution (10 mL), the organic 
layer dried (MgS04), and the solvent was removed by evaporation under reduced pressure. 
The crude product was purified by flash chromatography on silica (ethyl acetatelDCM, 
1 :19) to give pure diazoketone 2.50 (390 mg, 82%) as a yellow oil. Diazoketone 2.50 (390 
mg, 1.19 mmol, 1 equiv) was dissolved in dry methanol (5 mL) under an inert atmosphere 
at -25°C with the exclusion of light. Silver benzoate (30 mg, 0.13 mmol, 0.11 equiv), 
dissolved in TEA (349 mg, 3.46 mmol, 2.9 equiv), was added and the reaction was allowed 
to warm to rt over 3 hrs. The solvent was removed by evaporation under reduced pressure 
and the residue was taken up in ethyl acetate. The organic layer was washed with aqueous 
saturated sodium bicarbonate (10 mL), saturated ammonium chloride (10 mL), and 
saturated brine solution (10 mL), the organic layer dried (MgS04), and the solvent was 
removed by evaporation under reduced pressure. The crude product was purified by flash 
chromatography on silica (ethyl acetate/petroleum ether, 1:4) to give 2.51 (170 mg, 51%) 
as a colourless oil. 
IH NMR (CDCh, 500 MHz) 0 1.41 (s, 9H, C(CH3)3), 2.39 (m, 2H, COCH2CH2), 2.55 (m, 
2H, COCH2CH2), 2.65 (m, 2H, CH2C02Me), 3.13 (m, 2H, SCH2), 3.68 (s, 3H, OCH3), 
4.06 (m, IH, NHCH), 5.00 (dd, J 1.2, 10.2 Hz, IH, CH=CHH) 5.05 (dd, J 1.2, 17.1 
Hz, IH, CH=CHH) 5.1O(br d, 7.5 Hz, IH, NH) 5.77 (m, IH, CH=CH2). 
13C NMR (CDCh, 75 MHz) 0 27.94, 29.03, 32.03, 37.36, 42.68, 47.30, 51.36, 78.99, 
115.57, 135.63, 154.73, 171.03, 197.78. 
HRMS (M+H) Found 332.1530 (Calcd for ClSH26NOsS 332.1532). 
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(2S, 2S)-2-(2-tert-Butoxycarbonylamino-3-phenyl-propionylamino )-6-(pent-4-enoyl-
amino)-hexanoic acid methyl ester (2.54) 
2.52, R = H.HCI 2.54 
2.53 
Na-Boc-Ne-pentenoyl-L-Lys-OMe 2.35 (86 mg, 0.25 mmol) was dissolved in ethyl acetate 
and hydrochloric gas was bubbled through the solution for 4 h to give a solid suspension. 
The solid was filtered, washed with ether, and dried under high vacuum. The resulting 
residue (2.52, 0.25 mmol) and Boc-L-Phe-OH 2.53 (76 mg, 0.29 mmol, 1.14 equiv) were 
treated with EDCI (62 mg, 0.33 mmol, 1.3 equiv) and HOBt (57 mg, 0.38 mmol, 1.5 
equiv) according to General Procedure VIr. The crude product was purified by flash 
chromatography on silica (petroleum ether/ethyl acetate, 1 :9) to give 2.54 (78 mg, 63%) as 
a white solid. 
mp 81-82°C 
IHNMR (CDCh, 500 MHz) (5 1.26-1.50 (m, 4H, CH2), 1.38 (s, 9H, (CH3)J), 1.64 (m, lH, 
NHCHLysCHH), 1.78 (m, 1H, NHCHLysCHH), 2.27 (m, 2H, COCH2CH2), 2.36 (m, 2H, 
COCH2), 3.00-3.23 (m, 4H, CH2NH, CH2Ph), 3.69 (s, 3H; OCH3), 4.36 (m br, lH, 
NHCHPhe), 4.51 (m br, lH, NHCHLys), 4.98 (dd, J= 1.8, 10.3 Hz, 1H, =CHH), 5.03 (ddd, 
J = 1.8,3.5, 17.1 Hz, IH, =CHH), 5.13 (s br, 1H, NHCHPhe), 5.78 (m, 1H, CH=CH2), 5.95 
(s br, 1H, NHCH2), 6.66 (d br, 7.3 Hz, IH, NHCHLys), 7.18-7.45 (m, 5H, ArH). 
l3C NMR (CDC!), 75 MHz) (5 22.24, 28.16, 28.62, 29.63, 31.61, 35.65, 38.22, 38.86, 
52.02, 52.33, 55.70, 80.20, 115.51, 126.83, 128.51, 129.23, 136.44, 136.87, 155.51, 
171.69, 172.15, 173.25. 
HRMS (M+Na) Found 512.2734 (Caled for C26H39N306Na 512.2737). 
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(2R, 2S)~ 1 ~ [2~tert~ Butoxycarbonylamino~3~( undec~ 1 O-enoylsulfanyl)-propionyl]-pyrr-
olidine-2-carboxylic acid benzyl ester (2.57) 
2.48, R = Me 2.57 
2.56 
2.55, R= H 
Cysteine derivative 2.48 (400 mg, 1.0 mmol) was hydrolysed by treatment with 0.2 M 
aqueous lithium hydroxide (2 equiv) according to General Procedure VIII to give 2.55, 
which was not characterised. Carboxylic acid 2.55 (1.0 mmol, 1 equiv) and L-Pro-
OBn.HCl 2.56 (275 mg, 1.13 mmol, 1.14 equiv) were treated with EDCI (248 mg, 1.3 
mmol, 1.3 equiv) and HOBt (227 mg, 1.5 mmol, 1.5 equiv) according to General 
Procedure VII. The crude product was purified by flash chromatography on silica (ethyl 
acetatelDCM, 1 :9) to give 2.57 (414 mg, 72%) as a yellow oil. 
IH NMR (CDCb, 500:MHz) 0 1.38 (s, 9H, C(CH3)3), 1.62 (m, 2H, COCH2CH2), 1.99 (m, 
4H, NCH2CH2, =CHCH2), 2.17 (m, 2H, CHCH2proline), 2.52 (t, J 7.5 Hz, 2H, COCH2), 
2.70 (m, IH, SCHH), 3.30 (m, lH, SCHH), 3.71 (m, lH, NCHH), 3.91 (m, lH, NCHH), 
4.55 (m, 2H, NHCH, NCH), 4.89 (dd, J = 0.8, 10.2 Hz, 1H, CH=CHH), 4.95 (m, 1H, 
CH=CHH), 5.07 (d, J= 12.3 Hz, lH, OCHH), 5.17 (d, J= 12.3 Hz, lH, OCHH), 5.26 (m, 
lH, NH), 5.77 (m, 1H, CH=CH2), 7.30 (m, 5H, ArH). 
I3C NMR (CDCb, 75 MHz) 0 24.46, 25.09, 27.90, 28.44, 28.55, 28.62, 28.66, 28.77, 
28.80, 31.28, 33.35, 43.53, 46.59, 51.04, 58.58, 66.38, 79.14, 113.82, 127.70, 127.83, 
128.11, 135.22, 138.58, 155.07, 168.97, 170.97, 198.82. 
HRMS (M+Na) Found 597.2964 (Calcd for C31146N206NaS 597.2974). 
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(2S)-2-(2-Acetylamino-acetylamino)-6-(pent-4-enoylamino)-hexanoic acid methyl 
ester (2.59) 
LNH2.acetate H 0 N II .. Ac ..... ~N C02Me 
H 
2.58 
J~~ 
H 0 f~~. Ac/N~N CO2 Me 
H 
2.59 
Dipeptide acetate salt 2.58 (50 mg, 0.16 romo!, 1 equiv) and 4-pentenoic acid (18 mg, 0.18 
mmol, 1.14 equiv) were treated with EDCI (40 mg, 0.21 romol, 1.3 equiv) and HOBt (36 
mg, 0.24 romol, 1.5 equiv) according to General Procedure VII. The crude product was 
purified by flash chromatography on silica (methanoIIDCM, 1 :9) to give 2.59 (50 mg, 
93%) as a white solid. 
mp = 115-116°C 
IH NMR (CDCb, 500 MHz) 01.32 (m, 2H, CHCH2CH2), 1.49 (m, 2H, CH2CH2NH), 1.79 
(m, 2H, NHCHCH2), 2.05 (s, 3H, COCH3), 2.28 (m, 2H, COCH2CH2), 2.38 (m, 2H, 
COCH2CH2), 3.44 (m, 2H, CH2NH), 3.73 (s, 3H, OCRJ), 3.96 (m, 2H, NHCH2CO), 4.54 
(m, IH, NHCH), 5.00 (d, IH, J = 10.3 Hz, HHC=CH), 5.06 (d, IH, J 17.1 Hz, 
HHC=CH), 5.82 (m, 2H, H2C=CH, CH2CH2NH), 6.40 (br s, IH, NHCH2CO), 6.74 (d, IH, 
J = 7.80 Hz, NHCH) 
BC NMR (CDCb, 75 MHz) 0 22.18, 22.92, 28.89, 29.64, 31.20, 35.75, 38.52, 43.15, 
52.06,52.42, 115.50, 137.04, 169.67, 170.87, 172.49, 172.78. 
HRMS (M+H) Found 342.2036 (Calcd for C16H28N305 342.2029). 
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5.2.2 Synthesis of protected alcohol terminal alkene eM products 
2-Hex-5-enyloxy-tetrahydro-pyran (2.61) 
~OH 
2.63 2.61 
5-Hexen-l-012.63 (400 mg, 4.00 mmol, 1 equiv) and dihydropyran (2.04 g, 20.0 mmol, 5 
equiv) were treated with p-toluene sulfonic acid monohydrate (7.60 g, 40.0 mmol, 10 
equiv) according to General Procedure XIV. The crude product was purified by 
chromatography on silica (ethyl acetate/petroleum ether, 1:9) to give 2.61 (734 mg, 99%) 
as a colourless liquid. 
IH NMR (CDCh, 500 MHz) 8 1.42-1.68 (m, 8H, CH2), 1.70 (m, IH, OCHCHH), 1.80 (m, 
IH, OCHCHH), 2.05 (m, 2H, ~CHCH2CH2)' 3.36 (m, IH, OCHH), 3.47 (m, IH, OCHH), 
3.71 (m, IH, OCHH), 3.83 (m, IH, OCIDI), 4.54 (m, IH, OCHO), 4.91 (m, IH, 
HHC=CH), 4.98 (ddd, J= 2.0,3.9, 17.6 Hz, IH, HHC=CH), 5.78 (m, lH, CH2=CH). 
BC NMR (CDCh, 75 MHz) 8 19.31, 25.28, 25.39, 28.95, 30.47, 33.32, 61.78, 67.01, 
98.39, 114.18, 138.37. 
2-Dec-9-enyloxy-tetrahydro-pyran (2.65) 
2.65 
9-Decen-l-ol2.64 (876 mg, 5.60 mmol, 1 equiv) and dihydropyran (2.86 g, 28.0 mmol, 5 
equiv) were treated with p-toluene sulfonic acid monohydrate (10.7 g, 56.0 mmol, 10 
equiv) according to General Procedure XIV. The crude product was purified by 
chromatography on silica (ethyl acetate/petroleum ether, 3:17) to give 2.65 (1.21 g, 90%) 
as a colourless liquid. 
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IH NMR (CDCh, 500 MHz) 8 1.24-1.61 (m, 16H, CH2), 1.69 (m, 1H, OCHCHH), 1.81 
(m, 1H, OCHCHH), 2.01 (q, J= 7.1 Hz, 2H, =CHCH2CH2), 3.36 (m, 1H, OCHH), 3.48 
(m, 1H, OCHH), 3.71 (m, 1H, OCHH), 3.85 (m, 1H, OCHH), 4.55 (m, 1H, OCHO), 4.90 
(m, IH, HHC=CH), 4.97 (ddd, J = 2.0, 3.4, 17.1 Hz, 1H, HHC=CH), 5.79 (m, IH, 
CH2=CH). 
l3C NMR (CDCh, 75 MHz) 8 19.59, 25.43, 26.15, 28.82, 28.99, 29.34, 29.66, 30.69, 
33.71,62.17,67.55,98.70, 114.02, 139.04. 
(2S)-2-tert-Butoxycarbonylamino-6-[7 -( tetrahydro-pyran-2-yloxy )-hept-2-enoylam-
ino]-hexanoic acid methyl ester (2.66) 
2.66 
NG-Acryloy1lysine 2.37 (20 mg, 0.64 mmol, 1 equiv) was reacted with 2.61 (35 mg, 0.20 
mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (11 mg, 0.01 mmol, 0.2 equiv) 
according to General Procedure X. The crude product was purified by chromatography on 
silica (petroleum ether/ethyl acetate, 1 :4) to give 2.66 (27 mg, 91 %) as a brown oil. 
IH NMR (CDCh, 500 MHz) 8 1.32-1.80 (m, 16H, CH2), 1.39 (s, 9H, (CH3)3), 2.15 (m, 
2H, =CHCH2), 3.25 (m, 2H, CH2NH), 3.33 (m, IH, OCHH), 3.45 (m, 1H, OCHH), 3.69 
(s, 3H, OCH3), 3.73 (m, 1H, OCHH), 3.80 (m, 1H, OCHH), 4.21 (m br, 1H, NHCH), 4.52 
(m, 1H, OCHO), 5.15 (d br, J= 7.93 Hz, 1H, CHNH), 5.74 (d, J= 15.1 Hz, 1H, COCH=), 
5.85 (s br, 1H, CH2NH), 6.77 (m, 1H, =CHCH2). 
l3C NMR (CDCh, 75 MHz) 8 19.63, 22.56, 24.99, 25.45, 28.31, 28.95, 29.25, 30.72, 
31.79, 32.51, 39.05, 52.31, 53.06, 62.33, 67.16, 79.92, 98.85, 123.69, 144.39, 155.57, 
166.06, 173.24. 
HRMS (M+H) Found 471.3071 (Calcd for C24lL(3N207 471.3070). 
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(2S)-2-tert-Butoxycarbonylamino-6-[11-(tetrahydro-pyran-2-yloxy)-undec-2-enoyl-
amino]-hexanoic acid methyl ester (2.67) 
2.67 
Na-Acryloyllysine 2.37 (20 mg, 0.06 mmol, 1 equiv) was reacted with 2.65 (47 mg, 0.20 
mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (11 mg, 0.01 mmol, 0.2 equiv) 
according to General Procedure X. The crude product was purified by chromatography on 
silica (petroleum ether/ethyl acetate, 2:3) to give 2.67 (25 mg, 75%) as a brown oil. 
IH NMR (CDCh, 500 MHz) 8 1.21-1.79 (m, 24H, CH2), 1.39 (s, 9H, C(CH3)3), 2.10 (m, 
2H, CH=CHCH2), 3.25 (m, 2H, CH2NH) , 3.33 (m, 1H, OCHHCH2), 3.45 (m, 1H, 
OCHHCH2), 3.67 (s, 3H, OCiI3), 3.68 (m, 1H, OCHHCH2), 3.82 (m, 1H, OCIiHCH2), 
4.22 (m, 1H, NHCH), 4.52 (m, 1H, OCHO), 5.15 (d, J= 8.3 Hz, 1H, CHJ\TH), 5.73 (d, J= 
15.1 Hz, 1H, COCH=), 5.86 (br s, 1H, CH2NH), 6.77 (m, 1H, COCH=CH). 
l3C NMR (CDCh, 75 MHz) 8 19.60, 22.50, 25.37, 26.07, 28.12, 28.21, 28.85, 29.00, 
29.22,29.23,29.59,30.67,31.89,32.28,38.91,52.17, 53.03, 62.26, 67.54, 79.76, 98.77, 
123.40, 144.62, 155.47, 166.17, 173.15. 
HRMS (M+H) Found 527.3700 (Calcd for C2SHSIN207 527.3696). 
(2S)-2-tert-Bu toxycarbony lamino-6-[8-( tetrahydro-pyran-2-y loxy )-oct-3-enoylamino ]-
hexanoic acid methyl ester (2.68) 
J~~Ou 
BOC"-Ni C02M9 
H 
2.68 
Na-Propenoyllysine 2.36 (20 mg, 0.58 mmol, 1 equiv) was reacted with 2.61 (32 mg, 0.18 
mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (11 mg, 0.01 mmol, 0.2 equiv) 
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according to General Procedure X. The crude product was purified by chromatography on 
silica (petroleum ether/ethyl acetate, 1 :4) to give a mixture (16 mg, 57%) of 2.68 and the 
double bond migrated product 2.68a as a brown oil (3: 1 by IH NMR). 
IH NMR (CDCh, 500 MHz) from mixture 2.68 8 1.22-1.81 (m, l4H, CH2), 1.41 (s, 9H, 
C(CH3)3), 2.06 (m, 2H, CH=CHCH2CH2), 2.89 (d, J= 6.8 Hz, 2H, COCH2), 3.19 (m, 2H, 
CH2NH), 3.35 (m, lH, OCHHCH2), 3.45 (m, lH, OCHHCH2), 3.70 (s, 3H, OCH3), 3.71 
(m, lH, OCHHCH2), 3.84 (m, lH, OCHHCH2), 4.24 (m, lH, NHCHCO), 4.53 (m, lH, 
OCHO), 5.08 (d, J = 7.8 Hz, lH CHNH), 5.48 (dt, J = 7.0, 15.3 Hz, lH, CH=CH), 5.58 
(dt, J= 6.7, 15.3 Hz, lH, CH=CH), 5.76 (m, lH, CH2NH). 
Selected data IH NMR (CDCh, 500 MHz) from mixture 2.68a 8 2.17 (m, 
CH=CHCH2CH2), 2.96 (d, J = 7.8 Hz, COCH2CH=), 3.27 (m, CH2NH), 5.19 (br m, 
CHNH), 5.64 (m, CH=CH), 5.79 (m, CH2NH). 
l3C NMR (CDCh, 75 MHz) from mixture 2.688 19.63,22.50,25.37,25.76,28.22,28.97, 
29.l4, 30.67, 32.25, 35.11, 39.06,40.42, 52.l9, 53.08, 62.32, 67.27, 79.78, 98.83, 122.84, 
135.89, 155.39, 171.27, 173.27. 
HRMS (M+H) Found 485.3224 (Calcd for C2SH4SN207 485.3227). 
(2S)-2-tert-Butoxycarbonylamino-6-[12-( tetrahydro-pyran-2-yloxy)-dodec-3-enoyl-
amino]-hexanoic acid methyl ester (2.69) 
o 
2.69 
Ns-Propenoyllysine 2.36 (20 mg, 0.06 mmol, 1 equiv) was reacted with 2.65 (42 mg, 0.18 
mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (10 mg, 0.01 mmol, 0.2 equiv) 
according to General Procedure X. The crude product was purified by chromatography on 
silica (petroleum ether/ethyl acetate, 1 :4) to give a mixture (18 mg, 56%) of 2.69 and the 
double migrated product 2.69a as brown oil (3: 1 by 1 H NMR). 
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IH NMR (CDCh, 500 MHz) from mixture 2.69 0 1.24-1.71 (m, 22H, CH2), 1.41 (s, 9H, 
C(CHJ)3), 1.78 (m, 2H, =CHCH1CH2), 2.01 (m, 2H, =CHCH2CH1), 2.89 (d, J 7.0 Hz, 
2H, COCH2), 3.19 (m, 2H, CH2NH), 3.34 (m, 1H, OCHH), 3.46 (m, 1H, OCHH), 3.69 (m, 
1H, OCHH), 3.70 (s, 3H, OCH3), 3.83 (m, 1H, OCHH), 4.24 (br m, 1H, CHNH), 4.54 (m, 
1H, OCHO), 5.08 (br d, J 8.0 Hz, 1H, NHCH), 5.47 (dt, J = 7.1, 15.4 Hz, 1H, =CH), 
5.57 (dt, J= 6.7, 15.3 Hz, 1H, =CH), 5.72 (br s, 1H, CH1NH). 
Selected data IH NMR (CDCh, 500 MHz) from mixture 2.69a 0 2.96 (d, J 7.6 Hz, 
COCH2CH=), 3.27 (m, CH2NH), 5.13 (br m, CHNH), 5.64 (m, CH=CH), 5.74 (m, 
CH1NH). 
13C NMR (CDCh, 75 MHz) from mixture 2.690 19.62,22.49,25.39,26.12,28.22,28.98, 
29.04, 29.07, 29.29, 29.32, 29.63, 30.68, 32.24, 32.46, 39.06, 40.43, 52.19, 53.08, 62.28, 
67.57, 79.79,98.77, 122.46, 136.36, 155.38, 171.36, 173.13. 
HRMS (M+H) Found 541.3854 (Calcd for C19Hs3N107 541.3853). 
(2S)-2-tert-Butoxycarbonylamino-6-[9-(tetrahydro-pyran-2-yloxy)-non-4-enoyl-
amino]-hexanoic acid methyl ester (2.70) 
2.70 
Ns-Pentenoyllysine 2.35 (9 mg, 0.03 mmol, 1 equiv) was reacted with 2.61 (15 mg, 0.08 
mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (4 mg, 0.01 mmol, 0.2 equiv) 
according to General Procedure X. The crude product was purified by chromatography on 
silica (petroleum ether/ethyl acetate, 1:4) to give a mixture (7 mg, 54%) of 2.70 and the 
double bond migrated product 2.70a as a brown oil (6: 1 by IH NMR). 
IH NMR (CDCh, 500 MHz) from mixture 2.70 0 1.33-1.81 (m, 16H, CH2), 1.42 (s, 9H, 
C(CHJ)3), 1.99 (m, 2H, =CHCH2(CHlh), 2.19 (m, 2H, COCH2), 2.29 (m, 2H, 
COCH1CH2), 3.21 (m, 2H, CH2NH), 3.36 (m, 1H, OCHH), 3.47 (m, 1H, OCHH), 3.70 (m, 
1H, OCHH), 3.71 (s, 3H, OCH3), 3.83 (m, 1H, OCHH), 4.25 (br m, 1H, CHNH), 4.54 (m, 
1H, OCHO), 5.10 (br d, J = 7.2 Hz, 1H, NHCH), 5.41 (dtd, J = 6.6, 15.4, 21.9 Hz, 2H, 
CH=CH), 5.63 (br s, 1H, CH1NH). 
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Selected data IH NMR (CDCh, 500 MHz) from mixture 2.70a 3 2.90 (d, J 6.8 Hz, 
COCH2CH=), 3.28 (m, CH2NH), 5.49 (m, CH=CH). 
13C NMR (CDCh, 75 MHz) from mixture 2.708 19.67,22.53,25.45,26.00,28.29,28.63, 
29.00, 29.15, 30.74, 32.27, 32.38, 36.64, 38.97, 52.28, 53.10, 62.35, 67.43, 79.89, 98.85, 
128.63, 131.48, 155.49, 172.62, 173.21. 
HRMS (M+H) Found 499.3385 (Caled for C26H47N207 499.3383). 
(2S)-2-tert-Butoxycarbonylamino-6-[13-( tetrahydro-pyran-2-yloxy)-tridec-4-enoyl-
amino]-hexanoic acid methyl ester (2.71) 
o 
2.71 
NIl-Pentenoyllysine 2.35 (50 mg, 0.15 rnrnol, 1 equiv) was reacted with 2.65 (l05 mg, 0.44 
rnrnol, 3 equiv) and Grubbs second generation catalyst 1.17 (25 mg, 0.03 rnrnol, 0.2 equiv) 
according to General Procedure X. The crude product was purified by chromatography on 
silica (petroleum ether/ethyl acetate, 1:4) to give a mixture (41 mg, 51%) of 2.71 and the 
double bond migrated products 2.71a and 2.71b as a brown oil (23:4:1 by IH NMR). 
IH NMR (CDCh, 500 MHz) from mixture 2.71 8 1.26-2.05 (m, 26H, CH2), 1.42 (s, 9H, 
(CH3)3), 2.19 (m, 2H, COCH2CH2), 2.29 (m, 2H, COCH2), 3.21 (m, 2H, CH2NH), 3.36 
(m, 1H, OCHH), 3.48 (m, 1H, OCHH), 3.71 (m, 1H, OCHH), 3.72 (s, 3H, OCH3), 3.85 
(m, 1H, OCHH), 4.26 (m br, IH, NHCH), 4.55 (m, 1H, OCHO), 5.08 (br m, 1H, CHNH), 
5.36 (dt, J 6.4, 15.4 Hz, IH, CH=CH), 5.45 (dt, J= 6.6, 15.4 Hz, 1H, CH=CH), 5.59 (m, 
1H, CH2NH). 
Selected NMR data IH NMR (CDCh, 500 MHz) from mixture 2.71a and b 82.90 (d, J 
7.0 Hz, COCH2CH=), 2.98 (d, J 7.6 Hz, COCH2CH=), 3.29 (m, CH2NH), 5.49 (m, 
CH=CH), 5.66 (m, CH2NH). 
13C NMR (CDCh, 75 MHz) from mixture 2.71 8 19.51,22.39,25.29,26.01,28.12,28.50, 
28.86, 28.92, 28.96, 29.03, 29.22, 29.52, 30.58, 32.05, 32.30, 36.42, 38.71, 52.06, 53.01, 
62.152,67.46, 79.615, 98.66, 128.14, 131.55, 155.38, 172.55, 173.05. 
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HRMS (M+H) Found 555.3998 (Caled for C30HssN207 555.4009). 
(2S)-2-tert-Butoxycarbonylamino-6-[15-(tetrahydro-pyran-2-yloxy)-pentadec-l0-
enoylamino]-hexanoic acid methyl ester (2.72) 
.j) 
.OO'NiCQ'M: 
H 
2.72 
173 
Ne-Decenoyllysine 2.34 (20 mg, 0.05 mmol, 1 equiv) was reacted with 2.61 (26 mg, 0.14 
mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (8 mg, 0.01 mmol, 0.2 equiv) 
according to General Procedure X. The crude product was purified by chromatography on 
silica (petroleum ether/ethyl acetate, 3:7) to give 2.72 (20 mg, 67%) as a brown oil. 
IH NMR (CDCh, 500 MHz) 0 1.26-1.82 (m, 28H, CH2), 1.43 (s, 9H, C(CH3h), 1.97 (m, 
4H, CH2CH=CH), 2.13 (t, J 7.8 Hz, 2H, COCH2), 3.22 (m, 2H, CH2NH), 3.36 (m, lH, 
OCHH), 3.48 (m, IH, OCHH), 3.71 (m, IH, OCHH), 3.72 (s, 3H, OCH3), 3.85 (m, IH, 
OCHH), 4.27 (m, IH, NHCH), 4.56 (m, IH, OCHO), 5.07 (br d, J= 8.3 Hz, IH, NHCH), 
5.34 (m, 2H, CH=CH), 5.54 (br s, IH, CH2NH). 
l3C NMR (CDCh, 75 MHz) 0 19.58, 22.47, 25.38, 25.68, 26.01, 27.06, 28.19, 28.93, 
28.97, 29.00, 29.22, 29.32, 29.48, 29.62, 30.66, 32.27, 32.46, 36.68, 38.85, 52.16, 53.04, 
62.21,67.56, 79.74, 98.72, 130.l5, 130.22, 155.42, 173.12, 173.17. 
HRMS (M+H) Found 639.4929 (Calcd for C36H67N207 639.4948). 
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(2R)-2-tert-Butoxycarbonylamino-3-[15-(tetrahydro-pyran-2-yloxy)-pentadec-l0-
enoylsulfanyl]-propionic acid methyl ester (2.73) 
o 
S 
BOC"-Nf C02Me 
H 
2.73 
174 
N&-Decenoyl cysteine 2.48 (100 mg, 0.25 rnrnol, 1 equiv) was reacted with 2.61 (138 mg, 
0.75 rnrnol, 3 equiv) and Grubbs second generation catalyst 1.17 (42 mg, 0.05 rnrnol, 0.2 
equiv) according to General Procedure X. The crude product was purified by 
chromatography on silica (petroleum ether/ethyl acetate, 1:4) to give 2.73 (50 mg, 36%) as 
a brown oil. 
lH NMR (CDCb, 500 MHz) (5 1.25-1.82 (m, 22H, CH2), 1.42 (s, 9H, C(CH3)3), 1.99 (m, 
4H, =CHCH2), 2.53 (t, J 7.5 Hz, 2H, COCH2), 3.31 (m, 3H, OCHH, CH2S), 3.47 (m, 
IH, OCHH), 3.70 (m, IH, OCHH), 3.73 (s, 3H, OCH3), 3.84 (m, IH, OCHH), 4.49 (m, 
IH, CHNH), 4.56 (m, IH, OCHO), 5.33 (m, 3H, NH, CH=CH). 
l3C NMR (CDCb, 75 MHz) (5 19.45, 25.32, 25.40, 26.05, 28.10, 28.67, 28.88, 29.03, 
29.18, 29.35,29.44, 30.56, 30.72, 32.19, 32.37, 43.79, 52.43, 52.93, 62.03, 67.28, 79.90, 
98.56, 129.80, 130.44, 154.91, 170.83, 198.29. 
HRMS (M+Na) Found 580.3289 (Calcd for C29H51N07SNa 580.3284). 
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(2S, 2S)-2-(2-tert-Butoxycarbonylamino-3-phenyl-propionylamino)-6-[13-(tetrahydro-
pyran-2-yloxy)-tridec-4-enoylamino]-hexanoic acid methyl ester (2.74) 
2.74 
Na-Pentenoyl dipeptide 2.54 (15 mg, 0.03 mmol, 1 equiv) was reacted with 2.65 (23 mg, 
0.09 mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (5 mg, 0.01 mmol, 0.2 
equiv) according to General Procedure X. The crude product was purified by 
chromatography on silica (petroleum ether/ethyl acetate, 1 :4) to give a mixture (12 mg, 
56%) of2.74 and double bond migrated product 2.74a as a brown oil (5:1 by IH NMR). 
IH NMR (CDCl], 500 MHz) from mixture 2.74 () 1.26-1.94 (m, 24H, CH2), 1.39 (s, 9H, 
C(CH3)3), 1.83 (m, 2H, =CHCH2(CH2)7), 2.21 (m, 2H, COCH2), 2.30 (m, 2H, 
COCH2CH2), 3.07 (m, 2H, CH~h), 3.20 (m, 2H, CH2NH), 3.37 (m, 1H, OCHH), 3.48 (m, 
1H, OCHH), 3.69 (s, 3H, OCH3), 3.71 (m, 1H, OCHH), 3.86 (m, lH, OCHH), 4.35 (m, 
1H, NHCHPhe), 4.51 (m, 1H, NHCHLys), 4.56 (m, 1H, OCHO), 5.10 (br m, 1H, CHNHPhe), 
5.37 (dt, J = 6.4, 15.3 Hz, 1H, CH=CH), 5.45 (dt, J= 6.5, 15.3 Hz, 1H, CH=CH), 5.71 (br 
m, 1H, CH2NH), 6.56 (br d, 7.2 Hz, 1H, CHNHLys), 7.24 (m, 5H, ArH). 
Selected data IH NMR (CDCb, 500 MHz) from mixture 2.74a () 2.92 (d, J 7.0 
COCH2CH). 
13C NMR (CDCh, 75 MHz) from mixture 2.74 () 19.68,22.10,25.44,26.17,28.91,29.11, 
28.19,28.66,29.04,29.39, 29.69, 30.74, 31.68, 32.46, 38.19, 36.62, 38.62, 51.91, 52.32, 
55.71,62.34,67.64,80.11,98.83,126.85,128.23, 128.54, 129.29, 131.80,136.54,155.34, 
171.24, 172.16, 172.81. 
HRMS (M+H) Found 702.4692 (Caled for C39H64N30S 702.4693). 
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5.2.3 Synthesis of Sugar eM compounds 
Preparation of (2R, 3R, 4S, 5R, 6R)-2-allyl-3,4,5-tris-benzyloxy-6-benzyloxymethyl-
tetrahydro-pyran (1.51 b) 
OH OBn OBn OBn 
Ho""b",oOM, (ii) 
"OO""Q"'OH 
(iii) 
"OO,,,,6-0A, (iv) 
"OO""Q""''0'" .. .. .. 
HO OH BnO OBn BnO OBn BnO OBn 
2.77 2.78 2.79 1.51b 
(2S, 3R, 4S, 5R, 6R)-3,4,5-Tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-o1 
(2.78)14 A stirred solution of methyl-a-D-glucopyranose 2.77 (l g, 5.15 rnmol, 1 equiv) 
and potassium hydroxide powder (5 g, 89.3 mmol, 17.0 equiv) in dioxane (l00 mL) was 
slowly warmed to boiling point. During this time, freshly distilled benzyl chloride (2.75 g, 
21.7 rnmol, 4.20 equiv) was added dropwise. Once the solution had reached boiling point 
further benzyl chloride (2.75 g, 21.7 rnmol, 4.2 equiv) was added dropwise, and heating 
was continued for 2 h. The reaction mixture was cooled and the solvent was removed by 
rotary evaporation under high vacuum pressure. The residue was dissolved in water (50 
mL) and ethyl acetate (50 mL), and the aqueous layer washed twice with ethyl acetate (50 
mL). The organic layers were combined, washed twice with water, separated, and then the 
organic layer was treated with glacial acetic acid (43 mL) and 4 M aqueous sulfuric acid 
(24 mL) and heated to reflux then stirred overnight. The solution was cooled and a white 
precipitate formed. Water (11 mL) was added, the solution was cooled on ice, and the 
solid product filtered and washed successively with 1 M aqueous acetic acid (6 mL), water 
(6 mL) and aqueous methanol (75% vlv, 6 mL). The crude product was purified by flash 
chromatography on silica (ethyl acetateIDCM, 1 :9) to give 2.78 (795 mg, 29%) as a white 
solid. 
mp = 146-148°C 
1H NMR (CDCh, 500 MHz) 8 3.57-3.72 (m, 4H, sugar moiety), 3.96 (t, J = 9.3 Hz, 1H, 
sugar moiety), 4.03 (m, 1H, sugar moiety), 4.47-4.95 (m, 8H, CH2Ph), 5.22 (d, J= 3.5 Hz, 
1H, H-Canomeric), 7.13-7.35 (m, 20H, ArR). 
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13C NMR (CDCh, 75 MHz) 0 68.48, 69.93, 72.91, 73.25, 74.85, 75.57, 77.68, 79.79, 
81.61, 91.02, 127.46, 127.54, 127.57, l27.73, 127.84, 127.89, 127.96, 128.24, 128.32, 
137.62, 137.79, 138.05, 138.56. 
(3R, 4S, 5R, 6R)-Acetic acid 3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-
yl ester (2.79/5 To a solution of 2.78 (700 mg, 1.29 mmol, 1 equiv) in pyridine (7 mL) 
was added acetic anhydride (660 mg, 6.47 mmol, 5 equiv). The solution was stirred 
overnight, poured into chloroform (20 mL), and washed with water (15mL) and saturated 
aqueous sodium bicarbonate (20 mL). The resulting organic layer was dried (MgS04), and 
the solvent was removed by evaporation under reduced pressure. The crude product was 
purified by flash chromatography on silica (ethyl acetate/petroleum ether, 3:7) to give 2.79 
(756 mg, 97%) as a colourless, sticky oil and a mixture of isomers (1 *:3, 2R*:2S) at the 
anomeric carbon. 
IH NMR (CDCl3, 500 MHz) 0 2.04* (s, 3/4H, COCH3), 2.12 (s, 9/4H COCH3), 3.55-3.96(*) 
(m, 6H, sugar moiety), 4.46-4.96(*) (m, 8R, CHzPh), 5.60* (d, J 8.2 Hz, 1/4R, H-
Canomeric), 6.35 (d, J (*) * 3.5 Hz, 3/4R, H-Canomeric), 7.12-7.33 (m, 20R, ArH). (Denotes 
minor 2R isomer). 
13C NMR (CDCl3, 75 MHz) 0 (mixture of 2R and 28 isomers, peaks not assigned) 20.84, 
20.89, 67.89, 72.63, 72.97, 73.27, 73.31, 74.77, 74.80, 75.06, 75.24, 75.46, 76.74, 78.66, 
80.83, 81.45,84.56, 89.78, 93.83, 127.46, 127.50, 127.56, 127.64, 127.76, 127.93, 128.07, 
128.21,128.28, 137.40, 137.59, 137.66, 137.82, 137.91, 138.17, 138.43, 169.09, 169.22. 
(2R, 3R, 4S, 5R, 6R)-2-Allyl-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran 
(1.51b)16 To a stirred solution of acetyl derivative 2.79 (480 mg, 0.80 mmol, 1 equiv) in 
freshly distilled acetonitrile (6 mL) under an inert atmosphere was added allyltrimethyl 
silane (182 mg, 1.60 mmol, 2 equiv) and boron trifluoride diethyl etherate (454 mg, 3.2 
mmol, 4 equiv) at 4°C. The mixture was stirred under an inert atmosphere at 4°C for 24 h, 
then poured into a saturated aqueous sodium bicarbonate solution and extracted twice with 
DCM. The resulting organic layer was dried (MgS04), and the solvent was removed by 
evaporation under reduced pressure. The crude product was purified by flash 
chromatography on silica (ethyl acetate/petroleum ether, 1:4) to give 1.51b (228 mg, 50%) 
as a white solid and a single anomer. 
mp= 63-64°C 
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IH NMR (CDCb, 500 MHz) 8 2.52 (m, 2H, CH2CH=CH2), 3.62-3.85 (m, 6H, sugar 
moiety), 4.17 (m, IH, H-Canomeric), 4.49-4.98 (m, 8H, CH2Ph), 5.10 (dd, J = 2.0, 10.3 Hz, 
IH, CH=CHH), 5.14 (dd, J= 2.0,17.1 Hz, IH, CH=CHH), 5.85 (m, IH, CH=CH2), 7.15-
7.38 (m, 20H, ArH). 
l3C NMR (CDCb, 75 MHz) 8 29.58, 68.63, 70.87, 72.78, 73.18, 73.42, 74.80, 75.17, 
77.84, 79.77, 82.14, 116.68, 127.33, 127.37, 127.46, 127.53, 127.56, 127.60, 127.70, 
128.07,128.13,128.17,134.50,137.81,137.97,138.51. 
Micro. Calcd for C37H400S: C, 78.72; H, 7.09. Found: C, 78.53; H, 7.00. 
(2S)-(2R, 3R, 4S, 5R, 6R)-2-tert-Butoxycarbonylamino-6-[4-(3,4,5-tris-benzyloxy-6-
benzyloxymethyl-tetrahydro-pyran-2-yl)-but-2-enoylamino]-hexanoic acid methyl 
ester (2.80) 
2.80 
N8-Acryloyllysine 2.37 (10 mg, 0.03 mmol, 1 equiv) was reacted with 1.51b (54 mg, 0.10 
mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (5 mg, 0.01 mmol, 0.2 equiv) 
according to General Procedure X. The crude product was purified by chromatography on 
silica (petroleum ether/ethyl acetate, 1 :4) to give 2.80 (15 mg, 55%) as a pinky, white 
solid. 
mp = 125-128°C 
IH NMR (CDCb, 500 MHz) 8 1.34 (m, 2H, CHCH2CH2), 1.43 (s, 9H, C(CH3)3), 1.48 (m, 
2H, CH2CH2NH), 1.63 (m, IH NHCHCHH), 1.78 (m, IH, NHCHCHH), 2.58 (m, 2H, 
=CHCH2), 3.22 (m, 2H, CH2NH), 3.59-3.76 (m br, 6H, sugar moiety), 3.72 (s, 3H, OCH3), 
4.16 (m, IH, H-Canomeric), 4.27 (m br, IH, NHCH), 4.44-4.92 (m, 8H, CH2Ph), 5.09 (d br, J 
= 7.3 Hz, IH, CHNH), 5.46 (s br, IH, CH2NH), 5.85 (d, J= 15.1 Hz, IH, COCH=), 6.78 
(dt, J= 6.8,14.9 Hz, IH, =CHCH2), 7.12-7.34 (m, 20H, ArH). 
Chapter Five - Experimental 179 
13C NMR (CDCb, 75 MHz) 8 22.53, 27.70, 28.26, 28.93, 32.32, 38.99, 52.24, 53.08, 
68.93, 71.35, 73.09, 73.18, 73.44, 75.01, 75.38, 77.85, 79.65, 79.84,82.14, 125.80, 127.59, 
127.61, 127.72, 127.78, 127.81, 127.84, 127.89, 128.31, 128.35, 128.42, 137.93, 137.98, 
138.52, 140.04, 155.45, 165.68, 173.19. 
HRMS (M+Na) Found 873.4378 (Caled for C50H62N201ONa 873.4380). 
(2S)-(2R, 3R, 4S, 5R, 6R)-2-tert-Butoxycarbonylamino~6-[6-(3,4,5-tris-benzyloxy-6-
benzyloxymethyl-tetrahydro-pyran-2-yl)-hex-4-enoylamino]-hexanoic acid methyl 
ester (2.81) 
2.81 
Ne-Pentenoyllysine 2.35 (50 mg, 0.15 mmol, 1 equiv) was reacted with 1.51b (247 mg, 
0.44 mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (25 mg, 0.03 mmol, 0.2 
equiv) according to General Procedure X. The crude product was purified by 
chromatography on silica (petroleum ether/ethyl acetate, 3:7) to give a mixture (55 mg, 
43%) of 2.81 and the double bond migrated product 2.81a as a brown oil (6:1 by IH 
NMR). 
IH NIVlR (CDCb, 500 MHz) from mixture 2.81 8 1.25-1.48 (m, 4H, CH2), 1.43 (s, 9H, 
(CH3)3), 1.64 (m, 1H, NHCHCHH), 1.77 (m, 1H, NHCHCHH), 2.07 (m, 2H, COCH2), 
2.27 (m, 2H, COCH2CH2), 2.40 (m, 2H, =CHCH2CH), 3.15 (br m, 2H, CH2NH) , 3.48-
3.80 (m, 6H, sugar moiety), 3.72 (s, 3H, OCH3), 4.01 (m, 1H, H-Canomeric), 4.26 (br s, IH, 
NHCH), 4.44-4.94 (m, 8H, CH2Ph), 5.07 (d br, J = 7.8 Hz, 1H, NHCH), 5.45 (m br, 2H, 
HC=CH), 5.65 (s br, 1H, CH2NH), 7.11-7.32 (m, 20H, ArH). 
Selected data IH NMR (CDCb, 500 MHz) from mixture 2.81a 8 2.89 (d, J = 4.5 Hz, 
COCH2CH=), 5.58 (m, CH=CH), 5.77 (m, CH2NH). 
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l3C NMR (CDCb, 75 MHz) from mixture 2.81 022.34,28.09,28.15,28.53,28.79,31.86, 
36.13, 38.59,51.98,53.013,69.27, 70.82, 72.74, 72.88, 73.15, 73.20, 73.46, 74.81, 75.16, 
78.08, 79.53, 79.62, 79.79,82.06, 126.90, 127.35, 127.52, 127.59, 127.68, 127.73, 128.13, 
130.99, 137.60, 137.81, 137.94, 138.44, 155.31, 172.41, 173.02. 
HRMS (M+H) Found 879.4798 (Calcd for C52H67N2010 879.4796). 
(2S)-(2R, 3R, 4S, 5R, 6R)-2-tert-Butoxycarbonylamino-6-[12-(3,4,5-tris-benzyloxy-6-
benzyloxymethyl-tetrahydro-pyran-2-yl)-dodec-l0-enoylamino]-hexanoic acid methyl 
ester (2.82) 
o Bnq OBn L~~'''''q'''OB' B BnO oC"N C02Me 
H 
2.82 
Ne-Decenoyllysine 2.34 (15 mg, 0.04 mmol, 1 equiv) was reacted with 1.51b (60 mg, 0.12 
mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (6 mg, 0.01 mmol, 0.2 equiv) 
according to General Procedure X. The crude product was purified by chromatography on 
silica (petroleum ether/ethyl acetate, 1:1) to give 2.82 (22 mg, 65%) as a brown oil. 
IH NMR (CDCb, 500 MHz) 0 1.30-1.84 (m, 18H, CH2), 1.49 (s, 9H, C(CH3)3), 2.09 (m, 
2H, =CHCH2CH2), 2.17 (m, 2H, COCH2), 2.47 (m, 2H, =CHCH2CH), 3.27 (m, 2H, 
CH2NH), 3.65-3.85 (m, 6H, sugar moiety), 3.78 (s, 3H, OCH3), 4.12 (m, 1H, H-Canomeric), 
4.32 (s br, IH, NHCH), 4.50-5.00 (m, 8H, CH2Ph), 5.13 (d br, J= 7.4 Hz, IH, NHCH), 
5.43 (dt, 6.3, 15.7 Hz, 1H, CH=CH), 5.52 (dt, J= 6.4, 15.6 Hz, 1H, CH=CH), 5.59 (br 
s, 1H, CH2NH), 7.16-7.37 (m, 20H, ArH). 
l3C NMR (CDCb, 75 MHz) 0 22.52, 25.73, 28.28, 28.51, 29.00, 29.09, 29.30, 29.42, 
32.41, 32.62, 36.80, 38.96, 52.27, 53.08, 68.89, 70.93, 72.92, 73.38, 73.97, 75.04, 75.38, 
78.10, 79.79, 80.14, 82.38, 125.63, 125.85, 127.53, 127.57, 127,69, 127.75, 127.83, 
127.86, 127.94, 128.27, 128.36, 129.71, 132.96, 138.05, 138.15, 138.23, 138.73, 155.47, 
173.14, 173.20. 
HRMS (M+H) Found 963.5748 (Calcd for C5sH79N20lO 963.5735). 
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(2S)-(2R, 3R, 4S, 5R, 6R)-2-tert-Butoxycarbonylamino-6-[12-(3,4,5-trihydroxy-6-
hydroxymethyl-tetrahydro-pyran-2-yl)-dodecanoylaminoj-hexanoic acid methyl ester 
(2.83) 
2.83 
Compound 2.82 (12 mg, 0.012 mmol) was dissolved in ethanol (20 mL) and 10 % 
palladium/carbon (5 mg) was added. The mixture was placed in a Parr hydrogenator and 
stirred under an atmosphere of H2 at 74 PSI for 20 h. The solution was filtered through 
celite to remove the catalyst, and the resulting organic solvent was removed by evaporation 
under reduced pressure to give 2.83 (8 mg, quantitative) as a sticky, yellow oil. 
IHNlvlR (CD30D, 500 MHz) 8 1.34-1.80 (m, 22H, CHz), 1.47 (s, 9H, C(CH3)3), 2.20 (t, J 
= 7.3 Hz, 2B, COCHz), 3.19 (t, J= 6.8 Hz, 2B, CHzNH), 3.27-3.81 (m, 6H, sugar moiety), 
3.74 (s, 3H, OCH3), 3.90 (4.12 m, 1H, H-Canomeric), 4.11 (m, 1H, NHCH). 
BC NMR (CD30D, 75 MHz) 8 24.54, 25.69, 26.92, 27.38, 28.25, 29.01, 30.22, 30.59, 
30.71, 30.90, 31.00, 32.53, 37.45, 40.24, 52.88, 55.28, 63.40, 63.66, 72.71, 73.42, 74.61, 
75.54, 77.53, 80.84, 158.45, 175.27, 176.58. 
HRMS (M+B) Found 605.4012 (Calcd for C30Hs7N201O 605.4013). 
3-tert-Butoxycarbonylamino-7-[6-(3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetra-
hydro-pyran-2-yl)-hex-4-enoylamino]-heptanoic acid methyl ester (2.84) 
o Bnq OBn L~~""'S""o'" Boc C02Me BnO 'N 
H 
2.84 
Ne-pentenoyl-~-Lysine 2.43 (54 mg, 0.15 mmol, 1 equiv) was reacted with 1.51b (170 mg, 
0.5 mmol, 2 equiv) and Grubbs second generation catalyst 1.17 (26 mg, 0.02 mmol, 0.2 
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equiv) according to General Procedure X. The crude product was purified by 
chromatography on silica (petroleum ether/ethyl acetate, 1:4) to give a mixture (46 mg, 
34%) of 2.84 and double bond "migrated product 2.84a as a brown oil (3: 1 by 1 H NMR). 
IH NMR (CDCh, 500 MHz) from mixture 2.84 8 1.29-1.50 (m, 6H, CH2), 1.42 (s, 9H, 
C(CH3)3), 1.65 (m, 2H, CH2), 2.08 (m, 2H, COCH2CH2), 2.28 (m, 2H, COCH2CH2), 2.39 
(m, 2H, CHCH2CO), 2.49 (m, 2H, =CHCH2CH), 3.15 (m, 2H, CH2N), 3.49-3.79 (m, 6H, 
sugar moiety), 3.66 (s, 3H, OCH3), 3.87 (m, 1H, NHCH), 4.02 (m, 1H, H-Canomeric), 4.44-
4.93 (m, 9H, CH2Ph, NHCH), 5.45 (m, 2H, HC=CH), 5.66 (br s, 1H, CH2NH), 7.11-7.31 
(m, 20H, ArH). 
Selected data IH NMR (CDCh, 500 MHz) from mixture 2.84a 8 2.90 (d, J = 4.4 Hz, 
COCH2CH=), 5.58 (m, CH=CH), 5.77 (m, CH2NH). 
l3e NMR (CDCh, 75 MHz) from mixture 2.84823.05,28.23,28.62,28.98,33.89, 36.25, 
38.78, 39.04,40.30,47.17, 51.47, 69.31, 70.90, 72.86, 73.29, 73.57, 74.90, 75.25, 77.87, 
78.15, 79.89, 82.16, 126.95, 127.41, 127.56138.52" 127.59, 127.67, 127.76, 127.80, 
128.20,131.05,137.70,137.90; 138.03, 155.34, 171.85, 172.42. 
HRMS (M+H) Found 893.4959 (Caled for CS3H69N2010 893.4952). 
(2R)-(2R, 3R, 4S, 5R, 6R)-2-tert-Butoxycarbonylamino-3-[6-(3,4,5-tris-benzyloxy-6-
benzyloxymethyl-tetrahydro-pyran-2-yl)-hex-4-enoylsulfanyl]-propionic acid methyl 
ester (2.85) 
S-Pentenoyl cysteine 2.49a (20 mg, 0.06 mmol, 1 equiv) was reacted with 1.51b (107 mg, 
0.19 mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (11 mg, 0.01 mmol, 0.2 
equiv) according to General Procedure X. The c1"llcde product was purified by 
chromatography on silica (ethyl acetate/petroleum ether, 1:4) to give a mixture (23 mg, 
43%) of2.85 and a double bond migrated product 2.85a as a brown oil (4:1 by IH NMR). 
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IH NMR (CDCh. 500 MHz) from mixture 2.85 8 1.49 (s. 9H. CH3)3), 2.42 (m, 4H. 
CHzCH=CHCH2), 2.63 (t, J = 7.6 Hz, 2H, COCH2), 3.39 (m br, 2H, CH2S), 3.64-3.83 (m, 
6H, sugar moiety), 3.78 (s, 3H, OCH3), 4.11 (m, lH, H-Canomeric), 4.50-4.98 (m, 9H, 
CHzPh, NHCH), 5.31 (d br, J = 7.5 Hz, 1H, NH), 5.51 (dq, J = 5.4, 15.6 Hz, 2H, 
CH=CH), 7.16-7.37 (m, 20H, ArH). 
Selected data IH NMR (CDCh, 500 MHz) from mixture 2.85a 8 2.90 (d, J 4.3 Hz, 
COCHzCH=), 5.58 (m, CH=CH), 5.77 (m, NH). 
l3C NMR (CDCh, 75 MHz) from mixture 2.85 8 28.21, 28.39, 30.92, 43.62, 52.57, 52.98, 
68.84, 70.98, 72.96, 73.36, 73.77, 74.99, 75.34, 78.03, 79.97, 80.12, 82.27, 127.51, 127.58, 
127.65, 127.71, 127.78, 127.84, 127.89, 128.26, 128.31, 128.34, 129.72, 137.93, 138.06, 
l38.13, l38.64, 154.99, 170.88, 197.63. 
HRMS (M+H) FOUfld 854.3926 (Caled for C49HtioNOlOS 854.3938). 
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5.2.4 Synthesis of Fatty Acid eM compounds 
Undec-lO-enoic acid methyl ester (2.76) 
~C02Me 
2.76 
To a solution of lO-decenoic acid 2.7S (1 g, 5.43 mmol) in methanol (25 mL) was added 
Amberlyst 15 IER resin (870 mg). The solution was stirred overnight, filtered to remove 
the resin, and the solvent was removed by evaporation under reduced pressure. The crude 
product was purified by flash chromatography on silica (ethyl acetate/petroleum ether, 
1:19) to give 2.76 (803 mg, 75%) as a colourless liquid. 
IH NMR (CDCb, 500 MHz) (3 1.27 (m, 8H, CH2), 1.35 (m, 2H, CH=CH2CHZ), 1.60 (m, 
2H, CHzCH2CO), 2.02 (q, J 7.3 Hz, 2H, =CHCH1CH2), 2.29 (t, J 7.6 2H, 
COCH2), 3.65 (s, 3H, OCH3), 4.91 (dd, J = 1.5, 10.3 Hz, lH, CH=CHH), 4.97 (ddd, J 
1.5,3.4, l7.1Hz, lH, CH=CHH), 5.79 (m, 111, CH=CH2)' 
l3C NMR (CDCb, 75 MHz) (3 24.75, 28.71, 28.87, 28.95, 29.03, 29.11, 33.60, 33.84, 
51.12, 113.94, 138.82, 173.91. 
(SS)-ll-(S-tert-Butoxycarbonylamino-S-methoxycarbonyl-pentylcarbamoyl)-undec-
lO-enoic acid methyl ester (2.94) 
o 
JNj~co2Me 
B"'N~,M: H 
2.94 
Ns-Acryloyllysine 2.37 (20 mg, 0.06 mmol, 1 equiv) was reacted with 2.76 (38 mg, 0.20 
mmol,3 equiv) and Grubbs second generation catalyst 1.17 (11 mg, 0.01 mmol, 0.2 equiv) 
according to General Procedure X. The crude product was purified by chromatography on 
silica (petroleum ether/ethyl acetate, 3:7) to give a mixture (21 mg, 68%) of 2.94 and 
double bond migrated product 2.94a as a brown oil (12: 1 by IH NMR). 
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IH NMR (CDCh, 500 MHz) from mixture 2.94 8 1.25-1.41 (m, 12H, CH2), 1.41 (s, 9H, 
(CH3)3), 1.48-1.65 (m, 5H, CH2CH2NH, CH2CH2CO, NHCHCHH), 1.77 (m, 1H, 
NHCHCHH), 2.12 (m, 2H, =CHCH2), 2.26 (t, J= 7.6 Hz, 2H, CH2CO), 3.27 (q, J= 6.3 
Hz, 2H, CH2NH), 3.63 (s, 3H, OCH3), 3.70 (s, 3H, OCH3), 4.24 (m br, 1H, NHCH), 5.13 
(d br, J= 7.8 Hz, 1H, NHCH), 5.73 (m br, 2H, CH2NH, COCH=), 6.78 (dt, J= 6.8, 15.6 
Hz, 1H, =CHCH2). 
Selected data IH NMR (CDCh, 500 MHz) from mixture 2.94a 8 2.89 (d, J = 7.0 Hz, 
COCH2CH=), 3.19 (m, CH2NH), 5.51 (m, CH=CH). 
l3C NMR (CDCh, 75 MHz) from mixture 2.94 822.48,24.75,28.08,28.19,28.77,28.86, 
28.92,28.97,29.02,31.83,32.25,33.93,38.87,51.33, 52.15, 53.03, 79.72, 123.47, 144.45, 
155.45, 166.11, 173.12, 174.20. 
HRMS (M+H) Found 485.3224 (Caled for C25~5N207 485.3227). 
(5S)-13-(5-tert-Butoxycarbonylamino-5-methoxycarbonyl-pentylcarbamoyl)-tridec-
10-enoic acid methyl ester (2.95) 
2.95 
Ns-Pentenoyllysine 2.35 (50 mg, 0.15 mmol, 1 equiv) was reacted with 2.76 (87 mg, 0.44 
mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (25 mg, 0.03 mmol, 0.2 equiv) 
according to General Procedure X. The crude product was purified by chromatography on 
silica (petroleum ether/ethyl acetate, 3:7) to give a mixture (36 mg, 48%) of 2.95 and 
double bond migrated isomers 2.95a and b as a brown oil (34:4:1 by IHNMR). 
IH NMR (CDCh, 500 MHz) from mixture 2.95 8 1.22-1.38 (m, 12H, CH2), 1.39 (s, 9H, 
(CH3)3), 1.47 (m, 1H, CH2CH2NH), 1.58 (m br, 5H, CH2CH2CO, NHCHCHH), 1.74 (m, 
1H, NHCHCHH), 1.91 (m, 2H, =CHCH2(CH2)7), 2.17 (m, 2H, COCH2CH2=CH), 2.26 (m, 
4H, COCH2), 3.18 (m, 2H, CH2NH), 3.62 (s, 3H, OCH3), 3.69 (s, 3H, OCH3), 4.22 (m br, 
1H, NHCH), 5.12 (d br, J= 7.9 Hz, IH, NHCH), 5.37 (dt, J= 6.3, 14.1 Hz, 1H, CH=CH), 
5.45 (dt, J= 6.5, 14.1 Hz, 1H, CH=CH), 5.77 (s br, 1H, CH2NH). 
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Selected data IH NMR (CDC!), 500 MHz) from mixture 2.95a and b 0 2.91 (d, J 6.9 Hz, 
COCH2CH=), 2.98 (d, J 7.6 Hz, COCH2CH=), 3.30 (m, CH2NH), 5.51 (m, CH=CH), 
5.65 (m, CH2NH). 
l3C NMR (CDCh, 75 MHz) from mixture 2.95022.35,24.67, 28.07,28.45,28.77,28.83, 
28.93, 28.99,29.05,29.16, 31.95, 32.23, 32.82, 36.36, 38.65, 51.20, 52.00, 53.00, 79.54, 
128.16,131.44,155.36,172.55,173.03,174.11. 
HRMS (M+H) Found 513.3535 (Calcd for C27Rt9N207 513.3540). 
(5S)-19-(5-tert-Butoxyearbonylamino-5-methoxyearbonyl-pentylearbamoyl)-nonadee-
10-enoie acid methyl ester (2.96) 
o 
B"'N~~ 
H 
2.96 
Nc-Decenoyllysine 2.34 (20 mg, 0.05 mmol, 1 equiv) was reacted with 2.76 (29 mg, 0.14 
mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (8 mg, 0.01 mmoI, 0.2 equiv) 
according to General Procedure X. The crude product was purified by chromatography on 
silica (petroleum ether/ethyl acetate, 1:4) to give 2.96 (18 mg, 64%) as a brown oil. 
lH NMR (CDCb, 500 MHz) 0 1.25-1.38 (m br, 24H, CH2), 1.41 (s, 9H, C(CH3)3), 1.48 
(m, 2H, CH2CH2NH), 1.57-1.64 (m br, 5H, COCH2CH2, NHCHCHH), 1.77 (m, 1H, 
NHCHCHH), 1.95 (m, 4H, CH2CH=CH2), 2.12 (t, J = 7.5 Hz, 2H, COCH2), 2.27 (t, J 
7.3 Hz, 2H, COCH2), 3.20 (m, CH2NH), 3.63 (s, 3H, OCH3), 3.71 (s, 3H, OCH3), 4.24 (m 
br, 1H, NHCH), 5.12 (d br, J 7.7 Hz, 1H, CHNH), 5.34 (m, 2H, CH=CH), 5.72 (s br, 
IH, CH2NH). 
l3C NMR (CDCb, 75 MHz) 0 22.49, 24.85, 25.72, 27.09, 28.23, 28.97, 29.03, 29.12, 
29.19, 29.26,28.51, 29.49, 29.62, 32.31, 32.48, 34.01, 36.73, 38.89, 51.36, 52.20, 53.06, 
79.79, 129.76, 130.22, 155.45, 173.15, 173.21, 174.27. 
HRMS (M+H) Found 597.4472 (Calcd for C33H6lN207 597.4479). 
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(2S,5S)-13-[5-(2-tert-Butoxycarbonylamino-3-phenyl-propionylamino)-5-methoxy-
carbonyl-pentylcarbamoyl]-tridec-10-enoic acid methyl ester (2.97) 
o 
2.97 
Na-Pentenoyl dipeptide 2.54 (20 mg, 0.04 mmol, 1 equiv) was reacted with 2.76 (24 mg, 
0.12 mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (7 mg, 0.01 mmol, 0.2 
equiv) according to General Procedure X. The crude product was purified by 
chromatography on silica (petroleum ether/ethyl acetate, 1 :4) to give a mixture (11 mg, 
41%) of2.97 and double bond migrated product 2.97a as a brown oil (4:1 by IHNMR). 
IH NMR (CDCb, 500 MHz) from mixture 2.97 0 1.31-1.51 (m, 14H, CH2), 1.43 (s, 9H, 
(CH3)3), 1.67 (m, 3H, CH2CH2NH, NHCHCHH), 1.84 (m, IH, NHCHCHH), 2.03 (m,2H, 
=CHCH2(CH2)7), 2.26 (m, 2H, CH2CH=CH2), 2.33 (m, 4H, COCH2), 3.10 (m br, 2H, 
CH2Ph), 3.24 (m, 2H, CH2NH), 3.70 (s, 3H, OCH3), 3.73 (s, 3H, OCH3), 4.41 (m br, 1H, 
NHCHPhe), 4.55 (m br, lH, NHCHLys), 5.19 (s br, 1H, NHCHPhe), 5.41 (dt, J = 6.0, 15.4 
Hz, tH, CH=CH), 5.49 (dt, 6.3, 15.3 Hz, IH, CH=CH), 5.87 (8 br, 1H, CH2NH), 6.70 
(d br, 1H, J= 7.5 Hz, NHCHLys), 7.23-7.33 (m, 5H, ArH). 
Selected data IH NMR (CDCb, 500 MHz) from mixture 2.97a 0 2.96 (d, J = 6.9 Hz, 
COCH2CH=), 5.59 (m, CH=CH). 
13C NMR (CDCb, 75 MHz) from mixture 2.97 0 22.11, 24.87, 28.19, 28.66, 28.91, 28.99, 
29.05,29.14,29.20, 29.36, 31.68, 32.44, 34.05, 36.61, 38.62, 38.74, 51.42, 51.92, 52.32, 
55.69, 80.11, 126.84, 128.27, 128.53, 129.29, 131.76, 136.55, 155.43, 171.28, 172.17, 
172.84, 174.32. 
HRMS (M+H) Found 660.4208 (Caled for C36HS8N30g 660.4224). 
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(2R)-19-(2-tert-Butoxycarbonylamino-2-methoxycarbonyl-ethylsulfanylcarbonyl)-
nonadec-l0-enoic acid methyl ester (2.98) 
o 
S 
BOC"NLcozMe 
H 
2.98 
COzMe 
188 
NE-Decenoyl cysteine 2.48 (30 mg, 0.07 mmol, 1 equiv) was reacted with 2.76 (45 mg, 
0.23 mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (13 mg, 0.01 mmol, 0.2 
equiv) according to General Procedure X. The crude product was purified by 
chromatography on silica (ethyl acetate/petroleum ether, 1:4) to give 2.98 (26 mg, 61 %) as 
a brown oiL 
IH NMR (CDCh, 500 MHz) (5 1.27 (m, 20H, CH2), 1.41 (s, 9H, (CH3)3), 1.60 (m, 4H, 
COCH2CH2), 1.94 (m, 4H, CH2CH=CH2), 2.27 (t, J = 7.5 Hz, 2H, OCOCH2), 2.52 (t, J = 
7.5 Hz, 2H, SCOCH2), 3.31 (m, 2H, SCH2), 3.64 (s, 3H, OCH3), 3.72 (s, 3H, OCH3), 4.49 
(m br, IH, NHCH), 5.22 (d br, J= 7.5 Hz, IH, NH), 5.33 (m,2H, CH=CH). 
BC NMR (CDCh, 75 MHz) (5 24.83, 25.49, 27.07, 28.17, 28.75, 28.96, 29.00, 29.03, 
29.08, 29.11, 29.14, 29.19, 29.43, 29.47, 30.83, 32.46, 33.98, 43.89, 51.32, 52.52, 53.00, 
80.00, 130.18, 130.23, 154.97, 170.90, 174.20, 198.39. 
HRMS (M+H) Found 572.3625 (Calcd for C30H54N07S 572.3621). 
(2R)-13-(2-tert-Butoxycarbonylamino-3-methoxycarbonyl-pr()pylsulfanylcarbonyl)-
tridec-l0-enoic acid methyl ester (2.99) 
o 
s -;:?' BOC"N~C02Me 
H 
2.99 
S-Pentenoyl-~-cysteine 2.51 (60 mg, 0.18 mmol, 1 equiv) was reacted with 2.76 (108 mg, 
0.54 mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (31 mg, 0.04 mmol, 0.2 
equiv) according to General Procedure X. The crude product was purified by 
Chapter Five - Experimental 189 
chromatography on silica (ethyl acetatelDCM, 1:19) to give 2.99 (53 mg, 59%) as a brown 
oiL 
IH NMR (CDCh, 500 MHz) 8 1.25 (m, 12H, CH2), 1.39 (s, 9H, C(CH3)3), 1.57 (m, 2H, 
CH2), 1.92 (m, 2H, =CHCH2), 2.28 (m, 4H, COCH2CH2, COCH2(CH2)7), 2.56 (m, 4H, 
SCOCH2, COCH2CH), 3.10 (m, 2H, SCH2), 3.63 (s, 3H, OCH3), 3.66 (s, 3H, OCH3), 4.04 
(m, IH, NHCH), 5.11 (br d, 7.8 Hz, IH, NH), 5.32 (td, J 6.5, 14.3 Hz, IH, CH=CH), 
5.42 (td,J= 6.7,15.2 Hz, IH, CH=CH). 
BC NMR (CDCb, 75 MHz) 8 24.77, 28.18, 28.37, 28.88, 28.92, 28.96, 29.04, 29.10, 
29.17, 32.28, 33.92, 37.44, 43.82, 47.50, 51.27, 51.64, 79.38, 127.10, 132.11, 154.94, 
171.32, 174.12, 198.33. 
HRMS (M+H) Found 502.2836 (Calcd for C2sH44N07S 502.2839). 
(2S)-Icos-1 O-enedioic acid 2-tert-butoxycarbonylamino-2-m ethoxycarbonyl-ethyl ester 
methyl ester (2.100) 
o 
o 
BOC'NLC02M6 
H 
2.100 
Ne-Decenoyl serine 2.46 (20 mg, 0.05 mmol, 1 equiv) was reacted with 2.76 (31 mg, 0.16 
mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (9 mg, 0.01 mmol, 0.2 equiv) 
according to General Procedure X. The crude product was purified by chromatography on 
silica (ethyl acetate/petroleum ether, 1 :4) to give 2.100 (21 mg, 73%) as a brown oil. 
IH NMR (CDCb, 500 MHz) 8 1.28 (m, 20H, CH2), 1.44 (s, 9H, (CH3)3), 1.59 (m, 4H, 
COCH2CH2), 1.94 (m, 4H, CH2CH=CH2), 2.28 (m, 4H, COCH2), 3.65 (s, 3H, OCH3), 
3.75 (s, 3H, OCH3), 4.30 (dd, J 3.6, 11.3 Hz, lH, OCHH), 4.44 (dd, J = 3.6, 11.3 Hz, 
1H, OCHH), 4.55 (m br, IH, NHCH), 5.27 (d br, J = 8.2 Hz, 1H, NH), 5.36 (m, 2H, 
CH=CH). 
l3C NMR (CDCb, 75 MHz) 8 24.73, 24.86, 28.19, 28.64, 28.85, 28.99, 29.02, 29.05, 
29.16, 29.21,29.35, 29.46, 29.51, 32.46, 32.49, 33.89, 34.01, 51.35, 52.61, 52.86, 63.96, 
80.20, 130.25, 130.34, 155.06, 170.24, 173.22, 174.23. 
HRMS (M+H) Found 556.3873 (Calcd for C30Hs,.NOg 556.3849). 
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1-[2-tert-Butoxycarbonylamino-3-(19-methoxycarbonyl-nonadec-1 O-enoylsulfanyl)-
propionyl]-pyrrolidine-2-carboxylic acid benzyl ester (2.101) 
o 
s B"'N~9 
H 0 C02Bn 
2.101 
NE-Decenoyl dipeptide 2.57 (50 mg, 0.09 mmol, 1 equiv) was reacted with 2.76 (52 mg, 
0.03 mmol, 3 equiv) and Grubbs second generation catalyst 1.17 (15 mg, 0.02 mmol, 0.02 
equiv) according to General Procedure X. The crude product was purified by 
chromatography on silica (ethyl acetatelDCM, 1:9) to give 2.101 (28 mg, 43%) as a brown 
oil. 
IH NMR (CDCb, 500 MHz) 0 1.26 (m, 18H, CH2), 1.39 (s, 9H, C(CH3)3), 1.61 (m,4H, 
CH2), 1.96 (m, 8H, CH2),2.18 (m, 1H, COCHCHH), 2.27 (m, 3H, OCHCH2, 
COCHCHH), 2.53 (t, J 7.3 Hz, 2H, SCOCH2), 2.71 (m, 1H, SCHH), 3.31 (m, IH, 
SCHH), 3.63 (s, 3H, OCH3), 3.72 (m, 1H, NCHH), 3.92 (m, 1H, NCHH), 4.56 (m, 2H, 
NHCH, NCH), 5.09 (m, IH, OCHH), 5.17 (m, 1H, OCHH), 5.31 (m, IH, NH), 5.35 (m, 
2H, CH=CH), 7.31 (m, 5H, ArH). 
l3C NMR (CDCb, 75 MHz) 0 24.80, 24.85, 25.44, 28.20, 28.83, 28.90, 29.01, 29.04, 
29.13,29.17,29.20,29.45,29.51,31.74,32.48,34.00, 34.42,43.93,46.97,51.34,58.93, 
66.82, 79.67, 125.78, 128.08, 128.21, 128.46, 130.22, 135.45, 155.38, 169.36, 171.33, 
174.21,199.30, 
HRMS (M+H) Found 745.4478 (Calcd for C41H65N20gS 745.4462). 
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5.2.5 Solid Phase Synthesis 
(6S)-6-Amino-2-(9H-fluoren-9-ylmethoxycarbonylamino )-hexanoic acid methyl ester 
hydrochloride salt (2.102b) 
2.102a 2.102b 
Fmoc-L-Lys-OH 2.102a (4 g, 9.9 mmol) was treated with Amberlyst 15 IER (1.6 g) 
according to General Procedure XV, to give 2.102b (3.1 g, 75%) as a pale yellow, sticky 
oil that was used without purification. 
(2S)-2-(9H -Fluoren-9-ylmethoxycarbonylamino )-6-(pent-4-enoylamino )-hexanoic acid 
methyl ester (2.103) 
2.103 
Fmoc-L-Lys-OMe 2.102b (503 mg, 1.2 mmol, 1 equiv) and 4-pentenoic acid (113 mg, 1.4 
mmol, 1.14 equiv) were treated with EDCI (198 mg, 1.56 mmol, 1.3 equiv) and HOBt (272 
mg, 1.8 mmol, 1.5 equiv) according to General Procedure VII. The crude product was 
purified by flash chromatography on silica (petroleum ether/ethyl acetate, 2:3) to give 
2.103 (344 mg, 66%) as a white solid. 
mp 88-89°C 
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IH NMR (CDCh, 500 MHz) 0 1.37 (m, 2H, CH2), 1.51 (m, 2H, CH2), 1.70 (m, 1H, 
NHCHCHH), 1.85 (m, lH, NHCHCHH), 2.23 (t, J = 7.4 Hz, 2H, COCH2), 2.36 (m, 2H, 
COCH2CH2), 3.23 (m, 2H, NHCH2), 3.74 (s, 3H, OCH3), 4.21 (t, J = 7.0 Hz, 1H, CHpmoc), 
4.38 (m, 3H, NHCH, CH2Pmoc), 5.00 (m, 2H, CH=CH2), 5.45 (br d, J = 8.1 Hz, 1H, 
NHCH), 5.60 (br s, 1H, NHCH2), 5.78 (m, 1H, CH=CH2). 
13e NMR (CDCh, 75 MHz) 0 22.19, 29.34, 31.41, 35.30, 38.49, 46.75, 52.02, 53.43, 
66.64, 115.05, 119.64, 124.74, 126.72, 127.38, 136.75, 140.88, 143.36, 143.50, 155.95, 
172.40, 172.67. 
HRMS (M+H) Found 465.2389 (Caled for C27H33N20S 465.2389). 
(2S)-2-(9H-Fluoren-9-ylmethoxycarbonylamino )-6-(undec-l0-enoylamino )-hexanoic 
acid methyl ester (2.104) 
2.104 
Fmoc-L-Lys-OMe 2.102b (1.5 g, 3.4 mmol, 1 equiv) and 10-decenoic acid (751 mg, 4.1 
mmol, 1.14 equiv) were treated with EDCI (844 mg, 4.42 mmol, 1.3 equiv) and HOBt (770 
mg, 5.1 mmol, 1.5 equiv) according to General Procedure VII. The crude product was 
purified by flash chromatography on silica (ethyl acetate/DCM, 2:3) to give 2.104 (1.72 g, 
88%) as a white solid. 
mp= 97-99°C 
IH 1\TMR (CDCh, 500 MHz) 0 1.24 (s, 9H, C(CH3)3), 1.34 (m, 8H, CH2) , 1.52 (m, 4H, 
CH2), 1.59 (m, 4H, CH2), 1.71 (m, 1H, NHCHCHH), 1.85 (m, 1H, NHCHCHH), 2.01 (m, 
2H, CH2CH=CH2), 2.12 (t, J= 7.6 Hz, 2H, COCH2), 3.23 (m, 2H, CH2NH), 3.74 (s, 3H, 
OCH3), 4.22 (t, J = 7.1 Hz, 1H, CHpmoc), 4.38 (m, 3H, NHCH, CH2Pmoc), 4.91 (m, 1H, 
CH=CHH), 4.97 (m, 1H, CH=CHH), 5.45 (br d, J = 8.1 Hz, 1H, NHCH), 5.54 (br s, 1H, 
CH2NH), 5.78 (m, lH, CH=CH2), 7.29-7.76 (m, 8H, ArH). 
13C NMR (CDCh, 75 MHz) 0 22.22, 25.53, 28.55, 28.68, 28.75, 29.02, 31.49, 33.46, 
36.36, 38.48, 46.80, 52.03, 53.44, 66.68, 113.87, 119.66, 124.77, 126.74, 127.40, 138.77, 
140.92, 143.38, 143.54, 155.95, 172.67, 173.23. 
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HRMS (M+H) Found 549.3334 (Calcd for C33H4SN20S 549.3328). 
(2S)-2-(9H -Fluoren-9-ylmethoxycarbonylamino )-6-( undec-l O-enoylamino )-hexanoic 
acid (2.106) 
2.106 
Na-Fmoc-NE-decenoyl-L-Lys-OMe 2.104 (508 mg, 0.93 mmol, 1 equiv) was treated with 
0.2 M lithium hydroxide (2 equiv) according to General Procedure VIII to give 2.106 (477 
mg, 96%) as a yellow solid. 
mp = 85-90°C 
lH NMR (CDCh, 500 MHz) 8 1.22 (s, 9H, C(CH3)3), 1.29-1.57 (m, 16H, CH2), 1.76 (m, 
lH, NHCHCHH), 1.89 (m, 1H, NHCHCHH), 2.00 (m, 2H, CH2CH=CH2), 2.14 (t, J= 7.5 
Hz, 2H, COCH2), 3.22 (m, 2H, CH2NH), 4.18 (t, J= 7.1 Hz, 1H, CHFmoc), 4.35 (m, 3H, 
NHCH, CH2Fmoc), 4.91 (m, 1H, CH=CHH), 4.96 (m, 1H, CH=CHH), 5.78 (m, 1H, 
CH=CH2), 5.85 (br d, J= 8.0 Hz, 1H, NHCH), 5.99 (br s, 1H, CH2NH), 7.25-7.73 (m, 8H, 
ArH). 
13C NMR (CDCh, 75 MHz) 8 22.21, 25.71, 28.74, 28.94, 29.12, 29.14, 29.19, 33.64, 
36.41, 39.14,46.95,53.45, 66.98, 114.04, 119.83, 124.99, 126.93, 127.59, 128.61, 138.99, 
141.09, 143.51, 156.29, 174.60, 174.91. 
HRMS (M+H) Found 535.3165 (Calcd for C32~3N20S 535.3172). 
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Attempted solid-phase synthesis of 2.111 
HO 
HO (i) 10% _X:xc---ii) _. f'~~ 
FmOC'N~O" 
H 0 
2.109 
2.107 
Wang Resin 90% 
2.108 • (iii) 
o 
[N~OTHP H 8 (iv) 
--------------
FmOc'N C02H H 
2.111 
194 
Capping of Wang Resin 2.107. Wang Resin 2.107 (384 mg, ~0.23 mmol) was swelled in 
DCM (3.5 mL) for 30 min and then treated with tert-butyldimethylsilyl chloride (31 mg, 
0.21 mmol) and TEA (13 mL). The reaction was shaken for 18 h, filtered, and washed 
with DCM and ether. The resulting resin (2.108) was dried overnight under high vacuum. 
Attempted loading of resin 2.108. Capped Wang resin 2.108 (1 eq uncapped binding sites) 
was swelled in a minimal amount of DCM for 30 min, and then EDCI (8mg, 0.04 mmol, 
1.8 eq), DMAP (2mg, 0.02 mmol, 0.7 eq), and 2.106 (18mg, 0.03 mmol, 1.4 eq) in DCM 
(2 mL) were added and the mixture shaken for 24 hr. The resin was washed with DCM 
and ether, and dried under high vacuum overnight to give 2.109. 
Attempted cross metatllesis coupling. The Wang resin 2.109 was swelled in a minimal 
amount ofDCM for 30 min. A solution of2.65 (31mg, 0.13 mmol, 4 eq) and catalyst 1.17 
(3mg) in DCM was added, and the mixture shaken for 24 hr. The resin was washed with 
DCM and ether, and dried overnight under high vacuum. The resulting dry resin was 
swelled in a minimal amount of DCM, and TF A (1.6mL) and DCM (4mL) were added and 
the mixture shaken for 24 hr. The resin was then washed with DCM and the filtrate 
collected, and the solvents removed by evaporation under reduced pressure. 
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Preparation of 6-(3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yl)-
hex-4-enoic acid 2-benzyloxycarbonyl-2-(9H -fluoren-9-ylmethoxycarbonylamino)-
ethyl ester (2.116) 
2.113 2.114 2.115 
~ BnQ OBn ro~'''''0''''OBn 
Fmoc"-NA C0
2
Bn ~-) 
H 2.116 ,<O-C:~".}-<'".:B" 
y ~-) 
2.116a Y = 1 and/or 2 BnO 
o HOq' OH 
IO~"'" 0 ""OH oil( )( 
Fmoc"-NAC02H HO 
H 
2.117 
(2S)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-propionic acid benzyl ester 
(2.114) L-Ser-OBn.HCI2.113 (1 g, 4.32 mmol, 1 equiv) was dissolved in DCM (30 mL) 
and DIPEA (614 mg, 4.75 mm01, 1.1 equiv) was added dropwise at O°C. After stirring for 
10 min a solution of Fmoc-CI (1.23 g, 4.75 mmol, 1.1 equiv) in DCM (10 mL) was added 
dropwise and the solution was allowed to warm to rt with stirring for 1 h. The solution 
was diluted with DCM, and washed once with 1 % aqueous sodium bicarbonate, saturated 
sodium bicarbonate, water, and saturated brine sequentially. The organic layer was dried 
(MgS04) and the solvent removed by evaporation under reduced pressure to give a 
colourless oil that was recrystalised (petroleum ether/ethyl acetate) to give 2.114 (1.619 g, 
90%) as a white solid. 
mp = 97-100°C 
IH NMR (CDCb, 500 MHz) {) 3.92 (m, IH, CHHOH), 4.01 (m, IH, CHHOH), 4.20 (t, J = 
6.8 Hz, IH, CHFmoc), 4.41 (m, 2H, CH2Fmoc), 4.49 (m, IH, NHCH), 5.21 (s, 2H, OCH2Ph), 
5.78 (br d, J= 7.0 Hz, 1H, NH), 7.28-7.76 (m, 13H, ArH). 
l3C NMR (CDCb, 75 MHz) {) 46.67, 55.97, 62.53, 66.91, 67.05, 119.65, 124.79, 126.78, 
127.40, 127.73, 128.04, 128.23, 134.85, 140.90, 143.33, 156.26, 170.39. 
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(2S)-Pent-4-enoic acid{2-benzyloxycarbonyl-2-(9H-fllloren-9-ylmethoxycarbonyl-ami-
no)]-ethyl ester (2.115) Fmoc-L-Ser-OBn 2.114 (1.12 g, 2.7 mmol, 1 equiv) and 4-
pentenoic acid (306 mg, 3.1 mmol, 1.14 equiv) were treated with EDCI (562 mg, 2.94 
mmol, 1.09 equiv) and DMAP (3 mg, 0.03 mmol, 0.01 equiv) according the General 
Procedure XII. The crude product was purified by flash chromatography on silica (ethyl 
acetateIDCM, 2.5:97.5) to give 2.115 (1.13 g, 94%) as a white solid. 
mp 81-83°C 
IH NMR (CDCh, 500 MHz) 8 2.32 (m, 4H, COCH2CH2), 4.23 (t, J 7.1 Hz, IH, 
CHFmoc), 4.39 (m, 3H, CH2Fmoc, NHCHCHH), 4.51 (m, IH, NHCHCHH), 4.67 (m, IH, 
NHCH), 5.01 (m, 2H, CH=CH2), 5.21 (m, 2H, OCH2Ph), 5.59 (br d, J= 8.2 Hz, IH, NH), 
5.77 (m, IH, CH=CH2), 7.29-7.77 (m, 13H, ArH). 46.76, 
l3C NMR (CDCh, 75 MHz) 8 28.27, 32.69, 53.21, 63.61, 66.91, 67.27, 115.34, 119.70, 
124.77, 126.77, 127.42, 128.05, 128.24, 128.29, 134.75, 136.17, 140.96, 143.39, 143.52, 
155.51,169.07,172.03. 
HRMS (M+H) Found 500.2078 (Calcd for C30H30N06 500.2073). 
6-(3,4,5-Tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yl)-hex-4-enoic acid 2-
benzyloxycarbonyl-2-(9H-fllloren-9-ylmethoxycarbonylamino)-ethyl ester (2.116) 0-
Pentenoyl serine 2.115 (60 mg, 0.12 mmol, 1 equiv) was reacted with 1.51b (136 mg, 0.24 
mmol, 2 equiv) and Grubbs second generation catalyst 1.17 (20 mg, 0.02 mmol, 0.2 equiv) 
according to General Procedure X. The crude product was purified by chromatography on 
silica (ethyl acetate/DCM, 1: 19) and then recrystalised (pet ether/ethyl acetate) to give a 
mixture (42mg, 36%) of 2.116 and the double bond migrated product 2.116a as a white 
solid (12:1 by IHNMR). 
mp = 75-77°C 
IH NMR (CDCb, 500 MHz) from mixture 2.116 8 2.24 (m, 4H, CH2CH=CHCH2), 2.42 
(m, 2H, COCH2), 3.59-3.76 (m, 6H, sugar moiety), 4.06 (m, lH, H-Camomeric), 4.22 (t, J= 
6.7Hz, IH, CHFmoc), 4.35-4.90 (rn, 13H, CH2Phsugar, CH2Fmoc, NHCH, CH20CO), 5.19 (m, 
2H, CH2Phbenzyl ester), 5.45 (m, 2H, HC=CH), 5.62 (d, J = 8.0Hz, IH, NH), 7.11-7.75 (m, 
33H, ArH). 
Selected data IH NMR (CDCb, 500 MHz) from mixture 2.116a 8 2.93 (d, J 8.4 Hz, 
COCH2CH=), 5.54 (m, CH=CH), 5.82 (m, NH). 
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l3C NMR (CDCh, 75 MHz) from mixture 2.116 8 27.65, 28.38, 33.59, 47.02, 53.478, 
63.87, 67.26, 67.62, 68.86, 71.02, 72.96, 73.36, 73.84, 75.01, 75.35, 78.05, 80.00, 82.32, 
119.95, 125.04, 127.05, 127.42, 127.52, 127.57, 127.70, 127.79, 127.86, 127.91, 128.27, 
128.33, 128.36, 128.59, 130.18, 134.92, 137.98, 138.11, 138.16, 138.68, 141.23, 143.61, 
155.69, 169.28, 172.45. 
HRMS (M+H) Found 1036.4642 (Calcd for C65H66N016 1036.4636). 
Attempted synthesis of 6-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yl)-
hexanoic acid 2-carboxy-2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethyl ester (2.117) 
Compound 2.116 (40 mg, 0.02 mmol) was dissolved in methanol/ethyl acetate (20 mL, 
1:1) and 10 % palladium/carbon (10 mg) was added. The mixture was stirred under an 
atmosphere of hydrogen (H2 balloon) at rt overnight. The solution was filtered through 
celite to remove the catalyst, and the resulting organic solvent was removed by evaporation 
under reduced pressure to give a complex mixture of products (15 mg) as a yellow oil. 
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5.3 EXPERIMENTAL WORK AS DESCRIBED IN CHAPTER 
THREE 
(2S)-Oct-4-enedioic acid bis-(2-tert-butoxycarbonylamino-2-methoxycarbonyl-ethyI) 
ester (3.22) 
3.22 
O-Pentenoyl serine 2.45 (50 mg, 0.17 mmol, 2 equiv) was treated with Grubbs second 
generation catalyst 1.17 (14 mg, 0.02 mmol, 0.2 equiv) according to General Procedure IX. 
The crude product was purified by flash chromatography on silica (ethyl acetate/DCM, 
1 :9) to give a mixture (42 mg, 86%) of 3.22 and the double bond migrated products 3.22a 
and b as a brown oil (20:3:1 by IHNMR). 
IH NMR (CDCh, 500 MHz) from mixture 3.22 0 1.39 (s, 18H, C(CH3)3), 2.23 (m, 4H, 
CH2CH=Clh), 2.31 (m, 4H, COCH2), 3.70 (s, 6H, OCH3), 4.27 (m, 2H, OCH2), 4.38 (m, 
2H, OCH2), 4.51 (m, 2H, NHCH), 5.32 (br m, 2H, NH), 5.38 (m, 2H, CH=CH). 
Selected data IH NMR (CDCh, 500 MHz) from mixture 3.22a and b 0 3.01 (d, J 4.5 Hz, 
COCH2CH=), 3.09 (d, 6.5 Hz, COCH2CH=), 5.52 (m, CH=CH). 
l3C NMR (CDCb, 75 MHz) from mixture 3.22027.44,28.13, 33.61, 52.59, 52.74, 64.02, 
80.15, 129.22, 155.02, 170.15, 172.36. 
HRMS (M+H) Found 575.2818 (Calcd for C26H43NZ012 575.2816). 
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(2S)-Icos-10-enedioic acid bis-{2-tert-butoxycarbonylamino-2-methoxycarbonyl-ethyl) 
ester (3.23) 
3.23 
O-Decenoyl serine 2.46 (60 mg, 0.13 mmol, 2 equiv) was treated with Grubbs second 
generation catalyst 1.17 (14 mg, 0.02 mmol, 0.2 equiv) according to General Procedure IX. 
The crude product was purified by flash chromatography on silica (ethyl acetate/DCM, 
I :9) to give 2.23 (30 mg, 62%) as a brown oil. 
lH NMR (CDCh, 500 MHz) (5 1.28 (m, 18H, CH2), 1.44 (s, 18H, C(CH3)3), 1.58 (m, 6H, 
CH2), 1.96 (m, 4H, =CHCH2), 2.28 (t, J= 7.5 Hz, 4H, COCH2), 3.75 (s, 6H, OCH3), 4.30 
(m, 2H, OCH2), 4.44 (m, 2H, OCH2), 4.55 (m, 2H, NHCH), 5.27 (br d, J 8.0 Hz, 2H, 
NH), 5.36 (m, 2H, CH=CH). 
l3C NMR (CDCh, 75 MHz) (5 24.68, 28.15, 28.93, 29.08, 29.17, 29.43, 29.47, 32.44, 
33.84,52.56,52.81,63.89,80.13, 130.17, 155.01, 170.19, 173.16. 
HRMS (M+H) Found 743.4714 (Calcd for C38H67N2012 743.4694). 
{2R, 2R)-2-tert-Butoxycarbonylamino-3-[7-{2-tert-butoxycarbonylamino-2-methoxy-
carbonyl-ethylsulfanylcarbonyl)-hept-4-enoylsulfanyl]-propionic acid methyl ester 
(3.24) 
3.24 
S-Pentenoyl cysteine 2.49a (30 mg, 0.09 mmol, 2 equiv) was treated with Grubbs second 
generation catalyst 1.17 (8 mg, 0.01 mmol, 0.2 equiv) according to General Procedure IX. 
The crude product was purified by flash chromatography on silica (ethyl acetate/petroleum 
ether, 3:7) to give 3.24 (13 mg, 45%) as a brown oil. 
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IH NMR (CDCb, 500 MHz) 8 1.42 (s, 18H, C(CH3)3), 2.31 (m, 4H, =CHCH2), 2.59 (t, J = 
7.4 Hz, 4H, COCH2), 3.32 (m, 4H, SCHz), 3.72 (s, 6H, OCH3), 4.50 (m, 2H, NHCH), 5.23 
(br d, 7.4 Hz, 2H, NH), 5.41 (m, 2H, CH=CH). 
13C NMR (CDCb, 75 MHz) 8 24.59, 28.23, 30.97, 43.50, 52.97, 52.61, 80.13, 129.14, 
155.00, 170.89, 197.57. 
HRMS (M+H) Found 607.2354 (Caled for C26H43N201OS2 607.2359). 
(2R, 2R)-2-tert-Butoxycarbonylamino-3-[19-(2-tert-butoxycarbonylamino-2-methoxy-
carbonyl-ethylsulfanylcarbonyl)-nonadec-lO-enoylsulfanyl]-propionic acid methyl 
ester (3.25) 
3.25 
S-Decenoyl cysteine 2.48 (50 mg, 0.12 mmol, 2 equiv) was treated with Grubbs second 
generation catalyst 1.17 (10 mg, 0.01 mmol, 0.2 equiv) according to General Procedure IX. 
The crude product was purified by flash chromatography on silica (ethyl acetate/petroleum 
ether, 3:7) to give 3.25 (35 mg, 73%) as a brown oiL 
IH NMR (CDCb, 500 MHz) 8 1.24 (m, 20H, CH2), 1.41 (s, 18H, (CH3)3), 1.60 (m, 4H, 
COCH2CH2), 1.92 (m,4H, CH2CH=CH2), 2.52 (m, 4H, COCHz), 3.30 (m br, 4H, SCH2), 
3.71 (s, 6H, OCH3), 4.49 (m br, 2H, NHCH), 5.22 (d br, J = 7.9 Hz, 2H, NB), 5.34 (m, 
2H,CH=CH). 
13C NMR (CDCb, 75 MHz) 8 25.48, 28.16, 28.74, 28.95, 29.07, 29.12, 29.46, 30.82, 
32.44,43.88,52.51,52.99, 79.99, 130.19, 154.95, 170.89, 198.39. 
HRMS (M+H) Found 775.4224 (Calcd for C3sH67N201OS2 775.4237). 
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(2R, 2S)-19-(2-tert-Butoxycarbonylamino-2-methoxycarbonyl-ethylsulfanylcarbonyl)-
nonadec-10-enoic acid-(2-tert-butoxycarbonylamino-2-methoxycarbonyl)-ethyl ester 
(3.26) 
o 
o 
3.26 
O-Decenoyl serine 2.46 (20 mg, 0.05 mmol, 1 equiv) and S-decenoyl cysteine 2.48 (42 mg, 
0.10 mmol, 2 equiv) were treated with Grubbs second generation catalyst 1.17 (9 mg, 0.01 
mmol, 0.2 equiv) according to General Procedure X. The crude product was purified by 
flash chromatography on silica (ethyl acetate/petroleum ether, 3:7) to give 3.26 (26 mg, 
66%) as a brown oiL 
lH NMR (CDC!), 500 MHz)1 0 1.26 (m, 20H, CH2), 1.41 (s, 9H, C(CH3)3), 1.43 (8, 9H, 
C(CH3)3), 1.59 (m, 4H, COCH2CH2), 1.93 (m, 4H, CH2CH=CH2), 2.27 (t, 7.6 Hz, 2H, 
OCOCH2), 2.53 (t, 7.5 Hz, 2H, SCOCH2), 3.31 (br m, 2H, SCH2), 3.72 (s, 3H, OCH3), 
3.74 (8, 3H, OCH3), 4.29 (m, IH, OCHH), 4.42 (m, IH, OCHH), 4.50 (m, IH, NHCH), 
4.54 (m, IH, NHCH), 5.23 (br d, J= 7.7 Hz, IH, NH), 5.27 (br d, J 8.3 Hz, NH), 5.35 
(m, 2H, CH=CH). 
BC NMR (CDC!), 75 MHz) 0 24.74, 25.53, 28.21, 28.78, 28.81, 28.89, 29.00, 29.04, 
29.12,29.14,29.18,29.24,29.53,30.89,32.51,33.91, 40.28,43.94,52.58,52.64,52.87, 
53.04, 63.98, 80.08, 80.25, 130.24, 130.29, 155.00, 155.08, 170.26, 170.94, 173.25, 
198.46. 
HRMS (M+H) Found 759.4453 (Calcd for C3sH67N20nS 759.4466). 
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(2R, 2S)-13-(2-tert-Butoxycarbonylamino-2-methoxycarbonyl-ethylsulfanylcarbonyl)-
tridec-l0-enoic acid-(2-tert-butoxycarbonylamino-2-methoxycarbonyl)-ethyl ester 
(3.27) 
o 
3.27 
O-Decenoyl serine 2.46 (20 mg, 0.05 mmol, 1 equiv) and S-pentenoyl cysteine 2.49a (33 
mg, 0.1 mmol, 2 equiv) were treated with Grubbs second generation catalyst 1.17 (9 mg, 
0.01 mmol, 0.2 equiv) according to General Procedure X. The crude product was purified 
by flash chromatography on silica (ethyl acetate/petroleum ether, 2:3) to give 3.27 (18 mg, 
51 %) as a brown oil. 
IH NMR (CDCh, 500 MHz) 0 1.24 (m, 10H, CH2), 1.42 (s, 9H, C(CH3)3), 1.43 (s, 9H, 
C(CH3)3), 1.56 (m, 2H, CH2), 1.94 (m, 2H, =CHCH2(CH2)7CO), 2.29 (m, 4H, OCOCH2, 
=CHCH2CH2CO), 2.59 (t, J= 7.5 Hz, 2H, SCOCH2), 3.32 (br m, 2H, CH2S), 3.72 (s, 3H, 
OCH3), 3.74 (s, 3H, OCH3), 4.29 (m, 1H, OCHH), 4.43 (m, 1H, OCHH), 4.50 (m, 1H, 
NHCH), 4.54 (m, 1H, NHCH), 5.22 (br d, J= 7.4 Hz, 1H, NH), 5.27 (br d, J= 8.5 Hz, IH, 
NH), 5.33 (dt, J= 6.7,15.2 Hz, 1H, CH=CH), 5.42 (dt, J= 6.6,15.2 Hz, 1H, CH=CH). 
BC NMR (CDCh, 75 MHz) 0 24.72, 27.10, 28.20, 28.38, 28.97, 29.11, 29.19, 29.25, 
30.89,32.36,33.89,43.87,52.57,52.62,52.86, 53.00,63.97,80.07,80.22, 127.10, 132.23, 
154.98, 155.05, 170.25, 170.89, 173.22, 197.76. 
HRMS (M+H) Found 675.3527 (Caled for C32HSSN2011S 675.3527). 
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5.4 EXPERIMENTAL WORK AS DESCRIBED IN CHAPTER 
FOUR 
5.4.1 Lysine-based single amino acid cyclic compounds 
Preparation of (2S)-2,6-bis-acryloylamino-hexanoic acid methyl ester (4.3) 
LNH'.HCI 
HCI.H2N C02R 
,--- 4.1, R= H 
"------~.. 4.2, R = Me 4.3 
(2S)-2,6-Diamino-hexanoic acid methyl ester dihydrochloride salt (4.2) L-Lys.HCI4.1 (3 
g, 16.5 mmol) was suspended in 2,2-dimethoxypropane (200 mL) and concentrated 
hydrochloric acid (16.5 mL) was added. Methanol (60 mL) was added and the solution 
was refluxed for 2 h, and then stirred at rt for 18 h. The solvents were removed by 
evaporation under reduced pressure and the residue dissolved in a minimum volume of 
methanol. Ether (300 mL) was added until the product crashed out of solution. The solid 
was filtered, and then recrystalised from water/acetone and 2,2-dimethoxypropane to give 
L-Lys-OMe.2HCI4.2 (3.26 g, 84%) as a white solid. 
mp = 205-207DC. NMR data was consistent with the literature. 17 
(2S)-2,6-Bis-acryloylamino-hexanoic acid methyl ester (4.3) To a stirred solution of L-
Lys-OMe.2HCI 4.2 (50 mg, 0.12 mmol, 1 equiv) in DCM (2.5 mL) was added DIPEA 
dropwise at ODC until a pH of 8-9 (Universal indicator paper) was obtained. Acryloyl 
chloride (69 mg, 0.77 mmol, 3.6 equiv) was added dropwise and the reaction warmed to rt 
with stirring overnight. The solution was washed successively three times with 1 M 
aqueous hydrochloric acid and water. The organic layer was dried O~a2S04)' and the 
solvent was removed by evaporation under reduced pressure. The crude product was 
purified by flash chromatography on silica (methanol/ethyl acetate, 1: 19) to give 4.3 (8 mg, 
14%) as a sticky, yellow solid. 
mp = >340DC, decomposed 
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IH NMR (CDCb, 500 MHz) 8 1.32 (m, 2H, CHCH2CH2), 1.50 (m, 2H, CH2CH2NH), 1.71 
(m, 1H, NHCHCHH), 1.80 (m, 1H, NHCHCHH), 3.24 (m, 2H, CH2NH), 3.67 (s, 3H, 
OCH3), 4.53 (m, 1H, CH), 5.58 (m, 2H, CH=CH2,), 6.11-6.23 (m, 4H, CH=CH2), 6.60 (br 
s, 1H, CHiI\TH), 6.93 (d, 1H, J= 7.3 Hz, NHCH). 
l3C NMR (CDCb, 75 MHz) 8 22.19, 28.56, 31.33, 38.50, 51.91, 52.28, 126.02, 126.97, 
130.26, 130.87, 165.64, 166.04, 172.73. 
Preparation of (2S)-8,15-dioxo-l, 7-diaza-cyclopentadec-ll-ene-2-carboxylic acid 
methyl ester (4.6) and (2S)-8,15-dioxo-l, 7 -diaza-cyclopentadecane-2-carboxylic acid 
methyl ester (4.8) 
LNH,.HCI 
HCI.H2N C02Me 
4.2 
4.6 4.8 
o 0 
4.5 (5il ~il H H ~ 0 OR ~ 0 
N C02Me N C02Me H H 
4.7a 4.7b 4.9 
(2S)-2,6-Bis-pent-4-enoylamino-hexanoic acid methyl ester (4.5) To a stirred solution of 
L-Lys-OMe.2HCI4.2 (1 g, 4.3 mmol, 1.1 equiv) and 4-pentenoic acid (774 mg, 7.7 mmol, 
2 equiv) in DCM (60 mL) was added EDCI (1.93 g, 10.1 mmol, 2.6 equiv) and HOBt (1.57 
g, 11.6 mmol, 3 equiv). DIPEA (1.60 mL, 8.47 mmol, 2.2 equiv) was added and the 
solution stirred overnight. The mixture was diluted with DCM (60 mL), and washed twice 
with saturated brine (100 mL). The aqueous washings were combined and back extracted 
twice with DCM (100 mL). The organic washings were combined, dried (MgS04), and the 
solvent was removed by evaporation under reduced pressure. The crude product was 
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purified by flash chromatography on silica (DCM/ethyl acetate, I :9) to give 4.5 (1.02 g, 
74%) as a waxy, pale yellow solid. 
mp 47-49°C 
IH NMR (CDCb, 500 MHz) 0 1.30 (m, 2H, CHCH2CH2), 1.48 (m, 2H, CH2CH2NH), 1.66 
(m, 1H, NHCHCHH), 1.78 (m, 1H, NHCHCHH), 2.22-2.36 (m, 8H, COCH2CH2), 3.19 
(m, 2H, CH2NH), 3.69 (s, 3H, OCH3), 4.51 (m, 1H, NHCH), 4.99 (m, 4H, CH=CH2), 5.77 
(m, 2H, CH=CH2), 6.02 (hr s, 1H, CH2NH), 6.42 (d, J= 7.3 Hz, 1H, CHNH). 
DC NMR (CDCb, 75 MHz) 0 22.04, 28.41, 28.99, 29.18, 30.64, 34.58, 34.96, 38.08, 
51.54,51.60,114.66,114.72,136.41,136.54,172.32,172.40,172.49. 
HRMS (M+H) Found 325.2130 (Caled for C17H29N204 325.2127). 
(2S)-8,15-Dioxo-l,7diaza-eyclopentadee-ll-ene-2-earboxylie acid methyl ester (4.6) and 
(2S)-8,14-dioxo-l, 7 diaza-eyclotetradee-ll-ene-2-earboxylie acid methyl ester (4. 7 alb) 
Diene 4.5 (200 mg, 0.62 mmol, 1 equiv) was treated with Grubbs second generation 
catalyst 1.17 (105 mg, 0.02 mmol, 0.2 equiv) according to General Procedure 1. The crude 
product was purified by chromatography on silica (methanol/ethyl acetate, 1 :9) to give an 
isomer mixture (134 mg, 73%) as a brown solid. The product was isolated as a mixture of 
15-membered 4.6 and ring-contracted 14-membered 4.7alb products in a 3:1 ratio 
respectively, that were inseparable on silica-gel based column chromatography. NB. 
There are two possible 14-membered ring-contracted products, which one of these that 
formed was not determined. 
mp = 200-203°C (isomer mixture) 
IH NMR (CDCb, 500 MHz) from mixture 4.6 0 1.23-1.90 (m, 6H, NHCH(CH2)3), 2.16-
2.52 (m, 8H, COCH2CH2), 2.98 (m, IH, NHCHH), 3.55 (m, 1H, NHCHH), 3.71 (s, 3H, 
OCH3), 4.59 (m, IH, NHCH), 5.51 (m, 2H, CH=CH), 5.76 (br s, 1H, CH2NH), 6.20 (br d, 
7.5 Hz, 1H, CHNH). 
Selected data IH NMR (CDCb, 500 MHz) from mixture 4.7a/b 0 3.05 (m, NHCHH), 3.43 
(m, NHCHH), 3.73 (s, OCH3), 4.46 (m, NHCH), 5.33 (m, CH=CH), 6.05 (br s, CH2NH), 
6.48 (hr d, 5.5 CHNH). 
13C NMR (CDCb, 75 MHz) from mixture 4.6 0 21.74, 28.02, 28.13, 28.41, 32.06, 36.15, 
36.42,37.94,51.15,52.38, 129.84, 129.97, 172.39, 172.88, 173.11. 
Selected data I3C NMR (CDCb, 75 MHz) from mixture 4.7a/b 0 21.07, 26.69, 26.85, 
31.37,35.60,35.65,37.67,51.19,52.32, 129.69, 172.83, 173.03. 
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Mass spectrometry showed both 15-membered 4.6 (M+H 297) and ring contracted 14-
membered 4.7alb (M+H = 283) compounds were present. 
(2S)-8,15-Dioxo-l, 7diaza-cyclopentadecane-2-carboxylic acid methyl ester (4.8) and 
(2S)-8,14-dioxo-l,7diaza-cyclotetradecane-2-carboxylic acid methyl ester (4.9) The 
isomer mixture of 4.6 and 4.7a/b (51 mg, 0.17 mmol, 1 equiv) was treated with 10% 
palladium/carbon (10 mg) according to General Procedure III. This gave a mixture of 15-
membered 4.8 and ring-contracted 14-membered 4.9 (51 mg, 100%) products in a 3:1 ratio 
respectively as a pink solid. 
mp = 209-211°C (mixture) 
IH NMR (CDCb, 500 MHz) from mixture 4.8 0 1.23-1.72 (m, 6H, NHCH(CH2)3), 2.06-
2.36 (m, 8H, COCH2CH2), 2.91 (m, 1H, NHCHH), 3.64 (m, 1H, NHCHH), 3.72 (s, 3H, 
OCH3), 4.62 (m, 1H, NHCH) , 5.67 (br s, 1H, CH2NH), 6.17 (br d, J = 8.4 Hz, 1H, 
CHNH). 
Selected data 1 H NMR (CDCh, 500 MHz) from mixture 4.9 0 2.99 (m, NHCHH), 4.67 (m, 
NHCH), 5.86 (br s, CH2NH), 6.35 (br d, J= 8.9 Hz, CHNH). 
13C NMR (CDCh, 75 MHz) from mixture 4.8 0 21.98, 24.78, 26.18,26.73,27.76,28.68, 
32.11,35.69,35.84,37.95,51.20,52.38, 173.06, 173.23, 173.59. 
Selected data BC NMR (CDCh, 75 MHz) from mixture 4.9 0 21.27, 24.71, 26.22, 26.88, 
27.49,31.04,34.73,35.54,37.38,50.90,52.35, 173.11, 173.40, 173.72. 
HPLC trace of 4.8 and 4.9 isomer mixture in 20% acetonitrile/water + 0.05% TFA. 
solvent 
front 4.9 
4.8 
Chapter Five Experimental 207 
Isomer mixture 4.6/4.7alb was then examined by analytical HPLC. A sample (1 mg/mL in 
MeOH) was run in an isocratic solvent system of 20% acetonitrile/water with 0.05% TF A. 
The trace showed two peaks at different retention times in a 3: 1 ratio. Semi-preparative 
HPLC was carried out in an isocratic system of 20% acetonitrile/water with 0.05% TF A to 
obtain pure samples of individual isomers. Refer to General Procedures section 5.1 for 
details of the reverse columns used. One purified both 4.8 and 4.9 were only sparingly 
soluble in CDCh. IH NMR spectra were run in CDCh to observe NH peaks, but 
experimental data given below is in CD30D as compounds were more soluble in this. 
IH NNIR (CD30D, 500 MHz) 4.8 0 1.33 (m, 8H, CHz), 1.53 (m, 6H, CHz), 1.65 (m, IH, 
NHCHCHH), 1.78 (m, 3H, NHCHH, CHz), 2.25 (m, 4H, COCHz)' 3.01 (m, IH, 
NHCHH), 3.41 (m, IH, NHCHH), 3.69 (s, 3H, OCH3), 4.45 (m, 1H, CH). 
l3c NMR (CD30D, 75 MHz) 4.8024.27,26.51,26.80,29.50,29.57,30.12,32.53,36.31, 
36.74,39.68,52.90,53.03, 174.53, 174.58, 176.56. 
HRMS (M+H) Found 299.1978. (Calcd for ClSH27N204 299.1972). 
IH NMR (CD30D, 500 MHz) 4.9 0 1.33 (m, 6H, CHz), 1.60 (m, 5H, NHCHCHH, CHz), 
1.88 (m, 1H, NHCHCHH), 2.22 (m, 4H, COCHz), 3.07 (m, lH, NHCHH), 3.40 (m, lH, 
NHCHH), 3.70 (s, 3H, OCH3), 4.50 (m, 1H, CH). 
l3c NMR (CD30D, 75 MHz) 4.9 0 22.20, 25.17, 25.28, 27.03, 27.92, 30.45, 35.38, 35.57, 
37.91,51.00,51.39, 172.85, 174.74, 174.75. 
HRMS (M+H) Found 285.1811 (Calcd for C14H2SN204 285.1814). 
Synthesis of 4.6/4.7a1b under microwave conditions 
Diene 4.5 (70 mg, 0.22 mmol, 1 equiv) was dissolved in TCE (20 mL) in a 100 mL glass 
round-bottomed flask. Grubbs second generation catalyst 1.17 (13 mg, 0.02 mmol, 0.7 
equiv) was added, the flask connected to a reflux condenser in the microwave, and the 
solution heated at 800 W for 3 min. The addition of catalyst (2 x 13 mg) followed by 
heating (800 W, 3 min) was repeated twice more. The solvent was removed by 
evaporation under reduced pressure to give the crude product. The crude product was 
purified by chromatography on silica (methanol/ethyl acetate, 1 :9) to give an isomer 
mixture (45mg, 70%) as a brown solid. This product was isolated as a mixture of 4.6 and 
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4.7a/b in a 4:1 ratio respectively. NMR data of the product mixture was consistent with 
that of refluxing DCM conditions. 
Preparation of (2S)-8,27 -dioxo-l, 7 -diaza-cycloheptacos-17 -ene-2-carboxylic acid 
methyl ester (4.13) 
LN~ H 7 o ~ ~_,,jl .. ~r'-.N COzMe 
H 
o 
4.2 4.12 4.13 
(2S)-2,6-Bis-undec-10-enoylamino-ltexanoic acid metltyl ester (4.12) To a stirred 
solution of L-Lys-OMe.2HCl 4.2 (500 mg, 2.2 mmol, 1 equiv) and 10-decenoic acid (920 
mg, 5.06 mmol, 2.3 equiv) in DCM (80 mL) was added EDCI (1.09 g, 5.72 mmol, 2.6 
equiv) and HOBt (891 mg, 6.6 mmol, 3 equiv). DIPEA (0.93 mL, 5.06 mmol, 2.3 equiv) 
was added and the solution stirred overnight. The reaction was worked-up a described in 
General Procedure VII. The crude product was purified by flash chromatography on silica 
(petroleum ether/ethyl acetate, 3:7) to give 4.12 (980 mg, 92%) as a white solid. 
mp 61-63°C 
IH NlVIR (CDCh, 500 NIHz) {) 1.23-1.68 (m, 30H, CH2), 2.01 (m, 4H, CH2CH=CH2), 2.16 
(m, 2H, COCH2), 2.22 (m, 2H, COCH2), 3.22 (m, 2H, CH2NH), 3.72 (s, 3H, OCH3), 4.55 
(m, 1H, NHCH) , 4.91 (m, 2H, CH=CHH), 4.97 (ddd, J 1.6, 3.5, 17.2 Hz, 2H, 
CH=CHH), 5.57 (br s, 1H, CH2NH), 5.78 (m, 2H, CH=CH2), 6.17 (d, J 7.3 Hz, 1H, 
NHCH). 
BC NMR (CDCh, 75 MHz) {) 21.98, 25.21, 25.39, 28.34, 28.54, 28.76, 28.85, 30.57, 
33.22,35.58,35.97,37.89,51.49,51.58, 113.64, 138.35, 172.39, 173.22, 173.35. 
HRMS (M+H) Found 493.3992 (Calcd for C29HS3N204 493.4005). 
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(2S)-(8,27-Dioxo-1, 7-diaza-cycloheptacos-17-ene-2-carboxylic acid methyl ester (4.13) 
Diene 4.12 (150 mg, 0.31 mmol, 1 equiv) was treated with Grubbs second generation 
catalyst 1.17 (52 mg, 0.06 mmol, 0.2 equiv) according to General Procedure I. The crude 
product was purified twice by chromatography on silica (methanolIDCM, 1: 19 then 
methanol/ethyl acetate 1:19) to give 4.13 (28 mg, 20%) as a brown solid. 
mp = 93-94°C 
IH NMR (CDCh, 500 MHz) (5 1.29 (m, 22H, CH2), 1.63 (m, 7H, CH2, NHCHCHH), 1.81 
(m, IH, NHCHCHH), 1.99 (m, 4H, =CHCH2), 2.20 (m, 4H, COCH2), 3.17 (m, IH, 
NHCHH), 3.33 (m, 1H, NHCHH), 3.72 (s, 3H, OCH3), 4.53 (m, 1H, NHCH), 5.31 (m, 
2H, CH=CH), 5.84 (br m, 1H, NH), 6.38 (br m, 1H, NH). 
l3C NMR (CDCh, 75 MHz) (5 21.68, 25.67, 25.88, 28.26, 28.50, 28.84, 28.88, 29.05, 
29.13,29.22,29.30,29.39,29.44,31.87,31.90,31.97,32.02, 36.49, 36.52, 36.78, 51.40, 
52.37, 130.71, 130.80, 173.08, 173.68, 173.90. 
HRMS (M+H) Found 465.3700 (Calcd for C27~9N204 465.3692). 
5.4.2 Lysine-based dipeptide cyclic compounds 
Preparation of (6S, 9S)-9-tert-butoxycarbonylamino-8,15,22-trioxo-l, 7,14-triaza-
cyclodocos-18-ene-6-carboxylic acid methyl ester (4.16) 
o 
sZN)~ 
H 
4.16a 
2.35 
~~::}O I Soc, ~~C02Me N HN 0 H 0 
4.16 
4.14, R1 = H.TFA 
R2 = Me 
2.41, R1 = Soc 
R2= H 
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(2S, 2S)-2-[2-tert-Butoxycarbonylamino-6-(pent-4-enoylamino)-hexanoylaminoJ-6-
(pent-4-enoylamino)-hexanoic acid methyl ester (4.15) Ne"'Pentenoyl lysine 2.35 (300 
mg, 0.88 mmol) was Boc-deprotected using TF A according to General Procedure VI to 
give TFA salt 4.14. In a separate reaction 2.35 (300 mg, 0.88 mmol) was treated with 0.2 
M aqueous lithium hydroxide (2 equiv) to give the free carboxylic acid 2.41 according to 
General Procedure VIII. The TFA salt 4.14 (assume 0.88 mmol) and the carboxylic acid 
2.41 (assume 0.88 mmol) were treated with HATU (401 mg, 1.06 mmol, 1.2 equiv) 
according to General Procedure V. The crude product was purified by flash 
chromatography on silica (methanoIIDCM, 1: 19) to give 4.15 (260 mg, 54%) as a white 
solid. 
mp = 104 - 107°C 
IH NMR (CDCh, 500 MHz) 0 1.28-1.53 (8H, CH2), 1.41 (s, 9H, (CH3)3), 1.72 (m, 2H, 
NHCHCHH), 1.82 (m, 2H, NHCHCHH), 2.25 (m, 4H, COCH2CH2), 2.35 (m, 4H, 
COCH2), 3.20 (m, 4H, CH2NH), 3.69 (s, 3H, OCH3), 4.12 (m, IH, NHCH), 4.46 (m, IH, 
NHCH), 4.99 (m, 4H, CH=CH2), 5.39 (br d, J = 7.5 Hz, lH, CHNH) , 5.78 (m, 2H, 
CH=CH2), 6.08 (m, 2H, CH2NH), 7.04 (br d, J= 7.1 Hz, IH, CHNH). 
13C NMR (CDCh, 75 MHz) 0 22.03, 22.24, 27.99, 28.56, 28.64, 29.36, 29.39, 30.72, 
31.72, 35.24, 38.26, 38.33, 51.88, 51.95, 53.88, 79.34, 114.94, 114.98, 136.80, 155.49, 
172.34, 172.42, 172.52, 172.75. 
HRMS (M+H) Found 553.3603 (Calcd for C28~9N407 553.3601). 
(6S, 9S)-9-tert-Butoxycarbonylamino-8,15,22-trioxo-1, 7,14-triaza-cyclodocos-18-ene-6-
carboxylic acid methyl ester (4.16) Diene 4.15 (149 mg, 0.27 mmol, 1 equiv) was treated 
with Grubbs second generation catalyst 1.17 (46 mg, 0.05 mmol, 0.2 equiv) according to 
General Procedure 1. The crude product was purified by chromatography on silica 
(methanolIDCM, 1:9) to give a mixture (42 mg, 30%) of 4.16 and double bond migrated 
product 4.16a as a brown oil (9: 1 by IH NMR). 
IH NMR (CD30D, 500 MHz) from mixture 4.160 1.28-1.50 (m, 8H, CH2), 1.44 (s, 9H, 
C(C~h), 1.78 (m, 4H, CH2), 2.25 (m, 4H, COCH2CH2), 3.15 (m, 4H, NHCH2), 3.70 (s, 
3H, OC H3), 4.01 (m, IH, NHCH), 4.37 (m, IH, NHCH), 5.45 (m, 2H, CH=CH). 
Selected data IH NMR (CD30D, 500 MHz) from mixture 4.16a 0 2.88 (d, J 5.0 Hz, 
NHCOCH2CH=), 5.57 (m, CH=CH). 
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l3C NMR (CD30D, 75 MHz) from mixture 4.16 0 23.56, 24.55, 29.01, 29.95, 30.07, 30.22, 
30.76,32.04,33.59,37.07,37.42,39.37,40.24,53.04, 53.52, 56.58, 80.89, 130.51, 131.40, 
157.91, 174.09, 175.41, 175.76. 
HRMS (M+H) Found 525.3301 (Calcd for CZ6lLtsN407 525.3288). 
Preparation of (6S, 9S)-9-tert-butoxycarbonylamino-8,15,34-trioxo-1, 7 ,14-triaza-
cyclotetratriacont-24-ene-6-carboxylic acid methyl ester (4.21) 
4.17 
BOC'N N~N H 0 ~ 
H 0 C02Me 0 . ~~~ 
4.21 4.20 0 
(2S)-2-tert-Blltoxycarbonylamino-6-(llndec-1 O-enoylamino)-Itexanoic acid (4.18) Boc-
L-Lysine 4.17 (2 g, 8.10 mmol, 1 equiv) was treated with 10-decenoyl chloride (1.92 mL, 
8.91 mmol, 1.1 equiv) according to General Procedure IV. The crude product was purified 
by flash chromatography on silica (DCMlethyl acetate, 1:1, then ethyl acetate 100%) to 
give 4.18 (2.36 g, 64%) as a white solid. 
mp 68 72°C 
IH NMR (CDCh, 500 MHz) 0 1.26-1.61 (m, 16H, CH2), 1.43 (s, 9H, C(CH3)3), 1.70 (m, 
1H, NHCHCHH), 1.84 (m, 1H, NHCHCHH), 2.02 (m, 2H, CH2CH=CHz), 2.16 (t, J 7.7 
Hz, 2H, COCH2), 3.23 (m, 2H, CH2NH), 4.27 (m, 1H, NHCH), 4.92 (dd, J 1.2, 10.3 
Hz, 2H, CH=CHH), 4.97 (ddd, J 1.6, 3.5, 17.1 Hz, 1H, CH=CHH), 5.28 (br d, J 7.9 
Hz, 1H, CHNH), 5.59 (m, 1H, CH=CHz), 5.85 (br s, 1B, CHzNH). 
BC NMR (CDCh, 75 MHz) 0 22.21, 25.56, 27.99, 28.49, 28.69, 28.94, 28.97, 31.92, 
33.41,36.12,38.96,52.84,79.39,113.85,138.65, 155.55, 174.34, 174.70. 
HRMS (M+H) Found 413.3034 (Calcd for CZZH41NzOs 413.3015). 
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(2S, 2S)-2-[2-tert-Butoxycarbonylamino-6-(undec-10-enoylamino)-hexanoylaminoJ-6-
(un-dec-10-enoylamino)-hexanoic acid methyl ester (4.20) Na -Boc-Ns-decenoy1-L-Lys-
OH 2.34 (230 mg, 0.54 mmol) was Boc-deprotected using TF A (2 equiv) according to 
General Procedure VI to give 4.19. The TF A salt 4.19 (0.54 mmo1, 1 equiv) and the 
carboxylic acid 4.18 (223 mg, 0.54 mmo1, 1 equiv) were treated with HATU (246 mg, 0.65 
mmo1, 1.2 equiv) according to General Procedure V. The crude product was purified by 
flash chromatography on silica (methano1/DCM, 1:19) to give 4.20 (340 mg, 87%) as a 
dirty white solid. 
mp=75-78DC 
IH NMR (CDCb, 500 MHz) 8 1.26 (s, 9H, C(CH3)3), 1.26-1.61 (m, 32H, CH2), 1.71 (m, 
2H, CHNHCHH), 1.82 (m, 2H, CHNHCHH), 2.01 (m, 4H, CH2CH=CH2), 2.14 (m, 4H, 
COCH2), 3.21 (m, 4H, CH2NH), 3.71 (s, 3H, OCH3), 4.11 (m, 1H, NHCH), 4.48 (m, 1H, 
NHCH), 4.90 (m, 2H, HC=CH2), 4.96 (ddd, J= 1.6,3.3,17.1 Hz, 2H, CH=CH2), 5.31 (br 
d, J= 7.l Hz, 1H, CHNH), 5.78 (m, 2H, CH=CH2), 5.86 (m, 2H, CH2NH), 6.94 (d, J= 7.5 
Hz, 1H, CHNH). 
13C NMR (CDCb, 75 MHz) 8 22.08, 22.28, 23.l2, 24.14, 25.58, 28.96, 28.03, 28.56, 
28.76, 29.05, 30.75, 31.38, 31.86, 33.45, 36.28, 38.29, 38.46, 47.05, 51.96, 53.85, 79.37, 
108.96, 113.86, 133.82, 138.73, 155.52, 167.51, 172.40, 173.54, 173.78. 
HRMS (M+H) Found 721.5482 (Caled for C4oH73N407 721.5479). 
(6S), (9S)-9-tert-Butoxycarbonylamino-8,15,34-trioxo-1, 7, 14-triaza-cyclotetratriacont-24-
ene-6-carboxylic acid methyl ester (4.21) Diene 4.20 (218 mg, 0.30 mmo1, 1 equiv) was 
treated with Grubbs second generation catalyst 1.17 (51 mg, 0.06 mmo1, 0.02 equiv) 
according to General Procedure I. The crude product was precipitated in ethyl acetate to 
give a brown solid that was purified by flash chromatography on silica (methanol/ethyl 
acetate, 1:19) to give 4.21 (59 mg, 28%) as a brown solid. 
mp = 99 - 10 1 DC 
IH NMR (CD30D, 500 MHz) 8 1.30 (m, 26H, CH2), 1.43 (s, 9H, C(CH3)3), 1.51 (m,2H, 
CH2), 1.59 (m, 5H, CHNHCHH, CH2), 1.72 (m, 2H, CHNHCHH), 1.84 (m, 1H, 
CHNHCHH), 1.99 (m, 4H, CH2CH=CH2), 2.16 (t, J= 7.5 Hz, 4H, COCH2), 3.l6 (m, 4H, 
NHCH2), 3.70 (s, 3H, OCH3), 4.03 (m, 1H, NHCH), 4.39 (m, 1H, NHCH), 5.38 (m, 2H, 
CH=CH). 
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13C NMR (CD30D, 75 MHz) 8 18.10, 20.04, 21.45, 24.31, 24.39, 27.35, 29.08, 30.14, 
30.18, 30.35,30.48, 30.61, 30.74,30.90, 31.03, 32.34, 33.27, 33.91, 37.45, 40.21, 40.32, 
53.01,53.73,56.01,80.70,131.24,131.74,157.91, 174.14, 175.45, 175.52, 176.34. 
HRMS (M+H) Found 693.5161 (Calcd for C3sH69N407 693.5166). 
Preparation of (28, 58)-2-( 4-benzyloxycarbonylamino-butyl)-3,11,18-trioxo-l,4,10-
triaza-cyclooctadec-14-ene-5-carboxylic acid methyl ester ( 4.27) 
o 
.r(Nj~ ~N,CbZ 
H ~~H 427. ~~5rCO'M'~ ...._____ _ 
o 
4.27 
jw·CbZ 
~Nfco'HH 
H 
4.25 
4.26 
(2S)-6-Benzyloxycarbonylamino-2-(pent-4-enoylamino)-hexanoic acid (4.25) Ns-Cbz-L-
Lys-OH.HCI 4.22 (5 g, 17.8 mmol, 1 equiv) was treated with 4-pentenoyl chloride 2.39 
(2.33 g, 19.6 mmol, 1.1 equiv) according to General Procedure IV. The crude product was 
recrystalised from hot acetone/ethyl acetate and cold petroleum ether to give 4.25 (4.05 g, 
63%) as a white solid. 
mp= 92-95°C 
IH NMR (CDCb, 500 MHz) 8 1.38 (m, 2H, CH2CH2CH2), 1.50 (m, 2H, CH2CH2CH2), 
1.75 (m, 1H, NHCHCHH), 1.86 (m, IH, NHCHCHH), 2.34 (m, 4H, COCH2CH2), 3.19 
(lll, 2H, CH2NH), 4.54 (m, IH, NHCH), 4.98-5.14 (m, 5H, CH=CH2, NH, OCH2), 5.79 
(m, IH, CH=CH2), 6.59 (d, 7.1 Hz, 1H, NH), 7.32 (m, 5H, ArH). 
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l3C NMR (CDCh, 75 MHz) 8 22.10, 29.12, 29.35, 31.26, 35.17,40.30, 51.97, 66.56, 
115.53; 127.82, 127.96, 128.35, 136.26, 136.56, 156.80, 173.48, 174.69. 
HRMS (M+H) Found 363.1921 (Calcd for C19I-h7N20S 363.1920). 
(2S, 2S)-2-[6-Benzyloxycarbonylamino-2-(pent-4-enoylamino)-hexanoylaminoJ-6-(pent-
4-enoylamino)-hexanoic acid methyl ester (4.26) TFA salt 4.14 (250 mg, 0.70 mmol, 1 
equiv) and No.-pentenoyl-Na-Cbz-L-Lys-OH 4.25 (254 mg, 0.70 mmol, 1 equiv) were 
treated with HATU (320mg, 0.84 mmol, 1.2 equiv) according to General Procedure V. 
The crude product was purified by chromatography on silica (methanoIIDCM, 1 :9) to give 
4.26 (316 mg, 77%) as an off white solid. 
mp 112-114°C 
IH NMR (CDCh, 500 MHz) 8 1.28-1.55 (m, 8H, CH2CH2CH2), 1.69 (m, 2H, 
NHCHCHH), 1.84 (m, 2H, NHCHCHH), 2.23-2.39 (m, 8H, COCH2CH2), 3.06-3.34 (m, 
4H, CH2NH), 3.66 (s, 3H, OCH3), 4.43 (m, 2H, NHCH), 4.97-5.15 (m, 5H, CH=CH2, 
NH), 5.06 (s, 2H, OCH2), 5.78 (m, 2H, CH=CH2), 6.00 (br s, 1H, NH), 6.46 (d, J = 7.2 
Hz, 1H, NH), 6.92 (d, J= 7.6 Hz, 1H, NH), 7.32 (m, 5H, ArH). 
l3C NMR (CDCb, 75 MHz) 8 21.92, 22.25, 28.67, 28.94, 29.33, 29.47, 30.58, 31.66, 
35.15, 35.40, 38.27, 40.08, 52.02, 52.06, 52.60, 66.24, 115.13, 115.31, 127.61, 127.76, 
128.22, 136.41, 136.60, 136.91, 156.50, 172.07, 172.38, 172.55, 172.80. 
HRMS (M+H) Found 587.3443 (Calcd for C31H47N407 587.3445). 
(2S, 5S)-2-( 4-Benzyloxycarbonylamino-butyl)-3,11 , 18-trioxo-l ,4,1 O-triaza-cyclooctadec-
14-ene-5-carboxylic acid methyl ester (4.27) Diene 4.26 (146 mg, 0.25 mmol, 1 equiv) 
was treated with Grubbs second generation catalyst 1.17 (43 mg, 0.05 mmol, 0.2 equiv) 
according to General Procedure I. The crude product was purified by chromatography on 
silica (methanoIIDCM, 1 :9) and then recrystalised petroleum ether/methanol to give a 
mixture (38 mg, 27%) of 4.27 and double bond migrated product 4.27a as a white solid 
(8: 1 by IH NMR). 
mp 123 128°C (mixture) 
IH 1\lMR (d6 DMSO, 500 MHz) from mixture 4.27 8 1.43 (m, 8H, CH2), 1.58 (m, 1H, 
NHCHCHH), 1.68 (m, 2B, NHCHCHH), 1.79 (m, 1H, NHCHCHH), 2.20 (m, 8H, 
COCH2CH2), 3.06 (m, 4H, NHCH2), 3.70 (s, 3H, OCH3), 4.32 (m, 2H, NHCH), 5.09 (s, 
2H, OCH2), 5.46 (m, 2H, HC=CH). 
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Selected data IH NMR (d6 DMSO, 500 MHz) from mixture 4.27a 0 2.87 (d, J = 5.9 Hz, 
COCH2CH=), 3.13 (m, CH2NH), 4.24 (m, NHCH), 5.14 (s, OCH2), 5.38 (m, CH=CH). 
l3C NMR (d6 DMSO, 75 MHz) from mixture 4.27 0 22.28, 22.52, 28.16, 28.19, 29.11, 
30.18,30.23,31.36,34.88,35.22,39.55,40.15,51.70, 51.76, 52.21, 65.05, 127.66, 128.28, 
129.19, 129.24, 129.26, 137.19, 156.00, 163.26, 171.38, 172.00, 172.48. 
HRMS (M+H) Found 559.3133 (Calcd for C29H43N407 559.3132). 
5.4.3 Serine-based cyclic compounds 
Preparation of (3S)-5,12-dioxo-1-oxa-4-aza-cyclododec-8-ene-3-carboxylic acid 
methyl ester (4.31) 
o 
o~ 
--- . ~Nfc02Me 
H 
,----- 4.28, R1 = H, R2. = H 
L--_ ..... 4.29, R1 = H.HCI, R2 = Me 
4.30 4.31 
2-Amino-3-hydroxy-propanoic acid methyl ester hydrochloride salt (4.29) L-Serine 4.28 
(5 g, 0.05 mol, 1 equiv) was treated with concentrated hydrochloric acid according to 
General Procedure II. The crude product was dissolved in a minimal amount of methanol 
and recrystalised with cold diethyl ether to give 4.29 (5.88 g, 80%) as a white solid. 
mp = 148-150°C 
IH NMR (D20, 500 MHz) 0 3.77 (s, 3H, OC~), 3.93 (d, J = 3.3 Hz, IH, CHHOH), 4.01 
(d, J= 4.3 Hz, 1H, CHHOH), 4.20 (t, 3.8 Hz, IH, CH). 
l3C NMR (D20, 75 MHz) 0 53.90, 54.78, 59.30, 168.90. 
(2S)-Pent-4-enoic acid-[2-methoxycarbonyl-2-(pent-4-enoylamino)]-ethyl ester (4.30) 
To a stirred solution of L-Ser-OMe.HCl4.29 (200 mg, 1.7 mmol, 1 equiv) and 4-pentenoic 
acid (370 mg, 3.74 mmol, 2.2 equiv) in DMF (50 mL) was added DIPEA (1.05g, 8.16 
mmol, 4.8 equiv) and HATU (1.53 g, 4.08 mmol, 2.4 equiv) and the solution was stirred 
overnight. The reaction was quenched with water (100 mL) and the resulting solution 
extracted with ethyl acetate (150 mL). The organic layer was then washed with aqueous 
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saturated sodium bicarbonate (100 mL), saturated ammonium chloride (100 mL), and 
saturated brine (100 mL). The resulting organic layer was dried (MgS04), and the solvent 
was removed by evaporation under reduced pressure. The crude product was purified by 
flash chromatography on silica (ethyl acetate/petroleum ether, 2:3) to give 4.30 (280 mg, 
59%) as a pale yellow oil. 
IH NMR (CDCh, 500 MHz) 0 2.35 (m, 8H, CH2CH2), 3.73 (s, 3H, OCH3), 4.33 (dd, J 
3.7,11.5 IH, OCHH), 4.43 (dd, J= 3.7,11.5 Hz, IH, OCHH), 4.83 (m, lH, NHCH), 
5.01 (m, 4H, CH=CH2), 5.78 (m, 2H, CH=CH2), 6.32 (d, J= 7.6 Hz, IH, NH). 
13 . C NMR (CDCh, 75 MHz) 0 28.30, 29.01, 32.81, 34.98, 51.29, 52.44, 63.43, 115.24, 
115.29,136.10,136.48,169.74,172.08,172.22. 
HRMS (M+H) Found 284.1494 (Calcd for Cl~22NOs 284.1498). 
(3S)-5,12-Dioxo-1-oxa-4-aza-cyclododec-8-ene-3-carboxylic acid methyl ester (4.31) 
Diene 4.30 (110 mg, 0.39 mmol, 1 equiv) was treated with Grubbs second generation 
catalyst 1.17 (66 mg, 0.08 mmol, 0.2 equiv) according to General Procedure 1. The crude 
product was purified by flash chromatography on silica (DCMlethyl acetate, 1:1) to give 
4.31 (45 mg, 45%) as brown crystals. Recrystalisation by slow evaporation from 
DCMlethyl acetate gave colourless crystals suitable for x-ray crystallography. See 
appendix for crystallography data. 
mp 151-153°C 
IH NMR (CDCh, 500 MHz) 0 2.09-2.44 (m, 8H, CH2CH2), 3.76 (s, 3H, OCH3), 4.24 (dd, 
J= 3.8,11.5 IH, OCHH), 4.63 (m, IH, OCHH), 4.98 (m, IH, NHCH), 5.39 (ddt, J= 
6.3, 11.5, 15.1 Hz, 2H, CH=CH), 5.92 (d, 8.6 Hz, IH, NH). 
13C NMR (CDCh, 75 MHz) 0 28.80, 28.85, 34.29, 36.42, 51.04, 52.51, 61.14, 130.03, 
130.27, 169.61, 171.94, 172.92. 
HRMS (M+H) Found 256.1183 (Calcd for C12HlSNOS 256.1185). 
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Preparation of (2S)-S,24-dioxo-l-oxa-4-aza-cyclotetracos-14-ene-3-carboxylic acid 
methyl ester (4.33) 
4.29 
4.33 
(2S)-Undec-10-enoic acid-[2-methoxycarbonyl-2-(undec-l O-enoylamino)]-ethyl ester 
(4.32) To a stirred solution of L-Ser-OMe.HCl 4.29 (200 mg, 1.7 mmol, 1 equiv) and 10-
decenoic acid (680 mg, 3.74 mmol, 2.2 equiv) in DMF (50 mL) was added DIPEA (1.05 g, 
8.16 mmol, 4.8 equiv) and HATU (1.53 g, 4.08 mmol, 2.4 equiv), and the solution stirred 
overnight. The reaction was quenched with water (100 mL) and the resulting solution 
extracted with ethyl acetate (150 mL). The organic layer was washed with aqueous 
saturated sodium bicarbonate (100 mL), saturated ammonium chloride (100 mL), and 
saturated brine (100 mL),then dried (MgS04), and the solvent was removed by evaporation 
under reduced pressure. The crude product was purified by flash cbromatography on silica 
(ethyl acetate/petroleum ether, 2:3) to give 4.32 (409 mg, 54%) as a waxy oil. 
IH NMR (CDCh, 500 MHz) 0 1.31 (m, 20H, CH2), 1.58 (m, 4H, CH2), 2.01 (m, 4H, 
CH2CH=CH2), 2.26 (m, 4H, COCH2), 3.74 (s, 3H, OCH3), 4.32 (dd, 3.5,11.4 Hz, 1H, 
OCHH), 4.45 (dd, J 4.0, 11.4 Hz, 1H, OCHH), 4.85 (m, IH, NHCH), 4.90 (m, 2H, 
HC=CHH), 4.96 (dd, J 1.3,17.3 Hz, 2H, HC=CHH), 5.78 (m, 2H, CH=CH2), 6.26 (d, J 
= 7.8 Hz, 1H, NH). 
13C NMR (CDCh, 75 MHz) 0 24.47, 25.21, 28.54, 28.56, 28.72, 28.74, 28.84, 28.88, 
28.97, 29.00, 33.44, 33.45, 35.58, 35.92, 51.37, 52.37, 63.26, 113.83, 113.86, 138.62, 
138.65, 169.86, 172.99, 173.11. 
HRMS (M+H) Found 452.3378 (Calcd for C26H46NOS 452.3376). 
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(2S)-5,24-Dioxo-l-oxa-4-aza-cyclotetracos-14-ene-3-carboxylic acid methyl ester (4.33) 
Diene 4.32 (119 mg, 0.26 mmol, 1 equiv) was treated with Grubbs second generation 
catalyst 1.17 (45 mg, 0.05 mmol, 0.2 equiv) according to General Procedure 1. The crude 
product was purified by chromatography on silica (ethyl acetate/petroleum ether, 3 :7) to 
give 4.33 (17 mg, 15%) as a brown solid. 
lllp = 88-90°C 
IH NMR (CDCh, 500 MHz) 8 1.28 (m, 20H, CH2), 1.59(m, 4H, CH2) , 1.99 (m, 4H, 
CH2CH=CH2), 2.24 (m, 4H, COCH2), 3.76 (s, 3H, OCH3), 4.41 (m, 2H, OCH2), 4.83 (m, 
1H, NHCH), 5.30 (m, 2H, CH=CH), 6.17 (d, J = 7.7 Hz, 1H, NH). 
13C NMR (CDCh, 75 MHz) 8 25.17, 25.89, 28.09, 28.76, 28.81, 28.93, 28.96, 29.04, 
29.10, 29.26, 32.05, 33.89, 34.19, 36.63, 51.57, 52.81, 63.12, 130.78, 130.81, 170.02, 
172.86, 173.29. 
HRMS (M+H) Found 424.3068 (Calcd for C24H42NOs 424.3063). 
Preparation of (3S, 6S)-6-tert-butoxycarbonylamino-5,9,16-trioxo-1,8-dioxa-4-aza-
cyclohexadec-12-ene-3-carboxylic acid methyl ester (4.37) 
o 
2.45, R 1 = Boc, R2 = Me j 
oj~ 
i 4.37a, b 
o 
o~ 
.. (- H 0 
Boc'N~NY"oj~ 
H 0 C02Me 
4.34, R1 = Boc, R2 = H 
4.35, R1 = H.TFA, R2 = Me 
4.36 
(l S, 2S)-Pent-4-enoic acid {2-tert-butoxycarbonylamino-2-{ (l-methoxycarbonyl-2-(pent-
4-enoyloxy)-ethylcarbamoyl})-ethyl ester (4.36) Boc-L-Ser-OMe 2.45 (300 mg, 1 mmol) 
was treated with TF A according to General Procedure VI to give TF A salt 4.35. In a 
separate reaction, Boc-L-Ser-OMe 2.45 (300 mg, 1 mmol) was treated with 0.2 M lithium 
hydroxide (2 equiv) according to General Procedure VIII to give unprotected carboxylic 
acid 4.34. Compounds 4.35 and 4.34 (assume each 1 mmol, 1 equiv) were then treated 
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with EDCI (248mg, 1.3 mmol, 1.3 equiv) and HOBt (227mg, 1.5 mmol, 1.5 equiv) 
according to General Procedure VII. The crude product was purified by flash 
chromatography on silica (ethyl acetate/DCM, 3:7) to give 4.36 (60 mg, 13%) as a pale 
yellow oil. 
IH NMR (CDCh, 500 MHz) 8 1.42 (s, 9H, C(CH3)3), 2.37 (m, 8H, COCH2CH2), 3.74 (s, 
3H, OCH3), 4.24-4.44 (m, 5H, OCH2, NHCH), 4.78 (m, 1H, NHCH) , 5.00 (m, 4H, 
CH=CH2), 5.32 (br d, J= 5.7 Hz, IH, NH), 5.77 (m, 2H, CH=CH2), 7.04 (d, J= 7.6 Hz, 
1H, NH). 
l3 . 
C NMR (CDCh, 75 MHz) 8 28.01, 28.37, 28.42, 32.87, 32.97, 51.68, 52.65, 53.21, 
63.35, 63.65, 80.24, 115.42, 115.45, 136.15, 136.30, 155.13, 169.01, 169.18, 172.26, 
172.49. 
HRMS (M+H) Found 471.2347 (Calcd for C22H3SN209 471.2343). 
(3S, 6S)-6-tert-Butoxycarbonylamino-5,9,16-trioxo-l, 8-dioxa-4-aza-cyclohexadec-12-
ene-3-carboxylic acid methyl ester (4.37) Diene 4.36 (40 mg, 0.09 mmol, 1 equiv) was 
treated with Grubbs second generation catalyst 1.17 (15 mg, 0.02 mmol, 0.2 equiv) 
according to General Procedure I. The crude product was purified by chromatography on 
silica (ethyl acetate/DCM, 3:7) to give a mixture (17 mg, 45%) of 4.37 and the double 
bond migrated products 4.37a and b as an off white solid (23:1:1 by IH NMR). 
mp = 141-143°C (mixture) 
IH NMR (CDCh, 500 MHz) from mixture 4.37 8 1.46 (s, 9H, C(CH3)3), 2.29-2.54 (m, 4H, 
COCH2CH2), 3.76 (s, 3H, OCH3), 4.31 (m, 1H, OCHH), 4.30-4.39 (m, 3H, OCH2, 
NHCH), 4.58 (dd, J = 3.1, 11.4 Hz, 1H, OCHH), 4.80 (br s, 1H, NHCH), 5.46 (m, 2H, 
HC=CH), 5.58 (br s, 1H, NH), 7.17 (d, J = 7.2 Hz, 1H, NH). 
Selected data IH NMR (CDCh, 500 MHz) from mixture 4.37a and b 8 2.97 (d, J = 6.2 Hz, 
COCH2CH=), 3.03 (d, J= 4.4 Hz, COCH2CH=), 4.51 (m, OCHH), 5.32 (m, CH=CH). 
l3C NMR (CDCh, 75 MHz) from mixture 4.37 27.01, 27.14, 28.14, 33.37, 33.48, 52.06, 
52.82, 54.26,64.14,64.26,80.73, 128.74, 129.30, 155.14, 169.01, 169.06, 172.60, 173.55. 
HRMS (M+H) Found 443.2028 (Caled for C2oH31N209 443.2030). 
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5.4.4 Cysteine-based cyclic compounds 
Preparation of (3R)-5,12-dioxo-1-thia-4-aza-cyclododec-8-ene-3-carboxylic acid 
methyl ester (4.40) 
4.40 
(2R)-2-(Pent-4-enoylamino)-3-(pent-4-enoylsulfanyl)-propionie acid methyl ester (4.39) 
To a stirred solution of 4-pentenoic acid (321 mg, 3.2 mmol, 2.2 equiv) in dry DCM (10 
mL) under an inert atmosphere was added dropwise TEA (876 mg, 8.6 mmol, 5.9 equiv) at 
O°C. After stirring for 20 min, this solution was added dropwise to a solution of BOP-Cl 
(890 mg, 3.5 mmol, 2.4 equiv) in dry DCM (20 mL) at O°C. A solution of L-Cys-
OMe.HCl 4.38 (250 mg, l.5 mmol, 1 equiv) in dry DCM (10 mL) was then added 
dropwise at O°C. After 15 min the reaction was allowed to warm to rt with stirring 
overnight. The solvent was removed by evaporation under reduced pressure and the 
residue dissolved in ethyl acetate (50 mL). The solution was washed twice with water (30 
mL), and then the organic layer washed twice with saturated aqueous sodium bicarbonate 
(30 mL), water (30 mL), and saturated brine solution (30 mL) sequentially. The resulting 
organic layer was dried (MgS04), and the solvent was removed by evaporation under 
reduced pressure. The crude product was purified by flash chromatography on silica (ethyl 
acetate/petroleum ether, 1:4) to give 4.39 (372 mg, 85%) as a colourless oil. 
IH NMR (CDCh, 500 MHz) 82.27 (m, 2H, COCH2), 2.36 (m, 4H, =CHCH2), 2.63 (t, J = 
7.3 Hz, 2H, COCH2), 3.35 (m, 2H, CH2S), 3.72 (s, 3H, OCH3), 4.77 (m, lH, NHCH), 
4.97-5.06 (m, 4H, CH=CH2), 5.77 (m, 2H, CH=CH2), 6.28 (br d, J= 7.1 Hz, lH, NH). 
l3C NMR (CDCh, 75 MHz) 8 28.53, 28.70, 29.67, 34.42, 42.l9, 5l.26, 5l.84, 114.62, 
115.22,135.27, 136.31, 167.00, l7l.84, 196.97. 
HRMS (M+H) Found 300.1273 (Calcd for Cl4H22N04S 300.l270). 
(3R)-5,12-Dioxo-l-thia-4-aza-eyclododee-8-ene-3-earboxylie acid methyl ester (4.40) 
Diene 4.39 (34 mg, 0.11 mmol, 1 equiv) was treated with Grubbs second generation 
catalyst 1.17 (19 mg, 0.02 mmol, 0.2 equiv) according to General Procedure 1. The crude 
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product was purified by flash chromatography on silica (petroleum ether/ethyl acetate, 1 :4) 
to give 4.40 (23 mg, 74%) as a white solid. Recrystalisation by slow evaporation from 
DCM/ethyl acetate gave crystals suitable for x-ray crystallography. See appendix for 
crystallography data. 
mp = 146-147°C 
IH NMR (CDCh, 500 MHz) 0 2.02 (m, 1H, COCHHCH2), 2.26-2.43 (m, 5H, =CHCH2, 
COCHHCH2), 2.62 (m, 1H, COCHHCH2), 2.69 (m, 1H,COCHHCH2), 3.45 (m, 2H, 
CH2S), 3.74 (s, 3H, OCH3), 4.80 (m, 1H, NHCH), 5.33 (m, 1H, CH=CH), 5.41 (m, 1H, 
CH=CH), 5.85 (br s, 1H, NH). 
l3C NMR (CDCh, 75 MHz) 0 29.01, 29.36, 29.50, 37.48, 42.74, 51.92, 52.64, 128.20, 
131.81, 170.77, 172.40, 199.12. 
HRMS (M+H) Found 272.0960 (Calcd for C12H1SN04 272.0957). 
Preparation of (3R)-5,24-dioxo-l-thia-4-aza-cyclotetracos-14-ene-3-carboxylic acid 
methyl ester (4.42) 
iSH 
HCI,H2N C02Me 
4.38 
j s~ 
~Nfc02Me 
H 
4.41 4.42 
(2R)-2-(Undec-1 O-enoylamino)-3-(undec-1 O-enoylsuljanyl)-propanoic acid methyl ester 
(4.41) To a stirred solution of lO-decenoic acid (590 mg, 3.2 mmol, 2.2 equiv) in dry 
DCM (10 mL) under an inert atmosphere was added dropwise TEA (876 mg, 8.6 mmol, 
5.9 equiv) at O°C. After stirring for 20 min, this solution was added dropwise to a solution 
of BOP-Cl (890 mg, 3.5 mmol, 2.4 equiv) in dry DCM (20 mL) at O°C. A solution of L-
Cys-OMe.HCl 4.38 (250 mg, 1.5 mmol, 1 equiv) in dry DCM (10 mL) was then added at 
O°C. After 15 min the reaction was allowed to warm to rt with stirring overnight. The 
solvent was removed by evaporation under reduced pressure and the residue dissolved in 
ethyl acetate (50 mL). The solution was washed twice with water (30 mL), and then the 
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organic layer washed twice with saturated aqueous sodium bicarbonate (30 mL), water (30 
mL), and saturated brine solution (30 mL) sequentially. The resulting organic layer was 
dried (MgS04), and the solvent was removed by evaporation under reduced pressure. The 
crude product was purified by flash chromatography on silica (ethyl acetate/petroleum 
ether, 1 :1) to give 4.41 (300 mg, 44%) as a white solid. 
mp 40-41°C 
IH NMR (CDCh, 500 MHz) () 1.30 (m, 20H, CH2), 1.59(m, 4H, CH2), 2.00 (m, 4H, 
CH2CB=CH2\ 2.16 (t, J = 7.6 Hz, 2H, NHCOCH2), 2.52 (t, J = 7.5 Hz, 2H, SCOCH2), 
3.32 (d, J 5.5 Hz, 2H, CH2S), 3.71 (s, 3H, OCH3), 4.76 (m, IH, NHCH), 4.89 (m, 2B, 
CH=CH2), 4.95 (ddd, J 1.6, 3.4, 17.1 Hz, 2H, CH=CH2), 5.77 (m, 2H, CH=CH2), 6.24 
(d, 7.5 Hz, 1H, NH). 
l3C NMR (CDCh, 75 MHz) () 25.18, 25.25, 28.54, 28.57, 28.70, 28.76, 28.85, 28.92, 
29.00, 29.01, 30.16, 33.44, 33.46, 35.97, 43.60, 51.70, 52.28, 113.85, 113.89, 138.62, 
138.67, 170.47, 172.76, 198.53. 
HRMS (M+H) Found 468.3166 (Calcd for C26H46N04S 468.3148). 
(3R)-5,24-Dioxo-l-thia-4-aza-cyclotetracos-14-ene-3-carhoxylic acid methyl ester (4.42) 
Diene 4.41 (50 mg, 0.11 mmol, 1 equiv) was treated with Grubbs second generation 
catalyst 1.17 (18 mg, 0.02 mmol, 0.2 equiv) according to General Procedure I. The crude 
product was purified by chromatography on silica (ethyl acetate/petroleum ether, 3:7) to 
give 4.42 (20 mg, 43%) as a white solid. 
mp 94-96°C 
IH NMR (CDCb, 500 MHz) () 1.30 (m, 16H, CH2), 1.60 (m, 8H, CH2), 2.00 (m, 4H, 
CH2CB=CH2), 2.16 (m, 2H, NHCOCH2), 2.55 (m, 2B, SCOCH2), 3.33 (m, 2H, SCH2), 
3.75 (s, 3H, OCH3), 4.77 (m, IH, NHCH), 5.31 (m, 2H, CH=CH), 6.16 (d,J= 8.0 Hz, 1H, 
NH). 
l3C NMR (CDCh, 75 MHz) () 25.91, 25.20, 27.94, 28.23, 28.65, 28.67, 28.81, 28.92, 
29.20,29.37,29.44,29.57,30.01,31.99,32.13,36.80, 43.90,52.25,52.73, 130.76, 130.94, 
170.77,173.13,199.92. 
HRMS (M+H) Found 440.2843 (Caled for C24H42N04S 440.2835). 
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Preparation of (3R, 6R)-6-tert-butoxycarbonylamino-5,9,16-trioxo-l,8-dithia-4-aza-
cyclohexadec-12-ene-3-carboxylic acid methyl ester (4.45) 
2.49a, R 1 Soc, R2 = Me 
J 
o 
S~ SOC'N~~Y"S~ 
H 0 C02Me 
2.49b, R1 = Soc, R2 H 
4.43, R1 :: H.TFA, R2 Me 
4.44 
o 
i 
s~ 
4.45a 
o 
sj~ 
.:):>,[5\ 
H 0 C02Me 
4.45 
(2R, 2R)-2-f2-tert-Butoxycarbonylamino-3-(pent-4-enoylsulfanyl)-propionylaminoJ-3-
(pent-4-enoylsulfanyl)-propionic acid methyl ester (4.44) Boc-L-Cys-OMe 2.49a (700 
mg, 2.2 mmol) was treated with TF A according to General Procedure VI to give TF A salt 
4.43. In a separate reaction, Boc-L-Cys-OMe 2.49a (700 mg, 2.2 mmol) was treated with 
0.2 M lithium hydroxide (2 equiv) according to General Procedure VIII to give unprotected 
carboxylic acid 2.49b. Compounds 4.43 and 2.49b (assume each 2.2 mmol, 1 equiv) were 
treated with HATU (456 mg, 1.2 mmol, 1.2 equiv) according to General Procedure V. The 
crude product was purified twice by flash chromatography on silica (ethyl acetate/DCM, 
1 :4 then 3 :7) to give 4.44 (90 mg, 11 %) as a pale yellow oiL 
IH NMR (CDCh, 500 MHz) 8 1.44 (s, 9H, C(CH3)3), 2.29-2.43 (m, 6H, CH2), 2.68 (t, J = 
7.4 Hz, 2H, COCH2), 3.20-3.46 (m, 4H, SCH2), 3.72 (s, 3H, OCH3), 4.43 (m, IH, CHNH), 
4.85 (m, IH, CHNH), 5.03 (m, 4H, CH=CH2), 5.31 (br d, J= 7.6 Hz, IH, NH), 5.79 (m, 
2H, CH=CH2), 6.33 (br d, 7.6 Hz, IH, NH). 
13 C NMR (CDCh, 75 MHz) 8 28.12, 29.11, 29.21, 30.06, 30.27, 35.14, 42.87, 51.40, 
52.59, 60.60, 80.54, 115.38, 116.07, 135.53, 136.73, 155.13, 170.42, 172.14, 198.66, 
199.43. 
HRMS (M+H) Found 503.1895 (Calcd for C22H3SN207S2 503.1886). 
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(3R, 6R)-6-tert-B utoxycarbonylamino-5,9,16-trioxo-l , 8-dithia-4-aza-cyclohexadec-12-
ene-3-carboxylic acid methyl ester (4.45) Diene 4.44 (53 mg, 0.11 mmol, 1 equiv) was 
treated with Grubbs second generation catalyst 1.17 (18 mg, 0.01 mmol, 0.2 equiv) 
according to General Procedure 1. The crude product was purified by chromatography on 
silica (ethyl acetate/DCM, 2:3) to give a mixture (18 mg, 36%) of 4.45 and the double 
bond migrated product 4.45a as a thick, brown oil (10: 1 by IH NMR). 
IH NIVIR (CDCh, 500 MHz) from mixture 4.45 8 1.43 (s, 9H, C(CH3)3), 2.23 (m, 2H, 
=CHCH2), 2.39 (m, 4H, =CHCH2, COCH2), 2.70 (m, 2H, COCH2), 3.35 (m, 4H, SCH2), 
3.74 (s, 3H,OCH3), 4.73 (m, 2H, CHNH), 5.55 (m, 2H, CH=CH), 5.66 (br d, J= 7.9 Hz, 
IH, NH), 6.42 (br d, J = 7.0 Hz, 1H, NH). 
Selected data IH NMR (CDCh, 500 MHz) from mixture 4.45a 8 2.99 (d, J = 7.3 Hz, 
COCH2CH=), 4.80 (m, CHNH), 5.34 (m, CH=CH), 6.35 )br d, J= 8.1 Hz, NH). 
l3C NMR (CDCh, 75 MHz) from mixture 4.45827.50,28.18,28.22,30.47,31.08,35.33, 
42.70,52.36,52.73,59.17,80.75, 129.24, 130.90, 154.86, 170.38, 172.65, 199.11,200.10. 
HRMS (M+H) Found 475.1577 (Caled for C20H31N207S2 475.1573). 
5.4.5 Synthesis of cysteine-tert-Ieucine-based dipeptide 
Preparation of (3S, 6R) 6-tert-butyl-5,8,15-trioxo-l-thia-4, 7 -diaza-cyclopentadec-ll-
ene-3-carboxylic acid methyl ester (4.46) 
4.48 4.49 
LO(( ~~\CO'M' H 0; ~ ... ---- S 
4.46 0 
R_~~y-CO'M' 
H 0 ) 
~s 
o 
4.50, R = Soc 
4.51, R = H.TFA 
J (iv) 
O~H ~ N"-./C02Me N -
H 0 ) 
~(s 
o 
4.52 
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(2S)-2-tert-Butoxycarbonylamino-3,3-dimethyl-butyric acid (4.49/8 Boc20 (182 mg, 
0.84 mmol, 1.1 equiv) was added to a solution of L-tert-Ieucine 4.48 (100 mg, 0.76 mmol, 
1 equiv) and NaOH (34 mg, 0.84 mmol, 1.1 equiv) in water/tert-butyl alcohol (1 mLl1 
mL). The reaction mixture was stirred at rt overnight, and was extracted three times with 
ethyl acetate (5 mL). The combined organic layers were washed with saturated aqueous 
sodium bicarbonate solution, and the combined water phases were acidified to pH 1.5-2.0 
(Universal indicator paper). The water phase was extracted four times with ethyl acetate (5 
mL), and the combined organic phases were washed with saturated brine solution, dried 
(MgS04), and the solvent removed by evaporation under reduced pressure to give 4.49 
(175 mg, 99%) as a colourless solid. 
mp = 122-123°C 
IH NMR (CDCb, 500 MHz,) 8 1.01 (s, 9H, C(CH3)31eu), 1.43 (s, 9H, C(CH3)3boc), 4.11 (d, 
J= 7.2 Hz, 1H, CH), 5.08 (d, J= 9.3 Hz, lH, NH). 
13 C NMR (CDCb, 75 MHz) 826.41,28.20,34.41,61.55, 79.83, 155.62, 176.22. 
(2S, 2R) 2-(2-tert-Butoxycarbonylamino-3,3-dimethyl-butyrylamin0) -3-(pent-4-enoyl-
sulJanyl)-propionic acid methyl ester (4.50) Nc-Pentenoyl cysteine 2.49a (1 g, 3.15 mmol, 
1 equiv) was treated with TF A according to General Procedure VI to give 4.43. TF A salt 
4.43 (3.15 mmol) and Boc-L-Ieu-OH 4.49 (831 mg, 3.6 mmol, 1.14 equiv) were treated 
with EDCI (782 mg, 4.1 mmol, 1.3 equiv) and HOBt (713 mg, 4.73 mmol, 1.5 equiv) 
according to General Procedure VII. The crude product was purified by flash 
chromatography on silica (ethyl acetate/DCM, 1:4) to give 4.50 (620 mg, 46%) as a pale 
yellow oil. 
IH NMR (CDCb, 500 MHz) 8 0.99 (s, 9H, C(CH3)31eu), 1.43 (s, 9H, C(CH3)3boc), 2.29 (m, 
2H, COCH2CH2), 2.36 (t, J = 7.0 Hz, 2H, COCH2CH2), 3.30 (dd, J = 5.0, 14.2 Hz, 1H, 
SCHH), 3.46 (dd, J= 4.6, 14.2 Hz, lH, SCHH), 3.70 (s, 3H, OCH3), 4.02 (d, J= 8.3 Hz, 
1H, CHleu), 4.86 (m, 1H, CHcys), 4.98 (d, J= 10.1 Hz, 1H, NH1eu), 5.04 (m, 2H, CH=CH2), 
5.81 (m, 1H, CH=CH2), 6.38 (d, J= 7.7 Hz, 1H, NHcys). 
13 C NMR (CDCb, 75 MHz) 8 26.71, 28.19, 29.15, 30.09, 33.79, 35.16, 51.53, 52.52, 
68.62, 80.37, 115.33, 136.76, 155.49, 170.59, 172.32, 199.50. 
HRMS Found (M+H) 431.2214 (Calcd for C2oH3sN206S 431.2216). 
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(2S, 2R) 2-[3,3-Dimethyl-2-(pent-4-enoylamino)-butyrylaminoJ-3-(pent-4-enoylsulfanyl)-
propionic acid methyl ester (4.52) Dipeptide 4.50 (620 mg, 1.44 mmol, 1 equiv) was 
treated with TF A according to General Procedure VI to give 4.51. TF A salt 4.51 (1.44 
mmol) and 4-pentenoic acid (164 mg, 1.6 mmol, 1.14 equiv) were treated with EDCI (358 
mg, 1.87 mmol, 1.3 equiv) and HOBt (326 mg, 2.16 mmol, 1.5 equiv) according to 
General Procedure VII. The crude product was purified by flash chromatography on silica 
(ethyl acetateIDCM, 1 :4) to give 4.52 (430 mg, 72%) as a colourless oil. 
IH NMR (CDCb, 500 MHz) (5 0.99 (s, 9H, C(CH3)3), 2.35 (m, 4H, COCH2CH2), 3.28 (dd, 
.1= 5.4, 1402Hz, IH, SCHH), 3.46 (dd, .1= 4.6, 14.2 Hz, IH, SCHH), 3.72 (s, 3H, OCH3), 
4.42 (d, .1 8.6 Hz, IH, CHleu), 4.83 (m, IH, CHcys), 4.98-5.11 (m, 4H, CH=CH2), 5.82 
(m, 2H, CH=CH2), 6.05 (d, 8.6 Hz, IH, NHleu), 6.35 (d, .1 7.7 Hz, 1H, NHcys). 
BC NMR (CDCh, 75 MHz) (5 26.44, 28.39, 28.92, 29.82, 32.88, 33.54, 34.73, 51.50, 
52.18,67.01, 115.00, 115.12, 136.43, 136.62, 170.23, 172.30, 173.06, 198.57. 
HRMS Found (M+H) 413.2115 (Calcd for C2oH32N20SS 413.2110). 
(3S, 6R) 6-tert-Butyl-5,8,15-trioxo-l-thia-4, 7-diaza-cyclopentadec-ll-ene-3-carboxylic 
acid methyl ester (4.46) Diene 4.52 (230 mg, 0.60 mmol, 1 equiv) was treated with 
Grubbs second generation catalyst 1.17 (102 mg, 0.12 mmol, 0.2 equiv) according to 
General Procedure I. The crude product was purified by flash chromatography on silica 
(l00% ethyl acetate) to give 4.52 (140 mg, 65%) as white solid. 
IH NMR (CDCh, 500 MHz) (5 0.99 (s, 9H, C(CH3)3), 2.20 (m, 4H, =CHCH2 (3H), COCH2 
(lH)), 2.44 (m, 3H, =CHCH2 (lR), COCH2 (2H)), 2.57 (m, 2H, COCH2), 3.11 (dd, .1 
3.9, 14.5 Hz, IH, SCHH), 3.46 (dd, .1 9.5, 14.5 Hz, IH, SCHH), 3.73 (s, 3H, OCH3), 
4.59 (m, 2H, NHCH), 5.52 (m, 2H, HC=CH), 5.86 (d, .1= 9.7 Hz, IH, NH), 6.41 (d, .1 
7.4 Hz, IH, NH). 
13C NMR (CDCb, 75 MHz) (5 26.48, 27.22, 27.63, 29.61, 34.10, 35.43, 35.73, 52.67, 
52.90,65.47, 129.71, 130.24, 170.84, 172.29, 172.45,200.16. 
HRMS Found (M + H) 385.1796 (Calcd for C18H29N20SS 385.1797). 
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Appendix 
Crystallographic data for twelve membered-cysteine ring 4.40 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system, space group 
Unit cell dimensions 
Volume 
Z, Calculated density 
Absorption coefficient 
F(OOO) 
Crystal size 
Theta range for data collection 
Limiting indices 
Reflections collected / unique 
Completeness to theta = 26.36 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F"'2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Absolute structure parameter 
Largest diff. peak and hole 
C12H17N04S 
271.33 
93(2) K 
0.71073 A 
Orthorhombic, P2(1)2(1)2(1) 
a = 4.9843(6) A alpha 90 deg. 
b 15.5996(18) A beta 90 deg. 
c 16.708(2) A gamma 90 deg. 
1299.1(3) A3 
4, 1.387 Mg/m3 
0.256 mm-1 
576 
0.62 x 0.43 x 0.13 mm 
2.44 to 26.36 deg. 
-5<=h<=6, -19<=k<=19, -1 
6179/2641 [R(int) = 0.0368] 
99.7% 
0.9675 and 0.8576 
Full-matrix least-squares on F2 
2641/0/168 
1.029 
Rl = 0.0324, wR2 = 0.0694 
RI = 0.0421, wR2 = 0.0724 
-0.02(8) 
0.192 and -0.235 e.A-3 
TabJe 1. Crystal data and structure refinement for 4.40. 
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x y z U(eq) 
S 1956(1) 10021(1) 7826(1) 16(1) 
N 4259(3) 8342(1) 6971(1) 13(1) 
C(1) 3812(4) 9711(1) 8681(1) 15(1) 
C(2) 2170(4) 9708(1) 9441(1) 15(1) 
C(3) 2156(5) 8812(1) 9816(1) 19(1) 
C(4) 983(4) 8168(1) 9264(1) 18(1) 
C(5) 2344(4) 7535(1) 8919(1) 16(1) 
C(6) 1237(4) 6922(1) 8318(1) 17(1) 
C(7) 2674(4) 6993(1) 7512(1) 14(1) 
C(8) 2123(4) 7839(1) 7105(1) 12(1) 
C(9) 4070(4) 9143(1) 6533(1) 13(1) 
C(10) 4484(4) 9928(1) 7062(1) 15(1) 
C(l1) 6138(4) 9153(1) 5865(1) 13(1) 
C(12) 7757(5) 8406(1) 4743(1) 25(1) 
0(1) 6142(3) 9517(1) 8659(1) 24(1) 
0(2) -171(3) 8039(1) 6901(1) 17(1) 
0(3) 5826(3) 8479(1) 5381(1) 19(1) 
0(4) 7820(3) 9699(1) 5769(1) 16(1) 
Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2 
x 103) for 4.40. U(eq) is defmed as one third ofthe trace ofthe orthogonalized Uij tensor. 
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S-C(l) 1.770(2) C(6)-H(6A) 0.9900 
S-C(10) 1.7989(18) C(6)-H(6B) 0.9900 
N-C(8) 1.342(2) C(7)-C(8) 1.510(3) 
N-C(9) 1.450(2) C(7)-H(7A) 0.9900 
N-H 0.83(2) C(7)-H(7B) 0.9900 
C(l)-O(1) 1.201(2) C(8)-O(2) ·1.233(2) 
C(1)-C(2) 1.511(3) C(9)-C(11) 1.520(3) 
C(2)-C(3) 1.531(3) C(9)-C(10) 1.523(3) 
C(2)-H(2A) 0.9900 C(9)-H(9) 1.0000 
C(2)-H(2B) 0.9900 C(10)-H(10A) 0.9900 
C(3)-C(4) 1.485(3) C(10)-H(10B) 0.9900 
C(3)-H(3A) 0.9900 C(11)-O(4) 1.205(2) 
C(3)-H(3B) 0.9900 C(1l)-O(3) 1.335(2) 
C(4)-C(5) 1.329(3) C(12)-O(3) 1.441(3) 
C(4)-H(4) 0.9500 C(12)-H(12A) 0.9800 
C(5)-C(6) 1.492(3) C(12)-H(12B) 0.9800 
C(5)-H(5) 0.9500 C(12)-H(12C) 0.9800 
C(6)-C(7) 1.529(3) 
Table 3. Bond lengths [A] for 4.40. Symmetry transformations used to generate 
equivalent atoms. 
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C(1 )-S-C(1 0) 100.63(9) C(8)-C(7)-C( 6) 111.97(16) 
C(8)-N-C(9) 122.46(17) C(8)-C(7)-H(7 A) 109.2 
C(8)-N-H 121.2(14) C( 6)-C(7)-H(7 A) 109.2 
C(9)-N-H 116.1(14) C(8)-C(7)-H(7B) 109.2 
0(1)-C(1)-C(2) 123.33(19) C(6)-C(7)-H(7B) 109.2 
0(1 )-C(1 )-S 123.31(16) H(7 A)-C(7)-H(7B) 107.9 
C(2)-C(1)-S 113.37(14) 0(2)-C(8)-N 122.78(17) 
C(1)-C(2)-C(3) 110.45(15) 0(2)-C(8)-C(7) 120.96(17) 
C(1)-C(2)-H(2A) 109.6 N-C(8)-C(7) 116.25(17) 
C(3)-C(2)-H(2A) 109.6 N-C(9)-C(11) 109.60(16) 
C(l )-C(2)-H(2B) 109.6 N-C(9)-C(10) 113.02(16) 
C(3)-C(2)-H(2B) 109.6 C(11)-C(9)-C(10) 109.02(15) 
H(2A)-C(2)-H(2B) 108.1 N-C(9)-H(9) 108.4 
C( 4)-C(3)-C(2) 111.39(16) C(11)-C(9)-H(9) 108.4 
C(4)-C(3)-H(3A) 109.4 C(10)-C(9)-H(9) 108.4 
C(2)-C(3)-H(3A) 109.4 C(9)-C(10)-S 112.43(13) 
C( 4)-C(3)-H(3B) 109.4 C(9)-C(1 O)-H(1 OA) 109.1 
C(2)-C(3)-H(3B) 109.4 S-C(1 O)-H(l OA) 109.1 
H(3A)-C(3)-H(3B) 108.0 C(9)-C(1 O)-H(1 OB) 109.1 
C(5)-C(4)-C(3) 124.8(2) S-C(1 O)-H(1 OB) 109.1 
C(5)-C(4)-H(4) 117.6 H(1 OA)-C(1 O)-H(1 OB) 107.9 
C(3)-C(4)-H(4) 117.6 0(4)-C(11)-0(3) 123.86(18) 
C(4)-C(5)-C(6) 125.3(2) 0(4)-C(11)-C(9) 12S.19(17) 
C(4)-C(5)-H(S) 117.3 0(3)-C(11 )-C(9) 110.94(16) 
C(6)-C(S)-H(S) 117.3 0(3)-C(12)-H(12A) 109.S 
C( S)-C( 6)-C(7) 111.93(16) 0(3)-C(12)-H(12B) 109.5 
C(S)-C(6)-H(6A) 109.2 H(12A)-C(12)-H(12B) 109.S 
C(7)-C(6)-H(6A) 109.2 0(3 )-C(12)-H(12C) 109.S 
C(5)-C(6)-H(6B) 109.2 H(12A)-C(12)-H(12C) 109.S 
C(7)-C(6)-H(6B) 109.2 H(12B)-C(12)-H(12C) 109.S 
H(6A)-C(6)-H(6B) 107.9 C(11)-0(3)-C(12) 11S.64(16) 
Table 4. Bond angles [deg] for 4.40. 
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Ull U22 U33 U23 U13 U12 
S 16(1) 19(1) 14(1) 2(1) 2(1) 4(1) 
N 9(1) 14(1) lS(1) 4(1) -1(1 ) 3(1) 
C(l) 16(1) 12(1) 16(1) -3(1) -1(1) -3(1) 
C(2) 17(1) 16(1) 14(1) -4(1) -1(1) 0(1) 
C(3) 24(1) 21(1) 13(1) 0(1) 3(1) 1(1) 
C(4) 19(1) 17(1) 18(1) 4(1) 4(1) -3(1) 
C(S) 17(1) 18(1) 14(1) 7(1) 1(1) 0(1) 
C(6) 20(1) lS(l) 16(1) 3(1) 3(1) 0(1) 
C(7) lS(l) 12(1) 16(1) 0(1) 0(1) -1(1) 
C(8) 13(1) 11(1) 11(1) -4(1) 1(1) 0(1) 
C(9) 14(1) 12(1) 12(1) 3(1) -1(1 ) 0(1) 
C(10) 19(1) 14(1) 14(1) 3(1) 3(1) -1(1) 
C(ll) 14(1) 12(1) 11(1) 2(1) -2(1) 3(1) 
C(12) 37(1) 18(1) 18(1) -3(1) 10(1) 0(1) 
0(1) 14(1) 39(1) 18(1) 0(1) -1(1) 2(1) 
0(2) 12(1) 18(1) 21(1) 3(1) -1(1) -1(1 ) 
0(3) 28(1) lS(l) lS(l) -3(1) 4(1) -4(1) 
0(4) 17(1) lS(l) 17(1) 1(1) 2(1) -2(1) 
Table 5. Anisotropic displacement parameters (A2 x 103) for 4.40. The anisotropic 
displacement factor exponent takes the form: -2 pi2 [ h2 a*2 U11 + ... + 2 h k a* h* U12 ]. 
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x y z U(eq) 
H 5790(40) 8187(13) 7095(12) 8(5) 
H(2A) 307 9885 9320 18 
H(2B) 2935 10124 9826 18 
H(3A) 4017 8644 9952 23 
H(3B) 1103 8825 10318 23 
H(4) -878 8211 9148 22 
H(5) 4172 7468 9067 19 
H(6A) -698 7039 8241 20 
H(6B) 1421 6330 8524 20 
H(7A) 4631 6930 7596 17 
H(7B) 2077 6519 7160 17 
H(9) 2244 9180 6288 15 
H(10A) 4456 10449 6724 18 
H(10B) 6271 9891 7319 18 
H(l2A) 7625 8908 4393 37 
H(12B) 7390 7886 4432 37 
H(12e) 9568 8373 4969 37 
Table 6. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2 x 103) 
for 4.40. 
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C(l O)-S-C(1 )-0(1) 0.8(2) 
C(1 O)-S-C(1 )-C(2) -178.85(13) 
0(1 )-C(l )-C(2)-C(3) -58.9(3) 
S-C(1 )-C(2)-C(3) 120.71(16) 
C(1)-C(2)-C(3)-C( 4) -60.1(2) 
C(2)-C(3)-C( 4)-C(5) 112.3(2) 
C(3 )-C( 4 )-C( 5)-C( 6) -175.35(17) 
C( 4 )-C( 5)-C( 6)-C(7) 117.7(2) 
C( 5)-C( 6)-C(7)-C(8) -67.5(2) 
C(9)-N -C(8)-0(2) -3.7(3) 
C(9)-N -C(8)-C(7) 175.36(17) 
C( 6)-C(7)-C(8)-0(2) -62.6(2) 
C( 6)-C(7)-C(8)-N 118.34(19) 
C(8)-N-C(9)-C(11) -127.74(19) 
C(8)-N -C(9)-C(1 0) 110.4(2) 
N-C(9)-C(10)-S -62.63(19) 
C(ll )-C(9)-C(1 O)-S 175.23(12) 
C(l )-S-C(1 0)-C(9) 105.90(14) 
N -C(9 )-C(11 )-O( 4) -124.5(2) 
C(1 0)-C(9)-C( 11 )-0(4) -0.3(3) 
N-C(9)-C(11)-0(3) 56.5(2) 
C(1 0)-C(9)-C(11 )-0(3) -179.34(16) 
0(4)-C(11)-0(3)-C(12) 3.4(3) 
C(9)-C(11 )-0(3)-C(12) -177.54(16) 
Table 7. Torsion angles [deg] for 4.40. Symmetry transformations used to generate 
equivalent atoms. 
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Crystallographic data for twelve membered-serine ring 4.31 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system, space group 
Unit cell dimensions 
Volume 
Z, Calculated density 
Absorption coefficient 
F(OOO) 
Crystal size 
Theta range for data collection 
Limiting indices 
Reflections collected 1 unique 
Completeness to theta 25.00 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data 1 restraints 1 parameters 
Goodness-of-fit on FA2 
Final R indices [I>2sigma(I)] 
R indices ( all data) 
Absolute structure parameter 
Largest diff. peak and hole 
C12 H17N 05 
255.27 
93(2) K 
0.71073 A 
Orthorhombic, P2(1 )2(1 )2(1) 
a = 8.1341 (18) A alpha = 90 deg. 
b = 9.049(2) A beta = 90 deg. 
c = 16.931(4) A gamma = 90 deg. 
1246.3(5) A3 
4, 1.360 Mg/m3 
0.106mm-1 
544 
0.75 x 0.44 x 0.14 mm 
2.41 to 24.99 deg. 
-9<=h<=9, -1O<=k<=9, -20<=1<=15 
5297/2186 [R(int) = 0.0208] 
99.5% 
Semi-empirical from equivalents 
0.99 and 0.88055 
Full-matrix least-squares on F2 
2186/0/164 
1.111 
R1 0.0256, wR2 = 0.0626 
R1 = 0.0285, wR2 = 0.0637 
-0.2(8) 
0.114 and -0.193 e.A-3 
Table 8. Crystal data and structure refmement for 4.31. 
235 
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x y z U(eq) 
C(1) 9083(2) -551(1) 1860(1) 19(1) 
C(2) 10597(2) -211(2) 2318(1) 21(1) 
C(3) 10343(2) -542(2) 3187(1) 23(1) 
C(4) 9085(2) 459(2) 3529(1) 22(1) 
C(5) 7601(2) 57(2) 3731(1) 21(1) 
C(6) 6274(2) 1068(2) 3991(1) 21(1) 
C(7) 4855(2) 1095(2) 3403(1) 17(1) 
C(8) 5404(2) 1742(1) 2636(1) 14(1) 
C(9) 5865(2) 1332(1) 1248(1) 17(1) 
C(10) 7237(2) 399(2) 911(1) 19(1) 
C(11) 4466(2) 1331(1) 667(1) 18(1) 
C(12) 2145(2) 52(2) 239(1) 29(1) 
N 5371(1) 845(1) 2015(1) 15(1) 
0(1) 8330(1) -1677(1) 1893(1) 27(1) 
0(2) 5872(1) 3020(1) 2593(1) 18(1) 
0(3) 3507(1) 170(1) 768(1) 24(1) 
0(4) 4277(1) 2232(1) 167(1) 29(1) 
0(5) 8664(1) 576(1) 1388(1) 20(1) 
Table 9. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2 
x 103) for 4.31. U(eq) is defmed as one third of the trace of the orthogonalized Uij tensor. 
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C(1)-O(l) 1.1899(17) C(7)-H(7B) 0.9700 
C(1)-O(5) 1.3407(16) C(8)-O(2) 1.2199(16) 
C(1)-C(2) 1.487(2) C(8)-N 1.3290(17) 
C(2)-C(3) 1.515(2) C(9)-N 1.4285(17) 
C(2)-H(2A) 0.9700 C(9)-C(11) 1.5043(19) 
C(2)-H(2B) 0.9700 C(9)-C(10) 1.5112(18) 
C(3)-C(4) 1.484(2) C(9)-H(9) 0.9800 
C(3)-H(3A) 0.9700 C(10)-O(5) 1.4223(16) 
C(3)-H(3B) 0.9700 C(10)-H(10A) 0.9700 
C(4)-C(5) 1.307(2) C(10)-H(10B) 0.9700 
C(4)-H(4) 0.9300 C(11)-O(4) 1.1853(16) 
C(5)-C(6) 1.481(2) C(11)-O(3) 1.3193(17) 
C(5)-H(5) 0.9300 C(12)-O(3) 1.4289(16) 
C(6)-C(7) 1.5247(18) C(12)-H(12A) 0.9600 
C(6)-H(6A) 0.9700 C(12)-H(12B) 0.9600 
C(6)-H(6B) 0.9700 C(12)-H(12C) 0.9600 
C(7)-C(8) 1.4918(18) N-H 0.8600 
C(7)-H(7A) 0.9700 
Table 10. Bond lengths [AJ for 4.31. Symmetry transformations used to generate 
equivalent atoms. 
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0(1 )-C(1 )-0(5) 123.28(13) C(6)-C(7)-H(7B) 109.6 
0(1 )-C(1 )-C(2) 125.39(12) H(7 A)-C(7)-H(7B) 108.1 
0(5)-C(1 )-C(2) 111.33(11) 0(2)-C(8)-N 122.50(12) 
C(1 )-C(2)-C(3) 110.58(12) 0(2)-C(8)-C(7) 121.17(11) 
C(1)-C(2)-H(2A) 109.5 N-C(8)-C(7) 116.33(11) 
C(3)-C(2)-H(2A) 109.5 N-C(9)-C(11 ) 112.43(11) 
C(1 )-C(2)-H(2B) 109.5 N-C(9)-C(10) 112.25(11) 
C(3 )-C(2)-H(2B) 109.5 C(11 )-C(9)-C(1 0) 108.13(11) 
H(2A)-C(2)-H(2B) 108.1 N -C(9)-H(9) 107.9 
C( 4)-C(3)-C(2) 110.65(12) C(11 )-C(9)-H(9) 107.9 
C(4)-C(3)-H(3A) 109.5 C(10)-C(9)-H(9) 107.9 
C(2)-C(3)-H(3A) 109.5 O( 5)-C(1 0)-C(9) 109.02(11) 
C(4)-C(3)-H(3B) 109.5 O( 5)-C(1 0)-H(1 OA) 109.9 
C(2)-C(3)-H(3B) 109.5 C(9)-C(1 O)-H(1 OA) 109.9 
H(3A)-C(3)-H(3B) 108.1 O( 5)-C(1 0)-H(1 OB) 109.9 
C(5)-C(4)-C(3) 124.72(14) C(9)-C(1 0)-H(1 OB) 109.9 
C( 5)-C( 4)-H( 4) 117.6 H(1 OA)-C(1 O)-H(1 OB) 108.3 
C(3)-C(4)-H(4) 117.6 0(4 )-C( 11 )-0(3) 124.29(13) 
C( 4 )-C( 5)-C( 6) 125.37(14) 0(4 )-C( 11 )-C(9) 124.41(12) 
C( 4 )-C( 5)-H( 5) 117.3 0(3)-C(11 )-C(9) 111.27(11) 
C(6)-C(5)-H(5) 117.3 0(3)-C(12)-H(12A) 109.5 
C( 5)-C( 6)-C(7) 111.53(12) 0(3)-C(12)-H(12B) 109.5 
C(5)-C(6)-H(6A) 109.3 H(12A)-C(12)-H(12B) 109.5 
C(7)-C(6)-H(6A) 109.3 0(3)-C(12)-H(12C) 109.5 
C(5)-C(6)-H(6B) 109.3 H(12A)-C(12)-H(12C) 109.5 
C(7)-C(6)-H(6B) 109.3 H(12B)-C(12)-H(12C) 109.5 
H(6A)-C(6)-H(6B) 108.0 C(8)-N-C(9) 121.72(11) 
C(8)-C(7)-C( 6) 110.38(11) C(8)-N-H 119.1 
C(8)-C(7)-H(7A) 109.6 C(9)-N-H 119.1 
C(6)-C(7)-H(7A) 109.6 C(11)-0(3)-C(12) 115.90(11) 
C(8)-C(7)-H(7B) 109.6 C(1)-0(5)-C(10) 117.40(11) 
Table 11. Bond angles [deg] for 4.31. 
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Ull U22 U33 U23 U13 U12 
C(l) 18(1) 18(1) 20(1) -1(1) 3(1) 4(1) 
C(2) 15(1) 24(1) 25(1) 0(1) 1(1) 2(1) 
C(3) 18(1) 28(1) 24(1) 1(1) -3(1) 2(1) 
C(4) 22(1) 25(1) 20(1) 0(1) -2(1) 0(1) 
C(5) 22(1) 21(1) 19(1) 6(1) -2(1) 2(1) 
C(6) 21(1) 26(1) 16(1) 3(1) 0(1) 0(1) 
C(7) 17(1) 18(1) 17(1) -1(1) 3(1) 0(1) 
C(8) 11(1) 15(1) 18(1) 1(1) 0(1) 3(1) 
C(9) 19(1) 15(1) 16(1) 2(1) 2(1) -1(1) 
C(10) 17(1) 23(1) 16(1) 0(1) -1(1) 0(1) 
C(ll) 18(1) 16(1) 18(1) 0(1) 4(1) 4(1) 
C(12) 22(1) 42(1) 23(1) 4(1) -8(1) -3(1) 
N 19(1) 12(1) 15(1) 1(1) 1(1) -2(1) 
0(1) 25(1) 20(1) 37(1) 3(1) -8(1) -1(1) 
0(2) 21(1) 14(1) 20(1) -2(1) 1(1) 0(1) 
0(3) 22(1) 27(1) 22(1) 6(1) -8(1) -5(1) 
0(4) 28(1) 31(1) 27(1) 14(1) -4(1) 1(1) 
0(5) 17(1) 21(1) 20(1) 3(1) 0(1) -2(1) 
Table 12. Anisotropic displacement parameters (A2 x 103) for 4.31. The anisotropic 
displacement factor exponent takes the form: -2 pi2 [h2 a*2 U11 + ... + 2 h k a* b* U12 ]. 
Appendix 240 
x y z U(eq) 
H(2A) 10877 824 2252 26 
H(2B) 11504 -798 2118 26 
H(3A) 9992 -1559 3249 28 
H(3B) 11373 -417 3467 28 
H(4) 9374 1443 3604 27 
H(5) 7357 -946 3710 25 
H(6A) 6715 2058 4049 25 
H(6B) 5869 752 4503 25 
H(7A) 4457 97 3317 21 
H(7B) 3959 1678 3616 21 
H(9) 6268 2348 1296 20 
H(10A) 6911 -631 903 22 
H(10B) 7471 704 374 22 
H(12A) 1455 907 292 44 
H(12B) 1523 -820 363 44 
H(12C) 2542 -12 -294 44 
H 5043 -51 2076 18 
Table 13. Hydrogen coordinates ( x 101\4) and isotropic displacement parameters (A2 x 
103) for 4.31. 
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0(1 )-C(1 )-C(2)-C(3) -50.21(18) 
0(5)-C(1 )-C(2)-C(3) 130.54(12) 
C(I)-C(2)-C(3)-C(4) -65.36(15) 
C(2)-C(3 )-C( 4)-C(5) 107.81(16) 
C(3)-C( 4)-C( 5)-C( 6) -172.97(13) 
C( 4)-C(5)-C(6)-C(7) 114.20(15) 
C( 5)-C( 6)-C(7)-C(8) -65.47(14) 
C( 6)-C(7)-C(8)-0(2) -63.16(16) 
C( 6)-C(7)-C(8)-N 116.02(12) 
N -C(9)-C(1 O)-O( 5) -64.66(14) 
C(11 )-C(9)-C(1 0)-0(5) 170.74(10) 
N-C(9)-C(11 )-0(4) 142.93(13) 
C(1O)-C(9)-C(11)-0(4) -92.58(15) 
N-C(9)-C(11)-0(3) -39.13(15) 
C(1 0)-C(9)-C(11 )-0(3) 85.37(13) 
0(2)-C(8)-N-C(9) -0.85(19) 
C(7)-C(8)-N-C(9) 179.98(12) 
C(ll )-C(9)-N -C(8) -115.1 0(13) 
C(10)-C(9)-N -C(8) 122.71(12) 
0(4)-C(11)-0(3)-C(12) -1.4(2) 
C(9)-C(11)-0(3)-C(12) -179.35(11) 
0(1 )-C(1 )-0(5)-C(1 0) 0.48(19) 
C(2)-C(1 )-O( 5)-C( 1 0) 179.74(11) 
C(9)-C(1 O)-O( 5)-C( 1) 106.45(13) 
Table 14. Torsion angles [deg] for 4.31. Symmetry transformations used to generate 
equivalent atoms. 
